"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn",55,"Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Vice President of Investor Relations, Mr. Michael Partridge. Sir, you may begin."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, chief commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join",281,"Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, chief commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for Q&A.
Our agenda tonight is as follows: Jeff will begin by reviewing Vertex's strategic priorities for 2015. Stuart will review the full year 2014 performance of KALYDECO, provide commentary on the outlook for KALYDECO in 2015 and will also discuss preparations for the launch of the lumacaftor ivacaftor combination. To close, Ian will review the full year 2014 financial results and discuss our 2015 financial guidance. We will then open the call for your questions. We expect today's call to run for no more than 45 minutes
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K and 10-Q, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of the lumacaftor ivacaftor combination and those about Vertex's other cystic fibrosis programs are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our fourth quarter 2014 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past",439,"Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past year in establishing a foundation for sustainable growth. First, we expanded the number of patients treated with KALYDECO through geographic and label expansion efforts. Second, we announced positive data from our Phase III studies of lumacaftor ivacaftor and submitted an NDA in the U.S. and MAA in the EU, paving the way to treat significantly more people with CF.
Third, we continue to manage our financial position, ending the year with approximately $1.4 billion in cash to support the future of our business. These accomplishments have fundamentally changed the outlook for our business and increased our confidence in the company's plans for the future and for people with CF and their families.
I had the opportunity to meet with many of our investors and analysts at the J.P. Morgan healthcare conference earlier this month and to talk about our strategy. So let me remind everyone about our priorities for 2015. First, approval and successful launch of the lumacaftor/ivacaftor combination while continuing to increase KALYDECO revenues, enabling us to treat even more people with CF and to accelerate our revenue growth. Second, significantly advancing our CF pipeline with a focus on next-generation medicines that have the potential to create regimens that may increase the benefit for CF patients. And third, expanding and diversifying our pipeline into other areas as evidenced by multiple programs advancing into the clinic during 2015.
If we are successfully meeting our goals, we expect to deliver to Vertex and its shareholders, a long-term financial profile that includes significant revenue and earnings growth.
Before turning the call over to Stuart, I wanted to take the opportunity to mention how proud we are at Vertex to be at the forefront of a new approach in developing medicines, broadly referred to as precision medicine. KALYDECO and hopefully soon, the combination of lumacaftor/ivacaftor are benefiting CF patients around the world and demonstrating the potential of this approach in developing medicines. We are pleased that our successes provided part of the basis for new research initiatives, discussed for the first time in the State of the Union address last week, to apply precision medicine approaches across a broad range of businesses. And we look forward to working closely with regulators and other government entities to apply the learnings of precision medicine so that we can help more patients and do it faster. With that, I'll turn it over to Stuart."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also",718,"Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also discuss our progress in preparing for the approval and launch of the lumacaftor/ivacaftor combination. 
KALYDECO has shown rapid growth since it was approved in 2012. Product sales increased 25% in 2014 to $464 million. At the start of 2014, nearly all eligible patients with the G551D mutation in the U.S. and Europe were being treated with KALYDECO. Growth in 2014 was driven by both additional patients initiating therapy in new and existing international markets and the U.S. approval of KALYDECO for use in 8 additional mutations.
Turning to 2015, there are again multiple potential growth drivers based on achieving reimbursement approvals and further label expansions. In the first half of 2015, we expect rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF who are expected to be eligible for treatment.
In the U.S. KALYDECO  was approved for use in children and adults ages 6 and older with the R117H mutation on December 29 last year. The first patients have already initiated treatment and we expect to see continued uptake in the months ahead.
In the second half of 2015, we expect to see the revenue impact from achieving reimbursement for gating mutations in some European countries. We also anticipate a potential approval in children with CF ages 2 to 5 with the G551D or other gating mutations in the U.S., which would be a growth driver in the second half of 2015. As a result, we expect the number of patients eligible for KALYDECO to increase from 3,100 today to more than 3,700 by the end of this year. Although all eligible patients will not be on treatment by the end of the year and the enrollment of the VX-661 pivotal study in gating patients will have an adverse impact on patients receiving commercial product, we expect another year of significant revenue growth and KALYDECO net sales in the range of $560 million to $580 million in 2015.
Now to the combination of lumacaftor and ivacaftor. We submitted the NDA and MAA in the U.S. and EU, respectively in November 2014 for children and adults with CF ages 12 and older to have 2 copies of the F5 08 Dell mutation. In the U.S. we received prior to review, with a PDUFA date of July 5, 2015. In the EU, we were granted accelerated assessment and we anticipate EU approval around Q4 of this year if discussions with regulators progress as expected. Following regulatory approval in the EU, individual reimbursement discussions will begin on a country by country basis.
I'm pleased to report our launch planning is on track. There are around 8,500 F5 08 Dell homozygous patients ages 12 years and older in the U.S. who are treated in approximately 275 CF centers. This represents an order of magnitude more patients than we currently treat. A key priority for us ahead of launch in the U.S. is to scale up our patient services team so that we can help providers and patients navigate the reimbursement process and also help with patient education and compliance. We have been adding case managers and we are also working to understand how CF centers plan to manage patient initiations.
We are investing in disease education to help payers estimate the number of eligible patients they may have in their plans and also from a medical perspective, to understand cystic fibrosis as a disease, its impact on patients and caregivers and the systemic effects of CFTR modulation.
Internationally, we are building out the required infrastructure in new and existing European markets to support the lumacaftor/ivacaftor launch. Infrastructure for each new country consists of a small number of medical and commercial staff. 
In summary, geographical and label extension will continue to drive significant growth in KALYDECO sales and we are well-positioned for long-term revenue growth as the number of people we treat with CF significantly increases with the launch of the lumacaftor/ivacaftor combination later this year. I'll now hand the call over to Ian."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track for long-term sustainable revenue and earnings growth. I'll be brief on the 2014 results and for a more det",812,"Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track for long-term sustainable revenue and earnings growth. I'll be brief on the 2014 results and for a more detailed discussion of these results, please refer to our press release we issued earlier today.
2014 financial performance was marked by the continuing growth in KALYDECO revenues, controlling the level of our operating expenses and completing the year with a strong balance sheet. As we look to 2015 and beyond, we see revenue growth continuing based on treating more patients with KALYDECO and then accelerating this revenue growth with the potential approval and launch of the lumacaftor/ivacaftor combination. As we anticipate this growth in our CF revenues, we also expect to control the level of operating investments into our company. We anticipate that this will enable us to deliver a future financial profile that includes high operating margins and significant earnings growth.
Now to the 2014 results. We generated $536 million in total non-GAAP revenues in 2014, including $464 million in KALYDECO revenues. This was a significant increase over 2013 KALYDECO revenues and we expect this growth to continue. We also recorded $72 million in royalty and collaborative revenues, including $35 million in revenue from the outlicense of VX-787 on novel flu medicine to Janssen.
When looking at the main components of our non-GAAP operating expenses, our combined non-GAAP R&D and SG&A expenses were $920 million in 2014, a decrease of $177 million compared to the prior year. This decrease reflects our prioritization towards CF medicines and continued focus on managing operating expenses.
The non-GAAP loss was $511 million or $2.17 per share compared to prior year loss of $203 million. This increased loss was the result of significantly reduced HCV revenues from 2013 and they are now excluded from our 2014 non-GAAP financials.
With the expectation of increasing CF revenues in 2015 and controlling our operating expenses, we see 2014 as a transition year into revenue growth and future profitability.
Now let's turn to 2015 and our financial guidance for the year and specifically KALYDECO revenues and the main components of our operating expenses. With the recent regulatory submissions and approvals for reimbursement, KALYDECO is well-positioned for 2015. We expect KALYDECO net revenues to be in the range of $560 million to $580 million as we continue to expand the number of patients we treat. Next, to the lumacaftor/ivacaftor combination. We look forward to this midyear launch to further accelerate our revenue growth. However, the revenues from this launch will be primarily US-based in 2015.
Based on regulatory timelines in the EU and the subsequent reimbursement time lines, we anticipate the first commercial revenues from ex U.S. territories will likely go in 2016. Now to the main components of our operating expenses. As previously announced, we expect the combined non-GAAP R&D and SG&A expense will be in the range of $1.05 billion to $1.1 billion for the full year and we expect these expenses to be fairly consistent each quarter of this year. We expect the non-GAAP R&D expense to be in the range of $770 million to $800 million, an increase of $75 million to $105 million compared to the prior year.
Now breaking down the R&D spend into its principal components. We expect to spend approximately $200 million investing in R or basic research to support the creation of future transformational medicines and specifically in CF. We expect to progress a next-generation corrector into the clinic later this year. This is very similar to basic research spending in prior years.
Now to the D or development spend, which we expect to be between $570 million and $600 million and this is primarily driven by CF clinical programs. More specifically, the Phase III pivotal program with VX-661 in combination with ivacaftor and the ongoing investment in lumacaftor/ivacaftor combination to patients who remain on long-term extension study. Other areas of focus for Vertex in research and development are programs in oncology and neurology, an expectation that certain programs will enter and advance in the clinic in 2015 is Incorporated into our guidance.
Turning now to 2015 SG&A guidance. We expect to spend $280 million to $300 million, which is an increase of $55 million to $75 million compared to 2014. The increase reflects cross-cultural investment in supporting ivacaftor/lumacaftor combination launch and establishing a larger international presence as we significantly increase the number of patients we expect to treat with our medicines.
I'll close by stating that we are in a strong financial position today and focused on delivering a financial profile consistent with our large cut biotech peers and move forward to updating you on the execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays.",13,"[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III what, and looking at the opportunity in heterozygous patients, what population, I guess, would you estimate, wou",67,"Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III what, and looking at the opportunity in heterozygous patients, what population, I guess, would you estimate, would be eligible for perhaps 661-plus KALYDECO? And from your basic research, what population may need a second corrector? And then I have one follow-up."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 buckets. You remember last year, we published a Phase II study. And adding 661 to KALYDECO in patients who h",435,"Jeff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 buckets. You remember last year, we published a Phase II study. And adding 661 to KALYDECO in patients who had a 508 allele mutation on 1 allele and some sort of gating mutation, that gets G551D on the other allele and we're able to show, if you remember, that once those patients, once they're stable on KALYDECO, if we added 661, we saw greater than a 4.5% improvement in absolute FEV1. And so the first part of the heterozygotes strategy that we're going to test in the Phase III program is basically a pivotal program around that population where we're trying to maximize the benefit that we can bring by adding 661 to KALYDECO in patients who are heterozygotes from 508 and the gating allele. And so if you think about that population, it's about 80% of all gating patients who have 508 on the other allele. The other population is what we call the heterozygotes, min population, not a very good term, I admit. But its patients have 508 on one allele and basically a non-KALYDECO responsive mutation on the other allele. So about 1,700 patients worldwide. As we've said, this is the hardest to treat population because those patients express half of the amount of the delta 508 protein than a delta 508 homozygote expresses, so they need better correction. 
We know, for example, that 809-plus KALYDECO doesn't work in that population. We looked at that in our TRAFFIC and TRANSPORT trials, you'll remember. So we're taking a two-pronged approach for these patients. Because today, they don't have any CFTR correction therapy, we're going to take an admittedly high risk but more rapid approach and try them with 661 plus KALYDECO, the 2-drug combination as part of our pivotal program and we'll start the program, as we said, in the first half of this year. The idea there is if we can see an effect, then we'll be able to get the medicines to patients much more quickly. But the high probability approach we're taking is the 3-drug combination and that's where we take 661 KALYDECO and the next-generation corrector, our cell based data suggest that will work in this population with a higher probability but, of course, that's slower because our next-generation corrector is in our lead optimization now and our goal to put the first of those and perhaps multiple in the clinic this year. And so that's the high probability but longer-term approach."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess that was more of my question of if you get the next GEN corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs and proof-of-concept studies and get an answer pretty quickly?",47,"I guess that was more of my question of if you get the next GEN corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs and proof-of-concept studies and get an answer pretty quickly?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, we'll be able to look at 2 unapproved drugs but getting an answer pretty quickly, I want to be clear about what we have to take this first generation correctors into the clinic by themselves first ,of course, do a Phase I study in normals, then we'l",84,"Well, we'll be able to look at 2 unapproved drugs but getting an answer pretty quickly, I want to be clear about what we have to take this first generation correctors into the clinic by themselves first ,of course, do a Phase I study in normals, then we'll be able to begin to explore accommodations. So if compared to the 661 KALYDECO trial, which we're going to start in the first half of this year and quickly enroll, it is a significantly longer approach."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe one follow-up on Jeff's question and then a second one. So first, just from a strategic standpoint, just wondering the benefit of developing 661 plus KALYDECO in patients that already benefit from KALYDECO, is it higher barriers to entry? Is it grea",74,"Maybe one follow-up on Jeff's question and then a second one. So first, just from a strategic standpoint, just wondering the benefit of developing 661 plus KALYDECO in patients that already benefit from KALYDECO, is it higher barriers to entry? Is it greater revenue per patient? Just maybe help frame for us the strategic thinking there. And then would love your latest thoughts on partnershps and/or BD within and outside of CF. Thanks."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden and I'll take the first part and Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can say those patients and that's our Number 1 priority. And as you know and I talked about thi",106,"This is Jeff Leiden and I'll take the first part and Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can say those patients and that's our Number 1 priority. And as you know and I talked about this last, we were very pleasant surprised, actually, with the Phase II data that showed the significant improvement over and above KALYDECO when we added 661 to those G551D 508 patients, and that was one of the one things that make as push quickly into the pivotal program so we can get those patients maximum benefit."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. 3 main areas. one being to understand the landscape of other CF apologies and medicines that may combine with wha",185,"And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. 3 main areas. one being to understand the landscape of other CF apologies and medicines that may combine with what we're doing here at Vertex to enhance benefits from regimens. Second area of focus has been to consider other technological or research-based approaches to create medicines. I mean, Vertex has been very successful over the years with small molecule development and certain molecule targets but there are other things going on there right now that we need to be involved in. So we're considering expanding our footprint as well. And then the third area of focus has been, can we diversify our pipeline, and by that it's both outlicensing noncore assets, which we've been successful with. And we're also considering bringing on other opportunities into our pipeline with Vertex's future. Idle to update you as we go to 2015 in terms of where we've been is putting our efforts and as I would outline, cystic fibrosis is our Number 1 priority."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick topics. One is on the Phase II VX-661 study that you're finishing and then you move into a Phase III homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID dosing",162,"Two quick topics. One is on the Phase II VX-661 study that you're finishing and then you move into a Phase III homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID dosing? I guess how could you do all that and take all that if you haven't even seen the full Phase II b data? And then my second question as it relates to the overall heterozygous population that we've been discussing the last couple of questions, I guess you talked a little bit about why it was high risk in the homozygous population. But we did see in the population, where you did have 551 508, it was additive by 4.6%, even with only half the expressions. So being in the heterozygous headwinds, you have had expression with the mutation so why wouldn't that work on that half and still get a somewhat similar effect? Thanks."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Let me take the first one. I think really, you have to step back and remember. In the fall of last year, with this Phase II data that we've had, post the data in the 508 homozygous patients and the patients that Jeff Leiden referred to with the 551D 508 p",172,"Let me take the first one. I think really, you have to step back and remember. In the fall of last year, with this Phase II data that we've had, post the data in the 508 homozygous patients and the patients that Jeff Leiden referred to with the 551D 508 patients, we already had 4 week data from those patients. So we had a fair amount of information. What then the 12-week study really contributed is really the primary objective, which was safety. It's a small study, 40 patients, only 20 on active and in fact, they're actually divided across a couple of doses. So that gave us the information at the interim to accelerate because we knew from the GSE review and our review that there was nothing there on that safety that fundamentally changed our profile. So that's really how we look at it and it was really the preponderance of data that we had at the 100-milligram dose that gave us that confidence using the opportunity to move faster."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Got it, okay.",3,"Got it, okay."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then on your other question, which is a good one. Can we just extrapolate from the G551D, 508 heterozygous to heterozygous mint. I really think the answer is no. We don't know lots of things about those heterozygous patients who are G551D for instance",116,"And then on your other question, which is a good one. Can we just extrapolate from the G551D, 508 heterozygous to heterozygous mint. I really think the answer is no. We don't know lots of things about those heterozygous patients who are G551D for instance, we don't know the effect of 661 on that G551D protein as well. So there could be a beneficial foaming effect on the G551D protein getting more protein to the surface and contributing for the 4.5% or 4.6% increase we saw when we added 661. So we don't, and I really wouldn't extrapolate from that G551D/508 data to 508 had been patient and that's why we think it's particularly high risk."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, in other words, it could be helping the 551 alleles, I think?",13,"Yes, in other words, it could be helping the 551 alleles, I think?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Correct.",1,"Correct."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to follow up on the last question. Jeff, you commented on the 661 Phase II b data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of an",167,"Just to follow up on the last question. Jeff, you commented on the 661 Phase II b data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of anything? Should we be thinking about this compound as being advantageous relative to 809 because of the drug like properties and lack of interactions, or is it actually something to look at on the efficacy side as potentially better? And then shifting gears, second question would be on these ATR inhibitor program in cancer, nice to see that. Coming forward. It looks like the approach here increases sensitivity to chemotherapy, if I find understand it correctly. So the question would be, do you need chemo combos for this to work? Or could the approach also work with other targeted agents or immunotherapies minus want to get a sense where we're going with that program? Thanks."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had and that was really the totality of the data from those multiple coh",81,"So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had and that was really the totality of the data from those multiple cohorts across the different populations that we've been referring to and then getting that information at an interim basis on primarily safety. That is really what contributed to our decision-making."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I can take the second part of this question. And Matt, I actually like the way you said that. I think we should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And that is it's best att",208,"Yes, I can take the second part of this question. And Matt, I actually like the way you said that. I think we should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And that is it's best attribute them if you will. No we're going to find more about what it does in some of these operations from the Phase III, certainly not from the 12 week studies, of course, there were no, for example, and no 551 Ds in that 12-week study. But Number one is it really has pharmaceutical properties that may allow us combination regimens, including the 3 drug regimens, which is going to be so important, I think, and in the. With respect to the ATR, yes might you recommend this as a DNA repair pathway as you know. And so the hypothesis here is that by simultaneously disrupting a DNA repair pathway while you're also providing DNA damage to the cell in the form of either cytotoxic chemo agent or radiation, you're going to potentiate the origination of the cytotoxic chemo agent. And then that will be the real basis of which we look at the drug rather than by looking at it by itself."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out as it is caused by the end of t",136,"I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out as it is caused by the end of the year or should we all be expecting to all come next year? And then we sort of seem to be dancing around this Phase II b efficacy result, but when that time from? And then lastly, related to that, Jeff, could you comment on the pharmaceutical companies of what you're seeing in the next GEN corrector? Do you have an optimist there or is it you're just sort of really establishing proof that you can target the particular pathway that you're going after?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, I'll take the first question in terms of the timing of results from the broad based Phase III program and then also the 12-week study, VX-661 it's currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we antic",169,"Jeff, I'll take the first question in terms of the timing of results from the broad based Phase III program and then also the 12-week study, VX-661 it's currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we anticipate towards the end of the first quarter,we'll  provide you top line data from that study. I'll just reiterate that as Jeff has mentioned, that it is a small study, our primary endpoint to safety and a lot of the data that we've got at around 661 already has provided us with the green light to head into this broad-based 3 program. And I'll also add that, that data was discussed with the regulatory authorities to allow us to proceed into that Phase III program. As far as the timing of the results from the Phase III program, we'd anticipate 2016. We'll provide you with a more clear update once we get an understanding of the rate of recruitment to the studies but we don't anticipate results within 2015."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. Then the second corrector?",5,"Great. Then the second corrector?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Really, I think that as we talked about, we're really focused on those markets both driving the efficacy but also having the pharmaceutic properties that are to allow it to be used in a 3 drug regimen, that's really our goal. And we do have, as we talked",81,"Really, I think that as we talked about, we're really focused on those markets both driving the efficacy but also having the pharmaceutic properties that are to allow it to be used in a 3 drug regimen, that's really our goal. And we do have, as we talked about, multiple compounds in the dark. Exactly what those properties are going to be, it's really, too early, already, we tested them in the clinic, I think it's really too early to say."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum from Evercore ISI."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous men appellation where you're planning to enroll 270 patients. If memory serves, that's about half th",188,"I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous men appellation where you're planning to enroll 270 patients. If memory serves, that's about half the size of the TRAFFIC -- each of the TRAFFIC and TRANSPORT trials, which were adequately powered trials in and of themselves. So presumably, the power 270 patients to the effect in that benefit is substantially less than it was in TRAFFIC and TRANSPORT. If I were a company designing a trial and choosing that, I would interpret that as having great confidence. I'm going to see a big benefit. Why am I correct or incorrect in that line of logic, so to speak? And then finally, just a follow-up on the Phase II b coming out for the 661 KALYDECO combination. Is there any reason biologically or study design-wise and the length is different to assume or postulate that the data of the FEB data would be significantly different from the roughly 4.8% improvement in that flu we saw in the prior experience? Thank you."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. In terms of the ongoing Phase II study with, we really just can't comment, that is an interim analysis and we are in the same are going to really have the results at the end of the first going. In terms of your question around compa",172,"It's Jeff Chodakewitz. In terms of the ongoing Phase II study with, we really just can't comment, that is an interim analysis and we are in the same are going to really have the results at the end of the first going. In terms of your question around comparing the 661 study versus TRAFFIC and TRANSPORT, I do think there are couple of very important considerations that differ between them. One is that in the TRAFFIC and TRANSPORT, we had 2 doses in that study which obviously complicates the sizing of the studies and that's a very big difference and we were very pleased to be able to focus on one dose as we move 661 into phase III. The other piece of that is that another consideration, an important consideration in the TRAFFIC and TRANSPORT studies was around secondary endpoints and being able to detect secondary endpoints. The 661 study in the headwind population is really focused and powered around FEV1. So that explains the differences that you are noting."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And why was it not in the secondaries and then I'll drop back in the queue.",17,"And why was it not in the secondaries and then I'll drop back in the queue."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for those secondary endpoints and we think that's really going to be able to anchor our program, so that's how we constructed the pro",49,"So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for those secondary endpoints and we think that's really going to be able to anchor our program, so that's how we constructed the program overall."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",13,"Our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is sitting in for Robin, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neurospace. Could you please help us understand your strategy with these assets? Do you expected double of these indications in-h",73,"This is sitting in for Robin, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neurospace. Could you please help us understand your strategy with these assets? Do you expected double of these indications in-house or do you I think partnership are also licensing is the way to go? I guess my ideal question is you see these assets as noncore assets or your core assets?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I think, this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicine or disease, very serious diseases with large unmet need and scientific opportunity. And so",134,"Yes, thanks for the question. I think, this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicine or disease, very serious diseases with large unmet need and scientific opportunity. And so if you look across our pipeline, whether it's in neurology or whether it's in oncology, each of the programs fulfills those criteria in different sorts of ways. So these are our strategic assets. In terms of plans for how to commercialize them, obviously, we'll be able to make detailed decisions once we begin to see clinical data from Phase II and Phase III studies. But we're very confident in that these kinds of assets, these transformational assets are high-value assets for the company and they do fit with our Corporate Strategy."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And, I would just add that we face these questions a lot when we engage with our investors and analysts. And it appears as there's always a category that we want to fit these assets and including maybe some of our neurology assets as well. And the categor",175,"And, I would just add that we face these questions a lot when we engage with our investors and analysts. And it appears as there's always a category that we want to fit these assets and including maybe some of our neurology assets as well. And the categories tends to be, you're either in the area or you're not in the area. And what I would like to be clear on is we're committing to these studies and we want to find out the results and we want to see where there is a potential for this transformational medicine as Jeff Wyden has explained. But we're in the area until we gather data and that doesn't mean that the company's committed to the oncology space for the next 10, 15 years, but it does mean we are committed to these studies and finding out whether they have potential to create new medicines. And I wish there was a third in there that I could give you but that's -- We're actually in that third category."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ian and I talked about, we're not an oncology company or a neurology company. We're a transformational medicines company and that's what we're trying to do here.",27,"Ian and I talked about, we're not an oncology company or a neurology company. We're a transformational medicines company and that's what we're trying to do here."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Leeza Baker from GMP Securities.",13,"Our next question comes from the line of Leeza Baker from GMP Securities."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to follow up on some discussion earlier. If we see a better treatment effect, a larger treatment effect in the 661 KALYDECO combo study on the homozygotes, by extension, does it make it feel that the heterozygous that is going to have more robust eff",61,"Just to follow up on some discussion earlier. If we see a better treatment effect, a larger treatment effect in the 661 KALYDECO combo study on the homozygotes, by extension, does it make it feel that the heterozygous that is going to have more robust effect that was seen in the lumacaftor/ivacaftor? Is that the right way to think about it?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question. I know what you're trying to get, Lisa, we really read out in the headman study and our impression about its chance of success and the answer is really no. We won't have a single headman patient in this study that they're obv",136,"Yes. Thanks for the question. I know what you're trying to get, Lisa, we really read out in the headman study and our impression about its chance of success and the answer is really no. We won't have a single headman patient in this study that they're obviously the relevant patients. And as I don't think our mind will change in terms of the risk and the speed of these 2 approaches we're going to take, there's no doubt, no matter what we see, that the 2-drug domination is a high risk but more rapid way to get to these patients today don't have any therapy. There's also no doubt in my mind that the trade of competition from everything we've seen him us a much higher probably to aparproach but unfortunately what's going to longer."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Fair enough. And then can we maybe just talk about the presentation of the,, how many possible been sort of what would the packaging be roughly for the lumacaftor/ivacaftor?",30,"Okay. Fair enough. And then can we maybe just talk about the presentation of the,, how many possible been sort of what would the packaging be roughly for the lumacaftor/ivacaftor?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Lisa, so the presentation is fix those combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablets then as well. So it'",49,"Yes, Lisa, so the presentation is fix those combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablets then as well. So it's a completely coformulated, coformulated product."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare our characterize how we should think of it compared to what they saw for the G551D population? Thank you.",39,"And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare our characterize how we should think of it compared to what they saw for the G551D population? Thank you."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, great question, Lisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high fo",305,"Yes, great question, Lisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high for the lumacaftor/ivacaftor combination, based on the things that you already know. It's an incredibly serious disease. The F5 08 dell mutation is a serious form of the disease and there aren't any other treatment options currently available to treat the underlying course of the disease. So everything we know about the profile of lumacaftor and ivacaftor and the reaction it has had from patients and providers since the Phase III data became available is very positive. So we're expecting the peak uptake to be very significant. In terms of the rate of uptake, I'm anticipating it's going to be lower than with G551D and really, that's just driven by the sheer volume of patients. You have to think about here, in the U.S. there's about 1,000 G551D patients that's treated at about 250 to 275 CF centers, that's on average, 3 or 4 patients per center. You think about the F5 08 Dell homozygotes population 12 and above, it's about an 8, 500 patients, so nearly in order of magnitude, greater, that's more like 30 patients per CF center on average. And so just the sheer volume of patients in the effort that goes into initiating a new patient on the therapy, the education, the counseling, navigating the reimbursement process, is going to take a significant amount of time and just the sheer volume of patients, I think, is going to lead to the absolute rate of uptake to be somewhat lower than we saw with G551D which you know well know was virtually vertical."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang from Bank of America millage.",15,"Our next question comes from the line of Ying Huang from Bank of America millage."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the. What would be the hurdle for you to continue to enroll it in the either 150 patients? And then, I think you've made a comment before that maybe",82,"So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the. What would be the hurdle for you to continue to enroll it in the either 150 patients? And then, I think you've made a comment before that maybe, should we assume that the 12-week trial for that cohort in Phase III would not be allowing us to capture any density and weight gain on excess emission reduction is that right assumption? Thank you."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff. So let's talk about the futility analysis which I think really reflects what we're talking about in terms of the low probability for the population with the combination. We don't have an exact final rules that we're going to use in the study",325,"So it's Jeff. So let's talk about the futility analysis which I think really reflects what we're talking about in terms of the low probability for the population with the combination. We don't have an exact final rules that we're going to use in the study, so we can give you specifics. But let me take a moment and walk you through how it was going to work to put it in perspective. As you noted that we are going to roll about 120 patients in the initial cohort, were going to then pause enrollment and clinical data from those patients will be collected and be reviewed by the DMC. We won't actually here at Vertex be seeing that data will be conducted independently by the DFC. And the goal of that is actually too assisted probability whether we can actually know from that amount of data that it is low probability, that it's unlikely that, that combination is going to be beneficial for the patients. If that's the case, the SMB will tell us and we'll stop the study. If they see something that we cannot conclude that, then we will restart enrollment and complete the study. And that's really the way it's going to roll out. I would also note that even if the study continues, we don't know for sure and we really won't know that the study is going to be positive until we get to the end. It's just that at that interim point, do we have enough information already to know that it's not working. That's the way the analysis is structured. And then your other question about the pulmonary exacerbation and so forth. We will surely collect that data. We'll look at it. There's a difference between saying that we haven't sized study to fully power for it versus that we will try to look and got all the information that we can out of the study."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That is a very helpful , Jeff. Can I add just one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or at the interim?",30,"That is a very helpful , Jeff. Can I add just one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or at the interim?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we haven't gotten into those details but again, it's going to be -- and of course, going to dependent on the rate of enrollment as well. When we get to that 120, we have to get patients through some of that -- get, collect the data, and allow time for",58,"So we haven't gotten into those details but again, it's going to be -- and of course, going to dependent on the rate of enrollment as well. When we get to that 120, we have to get patients through some of that -- get, collect the data, and allow time for the DMC's to do the analysis."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And, it gives me the opportunity to do a disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis we will just continue to expand our study and recruit more patients and so t",98,"And, it gives me the opportunity to do a disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis we will just continue to expand our study and recruit more patients and so that we will not be making that announcement. The only announcement that you would hear around this futility assessment as if it was negative and we had said this and we decided to curtail the study. And so before the question comes, that's our plan of disclosure around this as well."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Brian Abrahams from Wells Fargo Securities.",13,"Our next question comes from line of Brian Abrahams from Wells Fargo Securities."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A Commercial question on ivacaftor/lumacaftor. it seems that there's a large number of F5 08 Dell homozygous patients under age 12 and I'm just curious if you've gotten a sense to weather clinicians might treat any of these patients ages 6 to 11 at launch",84,"A Commercial question on ivacaftor/lumacaftor. it seems that there's a large number of F5 08 Dell homozygous patients under age 12 and I'm just curious if you've gotten a sense to weather clinicians might treat any of these patients ages 6 to 11 at launch and whether the drug might be or the combo might be reimbursed? When might you have the results of that upcoming phase III in patients age 6 to 11 to potentially extend the label into this younger population."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population postapproval, that's really very much a decision for the physician and the patient. But you raise",164,"I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population postapproval, that's really very much a decision for the physician and the patient. But you raised one of the important limitations there, which is likely to be whether it would be reimbursed. Given that the specialty products like CF products are managed with pretty rigorous authorizations to the label, my anticipation would be that it would be relatively few patients, if any, who are likely to get able to access to the product until we've got an FDA approval for that here in the U.S it's not to say that certain patients and their physicians may seek to appeal that with their payer, I'm sure that will happen, but I think it's likely to be a very, very small number who actually would like to get reimbursement after the launch later this year."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","and then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is to predict when the studies will be completed and be able to be filed. I will note that there is a little bit of a difference a",109,"and then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is to predict when the studies will be completed and be able to be filed. I will note that there is a little bit of a difference as you probably remember between the U.S. and Europe and that there's a smaller study that's focused primarily on pharmacokinetics and safety to support filing and ultimately approval in the U.S. while Europe has historically required larger studies with independent efficacy data. So just to set the stage, that the timing in the 2 areas will likely differ."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Cory Kasimov from JPMorgan.",11,"Our next question comes from line of Cory Kasimov from JPMorgan."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Most of my questions were asked already but I have 2 quick questions for you. First of all, with the launch of the 809 KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in h",91,"Most of my questions were asked already but I have 2 quick questions for you. First of all, with the launch of the 809 KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in homozygous patients, if any? And do you open up more sites in Europe to avoid the disruption given the different timelines there? And then secondly, I'm also curious how much of an impact FX has on your 2015 KALYDECO guidance? Thanks."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","HI, so it's Jeff. I'll take the first one. One of the benefits to actually being able to accelerate the start of the 661 program, particularly the homozygote study, is that we do plan to enroll patients in the U.S. but we think now, by starting this comin",94,"HI, so it's Jeff. I'll take the first one. One of the benefits to actually being able to accelerate the start of the 661 program, particularly the homozygote study, is that we do plan to enroll patients in the U.S. but we think now, by starting this coming month, we're going to be able to get enrollment completed and actually hopefully have patients well into the study. So we don't -- we think that that's really very consistent and we can't manage those issues and so we don't see it as a big risk."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning in January. We looked at spot rate at that point. We then looked to see what the ex U.S. revenues that were potentially at ri",119,"And to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning in January. We looked at spot rate at that point. We then looked to see what the ex U.S. revenues that were potentially at risk to currency fluctuations. We don't see a big impact to our revenue line, we have a hedge program for X U.S. revenues, both a hedge against those revenues but also the natural hedge for our investments in the different countries as well. So we dont see a big impact to the revenue line because of our hedging program. We also compared it to spot at the beginning of the year."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Howard Liang from the.",13,"And our next question comes from the line of Howard Liang from the."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple of questions on the expense. So thanks for the color. Given the development costs, I think with $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?",44,"A couple of questions on the expense. So thanks for the color. Given the development costs, I think with $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?"
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question, Harward. It helps me to talk more broadly about, let's say the direction of our operating or expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth. Bu",394,"Thanks for the question, Harward. It helps me to talk more broadly about, let's say the direction of our operating or expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth. But as we look at the operating expense line moving from 2014 into 2015, but then onwards, we see this increase from '14 into '15 as I described in my remarks earlier today. And that's because we are doing practically 2 Phase III studies through along, a lot of 2015. But then also, we're supporting the launch of ivacaftor and lumacaftor to treat many more patients. And those are driving the increase between 2014 and '15. However, as we look at '15 into '16 and '17, we see relatively little additional costs and the reason for that is because the company is now tried to move into a steady-state and when you look at all different aspects of the company that drive the resulting operating expense, we start becoming a study state in that we are committed to our levels of research, we like what we've got going on in our research, we like the productivity and production of the molecules that come from our research investment. Our development pipeline or our clinical pipeline is Phase I assets go to phase III assets and we expect that to continue to roll so as a Phase III program comes to an end, we hope that a Phase II program ends with a Phase III. So it rolls. And then as far as the SG&A is concerned, while our infrastructure already exists for the company to scale it and then as Stuart mentioned, with the launch of the ivacaftor lumacaftor, we are building up commercial infrastructure globally. But that starts to hit steady-states as well to serve the patients that we think we will treat in the future. So it helps to understand why we'd look into 2016 and '17 and talk about controlling the operating expense once we make this increased investment from 2014 into 2015. For that reason, bringing it backwards at a growth of the revenue line, we do believe that in future years and the successful launch of ivacaftor lumacaftor, that we do actually turn to profitability and growth in earnings and cash flow. And we look for the high operating margins."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you very much, that would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening.",37,"Thank you very much, that would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening."
36235,281186192,750425,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn",55,"Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Vice President of Investor Relations, Mr. Michael Partridge. Sir, you may begin."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join",281,"Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for Q&A.
Our agenda tonight is as follows: Jeff will begin by reviewing Vertex's strategic priorities for 2015. Stuart will review the full year 2014 performance of KALYDECO, provide commentary on the outlook for KALYDECO in 2015 and will also discuss preparations for the launch of the lumacaftor, ivacaftor combination. To close, Ian will review the full year 2014 financial results and discuss our 2015 financial guidance. We will then open the call for your questions. We expect today's call to run for no more than 45 minutes.
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K and 10-Q, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of the lumacaftor, ivacaftor combination and those about Vertex's other cystic fibrosis programs are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our fourth quarter 2014 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past",441,"Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past year in establishing a foundation for sustainable growth. First, we expanded the number of patients treated with KALYDECO through geographic and label expansion efforts. Second, we announced positive data from our Phase III studies of lumacaftor, ivacaftor and submitted an NDA in the U.S. and MAA in the EU, paving the way to treat significantly more people with CF.
Third, we continue to manage our financial position, ending the year with approximately $1.4 billion in cash to support the future of our business. These accomplishments have fundamentally changed the outlook for our business and increased our confidence in the company's plans for the future and for people with CF and their families.
I had the opportunity to meet with many of our investors and analysts at the JPMorgan Healthcare Conference earlier this month and to talk about our strategy. So let me remind everyone about our priorities for 2015. First, approval and successful launch of the lumacaftor, ivacaftor combination while continuing to increase KALYDECO revenues, enabling us to treat even more people with CF and to accelerate our revenue growth. Second, significantly advancing our CF pipeline with a focus on next-generation medicines that have the potential to create regimens that may increase the benefit for CF patients. And third, expanding and diversifying our pipeline into other areas as evidenced by multiple programs advancing into the clinic during 2015.
If we are successfully in meeting our goals, we expect to deliver to Vertex and its shareholders, a long-term financial profile that includes significant revenue and earnings growth.
Before turning the call over to Stuart, I wanted to take the opportunity to mention how proud we are at Vertex to be at the forefront of a new approach in developing medicines, broadly referred to as precision medicine. KALYDECO and hopefully soon, the combination of lumacaftor, ivacaftor are benefiting CF patients around the world and demonstrating the potential of this approach in developing medicines. We are pleased that our successes provided part of the basis for new research initiatives, discussed for the first time in the State of the Union address last week, to apply precision medicine approaches across a broad range of diseases. And we look forward to working closely with regulators and other government entities to apply the learnings of precision medicine so that we can help more patients and do it faster. With that, I'll turn it over to Stuart."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also",713,"Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also discuss our progress in preparing for the approval and launch of the lumacaftor, ivacaftor combination. 
KALYDECO has shown rapid growth since it was approved in 2012. Product sales increased 25% in 2014 to $464 million. At the start of 2014, nearly all eligible patients with the G551D mutation in the U.S. and Europe were being treated with KALYDECO. Growth in 2014 was driven by both additional patients initiating therapy in new and existing international markets, and the U.S. approval of KALYDECO for use in 8 additional mutations.
Turning to 2015, there are again multiple potential growth drivers based on achieving reimbursement approvals and further label expansions. In the first half of 2015, we expect rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF who are expected to be eligible for treatment.
In the U.S. KALYDECO  was approved for use in children and adults ages 6 and older with the R117H mutation on December 29 last year. The first patients have already initiated treatment and we expect to see continued uptake in the months ahead.
In the second half of 2015, we expect to see the revenue impact from achieving reimbursement for gating mutations in some European countries. We also anticipate a potential approval in children with CF ages 2 to 5 with the G551D or other gating mutations in the U.S., which would be a growth driver in the second half of 2015. As a result, we expect the number of patients eligible for KALYDECO to increase from 3,100 today to more than 3,700 by the end of this year. Although all eligible patients will not be on treatment by the end of the year and the enrollment of the VX-661 pivotal study in gating patients will have an adverse impact on patients receiving commercial product, we expect another year of significant revenue growth and KALYDECO net sales in the range of $560 million to $580 million in 2015.
Now to the combination of lumacaftor and ivacaftor. We submitted the NDA and MAA in the U.S. and EU, respectively in November 2014 for children and adults with CF ages 12 and older to have 2 copies of the F508del mutation. In the U.S. we received prior to review, with a PDUFA date of July 5, 2015. In the EU, we were granted accelerated assessment and we anticipate EU approval around Q4 of this year if discussions with regulators progress as expected. Following regulatory approval in the EU, individual reimbursement discussions will begin on a country-by-country basis.
I'm pleased to report our launch planning is on track. There are around 8,500 F508del homozygous patients ages 12 years and older in the U.S. who are treated at approximately 275 CF centers. This represents an order of magnitude more patients than we currently treat. A key priority for us ahead of launch in the U.S. is to scale up our patient services team so that we can help providers and patients navigate the reimbursement process and also help with patient education and compliance. We have been adding case managers and we are also working to understand how CF centers plan to manage patient initiations.
We're investing in disease education to help payers estimate the number of eligible patients they may have in their plans, and also from a medical perspective, understand cystic fibrosis as a disease, its impact on patients and caregivers and the systemic effects of CFTR modulation.
Internationally, we are building out the required infrastructure in new and existing European markets to support the lumacaftor, ivacaftor launch. Infrastructure for each new country consists of a small number of medical and commercial staff. 
In summary, geographic and label expansion will continue to drive significant growth in KALYDECO sales and we are well-positioned for long-term revenue growth as the number of people we treat with CF significantly increases with the launch of the lumacaftor, ivacaftor combination later this year. I'll now hand the call over to Ian."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track to long term sustainable revenue and earnings growth. I'll be brief on the 2014 results, and for a more det",819,"Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track to long term sustainable revenue and earnings growth. I'll be brief on the 2014 results, and for a more detailed discussion of these results, please refer to our press release we issued earlier today.
2014 financial performance was marked by the continuing growth in KALYDECO revenues, controlling the level of our operating expenses and completing the year with a strong balance sheet. As we look in 2015 and beyond, we see revenue growth continuing based on treating more patients with KALYDECO and then accelerating this revenue growth with the potential approval and launch of the lumacaftor, ivacaftor combination. As we anticipate this growth in our CF revenues, we also expect to control the level of operating investments into our company. We anticipate that this will enable us to deliver a future financial profile that includes high operating margins and significant earnings growth.
Now to the 2014 results. We generated $536 million in total non-GAAP revenues in 2014, including $464 million in KALYDECO revenues. This was a significant increase over 2013 KALYDECO revenues and we expect this growth to continue. We also recorded $72 million in royalty and collaborative revenues, including $35 million in revenue from the out-license of VX-787 on novel flu medicine to Janssen.
When looking at the main components of our non-GAAP operating expenses, our combined non-GAAP R&D and SG&A expenses were $920 million in 2014, a decrease of $177 million compared to the prior year. This decrease reflects our prioritization towards the CF medicines and continued focus on managing operating expenses.
The non-GAAP loss was $511 million or $2.17 per share compared to prior year loss of $203 million. This increased loss was the result of significantly reduced HCV revenues from 2013 and they are now excluded from our 2014 non-GAAP financials.
With the expectation of increasing CF revenues in 2015 and controlling our operating expenses, we see 2014 as a transition year into revenue growth and future profitability.
Now let's turn to 2015 and our financial guidance for the year, and specifically KALYDECO revenues and the main components of our operating expenses. With the recent regulatory submissions and approvals for reimbursement, KALYDECO is well-positioned for 2015. We expect KALYDECO net revenues to be in the range of $560 million to $580 million as we continue to expand the number of patients we treat. Next, to the lumacaftor, ivacaftor combination. We look forward to this midyear launch to further accelerate our revenue growth. However, the revenues from this launch will be primarily US-based in 2015.
Based on regulatory timelines in the EU and the subsequent reimbursement time lines, we anticipate the first commercial revenues from x U.S. territories will likely occur in 2016. Now to the main components of our operating expenses. As previously announced, we expect combined non-GAAP R&D and SG&A expense will be in the range of $1.05 billion to $1.1 billion for the full year, and we expect these expenses to be fairly consistent each quarter of this year. We expect the non-GAAP R&D expense to be in the range of $770 million to $800 million, an increase of $75 million to $105 million compared to the prior year.
Now breaking down the R&D spend into its principal components. We expect to spend approximately $200 million investing in R or basic research to support the creation of future transformational medicines and specifically in CF. We expect to progress a next-generation corrector into the clinic later this year. This is very similar to basic research spending in prior years.
Now to the D or development spend, which we expect to be between $570 million and $600 million and this is primarily driven by CF clinical programs. More specifically, the Phase III pivotal program with VX-661 in combination with ivacaftor and the ongoing investment in lumacaftor, ivacaftor combination to patients who remain on long-term extension study. Other areas of focus for Vertex in research and early development are programs in oncology and neurology, an expectation that certain programs will enter and advance in the clinic in 2015 is incorporated into our guidance.
Turning now to 2015 SG&A guidance. We expect to spend $280 million to $300 million, which is an increase of $55 million to $75 million compared to 2014. The increase reflects cross-functional investment in supporting ivacaftor, lumacaftor combination launch and establishing a larger international presence as we significantly increase the number of patients we expect to treat with our medicines.
I'll close by stating that we are in a strong financial position today and focused on delivering a financial profile consistent with our large cap biotech peers, and we look forward to updating you on the execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays.",13,"[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III, what -- and looking at the opportunity in heterozygous patients, what population, I guess, would you estimate,",71,"Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III, what -- and looking at the opportunity in heterozygous patients, what population, I guess, would you estimate, would be eligible for perhaps 661-plus KALYDECO? And from your basic research, what would -- what population may need a second corrector? And then I have one follow-up."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 bucket. You remember that last year, we published a Phase II study on adding 661 to KALYDECO in patients wh",441,"Geoff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 bucket. You remember that last year, we published a Phase II study on adding 661 to KALYDECO in patients who had a 508 allele mutation on 1 allele and some sort of gating mutation, in that case G551D on the other allele. And we're able to show, if you remember, that once -- those patients, once they were stable on KALYDECO, if we added 661, we saw greater than a 4.5% improvement in absolute FEV1. And so the first part of the heterozygotes strategy that we're going to test in the Phase III program is basically a pivotal program around that population where we're trying to maximize the benefit that we can bring by adding 661 to KALYDECO in patients who are heterozygotes for 508 and the gating allele. And so if you think about that population, it's about 80% of all gating patients who have 508 on the other allele. The other population is what we call the heterozygous men population, not a very good term, I admit. But its patients who have 508 on one allele and basically a non-KALYDECO responsive mutation on the other allele. It's about 17,000 patients worldwide. As we've said, this is the hardest to treat population because those patients express half of the amount of the Delta F508 protein than a Delta F508 homozygote expresses, so they need better correction. 
We know, for example, that 809-plus KALYDECO doesn't work in that population. We looked at that in our TRAFFIC and TRANSPORT trials, you'll remember. So we're taking a two-pronged approach with these patients. Because today, they don't have any CFTR correction therapy, we're going to take an admittedly high-risk, but more rapid approach and try them with 661 plus KALYDECO, the 2-drug combination as part of our pivotal program and we'll start the program, as we said, in the first half of this year. The idea there is if we can see an effect, then we'll be able to get the medicines to patients much more quickly. But the high probability approach we were taking is the 3-drug combination, and that's where we take 661 KALYDECO and the next-generation corrector, our cell based data suggest that, that will work in this population with a higher probability but, of course, that's slower because our next-generation correctors are in lead optimization now and our goal is to put the first to those and perhaps multiple in the clinic this year. And so that's the high probability but longer-term approach."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess that was more of my question of, if you get the next gen corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs and proof-of-concept studies and get an answer pretty quickly.",47,"I guess that was more of my question of, if you get the next gen corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs and proof-of-concept studies and get an answer pretty quickly."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, we'll be able to look at 2 unapproved drugs but getting an answer pretty quickly, I want to be clear about, we'll have to take this first generation correctors into the clinic by themselves first, of course, do a Phase I study in normals, then we'll",83,"Well, we'll be able to look at 2 unapproved drugs but getting an answer pretty quickly, I want to be clear about, we'll have to take this first generation correctors into the clinic by themselves first, of course, do a Phase I study in normals, then we'll be able to begin to explore combinations. So if compared to the 661 KALYDECO trial, which we're going to start in the first half of this year and quickly enroll, it is a significantly longer approach."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe one follow-up on Geoff's question and a second one. So first, just from a strategic standpoint, I was just wondering the benefit of developing 661 plus KALYDECO in the patients that already benefit from KALYDECO, is it higher barriers to entry? Is i",75,"Maybe one follow-up on Geoff's question and a second one. So first, just from a strategic standpoint, I was just wondering the benefit of developing 661 plus KALYDECO in the patients that already benefit from KALYDECO, is it higher barriers to entry? Is it greater revenue per patient? Just maybe help frame for us the strategic thinking there. And then would love your latest thoughts on partnerships and/or BD within and outside of CF."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden and I'll take the first part and then Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can to those patients and that's our #1 priority. And as you know, since we talked about t",107,"This is Jeff Leiden and I'll take the first part and then Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can to those patients and that's our #1 priority. And as you know, since we talked about this last, we were very pleasantly surprised, actually, by the Phase II data that showed this significant improvement over and above KALYDECO when we added 661 to those G551D 508 patients, and that was one of the things that really pushed us to go quickly into a pivotal program so we could get those patients maximum benefit."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. Three main areas: one, being to understand the landscape of other CF technologies and medicines that may combine",192,"And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. Three main areas: one, being to understand the landscape of other CF technologies and medicines that may combine with what we're doing here at Vertex to enhance benefits from regimens. Second area of focus has been to consider other technological or research-based approaches to creating medicines. I mean, Vertex has been very successful over the years with small molecule development and tox [ph] -- certain molecule targets, but there are other things that are going on out there right now that we need to get involved in. So we're considering expanding our scientific footprint as well. And then the third area of focus has been, can we diversify our pipeline? And by that it's both out-licensing non-core assets, which we've been successful with. While also considering bringing on other opportunities into our pipeline that fit with Vertex's future. I hope to update you as we go to 2015 in terms of where we've been spending our efforts and as I would outline, cystic fibrosis is our #1 priority."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick topics. One is on the Phase II VX-661 study that you're finishing and then you moved into a Phase III, both homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID",166,"Two quick topics. One is on the Phase II VX-661 study that you're finishing and then you moved into a Phase III, both homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID dose? And I guess, how could you do all that and take all that if you haven't even seen the full Phase IIb data? And then my second question as it relates to the overall heterozygous population that we've been discussing the last couple of questions, I guess you talked a little bit about why it was high-risk at the heterozygous population, but we did see in the population, where you did have 551 to 508, it was additive by 4.6%, even with only half the protein expressions. So being in the heterozygous headwinds, you have half the protein expression with the mutation, so why wouldn't that work on that half and still get a somewhat similar effect? Thanks."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So let me take the first one. I think that really, you have to step back and remember that in the fall of last year, with the Phase II data that we've had, post the data in the 508 homozygous patients and the patients that Jeff Leid",183,"It's Jeff Chodakewitz. So let me take the first one. I think that really, you have to step back and remember that in the fall of last year, with the Phase II data that we've had, post the data in the 508 homozygous patients and the patients that Jeff Leiden referred to with the 551D 508 patients, we already had 4 week data from those patients. So we had a fair amount of information. What then the 12-week study really contributed is really the -- it's primary objective, which was safety. It's a small study, 40 patients, only 20 on active and in fact, they're actually divided across a couple of different doses. So that gave us the information at the interim to accelerate because we knew from the DSMB review and our review that nothing -- there was nothing there on safety that fundamentally changed our profile. So that's really how we look at it, and it was really the preponderance of data that we had at the 100-milligram dose that gave us that confidence using the opportunity to move faster."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and then on your other question, which is a good one. Can we just extrapolate from the G551D 508 heterozygous to heterozygous men. I really think the answer is no. We don't know lots of things about those heterozygous patients who have G551D for inst",120,"Yes, and then on your other question, which is a good one. Can we just extrapolate from the G551D 508 heterozygous to heterozygous men. I really think the answer is no. We don't know lots of things about those heterozygous patients who have G551D for instance, we don't know the effect of 661 on that G551D protein as well. And so there could be a beneficial folding effect on the G551D protein, getting more protein to the surface and contributing to the 4.5% or 4.6% increase we saw when we added 661. So I -- we don't, and I really wouldn't extrapolate from that G551D 508 data to 508 had been patient, and that's why we think it's particularly high-risk."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, in other words, it's helping the -- it could be helping the 551 alleles as well, I think.",19,"Yes, in other words, it's helping the -- it could be helping the 551 alleles as well, I think."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Correct.",1,"Correct."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to follow up on the last question. Jeff, you commented on the 661 Phase IIb data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of any",165,"Just to follow up on the last question. Jeff, you commented on the 661 Phase IIb data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of anything? Should we be thinking about this compound as being advantageous relative to 809 because of the drug like properties and lack of interactions? Or is it actually something to look at on the efficacy side as potentially better? And then shifting gears, second question would be on these ATR inhibitor program in cancer, nice to see that coming forward. It looks like the approach here increase the sensitivity to chemotherapy, if I understand it correctly. So the question would be, do you need chemo combos for this to work? Or could the approach also work with other targeted agents or immunotherapies? Just trying to get a sense where we're going with that program?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had, and it was really the totality of the data from those multiple coho",81,"So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had, and it was really the totality of the data from those multiple cohorts across the different populations that we've been referring to and then getting that information at an interim basis on primarily safety. That is really what contributed to our decision-making."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I can take the second part. This is Jeff Leiden, and Matt, I think it's -- I actually like the way you said it. I think you should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And th",212,"Yes, I can take the second part. This is Jeff Leiden, and Matt, I think it's -- I actually like the way you said it. I think you should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And that's it's best attribute if you will. Now we're going to find more about what it does in some of these populations from the Phase III, certainly not from the 12-week study, because of course, there were no head mens [ph], for example, and no 551 Ds in that 12-week study. But number one is it really has pharmaceutical properties that allow us make combination regimens, including the 3-drug regimen, which is going to be so important, I think, in the head men [ph]. With respect to the ATR, yes, you're right. This is a DNA repair pathway as you know, and so the hypothesis here is that by simultaneously disrupting a DNA repair pathway while you're also providing DNA damage to the cell in the form of either cytotoxic chemo agent or radiation, you're going to potentiate the radiation of the cytotoxic chemo agent. And that will be the real basis on which we look at the drug rather than looking at it by itself."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out that you would disclose by the",136,"I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out that you would disclose by the end of the year? Or should we be expecting them to all come next year? And then we sort of seem to be dancing around this Phase IIb efficacy result, but when might that come? And then lastly, related to that, Jeff, could you comment on the pharmaceutical properties of what you're seeing in the next gen corrector? Do you have an optimized path [ph] right there? Or you're just sort of really establishing proof that you can target the particular pathway that you're going after?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll take the first question in terms of timing of results from the broad Phase III program and then also the 12-week study, VX-661 it's not currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we anticipate toward",168,"I'll take the first question in terms of timing of results from the broad Phase III program and then also the 12-week study, VX-661 it's not currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we anticipate towards the end of the first quarter,we'll  provide you top line data from that study. I'll just reiterate that as Jeff has mentioned, that it is a small study, our primary endpoint to safety and a lot of the data that we've gathered around 661 already has provided us with the green light to head into this broad Phase III program. And I'll also add that, that data was discussed with the regulatory authorities to allow us to proceed into that Phase III program. As far as the timing of the results from the Phase III program, we'd anticipate 2016. We'll provide you with a more clear update once we get an understanding of the rate of recruitment to the studies but we don't anticipate results within 2015."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. Then the second corrector.",5,"Great. Then the second corrector."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think that -- really, I think as we talked about, we're really focused on those markets, both driving the efficacy but also having the pharmaceutic properties that are going to allow it to be used in a 3-drug regimen, that's really our goal. And we d",88,"So I think that -- really, I think as we talked about, we're really focused on those markets, both driving the efficacy but also having the pharmaceutic properties that are going to allow it to be used in a 3-drug regimen, that's really our goal. And we do have, as we've talked about, multiple compounds in lead op [ph]. Exactly what those properties are going to be, it's really, to you actually, already, and we tested them in the clinic, I think it's really too early to say."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum from Evercore ISI."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous men population where you're planning to enroll 270 patients. If memory serves, that's only about hal",187,"I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous men population where you're planning to enroll 270 patients. If memory serves, that's only about half the size of the TRAFFIC and -- each of the TRAFFIC and TRANSPORT trials, which were adequately powered trials in and of themselves. So presumably, the power of 270 patients to the effect in FEV benefit is substantially less than it was in TRAFFIC and TRANSPORT. If I were a company designing a trial and choosing that, I would interpret that as having great confidence. I'm going to see a big benefit. Why am I correct or incorrect in that line of logic, so to speak? And then finally, just a follow-up on the Phase IIb coming out for the 661 KALYDECO combination. Is there any reason biologically or study design-wise and the length is different to assume or postulate that the data, the FEV data would be significantly different from the roughly 4.8% improvement and that's what we saw in the prior experience?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So again, in terms of the ongoing Phase II study with 12 weeks, we really just can't comment, that is an interim analysis and we are, as Ian just said, we're going to really have the results at the end of the first quarter. In terms",182,"It's Jeff Chodakewitz. So again, in terms of the ongoing Phase II study with 12 weeks, we really just can't comment, that is an interim analysis and we are, as Ian just said, we're going to really have the results at the end of the first quarter. In terms of your question around comparing the 661 head men [ph] study versus TRAFFIC and TRANSPORT, I do think there are couple of very important considerations that differ between them. One is that in the TRAFFIC and TRANSPORT, we had 2 doses in that study which obviously complicates the sizing of the studies, and that's a very big difference and we were very pleased to be able to focus on one dose as we move 661 into Phase III. The other piece of that is that another consideration, an important consideration in the TRAFFIC and TRANSPORT studies was around secondary endpoints and being able to detect secondary endpoints. The 661 study in the head men [ph] population is really focused and powered around FEV1. So that explains the differences that you are noting."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And why it was not paired one the secondaries? And then I'll drop back in the queue.",17,"And why it was not paired one the secondaries? And then I'll drop back in the queue."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for that -- for those secondary endpoints and we think that's really going to be able to anchor our program. And so that's how we con",53,"So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for that -- for those secondary endpoints and we think that's really going to be able to anchor our program. And so that's how we constructed the program overall."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",13,"Our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Moheed Bansas [ph] sitting in for Robyn, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neurospace. Could you please help us understand your strategy with these assets? Do you expect to double of th",76,"This is Moheed Bansas [ph] sitting in for Robyn, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neurospace. Could you please help us understand your strategy with these assets? Do you expect to double of these indications in-house? Or you think partnership are also licensing is the way to go? I guess my ideal question is, do you see these assets as non-core assets or your core assets?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I think -- this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicines for disease -- very serious diseases with large unmet need and scientific opportunity. A",135,"Yes, thanks for the question. I think -- this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicines for disease -- very serious diseases with large unmet need and scientific opportunity. And so if you look across our pipeline, whether it's in neurology or whether it's in oncology, each of the programs fulfills those criteria in different sorts of ways. So these are our strategic assets. In terms of plans for how to commercialize them, obviously, we'll be able to make detailed decisions once we begin to see clinical data from Phase II and Phase III studies. But we're very confident that these kinds of assets, these transformational assets are high-value assets for the company and they do fit with our corporate strategy."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I would just add that we face these questions a lot when we engage with investors and analysts. And it appears as there's always a category that we want to fit these assets in including maybe some of our early neurology assets as well. And the categories",173,"I would just add that we face these questions a lot when we engage with investors and analysts. And it appears as there's always a category that we want to fit these assets in including maybe some of our early neurology assets as well. And the categories tends to be, you're either in the area or you're not in the area. And what I would like to be clear on is that we're committing to the studies, and we want to find out the results and we want to see where there is a potential for this transformational medicine as Jeff Leiden has explained. But we're in the area until we gather data and that doesn't mean that the company's committed to the oncology space for the next 10, 15 years, but it does mean we're committed to these studies and finding out whether we have potential to create new medicines. And I wish there was a third [indiscernible] that I could give you but that's -- we're actually in that third category."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ian and I talked about, we're not an oncology company or a neurology company. We're transformational medicines company and that's what we're trying to do here.",26,"Ian and I talked about, we're not an oncology company or a neurology company. We're transformational medicines company and that's what we're trying to do here."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Liisa Bayko from JMP Securities.",13,"Our next question comes from the line of Liisa Bayko from JMP Securities."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to follow up on some discussion earlier. If we see a better treatment effect, a large treatment effect in the 661 KALYDECO combo study on the homozygotes, by extension, does that make us feel like the heterozygote study is going to have more robu",62,"And just to follow up on some discussion earlier. If we see a better treatment effect, a large treatment effect in the 661 KALYDECO combo study on the homozygotes, by extension, does that make us feel like the heterozygote study is going to have more robust effect that was seen with lumacaftor, ivacaftor? Is that the right way to think about it?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question. I know what you're trying to get at here Liisa, in terms of -- will this really read out in the head man [ph] study and our impression about its chance of success, and the answer is really no. We won't have a single head man",148,"Yes. Thanks for the question. I know what you're trying to get at here Liisa, in terms of -- will this really read out in the head man [ph] study and our impression about its chance of success, and the answer is really no. We won't have a single head man patient in this study that they're obviously the relevant patients. And as -- I don't think our mind will change in terms of the risks and the speed of these 2 approaches we're going to take, there's no doubt, no matter what we see, that the 2-drug domination is a high-risk but more rapid way to get to these patients who today don't have any therapy. There's also no doubt in my mind that the 3-drug combination from everything we've seen is a much higher probably to approach, but unfortunately, it's going to take us bit longer."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Fair enough. And then can we maybe just talk about the presentation of the combo? How many [indiscernible] would be? And sort of what would the packaging be roughly for the lumacaftor, ivacaftor combo?",35,"Okay. Fair enough. And then can we maybe just talk about the presentation of the combo? How many [indiscernible] would be? And sort of what would the packaging be roughly for the lumacaftor, ivacaftor combo?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, so the presentation is a fix dose combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablets then as well. So i",49,"Yes, Liisa, so the presentation is a fix dose combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablets then as well. So it's a completely co-formulated product."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare our characterize how we should think of it compared to what we saw for the G551D population?",37,"And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare our characterize how we should think of it compared to what we saw for the G551D population?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, great question, Liisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high f",302,"Yes, great question, Liisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high for the lumacaftor, ivacaftor combination, based on the things that you already know. It's an incredibly serious disease. The F508del mutation is a serious form of the disease and there aren't any other treatment options currently available to treat the underlying course of the disease. And so everything we know about the profile of lumacaftor and ivacaftor and the reaction it has had from patients and providers since the Phase III data became available is very positive. So we're expecting the peak uptake to be very significant. In terms of the rate of uptake, I'm anticipating it's going to be lower than with G551D, and really that's just driven by the sheer volume of patients. You have to think about here in the U.S. there's about 1,000 G551D patients that's treated at about 250 to 275 CF centers, that's on average, 3 or 4 patients per center. You think about the F508del homozygous population 12 and above, it's about 8,500 patients, so nearly in order of magnitude, greater, that's more like 30 patients per CF center on average. And so just the sheer volume of patients and the effort that goes into initiating a new patient on the therapy, the education, the counseling, navigating the reimbursement process, is going to take a significant amount of time and just the sheer volume of patients, I think, is going to lead to the absolute rate of uptake to be somewhat lower than we saw with G551D which you know -- well know was virtually vertical."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the head men cohort? What would be the hurdle for you to continue to enroll the other 150 patients? And then, I think you've made a comment before t",81,"So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the head men cohort? What would be the hurdle for you to continue to enroll the other 150 patients? And then, I think you've made a comment before that maybe, should we assume that the 12-week trial for that cohort in Phase III will not be allowing us to capture any benefit in weight gain or exacerbation reduction, is that right a assumption?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff. So let's talk about the futility analysis, which I think really reflects what we've been talking about in terms of the low probability for the population with the 2-drug combination. We don't have an exact final rule that we're going to use",329,"So it's Jeff. So let's talk about the futility analysis, which I think really reflects what we've been talking about in terms of the low probability for the population with the 2-drug combination. We don't have an exact final rule that we're going to use in the study, so we can't give you specifics. But let me take a moment and walk you through how it's going to work to put it in perspective. As you noted that we are going to roll about 120 patients in the initial cohort, we're going to then pause enrollment and clinical data from those patients will be collected and be reviewed by the DMC. We won't actually, here at Vertex be seeing that data, it will be conducted independently by the DMC. And the goal of that is actually to assess the probability whether we can actually know from that amount of data that it is low probability, that it's unlikely that, that combination is going to be beneficial for the patients. If that's the case, the SMB will tell us and we'll stop the study. If they see something that we cannot conclude that, then we will restart enrollment and complete the study. And that's really the way it's going to roll out. I would also note that the -- even if the study continues, we don't know for sure and we really won't know that the study is going to be positive until we get to the end. It's just that at that interim point, do we have enough information already to know that it's not working. That's the way the analysis is structured. And then your other question about pulmonary exacerbation and so forth. We will surely collect that data. We'll look at it. There's a difference between saying that we haven't sized the study to fully power for versus that we will try to look and get all the information that we can out of the study."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That was very helpful, Jeff. Can I just ask one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or in the interim?",29,"That was very helpful, Jeff. Can I just ask one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or in the interim?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we haven't gotten to those details but again, it's going to be -- and of course, it's going to dependent on the rate of enrollment as well. When we get to that 120, we have to get the patients through some of that, get -- collect the data, and allow ti",60,"So we haven't gotten to those details but again, it's going to be -- and of course, it's going to dependent on the rate of enrollment as well. When we get to that 120, we have to get the patients through some of that, get -- collect the data, and allow time for the DMC's to do the analysis."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It gives me the opportunity to help you understand with disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis if it's positive. You, as well just continue to expand that s",103,"It gives me the opportunity to help you understand with disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis if it's positive. You, as well just continue to expand that study and recruit more patients and so that we will not be making that announcement. The only announcement that you would hear around this futility assessment is if it was negative, and we had said this and we decided to curtail the study. And so before the question comes, that's our plan of disclosure around this as well."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Abrahams from Wells Fargo Securities.",14,"Our next question comes from the line of Brian Abrahams from Wells Fargo Securities."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Commercial question on ivacaftor, lumacaftor. It seems as if there's a large number of F508del homozygous patients under age 12, and I'm just curious if you've gotten a sense as to weather clinicians might treat any of these patients ages 6 to 11 at launc",84,"Commercial question on ivacaftor, lumacaftor. It seems as if there's a large number of F508del homozygous patients under age 12, and I'm just curious if you've gotten a sense as to weather clinicians might treat any of these patients ages 6 to 11 at launch and whether the drug might be or the combo might be reimbursed. And when might you have the results for that upcoming Phase III in patients age 6 to 11 to potentially expand the label into this younger population?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population post-approval, that's really very much a decision for the physician and the patient. But you rais",168,"I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population post-approval, that's really very much a decision for the physician and the patient. But you raised one of the most important limitations there, which is likely to be whether it would be reimbursed. And given that the specialty products, like CF products are managed with a pretty rigorous prior authorizations to the label, my anticipation would be that it would be relatively few patients, if any, who are likely to able to get access to the product until we've got an FDA approval for that here in the U.S. It's not to say that certain patients and their physicians may seek to appeal that with their payer, I'm sure that will happen, but I think it's likely to be a very, very small number who actually would like to get reimbursement after the launch later this year."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is for the -- to predict when the studies would be completed and be able to be filed. I will note that there is a little bit of a",113,"And then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is for the -- to predict when the studies would be completed and be able to be filed. I will note that there is a little bit of a difference as you probably remember between the U.S. and Europe and that -- there's a smaller study that's focused primarily on pharmacokinetics and safety to support filing and ultimately approval in the U.S. while Europe has historically required larger studies with independent efficacy data. So just to set the stage, that the timing in the 2 areas will likely differ."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Cory Kasimov from JPMorgan.",11,"Our next question comes from line of Cory Kasimov from JPMorgan."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Most of my questions were asked already, but I have 2 quick ones for you. So first of all, with the launch of the 809 KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in ho",91,"Most of my questions were asked already, but I have 2 quick ones for you. So first of all, with the launch of the 809 KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in homozygous patients, if any? And do you open up more sites in Europe to avoid the disruption given the different timelines there? And then secondly, I'm also curious how much of an impact FX has on your 2015 KALYDECO guidance?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff, I'll take the first one. One of the benefits of actually being able to accelerate the start of the 661 program, particularly the homozygous study, is that we do plan to enroll patients in the U.S. but we think now, by starting this coming mo",93,"So it's Jeff, I'll take the first one. One of the benefits of actually being able to accelerate the start of the 661 program, particularly the homozygous study, is that we do plan to enroll patients in the U.S. but we think now, by starting this coming month, we're going to be able to get enrollment completed and actually hopefully have patients well into the study. So we don't -- we think that, that's really very consistent and we can manage those issues, so we don't see it as a big risk."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Cory, to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning in January. We looked at spot rate at that point. We then did look to see what the x U.S. revenues that were potentially at",122,"Cory, to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning in January. We looked at spot rate at that point. We then did look to see what the x U.S. revenues that were potentially at risk to currency fluctuations. We don't see a big impact to our revenue line, we have a hedge program for our x U.S. revenues, both a hedge against those revenues but also the natural hedge for our investments in the different countries as well. So we dont see a big impact to the revenue line because of that hedging program. And we also compared it to spot at the beginning of the year."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Howard Liang from Leerink.",13,"And our next question comes from the line of Howard Liang from Leerink."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a question on the expense. Given the development costs, I think it was $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?",40,"I have a question on the expense. Given the development costs, I think it was $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?"
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question, Howard. It helps me to talk more broadly about, let's say the direction of our operating -- our expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth.",404,"Thanks for the question, Howard. It helps me to talk more broadly about, let's say the direction of our operating -- our expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth. But as we look at the operating expense line moving from 2014 into 2015, but then onwards, we see this increase from '14 into '15 as I described in my remarks earlier today. And that's because we are doing practically 2 Phase III studies through a long, a lot of 2015. But then also, we're supporting the launch of ivacaftor and lumacaftor to treat many more patients. And those are driving the increase between 2014 and '15. However, as we look at '15 into '16 and '17, we see relatively little additional costs, and the reason for that is because the company is now starting to move into a steady-state and when you look at all the different aspects of the company that drive the resulting operating expense, we start to become on a steady state in that we're committed to our levels of research, we like what we've got going on in research, we like the productivity and the production of the molecules that come from our research investment. Our development pipeline or our clinical pipeline is staged now, Phase I assets go to Phase III assets and we expect that to continue to roll so as a Phase III program comes to an end, we'd hope that a Phase II program ends to Phase III. So it rolls. And then as far as the SG&A is concerned, while our infrastructure is -- already exists to support the company to scale at this, and as Stuart has mentioned, with the launch of the ivacaftor, lumacaftor, we are building out commercial infrastructure globally. But that starts to hit steady-states as well to serve the patients that we think we will treat in the future. So it helps you understand why we look into 2016 and '17 and talk about controlling of the operating expense once we make this increased investment from 2014 into 2015. For that reason, bringing it backwards at a growth of the revenue line, we do believe that in future years and the successful launch of ivacaftor and lumacaftor, that we do actually turn to profitability and growth in earnings and cash flow. And we look for high operating margins."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you very much. That would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening.",37,"Thank you very much. That would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening."
36235,281186192,750532,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn",55,"Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Vice President of Investor Relations, Mr. Michael Partridge. Sir, you may begin."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join",281,"Thank you, operator and good evening everyone. Joining me on the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for Q&A.
Our agenda tonight is as follows: Jeff will begin by reviewing Vertex's strategic priorities for 2015. Stuart will review the full year 2014 performance of KALYDECO, provide commentary on the outlook for KALYDECO in 2015 and will also discuss preparations for the launch of the lumacaftor, ivacaftor combination. To close, Ian will review the full year 2014 financial results and discuss our 2015 financial guidance. We will then open the call for your questions. We expect today's call to run for no more than 45 minutes.
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K and 10-Q, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of the lumacaftor, ivacaftor combination and those about Vertex's other cystic fibrosis programs are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our fourth quarter 2014 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past",441,"Thanks, Michael, and good evening, everyone. 2014 was a year of continued success in delivering on our vision to be a leader in discovering and developing therapies for cystic fibrosis and other serious diseases. And we made significant progress this past year in establishing a foundation for sustainable growth. First, we expanded the number of patients treated with KALYDECO through geographic and label expansion efforts. Second, we announced positive data from our Phase III studies of lumacaftor, ivacaftor and submitted an NDA in the U.S. and MAA in the EU, paving the way to treat significantly more people with CF.
Third, we continue to manage our financial position, ending the year with approximately $1.4 billion in cash to support the future of our business. These accomplishments have fundamentally changed the outlook for our business and increased our confidence in the company's plans for the future and for people with CF and their families.
I had the opportunity to meet with many of our investors and analysts at the JPMorgan Healthcare Conference earlier this month and to talk about our strategy. So let me remind everyone about our priorities for 2015. First, approval and successful launch of the lumacaftor, ivacaftor combination while continuing to increase KALYDECO revenues, enabling us to treat even more people with CF and to accelerate our revenue growth. Second, significantly advancing our CF pipeline with a focus on next-generation medicines that have the potential to create regimens that may increase the benefit for CF patients. And third, expanding and diversifying our pipeline into other areas as evidenced by multiple programs advancing into the clinic during 2015.
If we are successfully in meeting our goals, we expect to deliver to Vertex and its shareholders, a long-term financial profile that includes significant revenue and earnings growth.
Before turning the call over to Stuart, I wanted to take the opportunity to mention how proud we are at Vertex to be at the forefront of a new approach in developing medicines, broadly referred to as precision medicine. KALYDECO and hopefully soon, the combination of lumacaftor, ivacaftor are benefiting CF patients around the world and demonstrating the potential of this approach in developing medicines. We are pleased that our successes provided part of the basis for new research initiatives, discussed for the first time in the State of the Union address last week, to apply precision medicine approaches across a broad range of diseases. And we look forward to working closely with regulators and other government entities to apply the learnings of precision medicine so that we can help more patients and do it faster. With that, I'll turn it over to Stuart."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also",713,"Thanks, Jeff and hello, everyone. Tonight I'll review the sales performance of KALYDECO in 2014 and outline our expectations for KALYDECO in 2015 that reflect strong underlying demand and the positive impact of label and geographic expansion. I will also discuss our progress in preparing for the approval and launch of the lumacaftor, ivacaftor combination. 
KALYDECO has shown rapid growth since it was approved in 2012. Product sales increased 25% in 2014 to $464 million. At the start of 2014, nearly all eligible patients with the G551D mutation in the U.S. and Europe were being treated with KALYDECO. Growth in 2014 was driven by both additional patients initiating therapy in new and existing international markets, and the U.S. approval of KALYDECO for use in 8 additional mutations.
Turning to 2015, there are again multiple potential growth drivers based on achieving reimbursement approvals and further label expansions. In the first half of 2015, we expect rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF who are expected to be eligible for treatment.
In the U.S. KALYDECO  was approved for use in children and adults ages 6 and older with the R117H mutation on December 29 last year. The first patients have already initiated treatment and we expect to see continued uptake in the months ahead.
In the second half of 2015, we expect to see the revenue impact from achieving reimbursement for gating mutations in some European countries. We also anticipate a potential approval in children with CF ages 2 to 5 with the G551D or other gating mutations in the U.S., which would be a growth driver in the second half of 2015. As a result, we expect the number of patients eligible for KALYDECO to increase from 3,100 today to more than 3,700 by the end of this year. Although all eligible patients will not be on treatment by the end of the year and the enrollment of the VX-661 pivotal study in gating patients will have an adverse impact on patients receiving commercial product, we expect another year of significant revenue growth and KALYDECO net sales in the range of $560 million to $580 million in 2015.
Now to the combination of lumacaftor and ivacaftor. We submitted the NDA and MAA in the U.S. and EU, respectively in November 2014 for children and adults with CF ages 12 and older who have 2 copies of the F508del mutation. In the U.S. we received prior to review, with a PDUFA date of July 5, 2015. In the EU, we were granted accelerated assessment and we anticipate EU approval around Q4 of this year if discussions with regulators progress as expected. Following regulatory approval in the EU, individual reimbursement discussions will begin on a country-by-country basis.
I'm pleased to report our launch planning is on track. There are around 8,500 F508del homozygous patients ages 12 years and older in the U.S. who are treated at approximately 275 CF centers. This represents an order of magnitude more patients than we currently treat. A key priority for us ahead of launch in the U.S. is to scale up our patient services team so that we can help providers and patients navigate the reimbursement process and also help with patient education and compliance. We have been adding case managers and we are also working to understand how CF centers plan to manage patient initiations.
We're investing in disease education to help payers estimate the number of eligible patients they may have in their plans, and also from a medical perspective, understand cystic fibrosis as a disease, its impact on patients and caregivers and the systemic effects of CFTR modulation.
Internationally, we are building out the required infrastructure in new and existing European markets to support the lumacaftor, ivacaftor launch. Infrastructure for each new country consists of a small number of medical and commercial staff. 
In summary, geographic and label expansion will continue to drive significant growth in KALYDECO sales and we are well-positioned for long-term revenue growth as the number of people we treat with CF significantly increases with the launch of the lumacaftor, ivacaftor combination later this year. I'll now hand the call over to Ian."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track to long term sustainable revenue and earnings growth. I'll be brief on the 2014 results, and for a more det",819,"Thanks, Stuart, and good evening to everyone. Tonight I would like to discuss our 2014 results then our 2015 guidance and how that puts us on track to long term sustainable revenue and earnings growth. I'll be brief on the 2014 results, and for a more detailed discussion of these results, please refer to our press release we issued earlier today.
2014 financial performance was marked by the continuing growth in KALYDECO revenues, controlling the level of our operating expenses and completing the year with a strong balance sheet. As we look to 2015 and beyond, we see revenue growth continuing based on treating more patients with KALYDECO and then accelerating this revenue growth with the potential approval and launch of the lumacaftor, ivacaftor combination. As we anticipate this growth in our CF revenues, we also expect to control the level of operating investments into our company. We anticipate that this will enable us to deliver a future financial profile that includes high operating margins and significant earnings growth.
Now to the 2014 results. We generated $536 million in total non-GAAP revenues in 2014, including $464 million in KALYDECO revenues. This was a significant increase over 2013 KALYDECO revenues and we expect this growth to continue. We also recorded $72 million in royalty and collaborative revenues, including $35 million in revenue from the out-license of VX-787, our novel flu medicine to Janssen.
When looking at the main components of our non-GAAP operating expenses, our combined non-GAAP R&D and SG&A expenses were $920 million in 2014, a decrease of $177 million compared to the prior year. This decrease reflects our prioritization towards the CF medicines and continued focus on managing operating expenses.
The non-GAAP loss was $511 million or $2.17 per share compared to prior year loss of $203 million. This increased loss was the result of significantly reduced HCV revenues from 2013 and they are now excluded from our 2014 non-GAAP financials.
With the expectation of increasing CF revenues in 2015 and controlling our operating expenses, we see 2014 as a transition year into revenue growth and future profitability.
Now let's turn to 2015 and our financial guidance for the year, and specifically KALYDECO revenues and the main components of our operating expenses. With the recent regulatory submissions and approvals for reimbursement, KALYDECO is well-positioned for 2015. We expect KALYDECO net revenues to be in the range of $560 million to $580 million as we continue to expand the number of patients we treat. Next, to the lumacaftor, ivacaftor combination. We look forward to this midyear launch to further accelerate our revenue growth. However, the revenues from this launch will be primarily US-based in 2015.
Based on regulatory timelines in the EU and the subsequent reimbursement time lines, we anticipate the first commercial revenues from x U.S. territories will likely occur in 2016. 
Now to the main components of our operating expenses. As previously announced, we expect combined non-GAAP R&D and SG&A expense will be in the range of $1.05 billion to $1.1 billion for the full year, and we expect these expenses to be fairly consistent each quarter of this year. We expect the non-GAAP R&D expense to be in the range of $770 million to $800 million, an increase of $75 million to $105 million compared to the prior year.
Now breaking down the R&D spend into its principal components. We expect to spend approximately $200 million investing in R, or basic research, to support the creation of future transformational medicines and specifically in CF. We expect to progress a next-generation corrector into the clinic later this year. This is very similar to basic research spending in prior years.
Now to the D, or development spend, which we expect to be between $570 million and $600 million and this is primarily driven by CF clinical programs. More specifically, the Phase III pivotal program of VX-661 in combination with ivacaftor and the ongoing investment in lumacaftor, ivacaftor combination to patients who remain on long-term extension study. Other areas of focus for Vertex in research and early development are programs in oncology and neurology, an expectation that certain programs will enter and advance in the clinic in 2015 is incorporated into our guidance.
Turning now to 2015 SG&A guidance. We expect to spend $280 million to $300 million, which is an increase of $55 million to $75 million compared to 2014. The increase reflects cross-functional investment in supporting ivacaftor, lumacaftor combination launch and establishing a larger international presence as we significantly increase the number of patients we expect to treat with our medicines.
I'll close by stating that we are in a strong financial position today and focused on delivering a financial profile consistent with our large cap biotech peers, and we look forward to updating you on the execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays.",13,"[Operator Instructions] Our first question comes from line of Geoff Meacham from Barclays."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III, what -- in looking at the opportunity in heterozygous patients, what population, I guess, would you estimate, w",71,"Obviously, everyone's focused on the upcoming 661 data. And I guess I wanted to get a sense from you guys, when you're planning your Phase III, what -- in looking at the opportunity in heterozygous patients, what population, I guess, would you estimate, would be eligible for perhaps 661-plus KALYDECO? And from your basic research, what would -- what population may need a second corrector? And then I have one follow-up."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 buckets. You remember that last year, we published a Phase II study on adding 661 to KALYDECO in patients w",440,"Geoff, this is Jeff Leiden. Thanks for the question. The way we're thinking about the heterozygotes and in terms of 661 and KALYDECO is really in 2 buckets. You remember that last year, we published a Phase II study on adding 661 to KALYDECO in patients who had a 508 allele mutation on 1 allele and some sort of gating mutation, in that case G551D on the other allele. And we're able to show, if you remember, that once -- those patients, once they were stable on KALYDECO, if we added 661, we saw greater than a 4.5% improvement in absolute FEV1. And so the first part of the heterozygotes strategy that we're going to test in the Phase III program is basically a pivotal program around that population where we're trying to maximize the benefit that we can bring by adding 661 to KALYDECO in patients who are heterozygotes for 508 and the gating allele. And so if you think about that population, it's about 80% of all gating patients who have 508 on the other allele. The other population is what we call the heterozygous min population, not a very good term, I admit. But it's patients who have 508 on one allele and basically a non-KALYDECO responsive mutation on the other allele. It's about 17,000 patients worldwide. As we've said, this is the hardest to treat population because those patients express half of the amount of the Delta F508 protein than a Delta F508 homozygote expresses, so they need better correction. 
We know, for example, that 809-plus KALYDECO doesn't work in that population. We looked at that in our TRAFFIC and TRANSPORT trials, you'll remember. So we're taking a two-pronged approach with these patients. Because today, they don't have any CFTR correction therapy, we're going to take an admittedly high-risk, but more rapid approach and try them with 661 plus KALYDECO, the 2-drug combination as part of our pivotal program. And we'll start the program, as we said, in the first half of this year. The idea there is if we can see an effect, then we'll be able to get the medicines to patients much more quickly. But the high probability approach we were taking is the 3-drug combination, and that's where we take 661, KALYDECO and the next-generation corrector, our cell-based data suggest that, that will work in this population with a higher probability but, of course, that's slower because our next-generation correctors are in lead optimization now and our goal is to put the first to those, and perhaps multiple, in the clinic this year. And so that's the high probability but longer-term approach."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess that was more of my question of, if you get the next gen corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs in proof-of-concept studies and get an answer pretty quickly.",47,"I guess that was more of my question of, if you get the next gen corrector in the clinic, you don't necessarily have to have 661 on the market, you'll be able to look at 2 unapproved drugs in proof-of-concept studies and get an answer pretty quickly."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, we'll be able to look at 2 unapproved drugs, but getting an answer pretty quickly, I want to be clear about, we'll have to take this first generation correctors into the clinic by themselves first, of course, do a Phase I study in normals, then we'l",83,"Well, we'll be able to look at 2 unapproved drugs, but getting an answer pretty quickly, I want to be clear about, we'll have to take this first generation correctors into the clinic by themselves first, of course, do a Phase I study in normals, then we'll be able to begin to explore combinations. So if compared to the 661, KALYDECO trial, which we're going to start in the first half of this year and quickly enroll, it is a significantly longer approach."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe one follow-up on Geoff's question and a second one. So first, just from a strategic standpoint, I was just wondering the benefit of developing 661 plus KALYDECO in the patients that already benefit from KALYDECO, is it higher barriers to entry? Is i",75,"Maybe one follow-up on Geoff's question and a second one. So first, just from a strategic standpoint, I was just wondering the benefit of developing 661 plus KALYDECO in the patients that already benefit from KALYDECO, is it higher barriers to entry? Is it greater revenue per patient? Just maybe help frame for us the strategic thinking there. And then would love your latest thoughts on partnerships and/or BD within and outside of CF."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden and I'll take the first part and then Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can to those patients and that's our #1 priority. And as you know, since we talked about t",107,"This is Jeff Leiden and I'll take the first part and then Ian will take the BD question. The strategic plan here is really simple. It's to bring the best benefit we can to those patients and that's our #1 priority. And as you know, since we talked about this last, we were very pleasantly surprised, actually, by the Phase II data that showed this significant improvement over and above KALYDECO when we added 661 to those G551D 508 patients, and that was one of the things that really pushed us to go quickly into a pivotal program so we could get those patients maximum benefit."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. Three main areas: one, being to understand the landscape of other CF technologies and medicines that may combine",190,"And turning to your second part of your question, in the last year, we've had a fairly active and broad business corporate development focus. Three main areas: one, being to understand the landscape of other CF technologies and medicines that may combine with what we're doing here at Vertex to enhance benefits from regimens. Second area of focus has been to consider other technological or research-based approaches to creating medicines. I mean, Vertex has been very successful over the years with small molecule development and targeting certain molecular targets, but there are other things that are going on out there right now that we need to get involved in. So we're considering expanding our scientific footprint as well. And then the third area of focus has been, can we diversify our pipeline? And by that it's both out-licensing non-core assets, which we've been successful with. While also considering bringing on other opportunities into our pipeline that fit with Vertex's future. I hope to update you as we go to 2015 in terms of where we've been spending our efforts and as I would outline, cystic fibrosis is our #1 priority."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick topics. One is on the Phase IIb 661 study that you're finishing and then you moved into a Phase III, both homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID d",165,"Two quick topics. One is on the Phase IIb 661 study that you're finishing and then you moved into a Phase III, both homozygous and heterozygous. I guess, how did you go about being certain on your 100-milligram QD dose? Why didn't you go with higher BID dose? And I guess, how could you do all that and take all that if you haven't even seen the full Phase IIb data? And then my second question as it relates to the overall heterozygous population that we've been discussing the last couple of questions, I guess you talked a little bit about why it was high-risk at the heterozygous population, but we did see in the population, where you did have 551 508, it was additive by 4.6%, even with only half protein expression. So being in the heterozygous het mins, you have half the protein expression with the mutation, so why wouldn't that work on that half and still get a somewhat similar effect? Thanks."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So let me take the first one. I think that really, you have to step back and remember that in the fall of last year, with the Phase II data that we had, post the data in the 508 homozygous patients and the patients that Jeff Leiden",183,"It's Jeff Chodakewitz. So let me take the first one. I think that really, you have to step back and remember that in the fall of last year, with the Phase II data that we had, post the data in the 508 homozygous patients and the patients that Jeff Leiden referred to with the 551D 508 patients, we already had 4 week data from those patients. So we had a fair amount of information. What then the 12-week study really contributed is really the -- it's primary objective, which was safety. It's a small study, 40 patients, only 20 on active and in fact, they're actually divided across a couple of different doses. So that gave us the information at the interim to accelerate because we knew from the DSMB review and our review that nothing -- there was nothing there on safety that fundamentally changed our profile. So that's really how we look at it, and it was really the preponderance of data that we had at the 100-milligram dose that gave us that confidence using the opportunity to move faster."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and then on your other question, which is a good one. Can we just extrapolate from the G551D 508 heterozygous to heterozygous min. I really think the answer is no. We don't know lots of things about those heterozygous patients who have G551D for inst",120,"Yes, and then on your other question, which is a good one. Can we just extrapolate from the G551D 508 heterozygous to heterozygous min. I really think the answer is no. We don't know lots of things about those heterozygous patients who have G551D for instance, we don't know the effect of 661 on that G551D protein as well. And so there could be a beneficial folding effect on the G551D protein, getting more protein to the surface and contributing to the 4.5% or 4.6% increase we saw when we added 661. So I -- we don't, and I really wouldn't extrapolate from that G551D 508 data to 508 het min patient, and that's why we think it's particularly high-risk."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, in other words, it's helping the -- it could be helping the 551 alleles as well, I think.",19,"Yes, in other words, it's helping the -- it could be helping the 551 alleles as well, I think."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Correct.",1,"Correct."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to follow up on the last question. Jeff, you commented on the 661 Phase IIb data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of any",164,"Just to follow up on the last question. Jeff, you commented on the 661 Phase IIb data that you see in terms of safety and in dosing as a necessary gating factor for moving into Phase III. But what can you tell us about what you saw and the efficacy of anything? Should we be thinking about this compound as being advantageous relative to 809 because of the drug like properties and lack of interactions? Or is it actually something to look at on the efficacy side as potentially better? And then shifting gears, second question would be on these ATR inhibitor program in cancer, nice to see that coming forward. It looks like the approach here increases sensitivity to chemotherapy, if I understand it correctly. So the question would be, do you need chemo combos for this to work? Or could the approach also work with other targeted agents or immunotherapies? Just trying to get a sense where we're going with that program?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had, and it was really the totality of the data from those multiple coho",81,"So Matt, I think in terms of the interim results, they really are just that and there's really just no way to comment on those results. I think I do go back to the prior data that we had, and it was really the totality of the data from those multiple cohorts across the different populations that we've been referring to and then getting that information at an interim basis on primarily safety. That is really what contributed to our decision-making."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I can take the second part. This is Jeff Leiden, and Matt, I think it's -- I actually like the way you said it. I think you should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And th",210,"Yes, I can take the second part. This is Jeff Leiden, and Matt, I think it's -- I actually like the way you said it. I think you should think about 661 as the foundation for multidrug regimens going forward because of its pharmaceutical properties. And that's it's best attribute if you will. Now we're going to find more about what it does in some of these populations from the Phase III, certainly not from the 12-week study, because of course, there were no het mins, for example, and no het 551Ds in that 12-week study. But number one is it really has pharmaceutical properties that allow us make combination regimens, including the 3-drug regimen, which is going to be so important, I think, in the het min. 
With respect to the ATR, yes, you're right. This is a DNA repair pathway as you know, and so the hypothesis here is that by simultaneously disrupting a DNA repair pathway while you're also providing DNA damage to the cell in the form of either cytotoxic chemo agent or radiation, you're going to potentiate the radiation of the cytotoxic chemo agent. And that will be the real basis on which we look at the drug rather than looking at it by itself."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out that you would disclose by the",135,"I wanted to ask a couple more questions about 661. Could you give us a sense of the, your expectations for enrollment of the trials and when we might see data? Is it realistic that any of these trials could give us read out that you would disclose by the end of the year? Or should we be expecting them to all come next year? And then we sort of seem to be dancing around this Phase IIb efficacy result, but when might that come? And then lastly, related to that, Jeff, could you comment on the pharmaceutical properties of what you're seeing in the next gen corrector? Do you have an optimized candidate there? Or are you just sort of really establishing proof that you can target the particular pathway that you're going after?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll take the first question in terms of timing of results from the broad Phase III program and then also the 12-week study, VX-661 it's not currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we anticipate toward",169,"I'll take the first question in terms of timing of results from the broad Phase III program and then also the 12-week study, VX-661 it's not currently ongoing. Firstly, just chronologically, the 12-week study that's currently ongoing, we anticipate towards the end of the first quarter, we'll  provide you top line data from that study. I'll just reiterate that as Jeff has mentioned, that it is a small study, our primary endpoint to safety and a lot of the data that we've gathered around 661 already has provided us with the green light to head into this broad Phase III program. And I'll also add that, that data was discussed with the regulatory authorities to allow us to proceed into that Phase III program. As far as the timing of the results from the Phase III program, we'd anticipate 2016. We'll provide you with a more clear update once we get an understanding of the rate of recruitment to the studies but we don't anticipate results within 2015."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. Then the second corrector.",5,"Great. Then the second corrector."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think that -- really, I think as we talked about, we're really focused on those markets, both driving the efficacy but also having the pharmaceutic properties that are going to allow it to be used in a 3-drug regimen, that's really our goal. And we d",88,"So I think that -- really, I think as we talked about, we're really focused on those markets, both driving the efficacy but also having the pharmaceutic properties that are going to allow it to be used in a 3-drug regimen, that's really our goal. And we do have, as we've talked about, multiple compounds in lead op. Exactly what those properties are going to be, it's really -- until you actually, already, and we've tested them in the clinic, I think it's really too early to say."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum from Evercore ISI."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous min population where you're planning to enroll 270 patients. If memory serves, that's only about hal",186,"I have really simple question. When I look at the design that you've chosen for Phase II trials, I'm particularly struck by the design of the heterozygous min population where you're planning to enroll 270 patients. If memory serves, that's only about half the size of the TRAFFIC and -- each of the TRAFFIC and TRANSPORT trials, which were adequately powered trials in and of themselves. So presumably, the power of 270 patients to the effect in FEV benefit is substantially less than it was in TRAFFIC and TRANSPORT. If I were a company designing a trial and choosing that, I would interpret that as having great confidence  I'm going to see a big benefit. Why am I correct or incorrect in that line of logic, so to speak? And then finally, just a follow-up on the Phase IIb coming out for the 661, KALYDECO combination. Is there any reason biologically or study design-wise and the length is different to assume or postulate that the data, the FEV data would be significantly different from the roughly 4.8% improvement in absolute we saw in the prior experience?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So again, in terms of the ongoing Phase II study with 12 weeks, we really just can't comment, that is an interim analysis and we are, as Ian just said, we're going to really have the results at the end of the first quarter. In terms",181,"It's Jeff Chodakewitz. So again, in terms of the ongoing Phase II study with 12 weeks, we really just can't comment, that is an interim analysis and we are, as Ian just said, we're going to really have the results at the end of the first quarter. In terms of your question around comparing the 661 het min study versus TRAFFIC and TRANSPORT, I do think there are couple of very important considerations that differ between them. One is that in the TRAFFIC and TRANSPORT, we had 2 doses in that study which obviously complicates the sizing of the studies, and that's a very big difference and we were very pleased to be able to focus on one dose as we move 661 into Phase III. The other piece of that is that another consideration -- an important consideration in the TRAFFIC and TRANSPORT studies was around secondary endpoints and being able to detect secondary endpoints. The 661 study in the het min population is really focused and powered around FEV1. So that explains the differences that you are noting."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And why was it not paired one the secondaries? And then I'll drop back in the queue.",17,"And why was it not paired one the secondaries? And then I'll drop back in the queue."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for that -- for those secondary endpoints and we think that's really going to be able to anchor our program. And so that's how we con",53,"So again, I think that we also have a study in 508 homozygous patients that is powered both in terms of size and duration for that -- for those secondary endpoints and we think that's really going to be able to anchor our program. And so that's how we constructed the program overall."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",13,"Our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Moheed Bansas [ph] sitting in for Robyn, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neuro space. Could you please help us understand your strategy with these assets? Do you expect to develop the",75,"This is Moheed Bansas [ph] sitting in for Robyn, moving aside from cystic fibrosis and looking at your pipeline, you have assets in oncology and neuro space. Could you please help us understand your strategy with these assets? Do you expect to develop these indications in-house? Or you think partnership or out-licensing is the way to go? I guess my real question is, do you see these assets as non-core assets or your core assets?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I think -- this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicines for disease -- very serious diseases with large unmet need and scientific opportunity. A",135,"Yes, thanks for the question. I think -- this is Jeff Leiden, as you know, we outlined our strategy a couple of years ago, which is to make transformational medicines for disease -- very serious diseases with large unmet need and scientific opportunity. And so if you look across our pipeline, whether it's in neurology or whether it's in oncology, each of the programs fulfills those criteria in different sorts of ways. So these are our strategic assets. In terms of plans for how to commercialize them, obviously, we'll be able to make detailed decisions once we begin to see clinical data from Phase II and Phase III studies. But we're very confident that these kinds of assets, these transformational assets are high-value assets for the company and they do fit with our corporate strategy."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I would just add that we face these questions a lot when we engage with investors and analysts. And it appears as there's always a category that we want to fit these assets in including maybe some of our early neurology assets as well. And the categories",173,"I would just add that we face these questions a lot when we engage with investors and analysts. And it appears as there's always a category that we want to fit these assets in including maybe some of our early neurology assets as well. And the categories tends to be, you're either in the area or you're not in the area. And what I would like to be clear on is that we're committing to the studies, and we want to find out the results and we want to see where there is a potential for this transformational medicine as Jeff Leiden has explained. But we're in the area until we gather data and that doesn't mean that the company's committed to the oncology space for the next 10, 15 years, but it does mean we're committed to these studies and finding out whether we have potential to create new medicines. And I wish there was a third category that I could give you but that's -- we're actually in that third category."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ian and I talked about, we're not an oncology company or a neurology company. We're transformational medicines company and that's what we're trying to do here.",26,"Ian and I talked about, we're not an oncology company or a neurology company. We're transformational medicines company and that's what we're trying to do here."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Liisa Bayko from JMP Securities.",13,"Our next question comes from the line of Liisa Bayko from JMP Securities."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to follow up on some discussion earlier. If we see a better treatment effect, a large treatment effect in the 661, KALYDECO combo study on the homozygotes, by extension, does that make us feel like the heterozygote study is going to have more rob",62,"And just to follow up on some discussion earlier. If we see a better treatment effect, a large treatment effect in the 661, KALYDECO combo study on the homozygotes, by extension, does that make us feel like the heterozygote study is going to have more robust effect that was seen with lumacaftor, ivacaftor? Is that the right way to think about it?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question. I know what you're trying to get at here Liisa, in terms of -- will this really read out in the het min study and our impression about its chance of success, and the answer is really no. We won't have a single het min patient",147,"Yes. Thanks for the question. I know what you're trying to get at here Liisa, in terms of -- will this really read out in the het min study and our impression about its chance of success, and the answer is really no. We won't have a single het min patient in this study that they're obviously the relevant patients. And as -- I don't think our mind will change in terms of the risks and the speed of these 2 approaches we're going to take, there's no doubt, no matter what we see, that the 2-drug domination is a high-risk but more rapid way to get to these patients who today don't have any therapy. There's also no doubt in my mind that the 3-drug combination from everything we've seen is a much higher probably to approach, but unfortunately, it's going to take us bit longer."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Fair enough. And then can we maybe just talk about the presentation of the combo? How many pills will it be? And sort of what would the packaging be roughly for the lumacaftor, ivacaftor combo?",36,"Okay. Fair enough. And then can we maybe just talk about the presentation of the combo? How many pills will it be? And sort of what would the packaging be roughly for the lumacaftor, ivacaftor combo?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, so the presentation is a fixed dose combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablet then as well. So",49,"Yes, Liisa, so the presentation is a fixed dose combination. So you'll take the 400 of lumacaftor that's combined with ivacaftor. You'll take that in the morning and then 12 hours later, you're also taking a fixed dose combination tablet then as well. So it's a completely co-formulated product."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare or characterize how we should think of it compared to what we saw for the G551D population?",37,"And then just final question for me on the trajectory that you anticipate for the combo. Can you maybe compare or characterize how we should think of it compared to what we saw for the G551D population?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, great question, Liisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high f",302,"Yes, great question, Liisa. So in terms of a destination, if I can describe it that way in terms of the overall level of uptake we're anticipating, we expect the level of uptake, the peak penetration, if you want to think of it that way, to be very high for the lumacaftor, ivacaftor combination, based on the things that you already know. It's an incredibly serious disease. The F508del mutation is a serious form of the disease and there aren't any other treatment options currently available to treat the underlying cause of the disease. And so everything we know about the profile of lumacaftor and ivacaftor and the reaction it has had from patients and providers since the Phase III data became available is very positive. So we're expecting the peak uptake to be very significant. In terms of the rate of uptake, I'm anticipating it's going to be lower than with G551D, and really that's just driven by the sheer volume of patients. You have to think about here in the U.S. there's about 1,000 G551D patients that's treated at about 250 to 275 CF centers, that's on average, 3 or 4 patients per center. You think about the F508del homozygous population 12 and above, it's about 8,500 patients, so nearly in order of magnitude, greater, that's more like 30 patients per CF center on average. And so just the sheer volume of patients and the effort that goes into initiating a new patient on the therapy, the education, the counseling, navigating the reimbursement process, is going to take a significant amount of time and just the sheer volume of patients, I think, is going to lead to the absolute rate of uptake to be somewhat lower than we saw with G551D which you know -- well know was virtually vertical."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the het min cohort? What would be the hurdle for you to continue to enroll the other 150 patients? And then, I think you've made a comment before th",81,"So can you categorically talk about the futility analysis after the first 120 patients will be enrolled in the het min cohort? What would be the hurdle for you to continue to enroll the other 150 patients? And then, I think you've made a comment before that maybe, should we assume that the 12-week trial for that cohort in Phase III will not be long enough to capture any benefit in weight gain or exacerbation reduction, is that a right assumption?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff. So let's talk about the futility analysis, which I think really reflects what we've been talking about in terms of the low probability for the population with the 2-drug combination. We don't have an exact final rule that we're going to use",330,"So it's Jeff. So let's talk about the futility analysis, which I think really reflects what we've been talking about in terms of the low probability for the population with the 2-drug combination. We don't have an exact final rule that we're going to use in the study, so we can't give you specifics. But let me take a moment and walk you through how it's going to work to put it in perspective. As you noted that we are going to roll about 120 patients in the initial cohort, we're going to then pause enrollment and clinical data from those patients will be collected and be reviewed by the DMC. We won't actually, here at Vertex, be seeing that data, it will be conducted independently by the DMC. And the goal of that is actually to assess the probability whether we can actually know from that amount of data that it is low probability, that it's unlikely that, that combination is going to be beneficial for the patients. If that's the case, the SMB will tell us and we'll stop the study. If they see something that we cannot conclude that, then we will restart enrollment and complete the study. And that's really the way it's going to roll out. I would also note that the -- even if the study continues, we don't know for sure and we really won't know that the study is going to be positive until we get to the end. It's just that at that interim point, do we have enough information already to know that it's not working. That's the way the analysis is structured. And then your other question about pulmonary exacerbations and so forth. We will surely collect that data. We'll look at it. There's a difference between saying that we haven't sized the study to fully power for it versus that we will try to look and get all the information that we can out of the study."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That was very helpful, Jeff. Can I just ask one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or in the interim?",29,"That was very helpful, Jeff. Can I just ask one follow-up? When is the futility analysis conducted? Is it at the end of 12 weeks or in the interim?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we haven't gotten to those details, but again, it's going to be -- and of course, it's going to dependent on the rate of enrollment as well. When we get to that 120, we have to get the patients through some of that, get -- collect the data, and allow t",60,"So we haven't gotten to those details, but again, it's going to be -- and of course, it's going to dependent on the rate of enrollment as well. When we get to that 120, we have to get the patients through some of that, get -- collect the data, and allow time for the DMC's to do the analysis."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It gives me the opportunity to help you understand the disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis if it's positive. You, as well just continue to expand that st",102,"It gives me the opportunity to help you understand the disclosure around this as well. So we do not anticipate that there will be a disclosure top line or anything around the futility analysis if it's positive. You, as well just continue to expand that study and recruit more patients and so that we will not be making that announcement. The only announcement that you would hear around this futility assessment is if it was negative, and we had -- and we decided to curtail the study. And so before the question comes, that's our plan of disclosure around this as well."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Abrahams from Wells Fargo Securities.",14,"Our next question comes from the line of Brian Abrahams from Wells Fargo Securities."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Commercial question on ivacaftor, lumacaftor. It seems as if there's a large number of F508del homozygous patients under age 12, and I'm just curious if you've gotten a sense as to whether clinicians might treat any of these patients ages 6 to 11 at launc",85,"Commercial question on ivacaftor, lumacaftor. It seems as if there's a large number of F508del homozygous patients under age 12, and I'm just curious if you've gotten a sense as to whether clinicians might treat any of these patients ages 6 to 11 at launch and whether the drug might be -- or the combo might be reimbursed. And when might you have the results for that upcoming Phase III in patients age 6 to 11 to potentially expand the label into this younger population?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population post-approval, that's really very much a decision for the physician and the patient. But you rais",168,"I'll let Jeff Chodakewitz answer the question on the timing of the study in the 6 to 11 population. In terms of whether we might see usage in that population post-approval, that's really very much a decision for the physician and the patient. But you raised one of the most important limitations there, which is likely to be whether it would be reimbursed. And given that the specialty products, like CF products are managed with a pretty rigorous prior authorizations to the label, my anticipation would be that it would be relatively few patients, if any, who are likely to able to get access to the product until we've got an FDA approval for that here in the U.S. It's not to say that certain patients and their physicians may seek to appeal that with their payer, I'm sure that will happen, but I think it's likely to be a very, very small number who actually would like to get reimbursement after the launch later this year."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is for the -- to predict when the studies would be completed and be able to be filed. I will note that there is a little bit of a",113,"And then, it's Jeff Chodakewitz, just as a follow up, I think it's really too early until we see what the rate of enrollment is for the -- to predict when the studies would be completed and be able to be filed. I will note that there is a little bit of a difference as you probably remember between the U.S. and Europe and that -- there's a smaller study that's focused primarily on pharmacokinetics and safety to support filing and ultimately approval in the U.S. while Europe has historically required larger studies with independent efficacy data. So just to set the stage, that the timing in the 2 areas will likely differ."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Cory Kasimov from JPMorgan.",11,"Our next question comes from line of Cory Kasimov from JPMorgan."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Most of my questions were asked already, but I have 2 quick ones for you. So first of all, with the launch of the 809, KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in h",91,"Most of my questions were asked already, but I have 2 quick ones for you. So first of all, with the launch of the 809, KALYDECO combo expected later this year, what kind of impact do you expect this to have on enrollment in the Phase III study of 661 in homozygous patients, if any? And do you open up more sites in Europe to avoid the disruption given the different timelines there? And then secondly, I'm also curious how much of an impact FX has on your 2015 KALYDECO guidance?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff, I'll take the first one. One of the benefits of actually being able to accelerate the start of the 661 program, particularly the homozygous study, is that we do plan to enroll patients in the U.S. but we think now, by starting this coming mo",93,"So it's Jeff, I'll take the first one. One of the benefits of actually being able to accelerate the start of the 661 program, particularly the homozygous study, is that we do plan to enroll patients in the U.S. but we think now, by starting this coming month, we're going to be able to get enrollment completed and actually hopefully have patients well into the study. So we don't -- we think that, that's really very consistent and we can manage those issues, so we don't see it as a big risk."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Cory, to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning of January. We looked at spot rate at that point. We then did look to see what the x U.S. revenues that were potentially at",122,"Cory, to the FX question, I know it's much, it's a broad topic at this point. We actually gave guidance back at JPMorgan, beginning of January. We looked at spot rate at that point. We then did look to see what the x U.S. revenues that were potentially at risk to currency fluctuations. We don't see a big impact to our revenue line, we have a hedge program for our x U.S. revenues, both a hedge against those revenues but also the natural hedge for our investments in the different countries as well. So we dont see a big impact to the revenue line because of that hedging program. And we also compared it to spot at the beginning of the year."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Howard Liang from Leerink.",13,"And our next question comes from the line of Howard Liang from Leerink."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a question on the expense. Given the development costs, I think it was $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?",40,"I have a question on the expense. Given the development costs, I think it was $570 million to $600 million mostly for CF, could that line item potentially decline in 2016 since Phase III may have mostly competed for 661?"
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question, Howard. It helps me to talk more broadly about, let's say the direction of our operating -- our expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth.",403,"Thanks for the question, Howard. It helps me to talk more broadly about, let's say the direction of our operating -- our expected direction of the operating investment. Clearly, there's a great expectation on our revenue line, which is significant growth. But as we look at the operating expense line moving from 2014 into 2015, but then onwards, we see this increase from '14 into '15 as I described in my remarks earlier today. And that's because we are doing practically 2 Phase III studies through a long, a lot of 2015. But then also, we're supporting the launch of ivacaftor and lumacaftor to treat many more patients. And those are driving the increase between 2014 and '15. However, as we look at '15 into '16 and '17, we see relatively little additional costs, and the reason for that is because the company is now starting to move into a steady-state and when you look at all the different aspects of the company that drive the resulting operating expense, we start to become on a steady state in that we're committed to our levels of research, we like what we've got going on in research, we like the productivity and the production of the molecules that come from our research investment. Our development pipeline or our clinical pipeline is staged now, Phase I assets go to Phase III assets and we expect that to continue to roll so as a Phase III program comes to an end, we'd hope that a Phase II program enters Phase III. So it rolls. And then as far as the SG&A is concerned, while our infrastructure is -- already exists to support the company to scale at this, and as Stuart has mentioned, with the launch of the ivacaftor, lumacaftor, we are building out commercial infrastructure globally. But that starts to hit steady-state as well to serve the patients that we think we will treat in the future. So it helps you understand why we look into 2016 and '17 and talk about controlling of the operating expense whilst we make this increased investment from 2014 into 2015. For that reason, bringing it back with the growth of the revenue line, we do believe that in future years and the successful launch of ivacaftor and lumacaftor, that we do actually turn to profitability and growth in earnings and cash flow. And we look for high operating margins."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you very much. That would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening.",37,"Thank you very much. That would conclude our call. We appreciate everybody joining us tonight. The Investor Relations team is going to be available tonight following the call if you have additional questions. Have a good evening."
36235,281186192,750561,"Vertex Pharmaceuticals Incorporated, Q4 2014 Earnings Call, Jan 28, 2015",2015-01-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day.",26,"Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to",52,"Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Osama Vice President of Investor Relations, Mr. Michael Partridge. Siry, you may begin."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by d",296,"Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by discussing key priorities of our business and reviewing the progress with our cystic fibrosis medicines. Stuart will review the first quarter performance of KALYDECO and will also discuss preparations for the anticipated launch, which we announced today as proposed trade name of the lumacaftor/ivacaftor combination. To close, Ian will review the first quarter 2015 financial results and reiterate our 2015 guidance. We will then open the call for your questions. Dr. Jeff Chodakewitz, Chief Medical Officer will not be on the call today as he is attending a scheduled meeting with the FDA. We expect today's call to run for approximately 45 minutes.
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K and 10-Q, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of the lumacaftor/ivacaftor combination and those about Vertex's other cystic fibrosis programs are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our first quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael and good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possi",494,"Thanks, Michael and good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possible and to enhance the benefits for those we treat. I want to start by acknowledging all of the CF patients and families who continue to reach out to us. We and they are eagerly awaiting the availability. I want to thank them for their support and encouragement as we seek to improve the lives of more people with CF.
There are 3 strategic priorities that we believe will allow Vertex to continue delivering on our vision to make the transformative medicines available to patients globally. We are focused on delivering on those priorities.
First, we're focused on getting approval in successfully launching ORKAMBI while continuing to grow KALYDECO, enabling us to treat even more people with CF. KALYDECO continues to treat more patients through both geographic end label expansion and we anticipate approximately 3,900 patients to be eligible for KALYDECO by the end of this year.
In addition, we are ready to bring ORKAMBI to the approximately 8,500 patients ages 12 and older in the U.S. who have 2 copies of the F508 Del mutation. We look forward to our meeting with the FDA advisory committee on May 12 to discuss ORKAMBI for the F 508 Del homozygous population who currently have don't have any treatment options to target the underlying cause of their disease.
Also we have just completed enrollment in the Phase III safety study evaluating this combination medicine in children ages 6 through 11 who have 2 copies of F508 Del mutation, which if successful positions us to provide ORKAMBI to these younger patients in the U.S. 
Our second priority. We are advancing our CF development pipeline with novel medicines with the potential to create regimens that may increase the benefit for CF patients. We believe that the X-661  can play an important role in the treatment of CF as a key component of a 2 or 3-drug combination. We're no enrolling 2 of the 4 studies included in the broad VX-661 plus ivacaftor pivotal Phase III development program in the third study we'll start in early May.
And our third priority is expanding and diversifying our early-stage pipeline. We continue to expect the next-generation CFTR corrector, as well as multiple programs outside of CF to enter the clinic by the end of 2015.
In summary, we continue to make significant progress in realizing our long-term vision to treat more people with cystic fibrosis and to enhance the benefit of those we treat. Of the continued execution on our strategy gives us the confidence that we will achieve sustainable growth in revenues and earnings and cash flows and create new medicines to treat other serious diseases beyond CF. 
With that, I'll hand it over to Stuart."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the a",139,"Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the anticipated approval and launch of ORKAMBI in the middle of this year in the United States.
KALYDECO revenues increased 31% over the same quarter last year. Global sales this quarter were $130 million, comprised of U.S. sales of approximately $72 million and X U.S. sales of approximately $58 million. There has been rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF in Australia who are eligible for treatment and the vast majority of those have already started to take KALYDECO."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Late last year, KALYDECO was approved in the U.S. by using children and adults ages 6 and older with the R117H mutation. More than 150 of these patients have already initiated treatment. And in March, the KALYDECO label was expended in the West to include",325,"Late last year, KALYDECO was approved in the U.S. by using children and adults ages 6 and older with the R117H mutation. More than 150 of these patients have already initiated treatment. And in March, the KALYDECO label was expended in the West to include children with CF ages 2 to 5 with 1 of 10 different CF mutations. The first children under the age of 5 have already begun treatment.
We are delighted that so many new children and adults with CF now have access to KALYDECO and later in 2015, we expect to make further progress as we achieve reimbursement approval to the gating mutations in the major European countries where these mutations are prevalent.
In summary, multiple growth drivers are in place with KALYDECO this year as we continue to deliver on our geographic and label expansion plans.
Now turning to ORKAMBI. Our PDUFA date in the U.S. is July 5 and our team is ready to bring this medicine to the many patients who are eagerly awaiting its approval. Our patient services team who help patients navigate the reimbursement process and also help with patient education and compliance is fully staffed and trained. We are having ongoing and productive discussions with payers. One of the main areas of focus is disease education to help payers understand cystic fibrosis as ABCs, its impact on patients and caregivers and also to estimate the number of eligible patients they may have in their plans. And from a supply chain perspective, our launch and supply is ready to be shipped shortly after approval and we now have sufficient supply to meet what we anticipate to be strong demand.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO and we are well-positioned for additional long-term revenue growth with the launch of ORKAMBI for F508 Del homozygous patients. 
I'll now hand the call over to Ian."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stewart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. Firstly to the financials, KALYDECO revenues were $130 million this quarter and are up 31% versus",306,"Thanks, Stewart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. 
Firstly to the financials, KALYDECO revenues were $130 million this quarter and are up 31% versus the first quarter of 2014 as we continue to expand the number of patients we treat. Our first quarter non-GAAP R&D and SG&A expenses were $246 million, an increase of $13 million compared to last year. This increase mainly being attributable to an increase in SG&A expenses as we prepare for the potential launch of ORKAMBI. 
And our non-GAAP net loss was $148 million, similar to prior year non-GAAP net loss of $151 million. Form a balance sheet perspective, we maintained a strong position with approximately $1.2 billion of cash and equivalents at the end of the quarter. 
Let's turn to our 2015 financial guidance, specifically the reiteration of KALYDECO revenues and combined R&D and SG&A expenses. KALYDECO revenues are on track and we continue to expect 2015 revenues to be between $560 million to $580 million and we also continue to expect the combined non-GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. And just now before closing that we expect our operating expenses will be higher than the second half of this year compared to the first half mainly as a result of anticipated progress with the VX-661 pivotal program and the investment to support the potential launch Orkambi.
I'll close by stating that we are in a strong financial position today and focus on delivering a future financial profile consistent with our large-cap biotech peers. And we look forward to updating you on the continued execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] .",3,"[Operator Instructions] ."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge. We received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phone,",83,"Operator, this is Michael Partridge. We received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phone, which we understand did not cut out. And I'll repeat the numbers that people can dial in within the U.S, it's 866-501-1537. The international, is 720-545-001. And we'll pause for just a minute to allow people to dial in."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you, sir. And please let me know when you're ready to take questions.",14,"Thank you, sir. And please let me know when you're ready to take questions."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge again. And we understand there are still people who are still dialing in. And we're going to wait for them to dial back. All right operator. we're back we're ready to start the Q&A and one thing I will say also is we",68,"Operator, this is Michael Partridge again. And we understand there are still people who are still dialing in. And we're going to wait for them to dial back. 
All right operator. we're back we're ready to start the Q&A and one thing I will say also is we will post the transcript tonight on the website when it becomes available for everybody who missed our prepared remarks earlier."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question from this evening comes from the line of Geoff Meacham from Barclays.",17,"[Operator Instructions] Our first question from this evening comes from the line of Geoff Meacham from Barclays."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a couple here. I know that Jeff isn't around for clinical questions. But just curious, what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plu",60,"I just have a couple here. I know that Jeff isn't around for clinical questions. But just curious, what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plus 661 KALYDECO? And then I have a commercial question for Stewart."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. It's a little difficult to give you a precise number so maybe I'll just sort of highlight how we're thinking about these second-gen correctors. As you remember, we have several of these molecules, which are in late-stage preclini",144,"Yes, this is Jeff Leiden. It's a little difficult to give you a precise number so maybe I'll just sort of highlight how we're thinking about these second-gen correctors. As you remember, we have several of these molecules, which are in late-stage preclinical development. Our goal is to get the first of those into the clinic this year and then follow with several others rapidly after that. And these will likely go through the typical development process which means a typical Phase I, a single those and then a multiple ascending dose looking predominantly for course of safety. And once we have that data, we'll be able to go on to patients. And I think the question that you're asking is can we go on to patients just with singles or with combinations and that's something we'll obviously have to discuss with the regulators."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for ORKAMBI across Europe, what are some of the factors that affect the speed of reimbursements? Do you think -- certainly, it's not a patient education question, but",81,"Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for ORKAMBI across Europe, what are some of the factors that affect the speed of reimbursements? Do you think -- certainly, it's not a patient education question, but obviously, it has a lot to do with the size of the market and the number of patients. And do you also think that budgets will play a role just given the greater number of patients for delta?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In Europe, I think there are really 2 different buckets of things, which again, will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has and some have a very formalized process with very",242,"In Europe, I think there are really 2 different buckets of things, which again, will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has and some have a very formalized process with very well laid out and rigid timelines. And others are much more fluid. So I think there's always that, which affects -- not just us, it affects every product which we're trying to secure reimbursement. And then specifically as it relates to us, it really is going to be discussions around the severity of the disease, level of unmet needs, the nature of the product and then the patient population. And as you say, one of the big considerations in Europe you alluded to, is the budget impact and that's where discussions around the patient population and making sure that payers understand the size of the place of patient population that this is and an orphan disease and that initial indication hopefully for Orkambi will be for a subset of the F508 homozygous population. So they really have a good sense of the size of the patient population and how relatively small it is, is obviously a really informed consideration for them if they're thinking through the budget impact. So those, I think, are the 2 types of considerations, one, systemic around the process and then the others, which are very specific to us and to Orkambi."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","On the second corrector which you mentioned comments about, maybe if you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you actually shown monotherapies, chlori",133,"On the second corrector which you mentioned comments about, maybe if you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you actually shown monotherapies, chloride TRANSPORT and those, or those are actually quite active as a single? And then the second question of, I guess for Ian, you did mention that you are thinking about profitability cash flows like large-cap year. So maybe you can expand a bit on that over the next few years, what is the philosophy of Vertex and how profitable do you guys think you can be, how important is it? I know there's been some discussion and maybe some references about what you can versus what you can in the past."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Michael, this is Jeff Leiden. Let me take the first question and I'll turn it over to Ian for the second. In terms of the second-gen correctors, again, let me just sort of remind you from my view, but for some who may not be as familiar. The idea here is,",374,"Michael, this is Jeff Leiden. Let me take the first question and I'll turn it over to Ian for the second. In terms of the second-gen correctors, again, let me just sort of remind you from my view, but for some who may not be as familiar. The idea here is, we have shown data that by adding a second generation corrector to a first GEN corrector like 809 or 661 plus KALYDECO, we can get very significant enhancement of chloride TRANSPORT, both in del 508 homozygous cells and in the del 508 het cells, which is obviously important. And so this is really a sort of 2-edged approach. One is to, we think it has a high likelihood of allowing us to treat patients, which we know are so difficult with the 2-drug application and the other one is, it enhances the benefit of the homozygous patients who frankly, anybody who has a Delta F508, thing single delta 508 allele. And so that's the idea. When we started the project, there were really 2 challenges. One was really a biologic challenge. That is, is that hypothesis correct? Could you actually identify molecule that would synergize with first-generation correctors and increase chloride TRANSPORT? And we've now definitively answered that question. We have multiple molecules that do that and provide very significant synergy. To me, that was actually the more challenging or question. The second part of course, is once you have such molecules turning them into drugs. And that's really a matter of lead optimization around parameters of PK and drug metabolism and pharmacokinetics. And that's the stage we're in now with multiple of these molecules. We're on track for what we have -- what our goal was this year, which is to get the first of those molecules in the clinic this year with multiple other molecules following thereafter. We -- and we have shown you a second part of the question which we have shown data to demonstrate that synergy? And we have shown that data. I'll refer you back to NACF even a year and a half ago or so I believe, where we showed several pieces of data on the synergy that we can produce with those second GEN correctors."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, but even nice mono, active mono, actually broaching that?",10,"Yes, but even nice mono, active mono, actually broaching that?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. We haven't shown data as monotherapy but we're looking at all the different combinations to produce the best, the most optimal regimen that we can produce.",27,"Yes. We haven't shown data as monotherapy but we're looking at all the different combinations to produce the best, the most optimal regimen that we can produce."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, thanks for the questions. And especially thanks, that I get a chance to reiterate the comments what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers and that's one of high operat",221,"And Mike, thanks for the questions. And especially thanks, that I get a chance to reiterate the comments what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers and that's one of high operating margins. I think we have the opportunity to do that as a business given the disease areas that we're in, specifically with the KALYDECO revenue growth that we're starting to see and we anticipate should increase with the label expansion and the geographic expansion. And then later this year, following the potential approval of Orkambi, we should see an acceleration of that revenue growth and that should accumulate to a significant revenue line. And if we continue to control our operating expenses, what that means is growing revenue line cascades over an operating base that allows us to achieve high operating margins as a business. I would also point out the main that financial profile, because of the scale of the revenue growth, we're still able to invest in R&D, which is a core principle of the company. So we're still able to reinvest in R&D while maintaining those high operating margins. So as we look out 3, 4 years from now, we do see that we're in a very strong position financially."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple just on the Orkambi events. First on the ad COM. It must be in the final stretches of preparation and I know Jeff is not here but perhaps just comment on what are the issues of what additional analysis or core areas of focus you should anticipate",124,"A couple just on the Orkambi events. First on the ad COM. It must be in the final stretches of preparation and I know Jeff is not here but perhaps just comment on what are the issues of what additional analysis or core areas of focus you should anticipate after that comp? And then one for Stuart. The same kind of thing. You must be engaged in discussions with payers both in the U.S. and outside U.S. How are they coming back to you in terms of their perceptions of the value of Orkambi compared to KALYDECO and how they're going to work with you to manage that? because's obviously, it's a significant stepup in their patient volume and revenue exposure in this category."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff, this is Jeff Leiden. I'll answer the ad comparable question and turn it over to Stuart. Just to put in context, I think as you're aware, these outcomes are fairly routine with new chemical entities and this certainly is a new chemical entity. A",202,"Yes, Jeff, this is Jeff Leiden. I'll answer the ad comparable question and turn it over to Stuart. Just to put in context, I think as you're aware, these outcomes are fairly routine with new chemical entities and this certainly is a new chemical entity. And they typically focus on 2 questions. What is the strength of the efficacy data versus the unmet needs? And what's the safety profile? And at the end of the day, is there a favorable benefit risk profile? And those are the questions that we expect to be discussed with the ad COM. Based on the data that you've already seen, we are very confident in our answers to all of those questions because we feel there's very significant clinical benefit. The drug was well tolerated from the safety perspective and when you put those together, you get a favorable benefit risk. In patients who today don't have any underlying therapy that treats the underlying cause of the disease. And that's consistent with what we're also hearing as feedback from KOLs or from the community. So we're looking forward to the discussion. We think it will be pretty much the typical ad come discussion around those issues."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","On discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of the di",267,"On discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of the disease, CF being an orphan disease and not necessarily something they've spent a lot of time focusing on, to talk about the disease, the impact it has on patients and caregivers, making sure they really understand the disease and the level of unmet need. It's clearly been a very important part of our early discussions with them. The other critical point of the discussion has really been around helping them understand the patient population. And as you know, one of the things that payers are very keen on understanding is having a high level of certainty and that's certainly one of the things that we can offer them in cystic fibrosis, is this is an incredibly well defined orphan population. So you're helping them understand the size of the population in total and specifically, the size of the eligible patient population likely to be in their plans or in their geographies has been really important. And then when we've been talking about the science behind the product, the fact that they treat the underlying cause of the disease, whether really is there anything that does that in the market today, when you put all those factors together, I think the general impression we've been getting is that this is the sort of innovation that they like to see and that they want to reimburse."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum from ever core ISI.",15,"And our next question comes from the line of Mark Schoenebaum from ever core ISI."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This actually this is actually sitting in for Mark. The question I had, had to do with -- has to do with thinking about the triple combination and optimizing each of the parts. I guess i just wanted to -- as much as fifth development has progressed over t",90,"This actually this is actually sitting in for Mark. The question I had, had to do with -- has to do with thinking about the triple combination and optimizing each of the parts. I guess i just wanted to -- as much as fifth development has progressed over the last 5 or 10 years, so just getting an into your confidence that where this first-generation second-generation corrector target, the sights, the sort of confidence in that synergy over perhaps a combination of correctors that target different sites in the CFTR."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that it's first-generation and second-generation corrector target different sites, different parts of the folding mechanism or folding pathway and we have direct evidence that shows that. And",239,"Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that it's first-generation and second-generation corrector target different sites, different parts of the folding mechanism or folding pathway and we have direct evidence that shows that. And so the idea here is that the delta 508 mutant CFTR actually has multiple defects at different points in the folding pathway. The first generation correctors like 809 or 661 target one of those, which is actually relatively early on in the folding pathway. But then we then search for second generation correctors that can target the second one that's further downstream in the pathway. The theory or the idea being that those 2 should be added over synergistic. And as I said before, we've been able to show that, I think very definitively. We can identify multiple molecules like that. They do add or synergize with the first generation correctors and our confidence in those is really based upon the totality of all the HB cell data that we have, which in each case, is translated into the clinic. And so we've shown you data that the first-generation, second-generation corrector, KALYDECO can produce significantly more chloride TRANSPORT in those cells in just the first GEN corrector in KALYDECO and that's why we're so confident that we translated into more benefit in the clinic. And anyone who basically has one or more delta 508 alleles. Does that answer your question?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I was just -- so my question was had to do with what the if there multiple defects or multiple sites, let's say a through e. And we know that the first-generation corrector targets a with a combination of A plus+ any of the others is perhaps isn't necessa",70,"I was just -- so my question was had to do with what the if there multiple defects or multiple sites, let's say a through e. And we know that the first-generation corrector targets a with a combination of A plus+ any of the others is perhaps isn't necessarily better than let's say, C, and another site. I guess that's all. I mean, just sort of the multiplicity of that."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, you're sort of asking what's the best combination. That's the question and we are trying to produce exactly that, The best combination. But another way of thinking about it might be how much chloride TRANSPORT relative to normal can you produce with",128,"Yes, you're sort of asking what's the best combination. That's the question and we are trying to produce exactly that, The best combination. But another way of thinking about it might be how much chloride TRANSPORT relative to normal can you produce with 2 different correctors plus KALYDECO? And we've shown some of that data before. We can produce quite a bit more, at least equivalent to what we see with KALYDECO on a G551D cell. And so the goal is to optimize those with the HBE's because we're very confident that, that translates into the clinic. And so we do have multiple correctors against multiple target sites, just as you say end that the goal is to produce the best combination and put it in the clinic."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn from Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been, or will that be in your discussions with paye",119,"Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been, or will that be in your discussions with payers both in the U.S. and ex U.S? And then just with respect to uptake of KALYDECO in the R117H patients. I think I heard you correctly about 150 patients currently on drug. I think you guys have said about 500 in the U.S. before. Maybe anything you're seeing in terms of uptake across a certain age or is there anything specific about those first group of patients that's come onto drug? Thanks."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes,, let me take those in reverse orders. So the R117H launch is going well. You're right, we do have at least 150, more than 150 patients we know who've initiated therapy. And we break them down into all sorts of different age groups. We are seeing use",210,"Yes,, let me take those in reverse orders. So the R117H launch is going well. You're right, we do have at least 150, more than 150 patients we know who've initiated therapy. And we break them down into all sorts of different age groups. We are seeing use across the range of ages from, as you know, our approved indications is for patients 6 and older and we are seeing patients from the younger age groups into the older age groups as well. So it's distributed across the age groups. In terms of the exacerbation data earlier, you're actual right, we have been gathering data on a number of different elements on exacerbations, things like the number and frequency of them, the severity of them, the impact it has on patients and caregivers and also the cost of the overall health care system. And that data is all going to be very important as we're putting together the dossiers that we will need to submit for reimbursement. And so make sure that we really have a very up-to-date set of information on those exacerbation rates by the major countries has been an important part of the world the call for economic schemas been doing in preparation for the launch."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you share any findings for that in terms of the cost of system?",14,"Can you share any findings for that in terms of the cost of system?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, it can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead hospitalizations and we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range of costs, if y",99,"Well, it can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead hospitalizations and we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range of costs, if you like, and it  varies by country and things like that, and we will be getting around to publishing that data. And when that data is publicly available, that's when you'll be able to see the kind of costs that we think these events are have for the health care system."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wondered if we could go back to the VC-661 Phase 1 2b. I thought maybe you could add a little bit of perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 12-week",139,"I wondered if we could go back to the VC-661 Phase 1 2b. I thought maybe you could add a little bit of perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 12-week result on a repeated measures basis was 3% and because that's the method is a little bit different than -- it's kind of apples and oranges between the 4 and 12 week. I wondered if you can talk about why you use the repeated measures method for the 12-week and point? And then maybe if you can give us a better sense of the progression of FEV1 throughout the 12-week trial and then at what point did you have the high water mark in the FEV1?."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, this is Jeff. Thanks for asking, giving me a chance to sort of clarify this because I know both have had some questions about it. I think it's perhaps more straightforward than people would imagine. First, let me just remind you about this trial. Th",385,"Matt, this is Jeff. Thanks for asking, giving me a chance to sort of clarify this because I know both have had some questions about it. I think it's perhaps more straightforward than people would imagine. First, let me just remind you about this trial. The idea was, we needed more safety data than we had to move into Phase III and so this trial is really designed predominantly as a safety trial to get us 12 weeks safety data that will cover us so we can accelerate into Phase III. And the first lining I would emphasize that we were particularly pleased with the fact that we didn't see any new safety concerns and that allowed us to accelerate pivotal program as you know, which is enrolling now. The other efficacy end points, as you said, predominantly FEV1. And what you're really asking us what was that sort of pattern that we saw. I would characterize it as this. First of all, the changes in FEV1 that we saw were consistent with what we've seen before, in that 4% range in multiple studies. The pattern was very similar to what we've seen before with all CFTR correctors, which means that the changes were rapid, it's on within 2 weeks and they were sustained through the 12 weeks of the study. It was a small study so there was some bouncing around on those but none of those were statistically significant. First thing went up by 2 weeks went up to 12 weeks and it was consistent through the 12 weeks of the trial. And that's consistent with the biology. We know that when you get underlying CFTR correction, there has been something that you've seen that's stable. And it's sustained. In terms of making a point estimate about what the effect is, we're certainly not going to be able to do that from these small Phase II trials, that's really going to wait for the Phase III trial, which is going to be much larger, obviously, and allow us to directly make the accurate point estimate. But there is nothing here in terms of FEV1 that was in any way consistent with what we've seen with 661 or frankly, with the other CFTR correctors in terms of the pattern. Did that answer your question?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks, is that correct?",27,"It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks, is that correct?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's correct. There was some bouncing around at different time points but the ad 12 week time point looked a lot like the ad 4 week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's",50,"That's correct. There was some bouncing around at different time points but the ad 12 week time point looked a lot like the ad 4 week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's what you're asking."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then if I could just sneak in   a quick commercial question, just wanted to check in on the expanded access program. Is this happening? If yes, in what geographies is it in and how many patients on program?",41,"Okay. Great. And then if I could just sneak in   a quick commercial question, just wanted to check in on the expanded access program. Is this happening? If yes, in what geographies is it in and how many patients on program?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff, I'll  take that one quickly. And so we do have an expanded access program in the U.S, it has sort of 2 parts, there's an initial enrollment of about 50 patients who have FEV1 of less than 40, so that's something that actually falls outs",98,"Yes, this is Jeff, I'll  take that one quickly. And so we do have an expanded access program in the U.S, it has sort of 2 parts, there's an initial enrollment of about 50 patients who have FEV1 of less than 40, so that's something that actually falls outside the official boundaries of the Phase II trial court we'd like to see more data on that operation. We'll collect an initial set the patients and then analyze that and based on that, will expand the access program as we go. And as we are enrolling as we speak."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko from JMP Securities.",14,"And our next question comes from the line of Liisa Bayko from JMP Securities."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is much effortless up reply have one is commercial, how do you think about the curve for Orkambi in the U.S. and maybe more specifically, like what are the doctors that you envision will be employed being different from the KALYDECO launch just aside",102,"This is much effortless up reply have one is commercial, how do you think about the curve for Orkambi in the U.S. and maybe more specifically, like what are the doctors that you envision will be employed being different from the KALYDECO launch just aside from just the volume of patients? And in Europe as a follow-up question, it took sometime in that geography to negotiate price and reimbursement for KALYDECO, now given your presence their some of the I think that the process will be softer? One quick housekeeping caution is that we the FX impact this quarter on top line?."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Michael. Just in consideration of other analysts who will asking questions, can we ask you to just focus on question? And then we'll be happy to address other questions you have after the call during follow-up. So, which question would you like to be",47,"It's Michael. Just in consideration of other analysts who will asking questions, can we ask you to just focus on question? And then we'll be happy to address other questions you have after the call during follow-up. So, which question would you like to be answered?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, first question is fine. On the adoption of in the U.S. and various factors that will be different from KALYDECO launch.",22,"Yes, first question is fine. On the adoption of in the U.S. and various factors that will be different from KALYDECO launch."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, great Marsha, it's Stuart here. Broadly speaking, we are dissipating the demand and patients to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatments that address t",311,"Yes, great Marsha, it's Stuart here. Broadly speaking, we are dissipating the demand and patients to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatments that address the underlying course of the disease and the communities positive reaction to the medical profile. So generally speaking, we are expecting there to be significant demand and quick update, specifically to address your question about what might be different around the uptake, the biggest difference I think is going to be around the patient volume. And if you have to think about, it's about 275 CF centers in the U.S, so for KALYDECO and G551D, they were seeing about 3 to 4 patients for the F508 del homozygous population 12 and over we've got about 8,500 patients so we're going to be seeing 30-plus patients in the average CF center, if there is such thing. And lastly, the initial decision to initiate therapy may be made very quickly by the physician in consultation with the patient, just that sheer volume of patients and the level of administrative burden that goes along with initiating the patient going to the reimbursement process prior authorizations and that sort of thing, I think these likely to lead to a slower relative rate of uptake relative to KALYDECO. The one last thing I do want to say though, relative KALYDECO is the important phrase that I mean, the KALYDECO uptake was virtually vertical. I mean, we were at 90% of peak penetration in 6 months. The fastest launch I've ever been involved in. So while we're seeing the relative uptake with Orkambi may be slightly slower as a result of some of these increased patient volume factors as I say, I we're still expecting the demand to be very significant from both patients and physicians."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Yaron Werber from Citi.",13,"And our next question comes from the line of Yaron Werber from Citi."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Ian, it's a question for you. I think it's a follow-up to some of the earlier comments, just talking about profitability and expenses obviously ramping up a little bit in the second half. Can you give us a sense, where are you sort of on your commercial p",123,"Ian, it's a question for you. I think it's a follow-up to some of the earlier comments, just talking about profitability and expenses obviously ramping up a little bit in the second half. Can you give us a sense, where are you sort of on your commercial preparation now? How much more do you need to  prepare if the sales force is already in place? And just maybe a little bit understanding, maybe just not in discrete terms, not in concrete terms but just broadly. is R&D broadly going to go up in line with revenues over time? Or less than revenues? I'm just trying to get a sense what profitability can be because that's the key question I'm getting all the time."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Ron. Actually, Stuart can follow my answer but still, because I heard 2 questions, Stuart can also help you understand where we are in the commercial preparations as well for launch of Orkambi. The way we look at this is, profitability should come",339,"Thanks, Ron. Actually, Stuart can follow my answer but still, because I heard 2 questions, Stuart can also help you understand where we are in the commercial preparations as well for launch of Orkambi. The way we look at this is, profitability should come with the launch of Orkambi and we continue to drive the revenue line with KALYDECO. With geographic and label expansion as we stated earlier on this call. Clearly, the revenue growth is accelerated by the potential approval of Orkambi. Therefore, as we look towards the end of this year and maybe in the beginning of next year, we start to see the company turn cash flow positive and profitable. As far as the operating expense is concerned and the future operating expense is concerned as you're asking. In the short term, we're committed to financial guidance of $1 billion to $1.05 billion to $1.1 billion and we reiterated that on the call tonight. So it helps you understand how we think about this year. And then as we think about the out years, I made some comments earlier that we continue to control that operating expense but with the revenue growth that we have, we see the opportunities to make significant operating margins. To use what you just said in the question, we do not see the company taking a proportion of its revenues and allocating those to R&D. The R&D investments in the company is based on our commitment to a research function that's been highly productive over the years. We like where we are with that and then the development spend and developments investment is a function of the opportunity of the products that we may create. And so we don't look at it as a financial metric to spend away the revenue line. it is more a function of control and having efficient R&D, having a control and efficient operating expense for controlling that to allow the revenues to generate significant operating margins. And Stuart, do you want to comment on Orkambi?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Yes, In terms of the launch preparations. In the U.S, we are launch ready. The additional commercial infrastructure we need here in the U.S, which was largely in our patient services team, which is the team that supports patients through the reimbur",179,"Sure. Yes, In terms of the launch preparations. In the U.S, we are launch ready. The additional commercial infrastructure we need here in the U.S, which was largely in our patient services team, which is the team that supports patients through the reimbursement process and helps with education and compliance, that team has been scaled up to reflect the larger patient population we hope to serve when Orkambi is approved later this year. So in the U.S, we're fully scaled up and launch ready. X U.S., essentially, we'll be using largely the same infrastructure that they've used for KALYDECO in those markets where we commercialize KALYDECO. The real growth in our X U.S. market is driven by us needing to build infrastructure in markets where we don't currently have a presence because there isn't really a large bowl of KALYDECO-eligible patients in those markets. And so that expansion is really happening in the second half of the year as we get ready for the approval. And then subsequent reimbursement submissions in Europe towards the back end of this year."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to understand the topic of profitability and cash flow for a second, but from a standpoint. I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whether",87,"I wanted to understand the topic of profitability and cash flow for a second, but from a standpoint. I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whether inside or outside of CF. And then I guess, as it specifically relates to CF, what's your view on the most value ad timing of a potential deal? In other words, much proof of concept do you need to see before trying to go after an asset?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think you mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy and I'll just go over that once again and then comment on the last part of your question, which is timing. The priori",417,"I think you mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy and I'll just go over that once again and then comment on the last part of your question, which is timing. The priority within business corporate development for us today is cystic fibrosis and so we continue to evaluate opportunities of other technologies or medicines that may enhance our approach to creating best combination medicines for our patients, as well as thinking about other modalities of how we may treat patients many years away from now. We're committed to the space. And so we continue to evaluate different technologies and different medicines at various different points of research and development to give them consideration of whether they would be better in combination with our based therapy. Second priority for us in the area is scientific footprint. Vertex has been highly successful in a small molecule drug development and looking at electric targets. It's time for us to continue and to consider other things and so we're looking at other modalities of science and there's a lot of exciting stuff out there and with working very hard on evaluating those as well. And then third, there is this consideration of being more opportunistic within licensing, I would say it's smaller scale. I don't want you to take away from this call, but Vertex is trying to buy revenue. We have a lot of internal growth with our own compounds. We got a lot to execute on in the CF space alone. So we don't need at this point to go out and take on risk of M&A to buy revenue. But we would consider balancing our pipeline opportunistically. And then to your point -- question of do we think about the timing, ideal timing for bringing in potential CF assets. We look at it by looking at our HVAC assets, to be honest, if we have an opportunity to study an external asset with our own assets and evaluate the combination therapies or even the standalone therapies to our HBE cells, we take a lot of confidence from that. And if we can at least do those kinds of lab experiments, it gives us confidence there to move forward. Where then, potentially the risk in the clinic is one mainly focused on safety. So for us, the ideal time is around this preclinical or translational time of medicines to look to do the combinations."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",14,"And our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is for Robin. So maybe diverting a little bit from cystic fibrosis. Can you please talk a little bit about your collaboration, which you did in October last year? And as in particular, VX 210 for spinal cord injury? And should it be taken as an indic",61,"This is for Robin. So maybe diverting a little bit from cystic fibrosis. Can you please talk a little bit about your collaboration, which you did in October last year? And as in particular, VX 210 for spinal cord injury? And should it be taken as an indication for the types of deals you are looking for outside the CF space?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. And I'll tell you a little about the deal and then I'll answer the second part of it. So just as a reminder, this was a licensing deal for a Phase II b ready inhibitor for a spinal cord injury. Strategically, obviously, it's the",251,"Yes, this is Jeff Leiden. And I'll tell you a little about the deal and then I'll answer the second part of it. So just as a reminder, this was a licensing deal for a Phase II b ready inhibitor for a spinal cord injury. Strategically, obviously, it's the kind of disease we're interested in. That means it's a serious disease with very large unmet medical need where even small improvements in neurologic function, make huge improvements for patients. It's a market that's of the right size, it is clearly a specialty market and very consistent size with markets like CF and other specialty markets on that, requiring large commercial infrastructure. And there was preclinical and early clinical data that was suggested of an effect. And it was, I think economically also, a very good deal for Vertex in terms of acquiring an option for what could be a very valuable asset to patients and us. The plan with that program as we've said is, to begin a Phase II b study later this year. And it's a study that we were deciding to be large enough to give us a clear answer on the effects of this particular molecule. Your second question, is this the kind of deal we're doing, there's no one answer for that but because of all those things I just told you, yes, it fits strategically, it's the right size, it's the right stage, it's the right kind of asset and it's potentially transformational for patients."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Tony Butler from Guggenheim partners.",14,"And our next question comes from the line of Tony Butler from Guggenheim partners."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, I'm respectful of your comments around core TRANSPORT HV cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get hindrance because you got 3 molecules there? And more imp",77,"Jeff, I'm respectful of your comments around core TRANSPORT HV cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get hindrance because you got 3 molecules there? And more importantly, how do you actually know from the in vitro assays that would you say will not or may not generate exhaustion when you move that in vivo or can you know that?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is, that they don't stay bou",260,"Great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is, that they don't stay bound to the target. In fact, that's important that they help with the bowling and they likely come off the target. At least, everything that we've seen since that happened. Which also gives us some interesting insights into the kinds of policy that you might really want to look at. I think that's one of the reasons we don't get and another reason, of course, is the size of these molecules compared to the size of these proteins is quite small. But I actually think it's the first reason more than anything else. These are binders which tend to come up, I think, during the folding process. And your second question is about exhaustion. I think in a way, that will be a nice problem to have in terms of driving chloride, driving CFQ-R and TRANSPORT up so high that you get exhaustion. But in fact, what we're seeing so far anyway is that you can drive these up very significantly with these 3 drug combinations and that the CFTR that's on the cell surface is functional, that's of course the most important thing and we're not saying what you might worry about, which is increased recycling of the CFTR or abnormal function the CFTR when it's folded by these 3 molecules, that's really not what we're seeing."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Katherine Xu from William Blair.",14,"And our next question comes from the line of Katherine Xu from William Blair."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a very quick question on the strategy for Orkambi in the children ages 6 to 11? Do you have a safety study plan? And any -- what other studies are you going to do for the eventual approval?",39,"Just a very quick question on the strategy for Orkambi in the children ages 6 to 11? Do you have a safety study plan? And any -- what other studies are you going to do for the eventual approval?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So it's a little -- thanks for the question, it's a little bit different in the U.S. and Europe and so it's important I think we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe it's the only -- we know it's the",157,"Yes. So it's a little -- thanks for the question, it's a little bit different in the U.S. and Europe and so it's important I think we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe it's the only -- we know it's the only study that we're going to need, assuming of course, we're successful to apply for approval in the U.S. In your comment a little bit less certain. In fact our assumption is typically in Europe that one would need both an efficacy endpoint and a safety end point. And so the current time, although we're still discussing it with the European regulators, we're planning a second study in Europe and it would have both the efficacy and safety endpoints about the same size to apply for approval in Europe in this patient population. And we would assume that, that would likely start sort of mid year."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Ying Huang from Bank of America Merrill Lynch.",15,"Our next question comes from line of Ying Huang from Bank of America Merrill Lynch."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First of all, the results you just released last month on the 12-week Phase II b for the efficacy on homozygous patients. Based on that 2% absolute between placebo and drug, does that change your view of the likelihood of excess for this combo in heterozy",96,"First of all, the results you just released last month on the 12-week Phase II b for the efficacy on homozygous patients. Based on that 2% absolute between placebo and drug, does that change your view of the likelihood of excess for this combo in heterozygous or you called the patients? And then secondly philosophically, how high do you think the barrier to entry of our competition is? It seems that everyone else is also developing drugs using your HB assay. So I was wondering what your view is for the competition that's coming your way?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, let me answer the second one first. Of course, there is now increasing competition. And that's typically is what happens when you show the kinds of success that we've shown pension. I think the strategy that we're taking is, to as quickly as possible",485,"Yes, let me answer the second one first. Of course, there is now increasing competition. And that's typically is what happens when you show the kinds of success that we've shown pension. I think the strategy that we're taking is, to as quickly as possible, find the maximal regimens and get the most patients we can on them. We do think we have a pretty considerable headstart. Most of these other assets are preclinical for just entering the clinic. And so as I told you, for the reasons I told you, we're confident that for instance, a 3-drug regimen will allow us to address 80s and 90% of the patients and get essentially maximal effects end that does of course, provide a barrier to entry, both in terms of even enrolling in clinical trials and certainly in terms of the commercially once you're already there. So that's already the competitive strategy. And it's supplemented by our business bonus strategy at the  inset. So if some of those assets come from externally and we can put them together and see even better combinations, all the better for patients and of course, for us. On the first question, really, what our confidence around 661 and as I said, the FEV1 response that we saw in that study in the delta 508 homozygous patients, it was pretty comparable to what we've seen in the other Phase II studies. So if anything that increase our confidence in the effects we're seeing since 1 through 12 weeks. I'd also remind you that there's a lot of other Phase II data out there. For example, adding 661 to patients who are on KALYDECO, who had a gating mutation in which in a Phase II study, we showed, I think about a 4.6% further increase in their FEV1. And of course, that's become a part of our Phase III program. I think one of the key questions that we have that others have is, what is the likelihood of success of the 2-drug combinations, 661-plus KALYDECO in the heterozygous min population. But they're really the most difficult population to treat. And as we said before, we think that has a lower probability. We haven't actually tested the drug yet there. But on the other hand, those patients have nothing today. So the way we're managing that in the Phase III program is, there is a separate study in that population. But it looks quite different, You're going to enroll a reasonably small number of patients about 120 and then we're going to do a futility analysis based on those 120 to decide whether to continue and enroll another 150, which will give us the 4 pivotal trials. So it allows us to manage the risk there if you look, while we're also bringing forward, of course, the next generation of correctors we think have a higher likelihood of success in that population."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question for today comes from the line of Matthew Harrison from Morgan Stanley.",16,"And our final question for today comes from the line of Matthew Harrison from Morgan Stanley."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So if I could just ask again on the next-generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, you know the sites you want to target, it sounded like you were still doing some work to get the molecule ready. I w",118,"So if I could just ask again on the next-generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, you know the sites you want to target, it sounded like you were still doing some work to get the molecule ready. I was wondering if you can be any more specific. Is this formulation work that's still necessary tox work is it that you have a few compounds and you're trying to pick which one you actually want to move forward and put in the clinic, so to me, if you could just be a little bit more specific there. And then separately, Ian, could you just talk about FX for 2015?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden and I'll answer the first part and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first line corrector",186,"Yes, this is Jeff Leiden and I'll answer the first part and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first line corrector like 661 and we're basically at the stage of lead optimization and as you know, what that involves is optimizing around several parameters. PK, drug-drug interaction and toxicity. And so there's molecules or various stages there about optimizing PK tox and drug-drug interaction and when we get the first one, which we expect to do this year optimize for those, we'll take that into the clinic. But our plan is not to just pick one and take it into the clinic. Our plan is actually to pick multiple versions here, they have slightly different flavors, they're buying to different sites, we believe, and so we will test multiple versions and multiple combinations in the clinic and as I said, starting this year and certainly going into next year. Does that answer your question about the second gen?"
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That does. Thank you.",4,"That does. Thank you."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the FX question I know it's always been a popular discussion through Q1 results. We also have X U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from X U.S. And so we suffered the same headwinds that",189,"And to the FX question I know it's always been a popular discussion through Q1 results. We also have X U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from X U.S. And so we suffered the same headwinds that the other companies have suffered. However, as you can see, we recorded $130 million with the revenues in the first quarter. The launch is going very well. To the broader story of the full year, we anticipated -- the FX does have an impact in our revenue line. However, we've taken appropriate measures in terms of hedging against those revenues. And then when you look at the bottom line for the company, we have a natural hedge because we have overseas operations while we're benefiting from a reduction in expense because we're getting favorable benefit there on the expense line. So we've managed the FX and for the rest of the year, we believe we're in good shape. We continue to be committed to our revenue guidance of $560 million to $580 million for KALYDECO and we're happy with our position."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks. That completes our call. We thank everybody for joining in. We apologize for the transition problems that occurred on the webcast earlier. We do plan, as we mentioned, to post a transcript on our website and in addition, when the replay of the web",78,"Thanks. That completes our call. We thank everybody for joining in. We apologize for the transition problems that occurred on the webcast earlier. We do plan, as we mentioned, to post a transcript on our website and in addition, when the replay of the webcast is available, it should be complete and free of breaks and interruptions. The IR team is available in the office tonight if you have any additional questions. Thanks, and have a good night."
36235,290824197,797920,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a good day."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to",53,"Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Vice President of Investor Relations, Mr. Michael Partridge. Sir, you may begin."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by d",300,"Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by discussing key priorities for our business and reviewing the progress with our cystic fibrosis medicines. Stuart will review the first quarter performance of KALYDECO and will also discuss preparations for the anticipated launch of Orkambi, which we announced today is the proposed trade name of the lumacaftor/ivacaftor combination. To close, Ian will review the first quarter 2015 financial results and reiterate our 2015 guidance. We will then open the call for your questions. Dr. Jeff Chodakewitz, Chief Medical Officer, will not be on the call today as he is attending a scheduled meeting with the FDA. We expect today's call to run for approximately 45 minutes.
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of Orkambi, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our first quarter 2015 financial results press release. And I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possible",488,"Thanks, Michael. Good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possible and to enhance the benefits for those we treat. I want to start by acknowledging all of the CF patients and families who continue to reach out to us. We and they are eagerly awaiting the availability of Orkambi. I want to thank them for their support and encouragement, as we seek to improve the lives of more people with CF.
There are 3 strategic priorities that we believe will allow Vertex to continue delivering on our vision to make new transformative medicines available to patients globally. We are focused on delivering on those priorities.
First, we're focused on gaining approval and successfully launching Orkambi while continuing to grow KALYDECO, enabling us to treat even more people with CF. KALYDECO continues to treat more patients through both geographic and label expansion, and we anticipate approximately 3,900 patients to be eligible for KALYDECO by the end of this year.
In addition, we are ready to bring Orkambi to the approximately 8,500 patients, ages 12 and older in the U.S. who have 2 copies of the F508del mutation. We look forward to our meeting with the FDA advisory committee on May 12 to discuss Orkambi for the F508del homozygous population who currently don't have any treatment options that target the underlying cause of their disease.
Also we have just completed enrollment in the Phase III safety study evaluating this combination medicine in children ages 6 through 11 who have 2 copies of F508del mutation, which if successful, positions us to provide Orkambi to these younger patients in the U.S. 
Our second priority. We are advancing our CF development pipeline with novel medicines with the potential to create regimens that may increase the benefit for CF patients. We believe that the VX-661 could play an important role in the treatment of CF, as a key component of a 2 or 3-drug combination. We're now enrolling 2 of the 4 studies included in the broad VX-661 plus ivacaftor pivotal Phase III development program, and the third study will start in early May.
And our third priority is expanding and diversifying our early-stage pipeline. We continue to expect the next-generation CFTR corrector as well as multiple programs outside of CF to enter the clinic by the end of 2015.
In summary, we continue to make significant progress in realizing our long-term vision to treat more people with cystic fibrosis and to enhance the benefit for those we treat. The continued execution on our strategy gives us the confidence that we will achieve sustainable growth in revenues, earnings and cash flows and create new medicines to treat other serious diseases beyond CF. 
With that, I'll hand it over to Stuart."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the a",462,"Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the anticipated approval and launch of Orkambi in the middle of this year in the United States.
KALYDECO revenues increased 31% over the same quarter last year. Global sales this quarter were $130 million, comprised of U.S. sales of approximately $72 million and X U.S. sales of approximately $58 million. There has been rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF in Australia who are eligible for treatment and the vast majority of those have already started to take KALYDECO. Late last year, KALYDECO was approved in the U.S. for use in children and adults ages 6 and older with the R117H mutation. More than 150 of these patients have already initiated treatment. And in March, the KALYDECO label was expanded in the U.S. to include children with CF ages 2 to 5 with 1 of 10 different CF mutations. The first children under the age of 5 have already begun treatment.
We are delighted that so many new children and adults with CF now have access to KALYDECO. And later in 2015, we expect to make further progress as we achieve reimbursement approval for gating mutations in the major European countries where these mutations are prevalent.
In summary, multiple growth drivers are in place for KALYDECO this year as we continue to deliver on our geographic and label expansion plans.
Now turning to Orkambi. Our PDUFA date in the U.S. is July 5, and our team is ready to bring this medicine to the many patients who are eagerly awaiting its approval. Our patient services team who help patients navigate the reimbursement process and also help with patient education and compliance is fully staffed and trained. We are having ongoing and productive discussions with payers. One of the main areas of focus is disease education to help payers understand cystic fibrosis as a disease, its impact on patients and caregivers and also to estimate the number of eligible patients they may have in their plans. And from a supply chain perspective, our launch supply is ready to be shipped shortly after approval and we have sufficient supply to meet what we anticipate to be strong demand.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO and we are well-positioned for additional long-term revenue growth with the launch of Orkambi for F508del homozygous patients. 
I'll now hand the call over to Ian."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. Firstly to the financials. KALYDECO revenues were $130 million this quarter and are up 31% versus t",308,"Thanks, Stuart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. 
Firstly to the financials. KALYDECO revenues were $130 million this quarter and are up 31% versus the first quarter of 2014, as we continue to expand the number of patients we treat. Our first quarter non-GAAP R&D and SG&A expenses were $246 million, an increase of $13 million compared to last year, this increase mainly being attributable to an increase in SG&A expenses as we prepare for the potential launch of Orkambi. 
And our non-GAAP net loss was $148 million, similar to prior year non-GAAP net loss of $151 million. From a balance sheet perspective, we maintained a strong position with approximately $1.2 billion of cash and equivalents at the end of the quarter. 
Let's turn to our 2015 financial guidance, specifically the reiteration of KALYDECO revenues and combined R&D and SG&A expenses. KALYDECO revenues are on track, and we continue to expect 2015 revenues to be between $560 million to $580 million. And we also continue to expect the combined non-GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. I would just note before closing that we expect our operating expenses will be higher in the second half of this year compared to the first half, mainly as a result of anticipated progress with the VX-661 pivotal program and the investment to support the potential launch of Orkambi.
I'll close by stating that we are in a strong financial position today and focused on delivering a future financial profile consistent with our large-cap biotech peers. And we look forward to updating you on the continued execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] .",3,"[Operator Instructions] ."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge. We've received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phon",83,"Operator, this is Michael Partridge. We've received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phone, which we understand did not cut out. And I'll repeat the numbers that people can dial in. Within the U.S, it's 866-501-1537. The international is 720-545-0001. And we'll pause for just a minute to allow people to dial in."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you, sir. And please let me know when you're ready to take questions.",14,"Thank you, sir. And please let me know when you're ready to take questions."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge again. And we understand there are still a few people dialing in. We'll wait for them to dial in, and we'll be right back. All right, operator. We're back. We're ready to start the Q&A. And one thing I will say also i",72,"Operator, this is Michael Partridge again. And we understand there are still a few people dialing in. We'll wait for them to dial in, and we'll be right back. 
All right, operator. We're back. We're ready to start the Q&A. And one thing I will say also is that we will post the transcript of tonight's call on our website when it becomes available for anybody who missed our prepared remarks earlier."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question for this evening comes from the line of Geoff Meacham from Barclays.",17,"[Operator Instructions] Our first question for this evening comes from the line of Geoff Meacham from Barclays."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a couple here. I know Jeff isn't around for clinical questions. But just curious, what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plus 661",59,"I just have a couple here. I know Jeff isn't around for clinical questions. But just curious, what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plus 661 KALYDECO? And then I have a commercial question for Stuart."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. It's a little difficult to give you a precise number, so maybe instead I'll just sort of outline how we're thinking about these second-gen correctors. As you'll remember, we have several of these molecules which are in late-stage",147,"Yes, this is Jeff Leiden. It's a little difficult to give you a precise number, so maybe instead I'll just sort of outline how we're thinking about these second-gen correctors. As you'll remember, we have several of these molecules which are in late-stage preclinical development. Our goal is to get the first of those into the clinic this year and then follow with several others rapidly after that. And these will likely go through the typical development process, which means a typical Phase I, a single ascending -- a single dose and then multiple ascending dose looking predominantly of course with safety. And once we have that data, we'll be able to go on to patients. And I think the question you're asking is can we go on to patients just with singles or with combinations and that's something we'll obviously have to discuss with the regulators."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for Orkambi across Europe, what are some of the factors that affect the speed of reimbursement? Do you think -- certainly, it's not a patient education question, but",81,"Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for Orkambi across Europe, what are some of the factors that affect the speed of reimbursement? Do you think -- certainly, it's not a patient education question, but it obviously has a lot to do with the size of the market and the number of patients. And do you also think that budgets will play a role, just given the greater number of patients for delta?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In Europe, I think there are really 2 different buckets of things, which again will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has, and some have a very formalized process with very",240,"In Europe, I think there are really 2 different buckets of things, which again will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has, and some have a very formalized process with very well laid out and rigid timelines. And others are much more fluid. So I think there's always that, which affects -- not just us, it affects every product which is trying to secure reimbursement. And then specifically, as it relates to us, it really is going to be discussions around the severity of the disease, level of unmet need, the nature of the product and then the patient population. And as you say, one of the big considerations in Europe you alluded to, is the budget impact and that's where discussions around the patient population and making sure that payers understand the size of the patient population that this is an orphan disease and that the initial indication hopefully for Orkambi will be for a subset of the F508 homozygous population. So they really have a good sense of the size of the patient population and how relatively small it is, is obviously a really important consideration for them as they're thinking through the budget impact. So those, I think, are the 2 types of considerations: one, systemic around the process; and then the others, which are very specific to us and to Orkambi."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","On the second corrector which you made some comments about, maybe you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you ever actually shown monotherapies, like",140,"On the second corrector which you made some comments about, maybe you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you ever actually shown monotherapies, like chloride or, I guess, a chloride transport assay data on those? Are those actually quite active as a single? And then the second question, I guess, for Ian. You did mention that you are thinking about profitability and cash flows like large-cap here. So maybe you could expand a bit on that. Over the next few years, what is the philosophy of Vertex and how profitable you guys think you can be? How important is it? I know there's been some discussion and maybe some nervousness about what you can do versus what's been in the past."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Michael, this is Jeff Leiden. Let me take the first question. Then I'll turn it over to Ian for the second. In terms of the second gen correctors, again, let me just sort of remind you -- not from my view, but for some who may not be as familiar. The idea",381,"Michael, this is Jeff Leiden. Let me take the first question. Then I'll turn it over to Ian for the second. In terms of the second gen correctors, again, let me just sort of remind you -- not from my view, but for some who may not be as familiar. The idea here is that we have shown data that by adding a second generation corrector to a first gen corrector like 809 or 661 plus KALYDECO, we can get very significant enhancement of chloride transport, both in Delta 508 homozygous cells and in Delta 508 het min cells, which is obviously important. And so this is really a sort of 2-edged approach. One is to -- we think it has a high likelihood of allowing us to treat the het min patients, which we know are so difficult with the 2-drug combination. And the other one is, it enhances the benefit of the homozygous patients and frankly, anybody who has a Delta 508, a single Delta 508 allele. So that's the idea. And when we started the project, there were really 2 challenges. One was really a biologic challenge. That is, was that hypothesis correct? Could you actually identify molecules that would synergize with first-generation correctors and increase chloride transport. And we've now definitively answered that question. We have multiple molecules that do that and provide very significant synergy. To me, that was actually the more challenging or worrisome question. The second part, of course, is once you have such molecules, turning them into drugs. And that's really a matter of lead optimization around parameters of PK and drug metabolism and pharmacokinetics. And that's the stage we're in now with multiple of these molecules. We're on track for what we have -- what our goal was this year, which is to get the first of those molecules in the clinic this year with multiple other molecules following thereafter. We -- and we have shown -- your second part of the question was, have we have shown data to demonstrate that synergy? And we have shown that data. I'd refer you back to NACF even 1.5 years ago or so, I believe, where we showed several pieces of data on the synergy that we can produce with those second gen correctors."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, but even as mono -- I mean, are they even active as mono? I actually have [indiscernible] that?",19,"Yes, but even as mono -- I mean, are they even active as mono? I actually have [indiscernible] that?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. We haven't shown data as monotherapy, but we're looking at all the different combinations to produce the best, the most optimal regimen we can produce.",26,"Yes. We haven't shown data as monotherapy, but we're looking at all the different combinations to produce the best, the most optimal regimen we can produce."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, thanks for the questions. Especially thanks, so that I get a chance to reiterate the comments of what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers, and that's one of high ope",222,"And Mike, thanks for the questions. Especially thanks, so that I get a chance to reiterate the comments of what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers, and that's one of high operating margins. I think we have the opportunity to do that as a business given the disease areas that we're in, specifically with the KALYDECO revenue growth that we're starting to see, and we anticipate should increase with the label expansion and the geographic expansion. And then later this year, following the potential approval of Orkambi, we should see an acceleration of that revenue growth and that should accumulate to a significant revenue line. And if we continue to control our operating expenses, what that means is that growing revenue line cascades over an operating base that allows us to achieve high operating margins as a business. I would also point out in that financial profile, because of the scale of the revenue growth, we're still able to reinvest in R&D, which is a core principle of the company. We're still able to reinvest in R&D, while maintaining those high operating margins. So as we look out to 3, 4 years from now, we do see that we're in a very strong position financially."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple, just on upcoming events. First on the AdCom. You must be in the final stretches of preparation and I know Jeff is not here but perhaps Jeff Leiden could comment on what are the issues and what additional analysis or core areas of focus we should",127,"A couple, just on upcoming events. First on the AdCom. You must be in the final stretches of preparation and I know Jeff is not here but perhaps Jeff Leiden could comment on what are the issues and what additional analysis or core areas of focus we should anticipate at the AdCom? And then one for Stuart. The same kind of thing. You must be engaged in discussions with payers, both in the U.S. and outside the U.S. now. And how are they coming back to you in terms of their perceptions of the value of Orkambi compared to KALYDECO? And how they're going to work with you to manage that? Because's obviously, it's a significant step-up in their patient volume and revenue exposure in this category."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff, this is Jeff Leiden. I'll answer the AdCom question and then turn it over to Stuart. Just to put in context, I think, as you're aware, these AdComs are fairly routine with new chemical entities, and this is certainly a new chemical entity. And",203,"Yes, Geoff, this is Jeff Leiden. I'll answer the AdCom question and then turn it over to Stuart. Just to put in context, I think, as you're aware, these AdComs are fairly routine with new chemical entities, and this is certainly a new chemical entity. And they typically focus on 2 questions. What is the strength of the efficacy data versus the unmet need? And what's the safety profile? And at the end of the day, is there a favorable benefit risk profile? And those are the questions that we expect to be discussed at the AdCom. Based on the data that you've already seen, we are very confident in our answers to all of those questions because we feel that there's very significant clinical benefit, there's -- the drug was well tolerated from a safety perspective and when you put those together, you get a favorable benefit risk in patients who today don't have any underlying therapy that treats the underlying cause of the disease. And that's consistent with what we're also hearing as feedback from KOLs and from the community. So we're looking forward to the discussion. We think it will be pretty much the typical AdCom discussion around those issues."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, on discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of",267,"Geoff, on discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of the disease. CF being an orphan disease and not necessarily something that they've spent a lot of time focusing on, so talking about the disease, the impact it has on patients and caregivers, making sure they really understand the disease and the level of unmet need, has clearly been a very important part of our early discussions with them. The other critical point of the discussion has really been around helping them understand the patient population. And as you know, one of the things that payers are very keen on understanding is having a high level of certainty and that's certainly one of the things that we can offer them in cystic fibrosis, is this is incredibly well-defined orphan population. So you're helping them understand the size of the population in total and specifically, the size of the eligible patient population likely to be in their plans or in their geographies has been really important. And then when we've been talking about the science behind the product, the fact that it treats the underlying cause of the disease, where there really isn't anything that does that in the market today, when you put all those factors together, I think the general impression we've been getting is that this is the sort of innovation that they like to see and that they want to reimburse."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum from Evercore ISI.",14,"And our next question comes from the line of Mark Schoenebaum from Evercore ISI."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is actually [indiscernible] sitting in for Mark. The question I had, had to do with -- has to do with sort of when thinking about the triple combination and optimizing each of the parts. I guess I just wanted to -- as much as CF development has progr",96,"This is actually [indiscernible] sitting in for Mark. The question I had, had to do with -- has to do with sort of when thinking about the triple combination and optimizing each of the parts. I guess I just wanted to -- as much as CF development has progressed over the last 5 or 10 years, sort of getting to understand your confidence that where this first generation, second generation corrector target, the sites, whether that's the sort of confidence in that synergy over perhaps a combination of correctors that target different sites on the CFTR."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that the first generation and second generation corrector target different sites, different parts of the folding mechanism or folding pathway, and we have direct evidence that shows that. And",246,"Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that the first generation and second generation corrector target different sites, different parts of the folding mechanism or folding pathway, and we have direct evidence that shows that. And so the idea here is that the Delta 508 mutant CFTR actually has multiple defects at different points in the folding pathway. That first generation correctors like 809 or 661 target one of those, which is actually relatively early on in the folding pathway. But that we then search for second generation correctors that could target a second one that's further downstream in the pathway, the theory or the idea being that those 2 should be added over synergistic. And as I said before, we've been able to show that, I think, very definitively. We can identify multiple molecules like that. They do add or synergize with the first generation correctors, and our confidence in those is really based upon the totality of all the HBE cell data that we have, which in each case, is translated into the clinic. And so we've shown you data that -- so first generation corrector, second generation corrector, KALYDECO can produce significantly more chloride transport in those cells than just the first gen corrector in KALYDECO, and that's why we're so confident that, that will translate into more benefit in the clinic, in anyone who basically has one or more Delta 508 allele. Does that answer your question?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I was just -- so my question more does have to do with whether -- for instance, if there are multiple defects and multiple sites, let's say, a through e. And we know that the first generation corrector targets a with a combination of a plus but any of the",77,"I was just -- so my question more does have to do with whether -- for instance, if there are multiple defects and multiple sites, let's say, a through e. And we know that the first generation corrector targets a with a combination of a plus but any of the others is perhaps -- is necessarily better than, let's say, c, and another site. I guess that's all. I mean, just sort of the multiplicity of the..."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, you're sort of asking what's the best combination. That's a good question, and we are trying to produce exactly that, the best combination. But another way of thinking about it might be how much chloride transport relative to normal can you produce w",127,"Yes, you're sort of asking what's the best combination. That's a good question, and we are trying to produce exactly that, the best combination. But another way of thinking about it might be how much chloride transport relative to normal can you produce with 2 different correctors plus KALYDECO? And we've shown some of that data before. We can produce quite a bit more, at least equivalent to what we see with KALYDECO on a 551D cell. And so the goal is to optimize those with HBEs because we're very confident that, that translates into the clinic. And so we do have multiple correctors against multiple target sites, just as you say, and the goal is to produce the best combination and put it in the clinic."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn from Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been or will that be in your discussions with payer",121,"Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been or will that be in your discussions with payers, both in the U.S. and x U.S? And then just with respect to uptake of KALYDECO in the R117H patients, I think I heard you correctly about 150 patients currently on drug. I think you guys have said about 500 in the U.S. before. Maybe anything you're seeing in terms of uptake across a certain age or is there anything specific about those -- that first group of patients that's come onto drug? Thanks."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Terence, let me take those in reverse order. So the R117H launch is going well. You're right. We do have at least 150, more than 150 patients we know who've initiated therapy. And without getting to break them down into all sorts of different age gro",213,"Yes, Terence, let me take those in reverse order. So the R117H launch is going well. You're right. We do have at least 150, more than 150 patients we know who've initiated therapy. And without getting to break them down into all sorts of different age groups, we are seeing use across the range of ages from, as you know, our approved indication is for patients 6 and older, and we are seeing patients from the younger age groups into the older age groups as well. So it's distributed across the age groups. In terms of the exacerbation data, yes, you're absolutely right. We have been gathering data on a number of different elements on exacerbations, things like the number and frequency of them, the severity of them, the impact it has on patients and caregivers and also the cost of the overall health care system. And that data is all going to be very important, as we're putting together the dossiers that we will need to submit for reimbursement. And so making sure that we have a really very up-to-date set of information on those exacerbation rates by the major countries has been an important part of the work that our Health Economics team has been doing in preparation for the launch."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you share any findings from that in terms of the cost of the system?",15,"Can you share any findings from that in terms of the cost of the system?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, there -- you can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead to hospitalizations. And we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range",101,"Well, there -- you can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead to hospitalizations. And we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range of costs, if you like, and it varies by country and things like that. And we will be getting around to publishing that data. And when that data is publicly available, that's when you'll be able to see the kind of costs that we think these events have for the health care system."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wondered if we could go back to the VX-661 Phase IIb data. I thought maybe you could add a little bit of a perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 1",140,"I wondered if we could go back to the VX-661 Phase IIb data. I thought maybe you could add a little bit of a perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 12-week result on a repeated measures basis was 3% and because that statistical method is a little bit different than what your -- it's kind of apples and oranges between the 4 and 12 week. I wondered if you could talk about why you use the repeated measures method for the 12-week endpoint? And then maybe if you could give us a better sense of the progression of FEV1 throughout the 12-week trial and at what time point did you have the high watermark in the FEV1?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, this is Jeff. Thanks for asking, giving us a chance to sort of clarify this because I know folks have had some questions about it. I think it's perhaps more straightforward than people imagine. First, let me just remind you about this trial. The ide",392,"Matt, this is Jeff. Thanks for asking, giving us a chance to sort of clarify this because I know folks have had some questions about it. I think it's perhaps more straightforward than people imagine. First, let me just remind you about this trial. The idea here was we needed more safety data than we had had to move into Phase III, and so this trial was really designed predominantly as a safety trial to get us 12 weeks of safety data that would cover us so we could accelerate into Phase III. And the first finding that I would emphasize that we were particularly pleased with was the fact that we didn't see any new safety concerns and that allowed us to accelerate the pivotal program, as you know, which is enrolling now. The other -- there were efficacy endpoints, as you said, predominantly FEV1. And what you're really asking is what was the sort of pattern that we saw. I would characterize it this way. First of all, the changes in FEV1 that we saw were consistent with what we've seen before, in that 4% range in multiple studies. The pattern was very similar to what we've seen before with all CFTR correctors, which means that the changes were rapid. You saw them within 2 weeks, and they were sustained through the 12 weeks of the study. It was a small study, so there was some bouncing around of those, but none of those were statistically significant. This thing went up by 2 weeks, went out to 12 weeks, and it was consistent through the 12 weeks of the trial. And that's consistent with the biology. We know that when you get underlying CFTR correction, that has been something that we've seen that's stable and is sustained. In terms of making a point estimate about what the effect is, we're certainly not going to be able to do that from these small Phase II trials. That's really going to wait for the Phase III trial, which is going to be much larger, obviously, and allow us to directly make the accurate point estimate. But there was nothing here in terms of FEV1 that was in anyway inconsistent with what we've seen with 661 or frankly, with the other CFTR correctors in terms of the pattern. Does that answer your question?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks. Is that correct?",27,"It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks. Is that correct?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's correct. There was some bouncing around at different time points but the at-12-week time point looked a lot like the at-4-week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's",46,"That's correct. There was some bouncing around at different time points but the at-12-week time point looked a lot like the at-4-week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's what you're asking."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then if I could just sneak in a quick commercial question. Wanted to check in on the expanded access program. Is this happening? If yes, in what geographies and how many patients on program?",37,"Okay. Great. And then if I could just sneak in a quick commercial question. Wanted to check in on the expanded access program. Is this happening? If yes, in what geographies and how many patients on program?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff. I'll take that one quickly. So we do have an expanded access program in the U.S. It has sort of 2 parts. There's an initial enrollment of about 50 patients who have FEV1s of less than 40, so that's something that actually falls outside",95,"Yes, this is Jeff. I'll take that one quickly. So we do have an expanded access program in the U.S. It has sort of 2 parts. There's an initial enrollment of about 50 patients who have FEV1s of less than 40, so that's something that actually falls outside the official boundaries of the Phase III trial. We'd like to see more data on that population. We'll collect an initial set of patients and then analyze that, and based on that, we'll expand the access program as we go. That trial is enrolling, as we speak."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko from JMP Securities.",14,"And our next question comes from the line of Liisa Bayko from JMP Securities."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Masha [indiscernible]. I have 3. One is commercial. How do you think about the adoption curve for Orkambi in the U.S. and maybe more specifically, like what are the doctors that you envision will be at play that are different from the KALYDECO lau",104,"This is Masha [indiscernible]. I have 3. One is commercial. How do you think about the adoption curve for Orkambi in the U.S. and maybe more specifically, like what are the doctors that you envision will be at play that are different from the KALYDECO launch, just aside from just the volume of patients? And in Europe, as a follow-up question, it took some time in that geography to negotiate price and then reimbursement for KALYDECO. Now given your presence there, do you think the process will be softer? One quick housekeeping question is, what was the FX impact this quarter on top line?."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Masha, this is Michael. Just in consideration of other analysts who will asking questions, could we ask you to just focus on one question? And then we're happy to address other questions you have after the call during follow-up. So do you have one questio",55,"Masha, this is Michael. Just in consideration of other analysts who will asking questions, could we ask you to just focus on one question? And then we're happy to address other questions you have after the call during follow-up. So do you have one question [indiscernible]. So which question would you like us to answer?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, first question is fine. On the adoption in the U.S. and various factors that will be different from KALYDECO launch.",21,"Yes, first question is fine. On the adoption in the U.S. and various factors that will be different from KALYDECO launch."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Great. Masha, it's Stuart here. Broadly speaking, we are anticipating the demand from patients and physicians to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatmen",316,"Yes, Great. Masha, it's Stuart here. Broadly speaking, we are anticipating the demand from patients and physicians to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatments that address the underlying course of the disease and the community's positive reaction to the clinical profile. So generally speaking, we are expecting there to be significant demand and quick uptake. Specifically to address your question about what might be different around the uptake, the biggest difference, I think, is going to be around the patient volume. And if you think about it, there's about 275 CF centers in the U.S. So for KALYDECO and G551D, they were seeing about 3 to 4 patients. For the F508del homozygous population, 12. I know we've got about 8,500 patients. So they're going to be seeing 30-plus patients in the average CF center, if there is such a thing. And whilst the initial decision to initiate therapy may be made very quickly by the physician in consultation with the patient, just that sheer volume of patients and the level of administrative burden that goes along with initiating a patient going to the reimbursement process, prior authorizations and that sort of thing, I think, is likely to lead to a slower relative rate of uptake relative to KALYDECO. The one last thing I do want to say though, relative to KALYDECO is the important phrase that I mean, the KALYDECO uptake was virtually vertical. I mean, we were at 90% of peak penetration in 6 months, the fastest launch personally I've ever been involved in. And so whilst we're saying the relative rate of uptake with Orkambi may be slightly slower as a result of some of these increased patient volume factors, as I say, we're still expecting the demand to be very significant from both patients and physicians."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Yaron Werber from Citi.",13,"And our next question comes from the line of Yaron Werber from Citi."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Ian, it's a question for you. I think it's a follow-up to some of your earlier comments, just talking about profitability and expenses obviously ramping up a little bit, second half. Can you give us a sense, where are you sort of on your commercial prepar",123,"Ian, it's a question for you. I think it's a follow-up to some of your earlier comments, just talking about profitability and expenses obviously ramping up a little bit, second half. Can you give us a sense, where are you sort of on your commercial preparation now? How much more do you need to  prepare since the sales force is already in place? And just maybe a little bit understanding, just -- maybe just not in discrete -- not in concrete terms, but just broadly. Is R&D broadly going to go up in line with revenues over time? Or less than revenues? I'm just trying to get a sense what profitability could be because that's the key question I'm getting all the time."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Yaron. I'll actually -- Stuart can follow my answer but Stuart can -- because I heard 2 questions. Stuart can also help you understand where we are in commercial preparation as well for launch of Orkambi. The way we look at this is, profitability",339,"Thanks, Yaron. I'll actually -- Stuart can follow my answer but Stuart can -- because I heard 2 questions. Stuart can also help you understand where we are in commercial preparation as well for launch of Orkambi. The way we look at this is, profitability should come with the launch of Orkambi and we continue to drive the revenue line with KALYDECO, with geographic and label expansion as we stated earlier on this call. Clearly, the revenue growth is accelerated by the potential approval of Orkambi. Therefore, as we look towards the end of this year and maybe beginning of next year, we start to see the company turn cash flow positive and profitable. As far as the operating expense is concerned and the future operating expense is concerned, as you're asking, in the short term, we've committed to financial guidance of $1 billion -- $1.05 billion to $1.1 billion, and we reiterated that on the call tonight. So it helps you understand how we think about this year. And then as we think about the out years, I made some comments earlier that we continue to control that operating expense but with revenue growth that we have, we see the opportunity to make significant operating margins. To use what you just said in the question, we do not see the company taking a proportion of its revenues and allocating those to R&D. The R&D investment in the company is based on our commitment to a research function that's been highly productive over the years. We like where we are with that, and then the development spend and development investment is a function of the opportunity of the products that we may create. And so we don't look at it as a financial metric to spend away the revenue line. It is more a function of controlling and having efficient R&D, having a controlled and efficient operating expense, but controlling that to allow the revenues to generate significant operating margins. And Stuart, do you want to comment on Orkambi?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Yes, In terms of the launch preparations, in the U.S., we are launch ready. The additional commercial infrastructure we need here in the U.S., which was largely in our patient services team, which is the team that supports patients through the reimb",180,"Sure. Yes, In terms of the launch preparations, in the U.S., we are launch ready. The additional commercial infrastructure we need here in the U.S., which was largely in our patient services team, which is the team that supports patients through the reimbursement process and helps with education and compliance, that team has been scaled up to reflect the larger patient population we hope to serve when Orkambi is approved later this year. So in the U.S., we're fully scaled up and launch ready. And x U.S., essentially, we'll be using largely the same infrastructure that we've used for KALYDECO in those markets where we commercialize KALYDECO. The real growth in our x U.S. market is driven by us needing to build infrastructure in markets where we don't currently have a presence because there isn't really a large bolus of KALYDECO-eligible patients in those markets. And so that expansion is really happening in the second half of the year, as we get ready for the approval and then subsequent reimbursement submissions in Europe towards the back end of this year."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Cory Kasimov from JPMorgan.",13,"And our next question comes from the line of Cory Kasimov from JPMorgan."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to stay on this topic of profitability and cash flow for a second, but from a BD standpoint, I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whethe",90,"I wanted to stay on this topic of profitability and cash flow for a second, but from a BD standpoint, I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whether inside or outside of CF. And then I guess, as it specifically relates to CF, what's your view on the most value ad timing of a potential deal? In other words, how much proof of concept do you need to see before trying to go after an asset?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","[ph][ph][ph]   I think I've mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy, and I'll just go over that once again and then comment on your last part of the question, which is t",425,"[ph][ph][ph]   I think I've mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy, and I'll just go over that once again and then comment on your last part of the question, which is timing. The priority within business and corporate development for us today is cystic fibrosis. And so we continue to evaluate opportunities of other technologies or medicines that may enhance our approach to creating the best combination medicines for our patients, as well as thinking about other modalities of how we may treat patients many years away from now. We're committed to the space. And so we continue to evaluate different technologies and different medicines that are at various different points of research and development to give them consideration of whether they would be better in combination with our base therapy. Second priority for us in the area is scientific footprint. Vertex has been highly successful in small molecule drug development and looking at molecular targets. It's time for us to continue and consider other things, and so we're looking at other modalities of science and there's lot of very exciting stuff out there and working very hard on evaluating those as well. And then third, there is this consideration of being more opportunistic with -- in licensing. I would say it's smaller scale. I don't want you to take away from this call that Vertex is trying to buy revenue. We have a lot of internal growth with our own compounds. We've got a lot to execute on in the CF space alone. So we don't need at this point to go out and take on risk of M&A to buy revenue. But we would consider balancing our pipeline opportunistically. And then to your point -- question of how do we think about the timing, the ideal timing for bringing in potential CF assets. We look at it by looking at our HBE assays, to be honest. We -- if we have an opportunity to study an external asset with our own assets and evaluate the combination therapies or even the standalone therapy through our HBE cells, we take a lot of confidence from that. And if we can at least do those kind of lab experiments, it gives us confidence there to move forward with, and potentially the risk in the clinic is one mainly focused on safety. So for us, the ideal time is around this preclinical or translational time of medicines to look to do the combinations."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",14,"And our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Mohit Bansal for Robin. So maybe like diverting a little bit from cystic fibrosis, can you please talk a little bit about your [indiscernible] collaboration, which you did in October last year? And the asset in particular, VX 210 for spinal cord i",67,"This is Mohit Bansal for Robin. So maybe like diverting a little bit from cystic fibrosis, can you please talk a little bit about your [indiscernible] collaboration, which you did in October last year? And the asset in particular, VX 210 for spinal cord injury? And then, should it be taken as an indication for the types of deal you are looking for outside the CF space?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. And I'll tell you a little about the deal and then answer the second part of it. So just as a reminder, this was a licensing deal for a Phase IIb ready [indiscernible] inhibitor for a spinal cord injury. Strategically, obviously,",252,"Yes, this is Jeff Leiden. And I'll tell you a little about the deal and then answer the second part of it. So just as a reminder, this was a licensing deal for a Phase IIb ready [indiscernible] inhibitor for a spinal cord injury. Strategically, obviously, it's the kind of disease we're interested in. That means a serious disease with very large unmet medical need, where even small improvements in neurologic function make huge improvements for patients. It's a market that's of the right size. It's clearly a specialty market and are very consistent in size with markets like CF and other specialty markets on that, requiring large commercial infrastructure. And there was preclinical and early clinical data that was suggestive of an effect. And it was, I think, economically also, a very good deal for Vertex in terms of acquiring an option for what could be a very valuable asset to patients and us. The plan with that program, as we've said, is to begin a Phase IIb study later this year. And it's a study that we were deciding to be large enough to really give us a clear answer on the effects of this particular molecule. Your second question, is this the kind of deal that we were doing, there's no one answer to that but because of all the things I just told you, yes, it fits strategically, it's the right size, it's the right stage, it's the right kind of asset, and it's potentially transformational for patients."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Tony Butler from Guggenheim partners.",14,"And our next question comes from the line of Tony Butler from Guggenheim partners."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, I'm respectful of your comments around core TRANSPORT and HBE cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get steric hindrance because you've got 3 molecules ther",81,"Jeff, I'm respectful of your comments around core TRANSPORT and HBE cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get steric hindrance because you've got 3 molecules there? And more importantly, how do you actually know from the in vitro assays that you -- what you say will not or may not generate exhaustion when you move that in vivo or can you know that?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Two great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is, that they don't stay",267,"Two great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is, that they don't stay bound to the target. In fact, that's important that they help with the folding and they likely come off the target. At least, everything that we've seen says that, that happens. Which also gives you some interesting insights into the kinds of potency that you might really want to look at. So I think that's one of the reasons we don't get steric hindrance and another reason, of course, is the size of these small molecules compared to the size of these proteins is quite small. But I actually think it's the first reason more than anything else. These are binders, which tend to come off, I think, during the folding process. And your second question is about exhaustion. In a way, that would be a nice problem to have in terms of driving chloride transport, driving CFTR traffic and chloride transport up so high that you get exhaustion. But in fact, what we're seeing so far anyway is that you can drive this up very significantly with these 3 drug combinations and that the CFTR that's on the cell surface is functional. That's, of course, the most important thing, and we're not seeing what you might worry about, which is increased recycling of the CFTR or abnormal function the CFTR when it's folded by these 3 molecules. That's really not what we're seeing."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Katherine Xu from William Blair.",14,"And our next question comes from the line of Katherine Xu from William Blair."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a real quick question on the strategy for Orkambi in children ages 6 to 11? Do you have a safety study plan? Any -- what other studies you're going to do for the eventual approval?",36,"Just a real quick question on the strategy for Orkambi in children ages 6 to 11? Do you have a safety study plan? Any -- what other studies you're going to do for the eventual approval?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So it's a little bit -- thanks for the question. It's a little bit different in the U.S. and Europe, and so it's important, I think, that we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe is -- we know is the o",156,"Yes. So it's a little bit -- thanks for the question. It's a little bit different in the U.S. and Europe, and so it's important, I think, that we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe is -- we know is the only study that we're going to need, assuming of course, it's successful to apply for approval in the U.S. In Europe, it's a little bit less certain. And In fact, our assumption is typically in Europe that one would need both an efficacy endpoint and a safety endpoint. And so at the current time, although we're still discussing it with European regulators, we're planning a second study in Europe that would have both the efficacy and safety endpoints about the same size to apply for approval in Europe in this patient population. And we would assume that, that would likely start sort of mid year."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Ying Huang from Bank of America Merrill Lynch.",15,"Our next question comes from line of Ying Huang from Bank of America Merrill Lynch."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First of all, the results you just released last month on the 12-week Phase IIb for VX-661 in homozygous patients, based on that 2% absolute change between placebo and drug, does that change your view of the likelihood of success for this combo in heteroz",98,"First of all, the results you just released last month on the 12-week Phase IIb for VX-661 in homozygous patients, based on that 2% absolute change between placebo and drug, does that change your view of the likelihood of success for this combo in heterozygous or you called the het min patients? And then secondly, philosophically, how high do you think the barrier to entry for your competition is? It seems that everyone else is also developing drugs using your HBE assay. So I was wondering what your view is for the competition that's coming on the way?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, let me answer the second one first. Of course, there is now increasing competition. That typically is what happens when you show the kinds of success that we've shown. I think the strategy that we're taking is, to as quickly as possible, find the max",485,"Yes, let me answer the second one first. Of course, there is now increasing competition. That typically is what happens when you show the kinds of success that we've shown. I think the strategy that we're taking is, to as quickly as possible, find the maximal regimens and get the most patients we can on them. We do think we have a pretty considerable headstart. Most of these other assets are preclinical. We're just entering the clinic. And so as I told you, for the reasons I've told you, we're confident that for instance, a 3-drug regimen will allow us to address 80% to 90% of the patients and get essentially maximal effects and that does, of course, provide a barrier to entry, both in terms of even enrolling clinical trials and certainly in terms of commercially once you're already there. So that's really the competitive strategy. And it's supplemented by our business development strategy, as Ian said. So if some of those assets come from externally and we can put them together and with even better combinations, all the better for patients and, of course, for us. And the first question is really, what's our confidence around 661. And as I said, the FEV1 response that we saw in that study in the Delta 508 homozygous patients, was pretty comparable to what we've seen in the other Phase II studies. So if anything, that increased our confidence in the effects we're seeing since it went through 12 weeks. I'd also remind you that there's a lot of other Phase II data out there. For example, adding 661 to patients who are on KALYDECO, who have a gating mutation in which in a Phase II study, we showed, I think about a 4.6% further increase in their FEV1. And of course, that's become a part of our Phase III program. I think one of the key questions that we have and that others have is, what is the likelihood of success of the 2-drug combinations, 661 plus KALYDECO in the heterozygous min population. That they're really the most difficult population to treat. And as we've said before, we think that has a lower probability. We haven't actually tested the drug yet there. But on the other hand, those patients have nothing today. So the way we're managing that in the Phase III program is, there is a separate study in that population. But it looks quite different, And we're going to enroll a reasonably small number of patients, about 120, and then we're going to do a futility analysis based on those 120 to decide whether to continue and enroll another 150, which would give us the full pivotal trial. So it allows us to manage the risk there, if you will, while we're also bringing forward, of course, the next generation correctors that we think have a higher likelihood of success in that population."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question for today comes from the line of Matthew Harrison from Morgan Stanley.",16,"And our final question for today comes from the line of Matthew Harrison from Morgan Stanley."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So if I could just ask again on the next generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, and you know the sites you want to target. It sounded like you were still doing some work to get the molecule ready.",117,"So if I could just ask again on the next generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, and you know the sites you want to target. It sounded like you were still doing some work to get the molecule ready. I was wondering if you could be anymore specific. Is this formulation work that's still necessary tox work? Is it that you have a few compounds and you're trying to pick which one you actually want to move forward and put in the clinic? So maybe, if you could just be a little bit more specific there. And then separately, Ian, could you just talk about FX for 2015?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff again. I'll answer the first part, and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first gen corrector lik",185,"Yes, this is Jeff again. I'll answer the first part, and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first gen corrector like 661. And we're basically at the stage of lead optimization. And as you know, what that involves is optimizing around several parameters; PK, drug-drug interaction and toxicity. And so these molecules are various stages there of optimizing PK tox and drug-drug interaction and when we get the first one, which we expect to do this year, optimize for those, we'll take that into the clinic. But our plan is not to just pick one and take it into the clinic. Our plan is actually to pick multiple versions here. They have different flavors. They buy into different sites, we believe, and so we will test multiple versions and multiple combinations in the clinic and as I said, starting this year and then certainly going into next year. Does that answer your question about the second gen?"
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That does. Thank you.",4,"That does. Thank you."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the FX question, I know it's been a popular discussion through Q1 results. We also have x U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from x U.S. And so we suffered the same headwinds the other c",186,"And to the FX question, I know it's been a popular discussion through Q1 results. We also have x U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from x U.S. And so we suffered the same headwinds the other companies have suffered. However, as you can see, we recorded $130 million with the revenues in the first quarter. The launch is going very well. To the broader story of the full year, we anticipate -- the FX does have an impact on our revenue line. However, we've taken appropriate measures in terms of hedging against those revenues. And then when you look at the bottom line for the company, we have a natural hedge because we have overseas operations while we're benefiting from a reduction in expense because we're getting favorable benefit there on the expense line. So we've managed the FX and for the rest of the year, we believe we're in good shape. We continue to be committed to our revenue guidance of $560 million to $580 million for KALYDECO, and we're happy with our position."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks. That will conclude tonight's call. We thank everybody for tuning in. We apologize for the transmission problems that occurred on the webcast earlier. We do plan, as we mentioned, to post a transcript on our website and in addition, when the replay",79,"Thanks. That will conclude tonight's call. We thank everybody for tuning in. We apologize for the transmission problems that occurred on the webcast earlier. We do plan, as we mentioned, to post a transcript on our website and in addition, when the replay of the webcast is available, it should be complete and free of breaks and interruptions. The IR team is available in the office tonight, if you have any additional questions. Thanks, and have a good night."
36235,290824197,798228,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a good day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a good day."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to",53,"Good evening, ladies and gentlemen, and thank you for joining Vertex Pharmaceuticals First Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Vice President of Investor Relations, Mr. Michael Partridge. Sir, you may begin."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by d",300,"Thank you, operator and good evening, everyone. Joining me in the call tonight are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Our agenda tonight is as follows: Jeff will begin by discussing key priorities for our business and reviewing the progress with our cystic fibrosis medicines. Stuart will review the first quarter performance of KALYDECO and will also discuss preparations for the anticipated launch of Orkambi, which we announced today is the proposed trade name of the lumacaftor/ivacaftor combination. To close, Ian will review the first quarter 2015 financial results and reiterate our 2015 guidance. We will then open the call for your questions. Dr. Jeff Chodakewitz, Chief Medical Officer, will not be on the call today as he is attending a scheduled meeting with the FDA. We expect today's call to run for approximately 45 minutes.
You can access the webcast slides by going to the events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which have been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of Orkambi, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our first quarter 2015 financial results press release. And I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Jeff Leiden."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possible",489,"Thanks, Michael. Good evening, everyone. 2015 is a very important year for Vertex. Vertex is the leader in the development of cystic fibrosis medicines that address the underlying cause of the disease. Our goal in CF is to treat as many people as possible and to enhance the benefits for those we treat. I want to start by acknowledging all of the CF patients and families who continue to reach out to us. We and they are eagerly awaiting the availability of Orkambi. I want to thank them for their support and encouragement, as we seek to improve the lives of more people with CF.
There are 3 strategic priorities that we believe will allow Vertex to continue delivering on our vision to make new transformative medicines available to patients globally. We are focused on delivering on those priorities.
First, we're focused on gaining approval and successfully launching Orkambi while continuing to grow KALYDECO, enabling us to treat even more people with CF. KALYDECO continues to treat more patients through both geographic and label expansion, and we anticipate approximately 3,900 patients to be eligible for KALYDECO by the end of this year.
In addition, we are ready to bring Orkambi to the approximately 8,500 patients ages 12 and older in the U.S. who have 2 copies of the F508del mutation. We look forward to our meeting with the FDA advisory committee on May 12 to discuss Orkambi for the F508del homozygous population who currently don't have any treatment options that target the underlying cause of their disease.
Also we have just completed enrollment in the Phase III safety study evaluating this combination medicine in children ages 6 through 11 who have 2 copies of F508del mutation, which if successful, positions us to provide Orkambi to these younger patients in the U.S. 
Our second priority. We are advancing our CF development pipeline with novel medicines that have the potential to create regimens that may increase the benefit for CF patients. We believe that the VX-661 could play an important role in the treatment of CF, as a key component of a 2- or 3-drug combination. We're now enrolling 2 of the 4 studies included in the broad VX-661 plus ivacaftor pivotal Phase III development program, and the third study will start in early May.
And our third priority is expanding and diversifying our early-stage pipeline. We continue to expect a next-generation CFTR corrector as well as multiple programs outside of CF to enter the clinic by the end of 2015.
In summary, we continue to make significant progress in realizing our long-term vision to treat more people with cystic fibrosis and to enhance the benefit for those we treat. The continued execution on our strategy gives us the confidence that we will achieve sustainable growth in revenues, earnings and cash flows and create new medicines to treat other serious diseases beyond CF. 
With that, I'll hand it over to Stuart."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the a",462,"Thanks, Jeff, and hello, everyone. I'll begin by reviewing KALYDECO performance in the first quarter, which reflects strong underlying demand, as well as the impact of label and geographic expansion. I will also discuss our progress in preparing for the anticipated approval and launch of Orkambi in the middle of this year in the United States.
KALYDECO revenues increased 31% over the same quarter last year. Global sales this quarter were $130 million, comprised of U.S. sales of approximately $72 million and X U.S. sales of approximately $58 million. There has been rapid uptake of KALYDECO by eligible patients in Australia, following the completion of reimbursement discussions in late 2014. There are more than 200 children and adults with CF in Australia who are eligible for treatment and the vast majority of those have already started to take KALYDECO. Late last year, KALYDECO was approved in the U.S. for use in children and adults ages 6 and older with the R117H mutation. More than 150 of these patients have already initiated treatment. And in March, the KALYDECO label was expanded in the U.S. to include children with CF ages 2 to 5 with 1 of 10 different CF mutations. The first children under the age of 5 have already begun treatment.
We are delighted that so many new children and adults with CF now have access to KALYDECO. And later in 2015, we expect to make further progress as we achieve reimbursement approval for gating mutations in the major European countries where these mutations are prevalent.
In summary, multiple growth drivers are in place for KALYDECO this year as we continue to deliver on our geographic and label expansion plans.
Now turning to Orkambi. Our PDUFA date in the U.S. is July 5, and our team is ready to bring this medicine to the many patients who are eagerly awaiting its approval. Our patient services team who help patients navigate the reimbursement process and also help with patient education and compliance is fully staffed and trained. We are having ongoing and productive discussions with payers. One of the main areas of focus is disease education to help payers understand cystic fibrosis as a disease, its impact on patients and caregivers and also to estimate the number of eligible patients they may have in their plans. And from a supply chain perspective, our launch supply is ready to be shipped shortly after approval and we have sufficient supply to meet what we anticipate to be strong demand.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO and we are well-positioned for additional long-term revenue growth with the launch of Orkambi for F508del homozygous patients. 
I'll now hand the call over to Ian."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. Firstly to the financials. KALYDECO revenues were $130 million this quarter and are up 31% versus t",308,"Thanks, Stuart, and good evening to everyone. Tonight, I'd like to discuss our first quarter 2015 financial results and then our 2015 financial guidance. 
Firstly to the financials. KALYDECO revenues were $130 million this quarter and are up 31% versus the first quarter of 2014, as we continue to expand the number of patients we treat. Our first quarter non-GAAP R&D and SG&A expenses were $246 million, an increase of $13 million compared to last year, this increase mainly being attributable to an increase in SG&A expenses as we prepare for the potential launch of Orkambi. 
And our non-GAAP net loss was $148 million, similar to prior year non-GAAP net loss of $151 million. From a balance sheet perspective, we maintained a strong position with approximately $1.2 billion of cash and equivalents at the end of the quarter. 
Let's turn to our 2015 financial guidance, specifically the reiteration of KALYDECO revenues and combined R&D and SG&A expenses. KALYDECO revenues are on track, and we continue to expect 2015 revenues to be between $560 million to $580 million. And we also continue to expect the combined non-GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. I would just note before closing that we expect our operating expenses will be higher in the second half of this year compared to the first half, mainly as a result of anticipated progress with the VX-661 pivotal program and the investment to support the potential launch of Orkambi.
I'll close by stating that we are in a strong financial position today and focused on delivering a future financial profile consistent with our large-cap biotech peers. And we look forward to updating you on the continued execution of our strategy throughout this year. With that, I'll ask the operator to please open the line for questions."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] .",3,"[Operator Instructions] ."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge. We've received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phon",83,"Operator, this is Michael Partridge. We've received several messages that the webcast for some participants was cutting in and out. And what we'd like to do for those webcast participants is offer them just a few minutes opportunity to dial in to the phone, which we understand did not cut out. And I'll repeat the numbers that people can dial in. Within the U.S, it's 866-501-1537. The international is 720-545-0001. And we'll pause for just a minute to allow people to dial in."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you, sir. And please let me know when you're ready to take questions.",14,"Thank you, sir. And please let me know when you're ready to take questions."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, this is Michael Partridge again. And we understand there are still a few people dialing in. We'll wait for them to dial in, and we'll be right back. All right, operator. We're back. We're ready to start the Q&A. And one thing I will say also i",72,"Operator, this is Michael Partridge again. And we understand there are still a few people dialing in. We'll wait for them to dial in, and we'll be right back. 
All right, operator. We're back. We're ready to start the Q&A. And one thing I will say also is that we will post the transcript of tonight's call on our website when it becomes available for anybody who missed our prepared remarks earlier."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question for this evening comes from the line of Geoff Meacham from Barclays.",17,"[Operator Instructions] Our first question for this evening comes from the line of Geoff Meacham from Barclays."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a couple here. I know Jeff isn't around for clinical questions. But just curious what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plus 661",59,"I just have a couple here. I know Jeff isn't around for clinical questions. But just curious what you guys would be thinking in terms of the pace that you can go from initial data on the second corrector to a proof of concept with that corrector plus 661 KALYDECO? And then I have a commercial question for Stuart."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. It's a little difficult to give you a precise number, so maybe instead I'll just sort of outline how we're thinking about these second-gen correctors. As you'll remember, we have several of these molecules which are in late-stage",147,"Yes, this is Jeff Leiden. It's a little difficult to give you a precise number, so maybe instead I'll just sort of outline how we're thinking about these second-gen correctors. As you'll remember, we have several of these molecules which are in late-stage preclinical development. Our goal is to get the first of those into the clinic this year and then follow with several others rapidly after that. And these will likely go through the typical development process, which means a typical Phase I, a single ascending -- a single dose and then multiple ascending dose looking predominantly of course with safety. And once we have that data, we'll be able to go on to patients. And I think the question you're asking is can we go on to patients just with singles or with combinations and that's something we'll obviously have to discuss with the regulators."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for Orkambi across Europe, what are some of the factors that affect the speed of reimbursement? Do you think -- certainly, it's not a patient education question, but",81,"Okay, that makes sense. And then just for Stuart, when you think about the reimbursement for Orkambi across Europe, what are some of the factors that affect the speed of reimbursement? Do you think -- certainly, it's not a patient education question, but it obviously has a lot to do with the size of the market and the number of patients. And do you also think that budgets will play a role, just given the greater number of patients for Delta?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In Europe, I think there are really 2 different buckets of things, which again will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has, and some have a very formalized process with very",240,"In Europe, I think there are really 2 different buckets of things, which again will affect the pace of reimbursement. The first one is kind of systemic, if you like. It's the process that each country has, and some have a very formalized process with very well laid out and rigid timelines. And others are much more fluid. So I think there's always that, which affects -- not just us, it affects every product which is trying to secure reimbursement. And then specifically, as it relates to us, it really is going to be discussions around the severity of the disease, level of unmet need, the nature of the product and then the patient population. And as you say, one of the big considerations in Europe you alluded to, is the budget impact and that's where discussions around the patient population and making sure that payers understand the size of the patient population that this is an orphan disease and that the initial indication hopefully for Orkambi will be for a subset of the F508 homozygous population. So they really have a good sense of the size of the patient population and how relatively small it is, is obviously a really important consideration for them as they're thinking through the budget impact. So those, I think, are the 2 types of considerations: one, systemic around the process; and then the others, which are very specific to us and to Orkambi."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee from RBC Capital Markets."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","On the second corrector which you made some comments about, maybe you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you ever actually shown monotherapies, like",140,"On the second corrector which you made some comments about, maybe you could talk about, within those different compounds that you've been working on, what is the gating factor to get in an IND underway? And have you ever actually shown monotherapies, like chloride or, I guess, a chloride transport assay data on those? Are those actually quite active as a single? And then the second question, I guess, for Ian. You did mention that you are thinking about profitability and cash flows like large-cap here. So maybe you could expand a bit on that. Over the next few years, what is the philosophy of Vertex and how profitable you guys think you can be? How important is it? I know there's been some discussion and maybe some nervousness about what you can do versus what's been in the past."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Michael, this is Jeff Leiden. Let me take the first question. Then I'll turn it over to Ian for the second. In terms of the second gen correctors, again, let me just sort of remind you -- not from my view, but for some who may not be as familiar. The idea",380,"Michael, this is Jeff Leiden. Let me take the first question. Then I'll turn it over to Ian for the second. In terms of the second gen correctors, again, let me just sort of remind you -- not from my view, but for some who may not be as familiar. The idea here is that we have shown data that by adding a second generation corrector to a first gen corrector like 809 or 661 plus KALYDECO, we can get very significant enhancement of chloride transport, both in Delta 508 homozygous cells and in Delta 508 het min cells, which is obviously important. And so this is really a sort of 2-edged approach. One is to -- we think it has a high likelihood of allowing us to treat the het min patients, which we know are so difficult with the 2-drug combination. And the other one is, it enhances the benefit of the homozygous patients and frankly, anybody who has a Delta 508, a single Delta 508 allele. So that's the idea. And when we started the project, there were really 2 challenges. One was really a biologic challenge. That is, was that hypothesis correct? Could you actually identify molecules that would synergize with first-generation correctors and increase chloride transport. And we've now definitively answered that question. We have multiple molecules that do that and provide very significant synergy. To me, that was actually the more challenging or worrisome question. The second part, of course, is once you have such molecules, turning them into drugs. And that's really a matter of lead optimization around parameters of PK and drug metabolism and pharmacokinetics. And that's the stage we're in now with multiple of these molecules. We're on track for what we have -- what our goal was this year, which is to get the first of those molecules in the clinic this year with multiple other molecules following thereafter. We -- and we have shown -- your second part of the question was, have we shown data to demonstrate that synergy? And we have shown that data. I'd refer you back to NACF even 1.5 years ago or so, I believe, where we showed several pieces of data on the synergy that we can produce with those second gen correctors."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, but even as mono -- I mean, are they even active as mono? I actually have [indiscernible] that.",19,"Yes, but even as mono -- I mean, are they even active as mono? I actually have [indiscernible] that."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. We haven't shown data as monotherapy, but we're looking at all the different combinations to produce the best, the most optimal regimen we can produce.",26,"Yes. We haven't shown data as monotherapy, but we're looking at all the different combinations to produce the best, the most optimal regimen we can produce."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, thanks for the questions. Especially thanks, so that I get a chance to reiterate the comments of what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers, and that's one of high ope",222,"And Mike, thanks for the questions. Especially thanks, so that I get a chance to reiterate the comments of what we target financially for the company few years from now. And it is to be a company similar to our larger cap peers, and that's one of high operating margins. I think we have the opportunity to do that as a business given the disease areas that we're in, specifically with the KALYDECO revenue growth that we're starting to see, and we anticipate should increase with the label expansion and the geographic expansion. And then later this year, following the potential approval of Orkambi, we should see an acceleration of that revenue growth and that should accumulate to a significant revenue line. And if we continue to control our operating expenses, what that means is that growing revenue line cascades over an operating base that allows us to achieve high operating margins as a business. I would also point out in that financial profile, because of the scale of the revenue growth, we're still able to reinvest in R&D, which is a core principle of the company. We're still able to reinvest in R&D, while maintaining those high operating margins. So as we look out to 3, 4 years from now, we do see that we're in a very strong position financially."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges from Bernstein.",13,"And our next question comes from the line of Geoffrey Porges from Bernstein."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple, just on upcoming events. First on the AdCom. You must be in the final stretches of preparation and I know Jeff is not there but perhaps Jeff Leiden could comment on what are the issues and what additional analysis or core areas of focus we shoul",127,"A couple, just on upcoming events. First on the AdCom. You must be in the final stretches of preparation and I know Jeff is not there but perhaps Jeff Leiden could comment on what are the issues and what additional analysis or core areas of focus we should anticipate at that AdCom? And then one for Stuart. The same kind of thing. You must be engaged in discussions with payers, both in the U.S. and outside the U.S. now. And how are they coming back to you in terms of their perceptions of the value of Orkambi compared to KALYDECO? And how they're going to work with you to manage that? Because obviously, it's a significant step-up in their patient volume and revenue exposure in this category."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff, this is Jeff Leiden. I'll answer the AdCom question and then turn it over to Stuart. Just to put in context, I think, as you're aware, these AdComs are fairly routine with new chemical entities, and this is certainly a new chemical entity. And",203,"Yes, Geoff, this is Jeff Leiden. I'll answer the AdCom question and then turn it over to Stuart. Just to put in context, I think, as you're aware, these AdComs are fairly routine with new chemical entities, and this is certainly a new chemical entity. And they typically focus on 2 questions. What is the strength of the efficacy data versus the unmet need? And what's the safety profile? And at the end of the day, is there a favorable benefit risk profile? And those are the questions that we expect to be discussed at the AdCom. Based on the data that you've already seen, we are very confident in our answers to all of those questions because we feel that there's very significant clinical benefit, there's -- the drug was well tolerated from a safety perspective and when you put those together, you get a favorable benefit risk in patients who today don't have any underlying therapy that treats the underlying cause of the disease. And that's consistent with what we're also hearing as feedback from KOLs and from the community. So we're looking forward to the discussion. We think it will be pretty much the typical AdCom discussion around those issues."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, on discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of",267,"Geoff, on discussions with payers, you're absolutely right. We have had and are continuing to have ongoing and very productive discussions with payers. One of the main areas of focus for us is obviously educating them on the disease and the seriousness of the disease. CF being an orphan disease is not necessarily something that they've spent a lot of time focusing on, so talking about the disease, the impact it has on patients and caregivers, making sure they really understand the disease and the level of unmet need, has clearly been a very important part of our early discussions with them. The other critical point of the discussion has really been around helping them understand the patient population. And as you know, one of the things that payers are very keen on understanding is having a high level of certainty and that's certainly one of the things that we can offer them in cystic fibrosis, is this is incredibly well-defined orphan population. So you're helping them understand the size of the population in total and specifically, the size of the eligible patient population likely to be in their plans or in their geographies has been really important. And then when we've been talking about the science behind the product, the fact that it treats the underlying cause of the disease, where there really isn't anything that does that in the market today, when you put all those factors together, I think the general impression we've been getting is that this is the sort of innovation that they like to see and that they want to reimburse."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum from Evercore ISI.",14,"And our next question comes from the line of Mark Schoenebaum from Evercore ISI."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is actually [indiscernible] sitting in for Mark. The question I had, had to do with -- has to do with sort of when thinking about the triple combination and optimizing each of the parts. I guess I just wanted to -- as much as CF development has progr",98,"This is actually [indiscernible] sitting in for Mark. The question I had, had to do with -- has to do with sort of when thinking about the triple combination and optimizing each of the parts. I guess I just wanted to -- as much as CF development has progressed over the last 5 or 10 years, sort of getting to understand as to your confidence that where this first generation, second generation corrector target, the sites, whether that's the sort of confidence in that synergy over perhaps a combination of correctors that target different sites on the CFTR."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that the first generation and second generation corrector target different sites, different parts of the folding mechanism or folding pathway, and we have direct evidence that shows that. And",247,"Yes. This is Jeff Leiden. Maybe just to clarify. We do believe that the first generation and second generation corrector target different sites, different parts of the folding mechanism or folding pathway, and we have direct evidence that shows that. And so the idea here is that the Delta 508 mutant CFTR actually has multiple defects at different points in the folding pathway. That the first generation correctors like 809 or 661 target one of those, which is actually relatively early on in the folding pathway. But that we then search for second generation correctors that could target a second one that's further downstream in the pathway, the theory or the idea being that those 2 should be added over synergistic. And as I said before, we've been able to show that, I think, very definitively. We can identify multiple molecules like that. They do add or synergize with the first generation correctors, and our confidence in those is really based upon the totality of all the HBE cell data that we have, which in each case, is translated into the clinic. And so we've shown you data that -- so first generation corrector, second generation corrector, KALYDECO can produce significantly more chloride transport in those cells than just the first gen corrector in KALYDECO, and that's why we're so confident that, that will translate into more benefit in the clinic, in anyone who basically has one or more Delta 508 allele. Does that answer your question?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Oh, I was just -- so my question more just had to do with whether -- for instance, if there are multiple defects or multiple sites, let's say, a through e. And we know that the first generation corrector targets a with a combination of a plus but any of t",78,"Oh, I was just -- so my question more just had to do with whether -- for instance, if there are multiple defects or multiple sites, let's say, a through e. And we know that the first generation corrector targets a with a combination of a plus but any of the others is perhaps -- is necessarily better than, let's say, c, and another site. I guess that's all. I mean, just sort of the multiplicity of the..."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, you're sort of asking what's the best combination. That's a good question, and we are trying to produce exactly that, the best combination. But another way of thinking about it might be how much chloride transport relative to normal can you produce w",127,"Yes, you're sort of asking what's the best combination. That's a good question, and we are trying to produce exactly that, the best combination. But another way of thinking about it might be how much chloride transport relative to normal can you produce with 2 different correctors plus KALYDECO? And we've shown some of that data before. We can produce quite a bit more, at least equivalent to what we see with KALYDECO on a 551D cell. And so the goal is to optimize those with HBEs because we're very confident that, that translates into the clinic. And so we do have multiple correctors against multiple target sites, just as you say, and the goal is to produce the best combination and put it in the clinic."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn from Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn from Goldman Sachs."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been or will that be in your discussions with payer",120,"Maybe first just one for Stuart. I know you guys were gathering data on the cost of hospitalization due to exacerbations. Can you maybe give us an update on where that data stands, how important has that been or will that be in your discussions with payers, both in the U.S. and x U.S? And then just with respect to uptake of KALYDECO in the R117H patients, I think I heard you correctly about 150 patients currently on drug. I think you guys have said about 500 in the U.S. before. Maybe anything you're seeing in terms of uptake across a certain age or is there anything specific about those -- that first group of patients that's come onto drug?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Terence, let me take those in reverse order. So the R117H launch is going well. You're right. We do have at least 150, more than 150 patients we know who've initiated therapy. And without kind of breaking them down into all the sorts of different age",214,"Yes, Terence, let me take those in reverse order. So the R117H launch is going well. You're right. We do have at least 150, more than 150 patients we know who've initiated therapy. And without kind of breaking them down into all the sorts of different age groups, we are seeing use across the range of ages from, as you know, our approved indication is for patients 6 and older, and we are seeing patients from the younger age groups into the older age groups as well. So it's distributed across the age groups. In terms of the exacerbation data, yes, you're absolutely right. We have been gathering data on a number of different elements on exacerbations, things like the number and frequency of them, the severity of them, the impact it has on patients and caregivers and also the cost of the overall health care system. And that data is all going to be very important, as we're putting together the dossiers that we will need to submit for reimbursement. And so making sure that we have a really very up-to-date set of information on those exacerbation rates by the major countries has been an important part of the work that our Health Economics team has been doing in preparation for the launch."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you share any findings from that in terms of the cost of the system?",15,"Can you share any findings from that in terms of the cost of the system?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, there -- you can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead to hospitalizations. And we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range",101,"Well, there -- you can be expensive. I mean, it obviously depends on the type of exacerbation and the severity and does it lead to hospitalizations. And we know that hospitalizations can be up to 2 weeks at a time and things like that. So there's a range of costs, if you like, and it varies by country and things like that. And we will be getting around to publishing that data. And when that data is publicly available, that's when you'll be able to see the kind of costs that we think these events have for the health care system."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matt Roden from UBS.",13,"And our next question comes from the line of Matt Roden from UBS."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wondered if we could go back to the VX-661 Phase IIb data. I thought maybe you could add a little bit of a perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 1",140,"I wondered if we could go back to the VX-661 Phase IIb data. I thought maybe you could add a little bit of a perspective on that because I have gotten a lot of questions on it. So the FEV1 at 4 weeks was 4.4% higher than baseline. But the final, through 12-week result on a repeated measures basis was 3% and because that statistical method is a little bit different than what your -- it's kind of apples and oranges between the 4 and 12 week. I wondered if you could talk about why you use the repeated measures method for the 12-week endpoint? And then maybe if you could give us a better sense of the progression of FEV1 throughout the 12-week trial and at what time point did you have the high watermark in the FEV1?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, this is Jeff. Thanks for asking, giving us a chance to sort of clarify this because I know folks have had some questions about it. I think it's perhaps more straightforward than people imagine. First, let me just remind you about this trial. The ide",393,"Matt, this is Jeff. Thanks for asking, giving us a chance to sort of clarify this because I know folks have had some questions about it. I think it's perhaps more straightforward than people imagine. First, let me just remind you about this trial. The idea here was we needed more safety data than we had had to move into Phase III, and so this trial was really designed predominantly as a safety trial to get us 12 weeks of safety data that would cover us so we could accelerate into Phase III. And the first finding that I would emphasize that we were particularly pleased with was the fact that we didn't see any new safety concerns and that allowed us to accelerate the pivotal program, as you know, which is enrolling now. The other -- there were efficacy endpoints, as you said, predominantly FEV1. And what you're really asking is what was the sort of pattern that we saw. I would characterize it this way. First of all, the changes in FEV1 that we saw were consistent with what we've seen before, in that 4% range in multiple studies. The pattern was very similar to what we've seen before with all CFTR correctors, which means that the changes were rapid. You saw them within 2 weeks, and they were sustained through the 12 weeks of the study. It was a small study, so there was some bouncing around of those, but none of those were statistically significant. This thing went up by 2 weeks, went out to 12 weeks, and it was consistent through the 12 weeks of the trial. And that's consistent with the biology. We know that when you get underlying CFTR correction, that has been something that we've seen that's stable and is sustained. In terms of making a point estimate about what the effect is, we're certainly not going to be able to do that from these small Phase II trials. That's really going to wait for the Phase III trial, which is going to be much larger, obviously, and allow us to directly make the accurate point estimate. But there was nothing here in terms of FEV1 that was in any way inconsistent with what we've seen with 661 or frankly, with the other CFTR correctors in terms of the pattern. Does that answer your question?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks. Is that correct?",27,"It does. But just to clarify, you're not describing a downward trend on the FEV1 benefit from baseline from 4 weeks to 12 weeks. Is that correct?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's correct. There was some bouncing around at different time points but the at-12-week time point looked a lot like the at-4-week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's",46,"That's correct. There was some bouncing around at different time points but the at-12-week time point looked a lot like the at-4-week time point. And so while there was some bouncing around, there was no statistical or consistent downward trend, if that's what you're asking."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then if I could just sneak in a quick commercial question. Wanted to check in on the expanded access program. Is this happening? If yes, in what geographies and how many patients on program?",37,"Okay. Great. And then if I could just sneak in a quick commercial question. Wanted to check in on the expanded access program. Is this happening? If yes, in what geographies and how many patients on program?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff. I'll take that one quickly. So we do have an expanded access program in the U.S. It has sort of 2 parts. There's an initial enrollment of about 50 patients who have FEV1s of less than 40, so that's something that actually falls outside",95,"Yes, this is Jeff. I'll take that one quickly. So we do have an expanded access program in the U.S. It has sort of 2 parts. There's an initial enrollment of about 50 patients who have FEV1s of less than 40, so that's something that actually falls outside the official boundaries of the Phase III trial. We'd like to see more data on that population. We'll collect an initial set of patients and then analyze that, and based on that, we'll expand the access program as we go. That trial is enrolling, as we speak."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko from JMP Securities.",14,"And our next question comes from the line of Liisa Bayko from JMP Securities."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Masha for Liisa. I have 3. One is commercial. How do you think about the adoption curve for Orkambi in the U.S. and maybe more specifically, like what are the factors that you envision will be at play that are different from the KALYDECO launch, j",105,"This is Masha for Liisa. I have 3. One is commercial. How do you think about the adoption curve for Orkambi in the U.S. and maybe more specifically, like what are the factors that you envision will be at play that are different from the KALYDECO launch, just aside from just the volume of patients? And in Europe, as a follow-up question, it took some time in that geography to negotiate price and then reimbursement for KALYDECO. Now given your presence there, do you think the process will be faster? One quick housekeeping question is, what was the FX impact this quarter on top line?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Masha, this is Michael. Just in consideration of other analysts who will be asking questions, could we ask you to just focus on one question? And then we're happy to address other questions you have after the call during follow-up. So do you have one ques",55,"Masha, this is Michael. Just in consideration of other analysts who will be asking questions, could we ask you to just focus on one question? And then we're happy to address other questions you have after the call during follow-up. So do you have one question? So which question would you like us to answer?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, first question is fine. On the adoption in the U.S. and various factors that will be different from KALYDECO launch.",21,"Yes, first question is fine. On the adoption in the U.S. and various factors that will be different from KALYDECO launch."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, great. Masha, it's Stuart here. Broadly speaking, we are anticipating the demand from patients and physicians to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatmen",316,"Yes, great. Masha, it's Stuart here. Broadly speaking, we are anticipating the demand from patients and physicians to be very high for Orkambi given the seriousness of the disease, the level of unmet need given that there's no currently available treatments that address the underlying cause of the disease and the community's positive reaction to the clinical profile. So generally speaking, we are expecting there to be significant demand and quick uptake. Specifically to address your question about what might be different around the uptake, the biggest difference, I think, is going to be around the patient volume. And if you think about it, there's about 275 CF centers in the U.S. So for KALYDECO and G551D, they were seeing about 3 to 4 patients. For the F508del homozygous population 12 and over, we've got about 8,500 patients. So they're going to be seeing 30-plus patients in the average CF center, if there is such a thing. And whilst the initial decision to initiate therapy may be made very quickly by the physician in consultation with the patient, just that sheer volume of patients and the level of administrative burden that goes along with initiating a patient going through the reimbursement process, prior authorizations and that sort of thing, I think, is likely to lead to a slower relative rate of uptake relative to KALYDECO. The one last thing I do want to say though, relative to KALYDECO is the important phrase that I mean, the KALYDECO uptake was virtually vertical. I mean, we were at 90% of peak penetration in 6 months, the fastest launch personally I've ever been involved in. And so whilst we're saying the relative rate of uptake with Orkambi may be slightly slower as a result of some of these increased patient volume factors, as I say, we're still expecting the demand to be very significant from both patients and physicians."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Yaron Werber from Citi.",13,"And our next question comes from the line of Yaron Werber from Citi."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Ian, it's a question for you. I think it's a follow-up to some of your earlier comments, just talking about profitability and expenses obviously ramping up a little bit, second half. Can you give us a sense, where are you sort of on your commercial prepar",123,"Ian, it's a question for you. I think it's a follow-up to some of your earlier comments, just talking about profitability and expenses obviously ramping up a little bit, second half. Can you give us a sense, where are you sort of on your commercial preparation now? How much more do you need to  prepare since the sales force is already in place? And just maybe a little bit understanding, just -- maybe just not in discrete -- not in concrete terms, but just broadly. Is R&D broadly going to go up in line with revenues over time? Or less than revenues? I'm just trying to get a sense what profitability could be because that's the key question I'm getting all the time."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Yaron. I'll actually -- Stuart can follow my answer but Stuart can -- because I heard 2 questions. Stuart can also help you understand where we are in commercial preparation as well for the launch of Orkambi. The way we look at this is, profitabil",341,"Thanks, Yaron. I'll actually -- Stuart can follow my answer but Stuart can -- because I heard 2 questions. Stuart can also help you understand where we are in commercial preparation as well for the launch of Orkambi. The way we look at this is, profitability should come with the launch of Orkambi and we continue to drive the revenue line with KALYDECO, with geographic and label expansion as we stated earlier on this call. Clearly, the revenue growth is accelerated by the potential approval of Orkambi. Therefore, as we look towards the end of this year and maybe beginning of next year, we start to see the company turn cash flow positive and profitable. As far as the operating expense is concerned and the future operating expense is concerned, as you're asking, in the short term, we've committed to financial guidance of $1 billion -- $1.05 billion to $1.1 billion, and we reiterated that on the call tonight. So it helps you understand how we think about this year. And then as we think about the out years, I made some comments earlier that we continue to control that operating expense but with the revenue growth that we have, we see the opportunity to make significant operating margins. To use what you just said in the question, we do not see the company taking a proportion of its revenues and allocating those to R&D. The R&D investment in the company is based on our commitment to a research function that's been highly productive over the years. We like where we are with that, and then the development spend and development investment is a function of the opportunity of the products that we may create. And so we don't look at it as a financial metric to spend away the revenue line. It is more a function of controlling and having efficient R&D, having a controlled and efficient operating expense, but controlling that to allow the revenues to generate significant operating margins. And Stuart, do you want to comment on Orkambi?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Yes, In terms of the launch preparations, in the U.S., we are launch ready. The additional commercial infrastructure we need here in the U.S., which was largely in our patient services team, which is the team that supports patients through the reimb",180,"Sure. Yes, In terms of the launch preparations, in the U.S., we are launch ready. The additional commercial infrastructure we need here in the U.S., which was largely in our patient services team, which is the team that supports patients through the reimbursement process and helps with education and compliance, that team has been scaled up to reflect the larger patient population we hope to serve when Orkambi is approved later this year. So in the U.S., we're fully scaled up and launch ready. And x U.S., essentially, we'll be using largely the same infrastructure that we've used for KALYDECO in those markets where we commercialize KALYDECO. The real growth in our x U.S. market is driven by us needing to build infrastructure in markets where we don't currently have a presence because there isn't really a large bolus of KALYDECO-eligible patients in those markets. And so that expansion is really happening in the second half of the year, as we get ready for the approval and then subsequent reimbursement submissions in Europe towards the back end of this year."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Cory Kasimov from JPMorgan.",13,"And our next question comes from the line of Cory Kasimov from JPMorgan."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to stay on this topic of profitability and cash flow for a second, but from a BD standpoint, I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whethe",90,"I wanted to stay on this topic of profitability and cash flow for a second, but from a BD standpoint, I'm wondering if you anticipate that you'll have the capacity to drive the bottom line while simultaneously being opportunistic with acquisitions, whether inside or outside of CF. And then I guess, as it specifically relates to CF, what's your view on the most value ad timing of a potential deal? In other words, how much proof of concept do you need to see before trying to go after an asset?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Cory, thanks for the question. I think I've mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy, and I'll just go over that once again and then comment on your last part of the ques",430,"Cory, thanks for the question. I think I've mentioned this on a number of earlier calls. So we have a very firm and committed corporate and business development strategy, and I'll just go over that once again and then comment on your last part of the question, which is timing. The priority within business and corporate development for us today is cystic fibrosis. And so we continue to evaluate opportunities of other technologies or medicines that may enhance our approach to creating the best combination medicines for our patients, as well as thinking about other modalities of how we may treat patients many years away from now. We're committed to the space. And so we continue to evaluate different technologies and different medicines that are at various different points of research and development to give them consideration of whether they would be better in combination with our base therapy. Second priority for us in the area is scientific footprint. Vertex has been highly successful in small molecule drug development and looking at molecular targets. It's time for us to continue and consider other things, and so we're looking at other modalities of science and there's a lot of very exciting stuff out there and working very hard on evaluating those as well. And then third, there is this consideration of being more opportunistic with -- in licensing. I would say it's smaller scale. I don't want you to take away from this call that Vertex is trying to buy revenue. We have a lot of internal growth with our own compounds. We've got a lot to execute on in the CF space alone. So we don't need at this point to go out and take on risk of M&A to buy revenue. But we would consider balancing our pipeline opportunistically. And then to your point -- question of how do we think about the timing, the ideal timing for bringing in potential CF assets. We look at it by looking at our HBE assays, to be honest. We -- if we have an opportunity to study an external asset with our own assets and evaluate the combination therapies or even the standalone therapy through our HBE cells, we take a lot of confidence from that. And if we can at least do those kind of lab experiments, it gives us confidence there to move forward with, and potentially the risk in the clinic is one mainly focused on safety. So for us, the ideal time is around this preclinical or translational time of medicines to look to do the combinations."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Robyn Karnauskas from Deutsche Bank.",14,"And our next question comes from the line of Robyn Karnauskas from Deutsche Bank."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Mohit Bansal for Robyn. So maybe like diverting a little bit from cystic fibrosis, can you please talk a little bit about your by exon collaboration, which you did in October last year? And the asset in particular, VX 210 for spinal cord injury? A",68,"This is Mohit Bansal for Robyn. So maybe like diverting a little bit from cystic fibrosis, can you please talk a little bit about your by exon collaboration, which you did in October last year? And the asset in particular, VX 210 for spinal cord injury? And then, should it be taken as an indication for the types of deal you are looking for outside the CF space?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. Thanks for the question. And I'll tell you a little about the deal and then answer the second part of it. So just as a reminder, this was a licensing deal for a Phase IIb ready rho inhibitor for a spinal cord injury. Strategicall",256,"Yes, this is Jeff Leiden. Thanks for the question. And I'll tell you a little about the deal and then answer the second part of it. So just as a reminder, this was a licensing deal for a Phase IIb ready rho inhibitor for a spinal cord injury. Strategically, obviously, it's the kind of disease we're interested in. That means a serious disease with very large unmet medical need, where even small improvements in neurologic function make huge improvements for patients. It's a market that's of the right size. It's clearly a specialty market and are very consistent in size with markets like CF and other specialty markets, so not requiring large commercial infrastructure. And there was preclinical and early clinical data that was suggestive of an effect. And it was, I think, economically also, a very good deal for Vertex in terms of acquiring an option for what could be a very valuable asset to patients and us. The plan with that program, as we've said, is to begin the Phase IIb study later this year. And it's a study that we were designing to be large enough to really give us a clear answer on the effects of this particular molecule. Your second question, is this the kind of deal that we were doing, there's no one answer to that but because of all the things I just told you, yes, it fits strategically, it's the right size, it's the right stage, it's the right kind of asset, and it's potentially transformational for patients."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Tony Butler from Guggenheim partners.",14,"And our next question comes from the line of Tony Butler from Guggenheim partners."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, I'm respectful of your comments around core TRANSPORT and HBE cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get steric hindrance because you've got 3 molecules ther",81,"Jeff, I'm respectful of your comments around core TRANSPORT and HBE cells for the triple combination or the addition of the second corrector. But the question is, as it begins to fold, why don't you get steric hindrance because you've got 3 molecules there? And more importantly, how do you actually know from the in vitro assays that you -- what you say will not or may not generate exhaustion when you move that in vivo or can you know that?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Two great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is that they don't stay",267,"Two great questions, actually, and we're thinking a lot about them. The first one is really interesting because it points to what I think is a fundamental property of these correctors in particular but also the potentiators, which is that they don't stay bound to the target. In fact, that's important that they help with the folding and they likely come off the target. At least, everything that we've seen says that, that happens. Which also gives you some interesting insights into the kinds of potency that you might really want to look at. So I think that's one of the reasons we don't get steric hindrance and another reason, of course, is the size of these small molecules compared to the size of these proteins is quite small. But I actually think it's the first reason more than anything else. These are binders, which tend to come off, I think, during the folding process. And your second question is about exhaustion. In a way, that would be a nice problem to have in terms of driving chloride transport, driving CFTR traffic and chloride transport up so high that you get exhaustion. But in fact, what we're seeing so far anyway is that you can drive this up very significantly with these 3 drug combinations and that the CFTR that's on the cell surface is functional. That's, of course, the most important thing, and we're not seeing what you might worry about, which is increased recycling of the CFTR or abnormal function the CFTR when it's folded by these 3 molecules. That's really not what we're seeing."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Katherine Xu from William Blair.",14,"And our next question comes from the line of Katherine Xu from William Blair."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a real quick question on the strategy for Orkambi in children ages 6 to 11. Do you have a safety study plan? Any -- what other studies you're going to do for the eventual approval?",36,"Just a real quick question on the strategy for Orkambi in children ages 6 to 11. Do you have a safety study plan? Any -- what other studies you're going to do for the eventual approval?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So it's a little bit -- thanks for the question. It's a little bit different in the U.S. and Europe, and so it's important, I think, that we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe is -- we know is the o",155,"Yes. So it's a little bit -- thanks for the question. It's a little bit different in the U.S. and Europe, and so it's important, I think, that we clarify that. In the U.S, the safety PK study, which is fully enrolled now, we believe is -- we know is the only study that we're going to need, assuming of course, it's successful to apply for approval in the U.S. In Europe, it's a little bit less certain. And in fact, our assumption is typically in Europe that one would need both an efficacy endpoint and a safety endpoint. And so at the current time, although we're still discussing it with European regulators, we're planning a second study in Europe that would have both the efficacy and safety endpoints about the same size to apply for approval in Europe in this patient population. And we would assume that, that would likely start sort of midyear."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from line of Ying Huang from Bank of America Merrill Lynch.",15,"Our next question comes from line of Ying Huang from Bank of America Merrill Lynch."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First of all, the results you just released last month on the 12-week Phase IIb for VX-661 in homozygous patients, based on that 2% absolute change between placebo and drug, does that change your view of the likelihood of success for this combo in heteroz",98,"First of all, the results you just released last month on the 12-week Phase IIb for VX-661 in homozygous patients, based on that 2% absolute change between placebo and drug, does that change your view of the likelihood of success for this combo in heterozygous or you called the het min patients? And then secondly, philosophically, how high do you think the barrier to entry for your competition is? It seems that everyone else is also developing drugs using your HBE assay. So I was wondering what your view is for the competition that's coming on the way?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, let me answer the second one first. Of course, there is now increasing competition. That typically is what happens when you show the kinds of success that we've shown. I think the strategy that we're taking is, to as quickly as possible, find the max",484,"Yes, let me answer the second one first. Of course, there is now increasing competition. That typically is what happens when you show the kinds of success that we've shown. I think the strategy that we're taking is, to as quickly as possible, find the maximal regimens and get the most patients we can on them. We do think we have a pretty considerable head start. Most of these other assets are preclinical or just entering the clinic. And so as I told you, for the reasons I've told you, we're confident that for instance, a 3-drug regimen will allow us to address 80% to 90% of the patients and get essentially maximal effects and that does, of course, provide a barrier to entry, both in terms of even enrolling clinical trials and certainly in terms of commercially once you're already there. So that's really the competitive strategy. And it's supplemented by our business development strategy, as Ian said. So if some of those assets come from externally and we can put them together into even better combinations, all the better for patients and, of course, for us. And the first question is really, what's our confidence around 661. And as I said, the FEV1 response that we saw in that study in the Delta 508 homozygous patients, was pretty comparable to what we've seen in the other Phase II studies. So if anything, that increased our confidence in the effects we're seeing since it went through 12 weeks. I'd also remind you that there's a lot of other Phase II data out there. For example, adding 661 to patients who are on KALYDECO, who have a gating mutation in which in a Phase II study, we showed, I think about a 4.6% further increase in their FEV1. And of course, that's become a part of our Phase III program. I think one of the key questions that we have and that others have is, what is the likelihood of success of the 2-drug combinations, 661 plus KALYDECO in the heterozygous min population, the really the most difficult population to treat. And as we've said before, we think that has a lower probability. We haven't actually tested the drug yet there. But on the other hand, those patients have nothing today. So the way we're managing that in the Phase III program is, there is a separate study in that population. But it looks quite different, and we're going to enroll a reasonably small number of patients, about 120, and then we're going to do a futility analysis based on those 120 to decide whether to continue and enroll another 150, which would give us the full pivotal trial. So it allows us to manage the risk there, if you will, while we're also bringing forward, of course, the next generation correctors that we think have a higher likelihood of success in that population."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question for today comes from the line of Matthew Harrison from Morgan Stanley.",16,"And our final question for today comes from the line of Matthew Harrison from Morgan Stanley."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So if I could just ask again on the next generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, and you know the sites you want to target. It sounded like you were still doing some work to get the molecule ready.",118,"So if I could just ask again on the next generation corrector. I think earlier, you suggested that it's -- you obviously know the targets, and you know the sites you want to target. It sounded like you were still doing some work to get the molecule ready. I was wondering if you could be any more specific. Is this formulation work that's still necessary tox work? Is it that you have a few compounds and you're trying to pick which one you actually want to move forward and put in the clinic? So maybe, if you could just be a little bit more specific there. And then separately, Ian, could you just talk about FX for 2015?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff again. I'll answer the first part, and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first gen corrector lik",186,"Yes, this is Jeff again. I'll answer the first part, and then I'll let Ian answer on the FX. So what we've said here is, and where we are here is that we have multiple second generation correctors, which do add to KALYDECO plus the first gen corrector like 661. And we're basically at the stage of lead optimization. And as you know, what that involves is optimizing around several parameters; PK, drug-drug interaction and toxicity. And so these molecules are at various stages there of optimizing PK tox and drug-drug interaction and when we get the first one, which we expect to do this year, optimize for those, we'll take that into the clinic. But our plan is not to just pick one and take it into the clinic. Our plan is actually to pick multiple versions here. They have different flavors. They buy into different sites, we believe, and so we will test multiple versions and multiple combinations in the clinic and as I said, starting this year and then certainly going into next year. Does that answer your question about the second gen?"
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That does.",2,"That does."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the FX question, I know it's been a popular discussion through Q1 results. We also have x U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from x U.S. And so we suffered the same headwinds that the ot",187,"And to the FX question, I know it's been a popular discussion through Q1 results. We also have x U.S. revenues. In fact, in the first quarter, approximately 45% of the KALYDECO revenues do come from x U.S. And so we suffered the same headwinds that the other companies have suffered. However, as you can see, we recorded $130 million with the revenues in the first quarter. The launch is going very well. To the broader story of the full year, we anticipate -- the FX does have an impact on our revenue line. However, we've taken appropriate measures in terms of hedging against those revenues. And then when you look at the bottom line for the company, we have a natural hedge because we have overseas operations where we're benefiting from a reduction in expense because we're getting favorable benefit there on the expense line. So we've managed the FX and for the rest of the year, we believe we're in good shape. We continue to be committed to our revenue guidance of $560 million to $580 million for KALYDECO, and we're happy with our position."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks. That will conclude tonight's call. We thank everybody for tuning in. We apologize for the transmission problems that occurred on the webcast earlier. We do plan, as we mentioned, to post the transcript on our website and in addition, when the repl",79,"Thanks. That will conclude tonight's call. We thank everybody for tuning in. We apologize for the transmission problems that occurred on the webcast earlier. We do plan, as we mentioned, to post the transcript on our website and in addition, when the replay of the webcast is available, it should be complete and free of breaks and interruptions. The IR team is available in the office tonight, if you have any additional questions. Thanks, and have a good night."
36235,290824197,798272,"Vertex Pharmaceuticals Incorporated, Q1 2015 Earnings Call, Apr 29, 2015",2015-04-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a good day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a good day."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Good evening, everyone, this is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded,",313,"Good evening, everyone, this is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded, and the replay will be available following the conclusion of tonight's call on our website. 
Earlier in July, we announced the approval of our and many of you joined for that call. Tonight, we will be focused on second quarter performance and our execution against our corporate strategy. 
Joining me on today's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Jeff Chodakewitz, our Chief Medical Officer, is traveling and is not with us tonight. 
Our agenda tonight is as follows: Jeff will begin by discussing key priorities for our business. Stuart will review the second quarter performance on KALYDECO and make a few comments on the Orkambi launch. And to close, Ian will review the second quarter 2015 financial results and update our 2015 guidance. You can access the webcast live by going to the events section of the Investor Relations page on our website. 
I would remind you that we will make forward-looking statements on this conference call. Be statements are subject to risks and uncertainties discussed in detail in today's press release and our 10-K, which has been without limitation. Those regarding the ongoing development and potential commercialization of Orkambi, those about Vertexs' other cystic fibrosis programs and Vertex' future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. 
Information regarding our use of GAAP and non-GAAP financial measures and the reconsolation of GAAP to non-GAAP is available on our second quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast. I will now turn the call over to Dr. Jeff Leiden."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. The approval of Orkambi on July 2 was an important milestone in our shared journey with the cystic fibrosis community. Orkambi is the first FDA approved medicine to treat the underlying cause of CF for the approxim",401,"Thanks, Michael. Good evening, everyone. The approval of Orkambi on July 2 was an important milestone in our shared journey with the cystic fibrosis community. Orkambi is the first FDA approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S,  12 years and older, with 2 copies of the F508del mutation. This is a big step forward toward a long-term vision of helping more people with CF. We feel very fortunate to be part of the CF community and we appreciate all of the positive feedback we have received and continue to receive from patients, caregivers, healthcare providers and the broader CF community. 
At the beginning of this year, we outlined 3 strategic priorities that will allow Vertex to continue to deliver on our vision to make new transformative medicines available to patients globally. Let me briefly review our progress toward meeting those goals. First, through both geographic and label expansion, we have continued to grow the number of patients treated with KALYDECO resulting in strong revenue growth. With the Orkambi approval and launch in the U.S., we have an even greater opportunity to treat more patients, resulting in additional revenue growth. 
Second, we know that there's still much more to do. We continue to make significant investments into multiple programs to create more CF medicines that may enable us to treat even more patients and to improve the benefit for the patients we treat. 
All 4 studies included in the VX-661 plus ivacaftor pivotal Phase III development program are initiated, and we also remain on track to bringing in next-generation CFTR corrector into the clinic by the end of 2015. 
And third, we have expanded and diversified our pipeline through our collaboration with to develop and commercialize investigational epithelial sodium channel, or E-mac inhibitors, for CF and other pulmonary diseases. We also continue to advance early-stage development programs outside of CF, including clinical programs in oncology and research programs focused in other areas. We look forward to updating you on these programs later this year. 
The continued execution on our strategy has fundamentally changed the outlook for our business. Specifically, moving forward, we expect to deliver a financial profile of growing revenues, earnings and cash flows, while also continuing to invest to create new medicines to treat more patients with CF and other serious diseases. 
With that, I'll hand it over to Stuart."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making Orkambi available to eligible patients in the U.S.. Global sales of KALYDECO this quarter were $155",409,"Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making Orkambi available to eligible patients in the U.S.. 
Global sales of KALYDECO this quarter were $155 million, comprised of U.S. sales of approximately $93 million and X U.S. sales of approximately $62 million. This represents a 37% increase compared to $113 million in the same quarter last year. The strong growth of KALYDECO is a result of both geographic and label expansion. We have seen good uptick in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015. 
Internationally, there's also been rapid uptake of KALYDECO by eligible patients in Australia following the reimbursement agreement reached in late 2014. Also during the second quarter, we achieved reimbursement approval for nonG551D gating mutations in several European countries where these mutations are prevalent, including Italy, France, England and The Netherlands. As a result, today, more than 85% of eligible gating patients in Europe now have access to KALYDECO.
So the growth in patients receiving KALYDECO will be tempered by enrollment in the VX-661 program as previously described, and this is reflected in our KALYDECO revenue guidance. 
Now turning to Orkambi. Since the FDA approval of Orkambi on July  2, we have been working to get the medicine to the approximately 8,500 eligible patients as rapidly as possible. Our field teams around the country had been educating healthcare providers on the Orkambi prescribing information. Since approval, they have visited the vast majority of the 275 CF centers in the U.S.. 
As we anticipated, interest in the medicine is very high. We believe that all eligible patients with CF should have access to Orkambi. Our public and private payer interactions to date have been productive, and our patient support team has begun to help patients navigate the reimbursement process. Thanks to these efforts and the commitment of healthcare providers that CF centers across the country, I'm happy to report that the first patients are already receiving Orkambi in the U.S.. 
In summary, geographic and labor expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of Orkambi, we are significantly expanding the number of eligible CF patients we treat. 
I'll now hand the call over to Ian."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Tonight, I'd like to discuss our second quarter 2015 financial results and then update our 2015 financial guidance. Firstly to the financials. KALYDECO revenues were $155 million this quarter and we're up 37%",342,"Thanks, Stuart, and good evening, everyone. Tonight, I'd like to discuss our second quarter 2015 financial results and then update our 2015 financial guidance. 
Firstly to the financials. KALYDECO revenues were $155 million this quarter and we're up 37% from the second quarter of 2014, and up 18% sequentially compared to our first quarter this year. We continued to nicely expand the number of our eligible patients we treat with KALYDECO. 
Our second quarter non-GAAP R&D and SG&A expenses were $254 million, an increase of $17 million compared to last year, mainly due to an increase in SG&A expenses supporting the launch of Orkambi. Our non-GAAP net loss was $131 million compared to prior year non-GAAP net loss of $142 million. 
From a bouncy perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter. 
Let's now turn to the 2015 financial guidance and specifically KALYDECO revenues and combined R&D and SG&A expenses. Earlier this year, we anticipated 2015 KALYDECO revenues to be between $560 million and $580 million. And based on an increased uptake due the label and geographic expansions as Stuart previously mentioned, we now expect KALYDECO revenues to be between $575 million and $590 million for the full year 2015. 
For the non-GAAP operating expenses, we continue to expect the combined non-GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. I'll just note that we expect our operating expense to be higher in the second of this year compared to the first half, mainly as a result of the anticipated progress with the VX-661 pivotal program and investment to support the launch of Orkambi. 
I will close by stating that we are in a strong financial position today. We are growing our revenues, and we expect to show a additional growth for Orkambi. We will continue to invest to create even more medicines and support access to those medicines already approved. 
With that, I'll ask the operator to please open the line for questions."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets.",13,"[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question for Stuart and a question for Ian. I guess Stuart appreciate the comments on the launch. Maybe if you could just comment on more specifically on reimbursement and the process for reimbursement that you're seeing our payers quickly getting peopl",134,"A question for Stuart and a question for Ian. I guess Stuart appreciate the comments on the launch. Maybe if you could just comment on more specifically on reimbursement and the process for reimbursement that you're seeing our payers quickly getting people on drug. Maybe walk us through that process and how long it takes to get people on drug, what you're seeing out there? And then for Ian, I know you've maintained the guidance for expenses, that's fantastic. I know people are thinking bigger picture as you transformed for a profitable company. Maybe you can comment about how R&D expenses -- how you're thinking about getting your inhibitor and all of these Phase III. So how are you thinking about controlling some of that are making sure we're going to be very profitable?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Stuart work. Thanks for the question. So in terms of the process of reimbursement, essentially, payers fall into a couple of different camps. Some comes in making formal decisions very quickly, and we've seen some of those. Most have a process",181,"Mike, it's Stuart work. Thanks for the question. So in terms of the process of reimbursement, essentially, payers fall into a couple of different camps. Some comes in making formal decisions very quickly, and we've seen some of those. Most have a process where they're going to have kind of the equivalent of a PMT committee and review the product. And those who often then put in serve interim policy as it were where they'll evaluate on a case-by-case basis where a patient can be initiated on Orkambi. And so as a result of those interim policy and some initial policy decisions, that's why we have already seen patient start on Orkambi in the first few weeks following launch. And then over the next few months, more and more payers will come to their final determinations on their coverage policies for Orkambi. As I say, based on the discussions we've had so far, we do continue to anticipate that we are going to have broaden and positive reimbursement for Orkambi. And I pass it over to Ian to the expense question."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, thanks for the question. I may take a little broader if you don't mind, really comment on what is our goal on, let's say, the Vertex financial profile. And it starts with growing revenue stream, which we are very confident around, given the recent a",214,"Mike, thanks for the question. I may take a little broader if you don't mind, really comment on what is our goal on, let's say, the Vertex financial profile. And it starts with growing revenue stream, which we are very confident around, given the recent approval of Orkambi. We look at growing that rapidly by providing access to the medicines that are already approved and basically holding the steady-state, our operating expenses in a -- in the company. The primary driver within our operating expense structure is R&D. That's a function of our commercial model is because we get provide access to the medicines around the world, which is highly leveraged with small investment required to provide access to these medicines actually. Access to medicines is more about education than it is about selling the drug. So that allows us as the business to reinvest in R&D yet still aim to have high operating margins. And as we see out over the next 3, 4 years, we do see ourselves as the business that if we can drive up our medicines to patients and hold our operating expense, which is exactly what we expect, that we generate high operating margins and operating margins that are consistent with our, let's say, logic cap biotech peers."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Geoff Meacham with Barclays.",10,"And our next question is from Geoff Meacham with Barclays."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple of more clinical questions. I'm open some of your answer. I noticed in the press release today, one of the endpoints for the younger population in Europe, 6 to 11, was absolute change in lung clearance. I wasn't sure if you guys were sort of reth",84,"A couple of more clinical questions. I'm open some of your answer. I noticed in the press release today, one of the endpoints for the younger population in Europe, 6 to 11, was absolute change in lung clearance. I wasn't sure if you guys were sort of rethinking some of the end points over all for development beyond FEV1? Or is this just a special case, just given the age of the population? I have a couple of other pipeline questions just to follow."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. Thanks for asking this question. We've been talking for some time, both with Wall Street and with regulators, about innovation that w",180,"Jeff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. Thanks for asking this question. We've been talking for some time, both with Wall Street and with regulators, about innovation that we are eager to explore additional endpoints to FEV1, particularly for younger population where it's more difficult to consistently good FEV1 for 2 or 3 years old. And as part of that, we've explored 3 or 4 different endpoints, including lunch clearance index. And this was a very nice opportunity in talking with European regulators about this younger population to begin to use lung clearance index, which is much less and much more consistent particularly in young patients as an efficacy endpoint. So it will be interesting from see the results of this study, which we think will be highly predictive using this endpoint. And we also plan to use of those kinds of results to begin to discuss without the regulators whether these other endpoints might be useful, particularly in the young -- very young patients."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that's helpful, Jeff. And then a question, just on the inhibitor. Does this change the priorities for you guys for the -- for your next-gen corrector? Or is this -- would you view this, this kind of complimentary to what you already have? And then a",68,"Okay, that's helpful, Jeff. And then a question, just on the inhibitor. Does this change the priorities for you guys for the -- for your next-gen corrector? Or is this -- would you view this, this kind of complimentary to what you already have? And then are we still on track to identify the third corrector by, I guess, by year end or early part of next year?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe I'll take those in reverse order, Jeff. Yes, we are absolutely on track to identify the third corrector. And just a reminder, I noticed that our strategy here has been to bring multiple next-gen collectors into the clinic and our goal is the first o",199,"Maybe I'll take those in reverse order, Jeff. Yes, we are absolutely on track to identify the third corrector. And just a reminder, I noticed that our strategy here has been to bring multiple next-gen collectors into the clinic and our goal is the first one by the end of this year, with several others following directly behind it, and that's progressing nicely and we are on track. With respect to the Orkambi inhibitors, yes, we do view them very much as complementary. And they could be complementary in a couple of ways, right? Because they fall outside of the classic CFTR correction. They may have activity as monotherapy, particularly in populations that don't have anything. And frankly, and other lung diseases as well, but we're particularly eager to study them on top of our current regiments, like Orkambi because they may amplify the signal that we're seeing here. So I wouldn't view them as one or the other, I would definitely view them as complimentary. And I guess your question is sort of getting at it anyway, slowdown or de-prioritize our next and corrector, and the answer is no. We are full-speed ahead of the next-gen practice."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matt Roden with UBS.",9,"Our next question is from Matt Roden with UBS."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First, Stuart, I wonder if you could elaborate on some lunch metrics that you're seeing? I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from prescription",152,"First, Stuart, I wonder if you could elaborate on some lunch metrics that you're seeing? I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from prescription to fill? Any other metrics you can shift to give us a sense on what's happening out there. And then I think this might be for Ian. If you could help us square the sales and the increase in guidance against your prior comments regarding the impact of enrollment of VX-661 trials on KALYDECO use. Do you have a same-store sales metric that enables you to see that, that impact is happening, but that the geographic expansion and label extension is compensating for that? Or is it just that it's actually not happening to the extent that you previously thought that is the impact of VX-661 trials?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, it's Stuart here. Just in terms of lunch metrics. I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how productive those are, the kind of the trajectory that we're seeing over al",174,"Matt, it's Stuart here. Just in terms of lunch metrics. I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how productive those are, the kind of the trajectory that we're seeing over all. As we said before, because of the interest in the product, the unmet need and the fact of the treat underlying cause, we're sent to and expecting the overall penetration of Orkambi in the eligible patient population will be high. And we've said all along that we do think though it will take longer for Orkambi to reach peak penetration compared to KALYDECO for a number of factors that we've gone into previously like the volume of patients and the time it's going to take to educate patients and get them to the reimbursement approval process. But yes, it's really much too early to be throwing around specific launch metrics right now. And I know the guidance in KALYDECO revenue question, I'll throw it over to Ian."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Matt, this for the question. First off, we're very pleased with the expansion of KALYDECO in let's say, treating more patients through geographic and label expansion. As far as the guidance we provided for the full year, we do actually now anticipate",164,"Yes, Matt, this for the question. First off, we're very pleased with the expansion of KALYDECO in let's say, treating more patients through geographic and label expansion. As far as the guidance we provided for the full year, we do actually now anticipate patients that would be available for the medicine, mainly in Europe actually, to go into the 661 trials. Remember, we -- as Orkambi was approved in the U.S., we switched equipment of the VX-661 pivotal studies to Europe. Europe is where we're starting to continue to recruit new patients potentially based on the label expansion of KALYDECO. And instead of going on to KALYDECO, we are starting to recruit those into our 661 studies. So we have built that into our guidance and, hence, why we come out with something that is between 5 75  and 5 90 , therefore, reflecting a lower growth rate than where we currently are between Q1 and Q2. We do think it will flatten out."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Geoffrey Porges with Bernstein.",9,"Our next question is from Geoffrey Porges with Bernstein."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question first related to the extension study for the patients that were on Orkambi coming to the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled in state on treatment? And then what numbe",79,"A question first related to the extension study for the patients that were on Orkambi coming to the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled in state on treatment? And then what number of them have rolled over to commercial drug? And then I just wanted a quick follow-up on VX 371. Jeff, you could address why do the study with Orkambi rather than with 661?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Jeff, to that would here without the exact numbers, but it was north of 90%",130,"Jeff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Jeff, to that would here without the exact numbers, but it was north of 90% of patients rolled over from TRAFFIC and TRANSPORT into the open-label extension. About half of those were in the United States. In the process of informing the centers and those patients that the commercial product is now available beginning to roll those patients over to commercial product is just beginning. But it's about 500 or so of the thousands who rolled over into the 105 study. We're here in the United States. And on the VX-371, I'll pitch   that to Jeff Leiden."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff. In terms of the VX-371  and where we're going with Orkambi, it's really a matter of how we get the medicine potentially to patients the fastest. So since Orkambi is already approved, simply adding 1 unapproved drug in getting result will let us",76,"Yes, Jeff. In terms of the VX-371  and where we're going with Orkambi, it's really a matter of how we get the medicine potentially to patients the fastest. So since Orkambi is already approved, simply adding 1 unapproved drug in getting result will let us, assuming that we have successful, get to -- get that new drug, VX-371 to patients the quickest. Then our goal all along has been improving therapy as quickly as we could."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Terence Flynn with Goldman Sachs.",10,"Our next question is from Terence Flynn with Goldman Sachs."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just to for me. Can you just remind us about the anticipated timing of Medicaid coverage for Orkambi? And regarding the VX-661 KALYDECO trial and, now that you started that trial, can you just maybe remind us of expectations for one that's in the ro",49,"Maybe just to for me. Can you just remind us about the anticipated timing of Medicaid coverage for Orkambi? And regarding the VX-661 KALYDECO trial and, now that you started that trial, can you just maybe remind us of expectations for one that's in the room analysis might occur?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives",", it's Stuart here. In terms of Medicaid coverage, there really isn't 1 answer. There's really 50   answers because, obviously, Medicaid managed state-by-state. So I really can't give you 1 answer to the Medicaid question. What I can share is that we've a",119,", it's Stuart here. In terms of Medicaid coverage, there really isn't 1 answer. There's really 50   answers because, obviously, Medicaid managed state-by-state. So I really can't give you 1 answer to the Medicaid question. What I can share is that we've already seen patients initiated on therapy in the first 4 weeks. And within that number of patients, we have patients who have commercial insurance to their primary insurance. We also have patients who have government insurance in the number people who've already been initiated. But to give 1 specific number for Medicaid is just impractical because there's really 50 answers to that particular question. And for the second part of the question, I'll hand it over to Jeff."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, in terms of the trial, just to reminder you, Terrace, we actually just announced that, that trial is open for enrollment so it's essentially, starting now if you want to think it about it that way. And to remind you the design of that trial, it actua",149,"Yes, in terms of the trial, just to reminder you, Terrace, we actually just announced that, that trial is open for enrollment so it's essentially, starting now if you want to think it about it that way. And to remind you the design of that trial, it actually has 2 parts. We enrolled around 150 patients, plus or minus. We then have the SMB that will do futility analysis. We want naturally see the numbers at that point reducing keep the list period if it's futile or to  continue. If they tell us to continue,  we then enroll another approximately 150 patients. Because of the shorter study than the 24-week homozygous study, we would still have visibility to that data by the time we had visibility to study.. We expect that to be some time to 2016, depending on how quickly the enrollment goes. Does that answer your question?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And maybe, Stuart, one follow-up on Medicaid. Can you just remind us in terms of KALYDECO what the benchmark was there? In terms of the -- I understand the level, but just what was the range in terms of how low the process took from the first day to the l",52,"And maybe, Stuart, one follow-up on Medicaid. Can you just remind us in terms of KALYDECO what the benchmark was there? In terms of the -- I understand the level, but just what was the range in terms of how low the process took from the first day to the last day?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, I mean, we're splitting hairs a little bit. That Terrace in the uptake with KALYDECO was so rapid. As you know, we've got to 90-plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both commercia",78,"Well, I mean, we're splitting hairs a little bit. That Terrace in the uptake with KALYDECO was so rapid. As you know, we've got to 90-plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both commercial payers and Medicaid. So there really wasn't much of a range that I could give you there. It was incredibly rapid for KALYDECO across all patient populations and all insurers."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Carrick Asimov with JC recently JPMorgan Chase.",12,"Our next question is from Carrick Asimov with JC recently JPMorgan Chase."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess just to follow-up on that. Just based on early discussions with payers on Orkambi, is there any change to your expectations for gross to net? Or maybe in other ways, reaction to the price has been about what you expected? Would you announced it ea",213,"I guess just to follow-up on that. Just based on early discussions with payers on Orkambi, is there any change to your expectations for gross to net? Or maybe in other ways, reaction to the price has been about what you expected? Would you announced it earlier this month? And then secondly on the new product you have, does the ongoing Phase II trial in patients with any CFTR mutation include heterozygous patients? On the ranch on the price, I would say, has been very balanced. Indeed, the focus of our discussions this really been less around the price and more around the clinical profile of Orkambi. And in terms of whether the changes our view on the gross to net, it really doesn't. The gross to net is almost exclusively driven by the payer mix. And as we explained previously, we are expecting the Medicaid payer mix to be a higher percentage for Orkambi than it was for KALYDECO, and it's likely to be in around sort of 35% to 40% of eligible patients we predict. We'll be covered by Medicaid. The vast majority of the rest will be covered by commercial insurance. But our view on that gross-to-net hasn't been changed by anything we've seen in the first 4 weeks."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Great And then in terms of that trial in this reminder, we're actually planning to close the first one is already under way. And that treal is basically monotherapy in any mutation the massive you're referring to headmans, and so the answer is yes.",90,"Okay. Great And then in terms of that trial in this reminder, we're actually planning to close the first one is already under way. And that treal is basically monotherapy in any mutation the massive you're referring to headmans, and so the answer is yes. Headmans would be there, with the obvious exception that KALYDECO treated patients and now going forward, Orkambi treated patients will be included in map study. The second study is going to be the inhibitor on top of Orkambi in patients who are treated with Orkambi."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Ying Huang with Bank of America Merrill Lynch.",13,"Our next question is from Ying Huang with Bank of America Merrill Lynch."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one maybe for Steve. It was reported that Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking Orkambi. I was wondering if that's a single isolated case? Or have you seen",129,"First one maybe for Steve. It was reported that Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking Orkambi. I was wondering if that's a single isolated case? Or have you seen that among the other payers or not? And then secondly on the R&D, I noticed that in the press release, you guys are adding 1 arm in the Phase III trial for 661. So the patients who have 1 a little of 508 and the other little with divestiture CFTR function. You're adding one off therapy at KALYDECO arm. Is that due to request from FDA? And also, are you going to add monotherapy on -- in the other Phase III trials in the CFTR trial?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and so I'm not going to comment think about not really going to comment on wood discussions we're having with individual pairs and plan. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to Orkambi an",77,"Yes, and so I'm not going to comment think about not really going to comment on wood discussions we're having with individual pairs and plan. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to Orkambi and it's proved to be a decision for the physician and patient whether they want to initiate those patients on Orkambi. And on the 661 program, I'll hand it off to Jeff."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, just to be clear, the design of the 661 program has not changed. We haven't added new ones. The residual function arm, the residual multiple placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there.",40,"Yes, just to be clear, the design of the 661 program has not changed. We haven't added new ones. The residual function arm, the residual multiple placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matthew Harrison with Morgan Stanley.",10,"Our next question is from Matthew Harrison with Morgan Stanley."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just wanted to go back to the just for a second. I mean, I think you talked a little bit about the rationale, but maybe you could expand upon the rationale for combining with Orkambi. And then secondly, I mean, what specifically might you hope to see",114,"So I just wanted to go back to the just for a second. I mean, I think you talked a little bit about the rationale, but maybe you could expand upon the rationale for combining with Orkambi. And then secondly, I mean, what specifically might you hope to see? Should we be looking for increased lung function? Should we be looking for a lowering of the exacerbation rate? I mean, what would you be hoping to see with that combination? And then separately, just on KALYDECO, I just want to make sure I understood your comments correctly. Are you saying that all of the growth came from increased penetration across the new gating mutations?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe I'll take the R&D question first. The Orkambi inhibitors and the in terms of the ocean and seaweed, but I can't be nearly that eloquent, but I can't be nearly the pelican so I'll take it from a more scientific standpoint maybe. The way we think abou",277,"Maybe I'll take the R&D question first. The Orkambi inhibitors and the in terms of the ocean and seaweed, but I can't be nearly that eloquent, but I can't be nearly the pelican so I'll take it from a more scientific standpoint maybe. The way we think about Orkambi work as you know si that II work is that enough to suffer China to soak in China that is also involved in hydrating the secretion in the mucus, in the lung. And so you can think about it as -- and it's actually even an interaction with CFTR. So CFTR's corrigenda that's then you ENaC it tells hybrid the mucus. And so the rationale is based upon preclinical studies is that if you combine the ENaC inhibitor with the potentiator, for example, or corrector potentiator, you get even better hydration of the mucus, which then should lead to better lung function. So what we're doing with the ENaC inhibitor program is were acting the question was best that ENaC inhibitor alone have the activity to help hydrate. Us and improve the functioning of mutations? And then if we think the ENaC inhibitor and added to KALYDECO or Orkambi, can we get better hydration them because of the single agent the loan? And the rationale is really based upon the work we've done in our human epithelial cell essays that sake then you had any ENaC inhibitor to a CFTR corrector or a corrector plus  potential, you actually get even better hydration. So the question is, does that translate into clinic and improvements in FEV1? And we definitely going to be looking at heart endpoints like FEV1."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where R117H patient population with added to the label at the back end of 2014. And the",144,"And in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where R117H patient population with added to the label at the back end of 2014. And then in March, we were also approved for use in children between 2 and 5, with eligible mutation. So there's labor expansion here in the United States. And then outside of the U.S., it really has been geographic expansion, such as G551D patients in Australia where the uptake has been very rapid. And then also addition of the gating patients in a number of countries in the EU. So there really isn't 1 answer to what's been driving that KALYDECO revenue growth. It really has been that combination of label expansion into new populations and geographic expansion into new markets."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Your next question is from March on an them with Evercore ISI.",12,"Your next question is from March on an them with Evercore ISI."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is sitting in for Mark. But just a few questions. One, around the Pittman trial. I'm wondering about potential disclosure or lack of disclosure at the interim. If it doesn't hit and expansion is required and for furnished for 150 patients. The second",173,"This is sitting in for Mark. But just a few questions. One, around the Pittman trial. I'm wondering about potential disclosure or lack of disclosure at the interim. If it doesn't hit and expansion is required and for furnished for 150 patients. The second question had to do with this long index. Just wondering, the Vertex is previously used at endpoint any of these from any data from any those drugs. vertex's previously used a template any chance have any data from any of these and if so, if not, in terms of thinking about how fun I felt about the and design of the study based on that. And then, the last question in terms of the next generation corrector and 1 coming by year and -- but as I understand, there'll be additional probably next-generation corrector, potentially next-generation translators. But next generation correctors that may follow. Which I was wondering if Vertex is perhaps, hiding or just quantify how many of those, maybe I to bring to the clinic in 2016."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Let me, this is Jeff, let me take the last 2 questions and then I'll turn it over to Ian on the disclosure question. Starting with the next general program, we've said previously that we have multiple next-gen correctors in lead optimization, which,",192,"Sure. Let me, this is Jeff, let me take the last 2 questions and then I'll turn it over to Ian on the disclosure question. Starting with the next general program, we've said previously that we have multiple next-gen correctors in lead optimization, which, as you know, is sort of for study of the drug like properties anti-pots that the photos molecules. As I said, we are tracking to bring the first of those into the clinic this year and to bring at least 2 or 3 additional behind that following completion off we optimization for those additional molecules and to compare several different next generation correctors. And then your consumate lung about lung clearance in this. Lung U.S. index is actually a fairly widely used measure of the ability to empty lungs of air effectively. And there is data from a number of studies showing, for instance, that when patients are G551D patients were treated with KALYDECO. There's a significant improvement on lungh clearance index. And we're happy to send you some of the study so it is an endpoint pharmacologically validated if you want to think about it that way."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question. Just refer to an earlier comment Jef fLeiden made, which was the initial of cohort of patients in terms of the hats men's study with 661 and the idea of that is a very safe utility assessment. That utility assessment is an indepen",190,"Thanks for the question. Just refer to an earlier comment Jef fLeiden made, which was the initial of cohort of patients in terms of the hats men's study with 661 and the idea of that is a very safe utility assessment. That utility assessment is an independent advisory board, teams that it is progressing forward. We would just continue to recruit patients in the study will be we would have that the disclosure point at that that will just continue to recruit into this study and wait for the complete and final results of that study. If the board deems that it is futile, effectively few without inducing those patients, they would advice of so -- and will curtail a study on stopping that study and working the patients on drug. We will provide a disclosure a collection of that that, that studies no longer going forward. The way to think about it is if this point is, it is because the study will progress and they will continue to recruit patients and if there is a an early closure of that study will advise you that point in time."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And I guess just to, there won't be necessary incase in number of patients on criticaltrials.gov, and increasing the number of patients on clinical front spoke of or anything of that sort?",32,"And I guess just to, there won't be necessary incase in number of patients on criticaltrials.gov, and increasing the number of patients on clinical front spoke of or anything of that sort?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, they won't be any disclosures.",6,"No, they won't be any disclosures."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Robyn Karnauskas with Deutsche Bank.",10,"Our next question is from Robyn Karnauskas with Deutsche Bank."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","There's 2 questions, one for Stuart and one for Ian. So you guys have talked a lot about centers there could be a backlog processing within the CF centers and there may not be a lot doubt that. Can you just talk a little bit about what you see or anything",103,"There's 2 questions, one for Stuart and one for Ian. So you guys have talked a lot about centers there could be a backlog processing within the CF centers and there may not be a lot doubt that. Can you just talk a little bit about what you see or anything done like help that process as patients through? And center or is that with the expectations? And then  for Ian, a lot of your comps are diversified and you still are Julia's company. And you still are company and what are your thoughts on the [indiscernible] patients over the next year?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Stuart here. Like what it's really does, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would, and those factors, just to remind you, is the volume of patient",310,"It's Stuart here. Like what it's really does, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would, and those factors, just to remind you, is the volume of patients is obviously much greater than it was when KALYDECO was initially approved just the G551D patients. So there's a volume of patients that centers need to get in. Then obviously, when a physician is making the decision to start the patient on a new drug, then, obviously this fair amount of discussion. Education is going to want to go on their, explaining the product, the mechanism of action, how to take it, all those sorts of things. And then, obviously, we move on to the sort of reimbursement approval process. And so all of this fact is that we anticipated prior to launch the involved in how the launches going to go have certainly been playing out exactly as we thought we -- as we thought they would. In terms of what we're doing to support centers, we're doing a number of things, clearly, providing education materials to support their discussions with their patients. We're providing them with help in terms of sort of materials they need to submit to the various payers, be it prior authorization, documentation and stuff like that. Providing them help with what documentation they're going to need, whether I place to send spend that is. It in and from a ner support funded become August our patient services group this is there to support individual patients to navigating navigated the reimbursement process as well. And so were as compliantly as possible. We are provide as much support as we can to help patients get access to the medicine. On the second, I'll pass it over to Ian."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robin, thanks for the question. I think we're focused on CF, we're very pleased about that. And -- but also I'd say that we still need to continue to be focused on CF and part of our, let's say, corporate or our business development strategy as well as ou",250,"Robin, thanks for the question. I think we're focused on CF, we're very pleased about that. And -- but also I'd say that we still need to continue to be focused on CF and part of our, let's say, corporate or our business development strategy as well as our investment research is about strengthening our position creating even better, combination medicines to treat more patients in CF. So that is one tactic, and so we're continuing to see I think it is the company to continue to raise the bar in terms of the benefit we provide patients with our medicines and that's why we reinvest. We also reinvest in other areas in the company, and I hope that later this year and early next later this year, we can tell you a little bit more  about those other disease areas that we're in, as well as other business development efforts, which are to expand our scientific footprint. And then also just to consider other products that may diversify and stage our pipeline, it tends to be earlier stage ideas. I think that's appropriate for a company our stage as we progress forward and our priority is still cystic fibrosis. I flow it over Jeff Leiden though because they think there's much more kind of a strategic comments it's worth making here, which is why we're successful in CF, we're not taking our eye off that we want to go into other disease. And maybe Jeff, you have a comment?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it is CF. Not only increasing the number of patients that we can treat with new medicines, but actually incre",258,"Yes, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it is CF. Not only increasing the number of patients that we can treat with new medicines, but actually increasing the benefit for all the patients we're treating. And I that many times is to get to the majority our goal is to that of the majority, more than 90% of patients with medicines that have KALYDECO better effects. And I think we're executing well on that and we're well on track. At the same time, obviously we are investing in areas outside of CF. As I've said, we'll bring more new compounds into the clinic this year at Vertex than we ever had in the history of the company. We're not talking a lot about that just, but to start view more news us the begin to get clinical results I think later and certainly the next year. And then the third part is that we're going to have that financial resources to also invest in innovation outside the company. And we're spending significant more time, effort, and money on our BD activities. You've heard a couple of deals, but they think you can anticipate more, again, typically focused on earlier stage sensitive platforms or assets. So it's really a 3-legged stool, and I think in the launch of you not, we'll have the financial wherewithal to invest in all 3 parts of this tool."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from the lady with Coen and Company.",11,"Our next question is from the lady with Coen and Company."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just 2 one scientific,  I guess actually both on clinical development. First on the VX-661 Phase III pick up the risk that for the future analysis hurdle is?  And then second, on the new second generation collectors. And then, second, on the new the secon",76,"Just 2 one scientific,  I guess actually both on clinical development. First on the VX-661 Phase III pick up the risk that for the future analysis hurdle is?  And then second, on the new second generation collectors. And then, second, on the new the second-generation correctors, can you give us some idea of what the clinical development, but is likely for those specifically how quickly could they get into combination therapy regimens within FEV1 and Park?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes, I think so we haven't disclosed the hurdle, and we want we will be Peter's closing. Asked Ian had, I think the first is that you would be didn't meet the hurdle and the study was to [indiscernible] what was going on. With do expect of them second-",155,"So yes, I think so we haven't disclosed the hurdle, and we want we will be Peter's closing. Asked Ian had, I think the first is that you would be didn't meet the hurdle and the study was to [indiscernible] what was going on. With do expect of them second-generation correctors, we really see them following a fairly straightforward development sort of pine you do a year with our previous medicines, and going to Phase I  in normal single-dose, multi-dose and following hopefully, successful safety results from those studies, we would put them both as monotherapy and as combination therapy into patients. I think we've figure out we've learned a lot over that's the risk about how to do the studies where quickly and very efficiently with small numbers the patients, so I think in the pretty definitive data using FEV1 as well as other endpoints on how they fare by themselves and in combination."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Tony Butler with Guggenheim partners.",11,"And our next question is from Tony Butler with Guggenheim partners."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, 2 brief questions. One, eliminating the sodium channel compounds for the moment. Is there a rationale for a next-gen corrector to actually be QD or BID, such as that it's more easily formulated with either ivacaftor and/or 661? And the second questi",72,"Jeff, 2 brief questions. One, eliminating the sodium channel compounds for the moment. Is there a rationale for a next-gen corrector to actually be QD or BID, such as that it's more easily formulated with either ivacaftor and/or 661? And the second question is, is there any rational from HIV experiment that actually to you that there may be the need for 3 correctors and additional -- in addition to a potentiator?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines because they've to take very large numbers of pills everyday. So we continue to",156,"Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines because they've to take very large numbers of pills everyday. So we continue to push for a coal formulated  product that's certainly had goal under 1 or small number of pills. And either QD or BID, both of those seem pretty accessible to patients and that's a certain our target profile with the next-gen correctors and combination. Do other question was, could we need 3 correctors? The answer is, we don't yet fully know, but certainly, our goal is to try to keep this to as few medicines as from drug-drug interaction and standpoint. From equal formulation standpoint. So again, if he asked me what our target profile, how was profile today, it would be he first GEN corrector or second Jen corrector and potentiator."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is going to be from Brian Skorney from Baird.",12,"Our next question is going to be from Brian Skorney from Baird."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess I just want to kind of get your temperature on how we should be thinking about pricing of the VX-661 combination and the context of Orkambi and KALYDECO's price? There obviously a different price points, but they're in different patient population",147,"I guess I just want to kind of get your temperature on how we should be thinking about pricing of the VX-661 combination and the context of Orkambi and KALYDECO's price? There obviously a different price points, but they're in different patient populations right now, but based on the 661 combo study, it's probably going to wind up in significant overlap between KALYDECO and Orkambi patients. I guess about 80% of KALYDECO responders and probably shown improvement on VX-661 plus ivacaftor based on the Phase 2. And it probably looks like there'll be a meaningful amount of clinical efficacy above and beyond Orkambi for the combination. So I guess is it more important to you guys to maintain price per patient for KALYDECO responders? Or to try to get Orkambi patients switch to the VX-661 combo? Because it doesn't seem like you can really do both."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I think, I mean, the most important things to us, overall, are to increase the number of patients that were able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our overa",116,"Yes, Brian, I think, I mean, the most important things to us, overall, are to increase the number of patients that were able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our overall strategy, and KALYDECO combined with VX-661 is a part of that overall strategy, but really, be commenting on price right now, is way too early. As you know, we've got days broad faced before starting across the multiple patient populations. And until we see the results, both safety and efficacy across those different patient population, it'd be inappropriate to be speculating on how we might price that combination."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess is, would there -- would you perceive any benefit outside of a double corrector potentiator combination to have patients on a 661 ivacaftor combo as opposed to Orkambi? Is this kind of a Phase II data ones up holding up and they look pretty simila",49,"I guess is, would there -- would you perceive any benefit outside of a double corrector potentiator combination to have patients on a 661 ivacaftor combo as opposed to Orkambi? Is this kind of a Phase II data ones up holding up and they look pretty similar efficacy wise?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not sure I understand your question. Do you ask again a double corrector combination? So basically what I'm getting at is would there be a reason to try to get patients on Orkambi to switch to 661 in your view? But the efficacy profiles relatively sim",48,"I'm not sure I understand your question. Do you ask again a double corrector combination? So basically what I'm getting at is would there be a reason to try to get patients on Orkambi to switch to 661 in your view? But the efficacy profiles relatively similar?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think it really depend on the totality of the profile. And while efficacy is one part of the equation, obviously, the safety as well. So it's really going to depend on what their position and patient think of the overall profile of the medicine if it's",105,"I think it really depend on the totality of the profile. And while efficacy is one part of the equation, obviously, the safety as well. So it's really going to depend on what their position and patient think of the overall profile of the medicine if it's successful in that population compared to their experience with Orkambi. So at this stage, it's really a very hypothetical discussion. We'll wait and see how the Phase III program plays out. When we got the results in hand, we'll be able to have a much more informed discussion about which patient populations maybe eligible for VX-661 and ivacaftor."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question is from Lisa Baker with JMP Securities.",11,"And our last question is from Lisa Baker with JMP Securities."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, okay. First question, I just want to better understand the guidance. So if we extrapolate the results this quarter and just assume its flat for the remainder of the year, we actually get to a number of certainly about your guidance. So I'm just wond",78,"Okay, okay. First question, I just want to better understand the guidance. So if we extrapolate the results this quarter and just assume its flat for the remainder of the year, we actually get to a number of certainly about your guidance. So I'm just wondering if there's was any stalking, or is there's some FX kind of considerations or greater gross-to-net in the future. What -- can help us better understand the guidance you provided for KALYDECO?"
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Lisa, thanks. We definitely saved the best for last. Congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying last 3 quarters of the same is the se",146,"So Lisa, thanks. We definitely saved the best for last. Congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying last 3 quarters of the same is the second and the first quarter is already done, now you do get to slightly above the 5 90, that's correct. I made comments earlier on the call thought that says we do anticipate patients that we expected to come onto KALYDECO treatment will now go towards the 661 Phase III study. And clearly, we're trying to estimate that, but we have taken a conservative approach, and we anticipate that, that will affect the growth of KALYDECO, specifically in Europe and therefore, we're not anticipating a significant growth in the second half of this year with KALYDECO."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That makes us a totally didn't put that together. And then just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made? Or in this population? Or how you powere",86,"That makes us a totally didn't put that together. And then just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made? Or in this population? Or how you powered it and kind of like what clinical difference you expect to see or make sense just because we're not as familiar within it and haven't seen as much of the data. That would be very helpful."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question, this is Jeff. We haven't disclosed the numbers there and probably won't until you get towards the end of the study. There is a fair amount literature out there that we can send you on what kind of numbers one might see, as I said,",78,"Thanks for the question, this is Jeff. We haven't disclosed the numbers there and probably won't until you get towards the end of the study. There is a fair amount literature out there that we can send you on what kind of numbers one might see, as I said, with KALYDECO as an example. The study is 200 patients, so it's appropriately powered to see kinds of differences that we think would be important to see clinical statistically."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow up question. I also mentioned that we will be presenting at a few investor conferences in t",79,"Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow up question. I also mentioned that we will be presenting at a few investor conferences in the coming months. And in early October, we will plan to host analyst and investors at the North American CF conference in Phoenix, so stay tuned for details on that. Thanks, and have a good night."
36235,306717990,841852,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a good day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a good day."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone, this is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded,",317,"Good evening, everyone, this is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Earlier in July, we announced the approval of ORKAMBI, and many of you joined for that call. Tonight, we will be focused on second quarter performance and our execution against our corporate strategy. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Jeff Chodakewitz, our Chief Medical Officer, is traveling and is not with us tonight. 
Our agenda tonight is as follows: Jeff will begin by discussing key priorities for our business; Stuart will review the second quarter performance of KALYDECO and make a few comments on the ORKAMBI launch; and to close, Ian will review the second quarter 2015 financial results and update our 2015 guidance. You can access the webcast live by going to the Events section of the Investor Relations page on our website. 
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which have been 
[Audio Gap] 
without limitation. Those regarding the ongoing development and the potential commercialization of ORKAMBI, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. 
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available on our second quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast. 
I will now turn the call over to Dr. Jeff Leiden."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. The approval of ORKAMBI on July 2 was an important milestone in our shared journey with the cystic fibrosis community. ORKAMBI is the first FDA-approved medicine to treat the underlying cause of CF for the approxim",403,"Thanks, Michael. Good evening, everyone. The approval of ORKAMBI on July 2 was an important milestone in our shared journey with the cystic fibrosis community. ORKAMBI is the first FDA-approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S.  12 years and older with 2 copies of the F508del mutation. This is a big step forward toward our long-term vision of helping more people with CF. We feel very fortunate to be part of the CF community, and we appreciate all of the positive feedback we have received and continue to receive from patients, caregivers, health care providers and the broader CF community. 
At the beginning of this year, we outlined 3 strategic priorities that will allow Vertex to continue to deliver on our vision to make new transformative medicines available to patients globally. Let me briefly review our progress toward meeting those goals. First, through both geographic and label expansion, we have continued to grow the number of patients treated with KALYDECO, resulting in strong revenue growth. With the ORKAMBI approval and launch in the U.S., we have an even greater opportunity to treat more patients, resulting in additional revenue growth. 
Second, we know that there is still much more to do. We continue to make significant investment into multiple programs to create more CF medicines that may enable us to treat even more patients and to improve the benefit for the patients we treat. All 4 studies included in the VX-661 plus ivacaftor pivotal Phase III development program are initiated, and we also remain on track to bringing a next-generation CFTR corrector into the clinic by the end of 2015. 
And third, we have expanded and diversified our pipeline, through our collaboration with Parion, to develop and commercialize investigational epithelial sodium channel, or ENaC inhibitors, for CF and other pulmonary diseases. We also continue to advance early-stage development programs outside of CF, including clinical programs in oncology and research programs focused on other areas. We look forward to updating you on these programs later this year. 
The continued execution on our strategy has fundamentally changed the outlook for our business. Specifically, moving forward, we expect to deliver a financial profile of growing revenues, earnings and cash flows, while also continuing to invest to create new medicines to treat more patients with CF and other serious diseases. 
With that, I'll hand it over to Stuart."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making ORKAMBI available to eligible patients in the U.S.Global sales of KALYDECO this quarter were $155 m",412,"Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making ORKAMBI available to eligible patients in the U.S.
Global sales of KALYDECO this quarter were $155 million, comprised of U.S. sales of approximately $93 million and x U.S. sales of approximately $62 million. This represents a 37% increase compared to $113 million in the same quarter last year. The strong growth of KALYDECO is a result of both geographic and label expansion. We have seen good uptake in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015. 
Internationally, there has also been rapid uptake of KALYDECO by eligible patients in Australia following the reimbursement agreement reached in late 2014. Also, during the second quarter, we achieved reimbursement approval for non-G551D gating mutations in several European countries where these mutations are prevalent, including Italy, France, England and The Netherlands. As a result, today, more than 85% of eligible gating patients in Europe now have access to KALYDECO.
Further growth in patients receiving KALYDECO will be tempered by enrollment in the VX-661 pivotal program, as previously described, and this is reflected in our KALYDECO revenue guidance. 
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been working to get the medicine to the approximately 8,500 eligible patients as rapidly as possible. Our field teams around the country have been educating health care providers on the ORKAMBI prescribing information. Since approval, they have visited the vast majority of the 275 CF centers in the U.S. 
As we anticipated, interest in the medicine is very high. We believe that all eligible patients with CF should have access to ORKAMBI. Our public and private payer interactions to date have been productive, and our patient support team has begun to help patients navigate the reimbursement process. Thanks to these efforts and the commitment of health care providers at CF centers across the country, I'm happy to report that the first patients are already receiving ORKAMBI in the U.S.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat. 
I'll now hand the call over to Ian."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Tonight, I'd like to discuss our second quarter 2015 financial results, and then, update our 2015 financial guidance. Firstly to the financials. KALYDECO revenues were $155 million this quarter and were up 37%",346,"Thanks, Stuart, and good evening, everyone. Tonight, I'd like to discuss our second quarter 2015 financial results, and then, update our 2015 financial guidance. 
Firstly to the financials. KALYDECO revenues were $155 million this quarter and were up 37% from the second quarter of 2014 and up 18% sequentially compared to our first quarter this year. We continued to nicely expand the number of our eligible patients we treat with KALYDECO. 
Our second quarter non-GAAP R&D and SG&A expenses were $254 million, an increase of $17 million compared to last year, mainly due to an increase in SG&A expenses supporting the launch of ORKAMBI. Our non-GAAP net loss was $131 million compared to prior year non-GAAP net loss of $142 million. 
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter. 
Let's now turn to the 2015 financial guidance and, specifically, KALYDECO revenues and combined R&D and SG&A expenses. Earlier this year, we anticipated 2015 KALYDECO revenues to be between $560 million and $580 million. And based on an increased uptake due to label and geographic expansions, as Stuart previously mentioned, we now expect KALYDECO net revenues to be between $575 million and $590 million for the full year 2015. 
For the non-GAAP operating expenses, we continue to expect the combined non-GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. I'll just note that we expect our operating expense to be higher in the second half of this year compared to the first half, mainly as a result of the anticipated progress with the VX-661 pivotal program and the investment to support the launch of ORKAMBI. 
I will close by stating that we are in a strong financial position today. We are growing our revenues, and we expect to show a additional growth from ORKAMBI. We will continue to invest to create even more medicines and support access to those medicines already approved. 
With that, I'll ask the operator to please open the line for questions."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets.",13,"[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question for Stuart, and then, a question for Ian. I guess, Stuart, I appreciate the comments on the launch. Maybe you could just comment on -- more specifically on reimbursement and the process for reimbursement that you're seeing. Are payers quickly g",139,"A question for Stuart, and then, a question for Ian. I guess, Stuart, I appreciate the comments on the launch. Maybe you could just comment on -- more specifically on reimbursement and the process for reimbursement that you're seeing. Are payers quickly getting people on drug? Maybe walk us through that process and how long it takes to get people on drug, what you're seeing out there. And then, for Ian, I know you maintained the guidance for expenses. That's fantastic. I know people are thinking, bigger picture, as you transform to a very profitable company, maybe you can comment about how R&D expenses -- how you're thinking about they're giving you now an ENaC inhibitor and all these Phase IIIs, how are you thinking about controlling some of that or making sure we're going to be very profitable?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","All right. Mike, it's Stuart. Thanks for the question. So in terms of the process for reimbursement, essentially, payers fall into a couple of different camps. Some come to making formal decisions very quickly, and we've seen some of those. Most have a pr",183,"All right. Mike, it's Stuart. Thanks for the question. So in terms of the process for reimbursement, essentially, payers fall into a couple of different camps. Some come to making formal decisions very quickly, and we've seen some of those. Most have a process where they're going to have kind of the equivalent of a P&T committee and review the product. And those will often, then, put in sort of interim policies as it were, where they'll evaluate on a case-by-case basis whether a patient can be initiated on ORKAMBI. And so as a result of those interim policies and some initial policy decisions, that's why we have already seen patients start on ORKAMBI in the first few weeks following launch. And then, over the next few months, more and more payers will come to their final determinations on their coverage policies for ORKAMBI. As I say, based on the discussions we've had so far, we do continue to anticipate that we are going to have broadened and positive reimbursement for ORKAMBI. And I'll pass it over to Ian handle the expenses question."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, thanks for the question. I'm going to take it a little broader, if you don't mind, and really comment on what is our goal with, let's say, the Vertex financial profile. And it starts with growing -- a growing revenue stream, which we are very confid",225,"Mike, thanks for the question. I'm going to take it a little broader, if you don't mind, and really comment on what is our goal with, let's say, the Vertex financial profile. And it starts with growing -- a growing revenue stream, which we are very confident around, given the recent approval of ORKAMBI. We look at growing that rapidly by providing access to the medicines that are already approved and, basically, holding at a steady state our operating expenses in a -- in the company. Now the primary driver within our operating expense structure is R&D that's a function of our commercial model, is because we get -- provide access to the medicines around the world, which is highly leveraged with small investment required to provide access to these medicines, actually. Providing access to the medicines is more about education than it is about selling a drug. So that allows us, as a business, to reinvest in R&D yet still aim to have high operating margins. And as we see out over the next 3, 4 years, we do see ourselves as a business that if we can drive up our medicines to patients and hold our operating expense, which is exactly what we expect, that we'd generate high operating margins and operating margins that are consistent with our, let's say, larger-cap biotech peers."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Geoff Meacham with Barclays.",10,"And our next question is from Geoff Meacham with Barclays."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple more clinical questions. I'm hoping -- some of it are answered, but I noticed in the press release today, one of the endpoints for the younger population in Europe, the 6 to 11, was absolute change in lung clearance. And I wasn't sure if you guys",86,"A couple more clinical questions. I'm hoping -- some of it are answered, but I noticed in the press release today, one of the endpoints for the younger population in Europe, the 6 to 11, was absolute change in lung clearance. And I wasn't sure if you guys were sort of rethinking some of the endpoints overall for development beyond FEV1, or is this just a special case, just given the age of the population? I have a couple of other pipeline questions as a follow-up."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. And thanks for asking that question. We've been talking for some time, both with Wall Street and with regulators, about the notion t",186,"Geoff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. And thanks for asking that question. We've been talking for some time, both with Wall Street and with regulators, about the notion that we are eager to explore additional endpoints to FEV1, particularly for younger populations where it's more difficult to consistently blow a good FEV1 if you're 2 or 3 years old. And as part of that, we've explored 3 or 4 different endpoints, including lung clearance index. And this was a very nice opportunity, in talking with European regulators about this younger population, to begin to use lung clearance index, which is much less effort-dependent and much more consistent, particularly in young patients, as an efficacy endpoint. So it'll be interesting from -- to see the results of this study, which, we think, will be highly predictive using this endpoint. And we also plan to use of those kinds of results to begin to discuss with other regulators whether these other endpoints might be useful, particularly in the young, very young patients."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that's helpful, Jeff. And then, a question just on the ENaC inhibitor. Does this change your priorities for you guys for the -- for your next-gen corrector? Or is this -- would you view this as kind of complementary what -- to what you already have?",70,"Okay, that's helpful, Jeff. And then, a question just on the ENaC inhibitor. Does this change your priorities for you guys for the -- for your next-gen corrector? Or is this -- would you view this as kind of complementary what -- to what you already have? And then, are we still on track to identify the third corrector by, I guess, by year-end or early part of next year?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Let me -- maybe I'll take those in reverse order, Geoff. So yes, we are absolutely on track to identify the third corrector. And just to remind you, I -- and I know you know this, that our strategy here has been to bring multiple next-gen correctors",215,"Yes. Let me -- maybe I'll take those in reverse order, Geoff. So yes, we are absolutely on track to identify the third corrector. And just to remind you, I -- and I know you know this, that our strategy here has been to bring multiple next-gen correctors into the clinic, and our goal is the first one by the end of this year, with several others following directly behind it. And that's progressing nicely, and we are on track. With respect to the ENaC inhibitors, yes, we do view them very much as complementary. And they could be complementary in a couple of ways, right, because they fall outside of the classic CFTR correction. They may have activity as monotherapy, particularly in populations like het-mins that don't have anything and, frankly, in other lung diseases as well. But we're particularly eager to study them on top of our current regimens like ORKAMBI because they may amplify the signal that we're seeing here. So I wouldn't view them as one or the other, I would definitely view them as complementary. And I guess, your question is sort of getting at do they, in any way, slow down or de-prioritize our next-gen correctors? And the answer is no. We're full speed ahead on the next-gen correctors."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matt Roden with UBS.",9,"Our next question is from Matt Roden with UBS."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. First, Stuart, I wonder if you could elaborate on some launch metrics that you're seeing. I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from presc",157,"Great. First, Stuart, I wonder if you could elaborate on some launch metrics that you're seeing. I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from prescription to fill? Any other metrics that you can share so we can get a sense of what's happening out there. And then, I think this might be for Ian. If you could help us square the sales and the increase in guidance against your prior comments regarding the impact of enrollment in the VX-661 trials on KALYDECO use. Do you have a same-store sales metric that enables you to see that, that impact is happening, but that the geographic expansion and the label extension is compensating for that? Or is it just that it's actually not happening to the extent that you previously thought, that is, the impact of 661 trials?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, it's Stuart here. Just in terms of launch metrics, I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how predictive those are of the kind of the trajectory that we're seeing over",176,"Matt, it's Stuart here. Just in terms of launch metrics, I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how predictive those are of the kind of the trajectory that we're seeing overall. As we've said before, because of the interest in the product, the unmet need and the fact that it treats the underlying cause, we're certainly expecting the overall penetration of ORKAMBI in the eligible patient population to be high. And we've said all along that we do think, though, it will take longer for ORKAMBI to reach peak penetration compared to KALYDECO for a number of factors that we've gone into previously, like the volume of patients and the -- just the time it's going to take to educate patients and get them to the reimbursement approval process. But yes, it's really much too early to be throwing around specific launch metrics right now. And then, on the guidance and KALYDECO revenue question, I'll throw that over to Ian."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Matt, thanks for the question. The -- well, first off, I'll say, we're very pleased with the expansion of KALYDECO in, let's say, treating more patients through geographic and label expansion. As far as the guidance we've provided for the full year,",168,"Yes, Matt, thanks for the question. The -- well, first off, I'll say, we're very pleased with the expansion of KALYDECO in, let's say, treating more patients through geographic and label expansion. As far as the guidance we've provided for the full year, we do actually now anticipate patients that would be available for the medicine, mainly in Europe, actually, to go into the 661 trials. Remember, we -- as ORKAMBI was approved in the U.S., we switched the recruitment of the VX-661 pivotal studies to Europe. Europe is where we're starting to continue to recruit new patients potentially, based on the label expansion of KALYDECO. And instead of going on to KALYDECO, we're starting to recruit those into our 661 studies. So we have built that into our guidance, and hence, why we come out with something that is between $575 million and $590 million, therefore, reflecting a lower growth rate than where we currently are between Q1 and Q2. We do think it will flatten out."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Geoffrey Porges with Bernstein.",9,"Our next question is from Geoffrey Porges with Bernstein."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question, first, related to the extension study for the patients that were on ORKAMBI coming into the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled and stayed on treatment? And then, wha",79,"A question, first, related to the extension study for the patients that were on ORKAMBI coming into the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled and stayed on treatment? And then, what number of them have rolled over to commercial drug? And then, I just wanted a quick follow-up on VX-371. Jeff, perhaps you could address why do the study with ORKAMBI rather than with 661."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Geoff, just afterwards, if you were here, we'd have the exact numbers.",138,"So Geoff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Geoff, just afterwards, if you were here, we'd have the exact numbers. But it was north of 90% of patients rolled over from TRAFFIC and TRANSPORT into the open-label extension. About half of those were in the United States. And the process of informing those centers and those patients that the commercial product is now available, beginning to roll those patients over to commercial product, is just beginning. But it's -- about 500 or so of the -- of 1,000 who rolled over into the 105 [ph] study were here in the United States. And on the VX-371, I'll pitch that to Jeff Leiden."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff. The -- in terms of the VX-371 and why we're going with ORKAMBI, it's really a matter of how do we get the medicine, potentially, to patients the fastest. So since ORKAMBI is already approved, simply adding 1 unapproved drug and getting the res",83,"Yes, Geoff. The -- in terms of the VX-371 and why we're going with ORKAMBI, it's really a matter of how do we get the medicine, potentially, to patients the fastest. So since ORKAMBI is already approved, simply adding 1 unapproved drug and getting the result will let us, assuming that we have success, will let us get to -- get that new drug, VX-371, to patients the quickest. And our goal all along has been improving therapy as quickly as we could."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Terence Flynn with Goldman Sachs.",10,"Our next question is from Terence Flynn with Goldman Sachs."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. Can you just remind us about the anticipated timing of Medicaid coverage for ORKAMBI? And then, regarding the VX-661 KALYDECO trial in het-mins, now that you've started that trial, can you just maybe remind us of expectations for when",49,"Maybe just 2 for me. Can you just remind us about the anticipated timing of Medicaid coverage for ORKAMBI? And then, regarding the VX-661 KALYDECO trial in het-mins, now that you've started that trial, can you just maybe remind us of expectations for when that interim analysis might occur?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Terence, it's Stuart here. In terms of Medicaid coverage, there really isn't one answer. There's, really, 50 answers because, obviously, Medicaid's managed state by state. So I really can't give you one answer to the Medicaid question. What I can sha",123,"Yes, Terence, it's Stuart here. In terms of Medicaid coverage, there really isn't one answer. There's, really, 50 answers because, obviously, Medicaid's managed state by state. So I really can't give you one answer to the Medicaid question. What I can share is that we've already seen patients initiated on therapy in the first 4 weeks. And within that number of patients, we have patients who have commercial insurance through their primary insurance. We also have patients who have government insurance in the number people who've already been initiated. But to give one specific number for Medicaid is just impractical, because there's really 50 answers to that particular question. And for the second part of the question, I'll hand it over to Jeff."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In terms of the het-min trial, just to remind you, Terence, we actually just announced that, that trial is open for enrollment, so it's essentially starting now, if you want to think it about it that way. And to remind you, the design of that trial,",157,"Yes. In terms of the het-min trial, just to remind you, Terence, we actually just announced that, that trial is open for enrollment, so it's essentially starting now, if you want to think it about it that way. And to remind you, the design of that trial, it actually has 2 parts. We enrolled around 150 patients, plus or minus. We then have a DSMB that will do a futility analysis. We won't actually see the numbers at that point, they'll simply tell us to stop if the -- if it's futile or to continue. If they tell us to continue, we then enroll another approximately 150 patients. Because it's a shorter study than the 24-week homozygous study, we would still have visibility to that data by the time we have visibility to the homozygous study. We expect that to be some time in 2016, depending on how quickly the enrollment goes. Does that answer your question?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes. And maybe, Stuart, just one follow-up on Medicaid. Can you just remind us, in terms of KALYDECO, what the benchmark was there in terms of the -- I understand it's at state level, but just what was the range in terms of how long the process took from",56,"Yes. And maybe, Stuart, just one follow-up on Medicaid. Can you just remind us, in terms of KALYDECO, what the benchmark was there in terms of the -- I understand it's at state level, but just what was the range in terms of how long the process took from the first day to the last day?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, I mean, we're splitting hairs a little bit there, Terence. I mean, the uptake with KALYDECO was so rapid. As you know, we got to 90-plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both comme",79,"Well, I mean, we're splitting hairs a little bit there, Terence. I mean, the uptake with KALYDECO was so rapid. As you know, we got to 90-plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both commercial payers and Medicaid. So there really wasn't much of a range that I could give you there. It was incredibly rapid for KALYDECO across all patient populations and all insurers."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Cory Kasimov with JP Morgan Chase.",11,"Our next question is from Cory Kasimov with JP Morgan Chase."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, just to follow up on that, just based on early discussions with payers on ORKAMBI, is there any change to your expectations for gross-to-net? Or maybe another way, has the reaction to the price been about what you expected when you announced it e",73,"I guess, just to follow up on that, just based on early discussions with payers on ORKAMBI, is there any change to your expectations for gross-to-net? Or maybe another way, has the reaction to the price been about what you expected when you announced it earlier this month? And then, secondly, on the new ENaC product you have, does the ongoing Phase II trial in patients with any CFTR mutation include heterozygous patients?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, on -- the reaction to the price, I would say, has been very balanced. Indeed, the focus of our discussions has really been less around the price and more around the clinical profile of ORKAMBI. And in terms of whether it changes our view on the g",139,"So Cory, on -- the reaction to the price, I would say, has been very balanced. Indeed, the focus of our discussions has really been less around the price and more around the clinical profile of ORKAMBI. And in terms of whether it changes our view on the gross-to-net, it really doesn't. The gross-to-net is almost exclusively driven by the payer mix. And as we've explained previously, we are expecting the Medicaid payer mix to be a higher percentage for ORKAMBI than it was for KALYDECO, and it's likely to be in around that sort of 35% to 40% of eligible patients, we predict, will be covered by Medicaid. The vast majority of the rest will be covered by commercial insurance. But our view on that gross-to-net hasn't been changed by anything we've seen in the first 4 weeks."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, in terms of the ENaC trial, just to remind you, they're actually -- we're planning 2 trials. The first one is already under way, and that trial is basically monotherapy in any mutation. I assume you're referring to het-mins, and so the answer is",91,"And then, in terms of the ENaC trial, just to remind you, they're actually -- we're planning 2 trials. The first one is already under way, and that trial is basically monotherapy in any mutation. I assume you're referring to het-mins, and so the answer is yes. Het-mins would be there, with the obvious exception that KALYDECO-treated patients, and now going forward, ORKAMBI-treated patients wouldn't be included in that study. The second study is going to be the ENaC inhibitor on top of ORKAMBI in patients who are treated with ORKAMBI."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Ying Huang with Bank of America Merrill Lynch.",13,"Our next question is from Ying Huang with Bank of America Merrill Lynch."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one, maybe for Steve (sic) [Stuart]. It was reported that the Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking ORKAMBI. I was wondering if that's a single isolated cas",135,"First one, maybe for Steve (sic) [Stuart]. It was reported that the Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking ORKAMBI. I was wondering if that's a single isolated case, or have you seen that among the other payers or not? And then, secondly, on the R&D front, I noticed that in the press release, you guys are adding 1 arm in the Phase III trial for 661 for the patients who have 1 allele of 508 and the other allele with residual CFTR function. You're adding 1 monotherapy of KALYDECO arm. Is that due to a request from FDA? Or -- and also, are you going to add monotherapy on -- in the other Phase III trials or not in 661 trial?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Ying, so I'm really not going to comment on what discussion that we're having with individual payers and plans. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to ORKAMBI, and it's for it to be a de",73,"Yes, Ying, so I'm really not going to comment on what discussion that we're having with individual payers and plans. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to ORKAMBI, and it's for it to be a decision for the physician and patient whether they want to initiate those patients on ORKAMBI. And on the 661 program, I'll hand it off to Jeff."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Just to be clear, the design of the 661 program has not changed. We haven't added any new arms. The residual function arm always had in it both the placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there.",44,"Yes. Just to be clear, the design of the 661 program has not changed. We haven't added any new arms. The residual function arm always had in it both the placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matthew Harrison with Morgan Stanley.",10,"Our next question is from Matthew Harrison with Morgan Stanley."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. So I just wanted to go back to ENaC just for a second. I mean, I think you talked a little bit about the rationale, and maybe you could expand upon the rationale for combining with ORKAMBI. And then, secondly, I mean, what, specifically, might you",115,"Great. So I just wanted to go back to ENaC just for a second. I mean, I think you talked a little bit about the rationale, and maybe you could expand upon the rationale for combining with ORKAMBI. And then, secondly, I mean, what, specifically, might you hope to see? Should we be looking for increased lung function? Should we be looking for a lowering of the exacerbation rate? I mean, what would you be hoping to see with that combination? And then, separately, just on KALYDECO, I just want to make sure I understood your comments correctly. Are you saying that all of the growth came from increased penetration across the new gating mutations?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe I'll take the R&D question first, the ENaC inhibitors. Ian described this in terms of the ocean and seaweed, but I can't be nearly that eloquent, so I'll just take it from a more scientific standpoint, maybe. The way we think about ENaC and the way",288,"Maybe I'll take the R&D question first, the ENaC inhibitors. Ian described this in terms of the ocean and seaweed, but I can't be nearly that eloquent, so I'll just take it from a more scientific standpoint, maybe. The way we think about ENaC and the way the ENaC inhibitors work, as you know, is that ENaC is a separate channel, the sodium channel, that is also involved in hydrating the secretions and the mucus in the lung. And so you could think about it as -- and there's actually even an interaction with CFTR. So CFTR's a chloride channel that helps hydrate the mucus; ENaC's the sodium channel, it helps hydrate the mucus. And so the rationale and it's based upon preclinical studies, is that if you combine an ENaC inhibitor with a potentiator, for example, or corrector potentiator, you'll get the even better hydration of the mucus, which, then, should lead to better lung function. So what we're doing with the ENaC inhibitor program is were asking the question, does the ENaC inhibitor alone have activity to help hydrate for mucus and improve lung function in all mutations? And then, if we take the ENaC inhibitor and add it to KALYDECO or ORKAMBI, can we get better hydration than we get with a single agent alone? And the rationale is really based upon the work we've done in our human bronchial epithelial cell assays that say when you add an ENaC inhibitor to a CFTR corrector or to a corrector plus potentiator, you actually get even better hydration. So the question is, does that translate into the clinic and improvements in FEV1? And we definitely are going to be looking at hard endpoints like FEV1."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where the R117H patient population was added to the label at the back end of 2014",144,"And then, in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where the R117H patient population was added to the label at the back end of 2014. And then, in March, we were also approved for use in children between 2 and 5 with eligible mutations. So there's label expansion here in the United States, and then, outside of the U.S., it really has been geographic expansion, such as G551D patients in Australia, where the uptake has been very rapid. And then, also, additional gating patients in a number of countries in the EU. So there really isn't one answer to what's been driving that KALYDECO revenue growth. It really has been that combination of label expansions into new populations and geographic expansion into new markets."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Mark Schoenebaum with Evercore ISI.",10,"Our next question is from Mark Schoenebaum with Evercore ISI."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Odysseus, [ph] sitting in for Mark. But just a few questions. One, around the het-min trial. Wondering about potential disclosure or lack of disclosure at the interim if it doesn't hit and there -- an extension is required and for an additional 15",175,"This is Odysseus, [ph] sitting in for Mark. But just a few questions. One, around the het-min trial. Wondering about potential disclosure or lack of disclosure at the interim if it doesn't hit and there -- an extension is required and for an additional 150 patients. The second question had to do with this lung clearance index. I'm just wondering whether Vertex has previously used that endpoint in any of its trials that have any data from any of these drugs. And if so, or if not, in terms of thinking about the -- how Vertex thought about the pairings [ph] and design of the study based on that. And then, the last question, in terms of the next-generation corrector and one coming by year-end -- but as I understand, there'll be additional, probably, next-generation correctors, potentially next-generation potentiators -- but next-generation correctors that may follow. Just wondering if Vertex is, perhaps, eyeing or if Vertex can sort of quantify how many of those they may be eyeing to bring to the clinic in 2016."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Let me -- this is Jeff. Let me take the last 2 questions, and I'll turn it over to Ian on the disclosure question. Starting with the next-gen program, we've said previously that we have multiple next-gen correctors in lead-optimization, which, as yo",194,"Sure. Let me -- this is Jeff. Let me take the last 2 questions, and I'll turn it over to Ian on the disclosure question. Starting with the next-gen program, we've said previously that we have multiple next-gen correctors in lead-optimization, which, as you know, is sort of the study of the drug-like properties and [indiscernible] data from those molecules. And as I said, we're on track to bring the first of those into the clinic this year, and our goal is to bring at least 2 or 3 additional behind that, following completion of lead-optimization for those additional molecules and to compare several different next-generation correctors. And then, your question about lung clearance index. Lung clearance index is actually a fairly widely used measure of the ability to empty the lungs of air effectively. And there is data from a number of studies showing, for instance, that when patients, such as G551D patients, were treated with KALYDECO, there's a significant improvement in lung clearance index. And we're happy to send you some of those studies. So it is an endpoint that's been pharmacologically validated, if you want to think about it that way."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Odysseus, thanks for the question. Just to refer to an earlier comment Jeff Leiden made, which was the initial part of -- this initial cohort of patients that enters the het-min study with 661. The idea of that is that there is futility assessment. Th",204,"And Odysseus, thanks for the question. Just to refer to an earlier comment Jeff Leiden made, which was the initial part of -- this initial cohort of patients that enters the het-min study with 661. The idea of that is that there is futility assessment. That futility assessment, if an independent advisory board deems that it is worth progressing forward, we will just continue to recruit patients and the study will be ongoing. We will not be at a disclosure point. At that point, we'll just continue to recruit into the study and wait for the complete and final results of that study. If the board deems that it is futile, effectively futile in dosing those patients, they will advise us so, and we will curtail the study on stopping that study and working the patients off the drug. We will provide a disclosure to let you know that, that study is no longer going forward. So I think, the way to think about this is that if there is no news, it is because the study will progress, that we'll continue to recruit het-min patients, and if there is an early closure of that study, we'll advise you at that point in time."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, just to clarify, so there won't be, say, an increase in the number of patients on ClinicalTrials.gov or anything of that sort?",24,"I guess, just to clarify, so there won't be, say, an increase in the number of patients on ClinicalTrials.gov or anything of that sort?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, there won't be any disclosures, so.",7,"No, there won't be any disclosures, so."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Robyn Karnauskas with Deutsche Bank.",10,"Our next question is from Robyn Karnauskas with Deutsche Bank."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just 2 questions, one for Stuart, one for Ian. So at this rate, you guys have talked a lot about in CF centers, there would be a backlog, like the processing within the CF centers, and there may not be a lot that you can do about that. Can you just talk a",119,"Just 2 questions, one for Stuart, one for Ian. So at this rate, you guys have talked a lot about in CF centers, there would be a backlog, like the processing within the CF centers, and there may not be a lot that you can do about that. Can you just talk a little bit about what you're seeing or anything you've done to like help that process as the patients move through, and if it's better or in line with your expectations? And then, for Ian, a lot of your competitors for COGS [ph] are diversifying, and you still are truly a CF company. And what are your thoughts on the importance of diversification over the next year?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, it's Stuart here. So you -- I think while it's early days, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would. And those factors, just to remind you, is t",315,"Robyn, it's Stuart here. So you -- I think while it's early days, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would. And those factors, just to remind you, is that the volume of patients is obviously much greater than it was when KALYDECO was initially approved, just the G551D patients. So there's a volume of patients that centers needed to get in. Then, obviously, when a physician is making the decision to start a patient on a new drug, then, obviously, there's a fair amount of discussion. Education is going to want to go on there, explaining the product, the mechanism of action, how to take it, all those sorts of things. And then, obviously, we move on to the sort of reimbursement approval process. And so all of those factors that we anticipated prior to launch, being involved in how the launch is going to go, have certainly been playing out exactly as we thought we -- as we thought they would. In terms of what we're doing to support centers, we're doing a number of things, clearly, providing education materials to support their discussions with their patients. We're providing them with help in terms of the sort of materials they need to submit to the various payers, be it prior authorization, documentation and stuff like that; providing them help with what documentation they're going to need, where the right place to send it is. And then, from a patient-support point of view, obviously, our patient services group is there to support individual patients navigate the reimbursement process as well. And so we're -- as compliantly as possible, we are providing as much support as we can to help patients get access to the medicine. On the second point, I'll pass it over to Ian."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, thanks for that question. I think we're focused on CF. We're very pleased about that. And -- but also, I would say that we still need to continue to be focused on CF, and part of our, let's say, corporate or business development strategy, as well a",262,"Robyn, thanks for that question. I think we're focused on CF. We're very pleased about that. And -- but also, I would say that we still need to continue to be focused on CF, and part of our, let's say, corporate or business development strategy, as well as our investments into research at Vertex, is about strengthening our position and creating even better combination medicines to treat more patients in CF. So that is one tactic. And so we're continuing with CF, and I think it is -- it behooves the company to continue to raise the bar in terms of the benefit we provide patients with our medicines, and that's why we reinvest. We also reinvest in other areas within the company, and I hope that later this year and early next year, we can tell you a little bit more  about those other disease areas that we're in as well as other business development efforts, which are looking to expand our scientific footprint. And then, also, just to consider other products that may diversify and stage our pipeline. It tends to be earlier-stage ideas. I think that's appropriate for a company at our stage as we progress forward, and our priority is still cystic fibrosis. I'll throw it over Jeff Leiden, though, because I think there's just much more of a -- kind of a strategic comment that's worth making here, which is while we're successful in CF, we're not taking our eye off that we want to go into other disease areas. And maybe Jeff, you have a comment?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it, is CF, and not only increasing the number of patients that we can treat with new medicines but actually",257,"Robyn, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it, is CF, and not only increasing the number of patients that we can treat with new medicines but actually increasing the benefit for all the patients we're treating. And we've said many times, our goal is to get to the majority, more than 90% of patients with medicines that have KALYDECO-like or better effects. And I think we're executing well on that, and we're well on track. At the same time, obviously, we are investing in areas outside of CF. As I've said, we'll bring more new compounds into the clinic this year at Vertex than we ever have in the history of the company. We're not talking a lot about that yet, but you'll start to hear more news us we begin to get clinical results, I think, later and certainly the next year. And then, the third part, as Ian said, is that we're going to have the financial resources to also invest in innovation outside the company. And we're spending significantly more time, effort, and money on our BD activities. You've heard a couple of deals, but I think you can anticipate more, again, typically focused on earlier-stage scientific platforms or assets. So it's really a 3-legged stool, and I think, with the launch of ORKAMBI, we'll now have the financial wherewithal to invest in all 3 parts of the stool."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Phil Nadeau with Cowen and Company.",12,"And our next question is from Phil Nadeau with Cowen and Company."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just 2, one scientific -- or I guess, actually, both on clinical development. First, on VX-661's Phase III. Have you ever disclosed what the futility analysis hurdle is? Or if not, would you care to disclose it now? And then, second, on the new -- the sec",78,"Just 2, one scientific -- or I guess, actually, both on clinical development. First, on VX-661's Phase III. Have you ever disclosed what the futility analysis hurdle is? Or if not, would you care to disclose it now? And then, second, on the new -- the second-generation correctors. Could you give us some idea of what the clinical development path is likely for those? Specifically, how quickly could they get into combination therapy regimens with an FEV1 endpoint?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for both questions. So we haven't disclosed the hurdle, and we're not -- we won't we be disclosing it today. As Ian said, the -- I think, the first news that you would get on that is if we didn't meet the hurdle and the study was stopped, we w",179,"Yes, thanks for both questions. So we haven't disclosed the hurdle, and we're not -- we won't we be disclosing it today. As Ian said, the -- I think, the first news that you would get on that is if we didn't meet the hurdle and the study was stopped, we would disclose, at that point, what was going on. With respect to the second-generation correctors, we really see them following a fairly straightforward development path. We've sort of pioneered the way here with our previous medicines. They go into Phase I in normal single-ascending dose, multi-ascending dose. And following, hopefully, successful safety results from those studies, we would put them both as monotherapy and as combination therapy into patients. And I think we've figured out -- we've learned a lot over the last few years about how to do those studies very quickly and very efficiently with small numbers of patients. So I think we can get pretty definitive data using FEV1 as well as other endpoints on how they fare, both by themselves and with a combination."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Tony Butler with Guggenheim partners.",11,"And our next question is from Tony Butler with Guggenheim partners."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, 2 brief questions. One is, eliminating the sodium channel compounds for the moment, is there a rationale for a next-gen corrector to actually be QD or BID, such that it's more easily formulated with either ivacaftor and/or 661? And the second questi",73,"Jeff, 2 brief questions. One is, eliminating the sodium channel compounds for the moment, is there a rationale for a next-gen corrector to actually be QD or BID, such that it's more easily formulated with either ivacaftor and/or 661? And the second question is, is there any rationale from HBE experiments that actually suggest to you that there may be the need for 3 correctors and additional -- in addition to a potentiator?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines, because they do take very large numbers of pills every day. And so we continue",160,"Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines, because they do take very large numbers of pills every day. And so we continue to push for co-formulated products, that's certainly our goal, into one pill or a small number of pills. And either QD or BID, both of those seem pretty accessible to patients, and that's a certainly our target product profile with the next-gen correctors and combinations. Your other question was, could we need 3 correctors? The answer is we don't yet fully know, but certainly, our goal is to try to keep this to as few medicines as possible, simply from drug-drug interaction standpoint, from a co-formulation standpoint. So again, if you ask me what our target profile -- product profile was today, it would be a first-gen corrector, a second-gen corrector and a potentiator."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is going to be from Brian Skorney from Baird.",12,"Our next question is going to be from Brian Skorney from Baird."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, I just want to kind of get your temperature on how we should be thinking about pricing of the VX-661 combination in the context of ORKAMBI and KALYDECO's price. They're obviously at different price points, but -- they're in different patient popu",151,"I guess, I just want to kind of get your temperature on how we should be thinking about pricing of the VX-661 combination in the context of ORKAMBI and KALYDECO's price. They're obviously at different price points, but -- they're in different patient populations right now, but based on the 661 combo studies, this is probably going to wind up being a significant overlap between KALYDECO and ORKAMBI patients. I guess, about 80% of KALYDECO responders have probably shown improvement on VX-661 plus ivacaftor based on the Phase 2 data, and it doesn't look like there'll be a meaningful amount of clinical efficacy above and beyond ORKAMBI for the combo. So I guess, is it more important to you guys to maintain price per patient for KALYDECO responders or to try to get ORKAMBI patients to switch to the VX-661 combo? Because it doesn't seem like you could really do both."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I think -- I mean, the most important things to us, overall, are to increase the number of patients that we're able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our ov",120,"Yes, Brian, I think -- I mean, the most important things to us, overall, are to increase the number of patients that we're able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our overall strategy. And KALYDECO combined with VX-661 is a part of that overall strategy. But to really be commenting on price, right now, is way too early. As you know, we've got this broad Phase III program starting across multiple patient populations. And until we see the results, both safety and efficacy, across those different patient populations, it would really be inappropriate to be speculating on how we might price that combination."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Well, then, I guess, is -- would there -- would you perceive any benefit outside of a double-corrector-potentiator combination to have patients on a 661 ivacaftor combo as opposed to ORKAMBI if kind of the Phase II data winds up holding up and they look p",48,"Well, then, I guess, is -- would there -- would you perceive any benefit outside of a double-corrector-potentiator combination to have patients on a 661 ivacaftor combo as opposed to ORKAMBI if kind of the Phase II data winds up holding up and they look pretty similar efficacy-wise?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not sure I understand your question. Could you ask that again? It's double-corrector combination? [indiscernible]",17,"I'm not sure I understand your question. Could you ask that again? It's double-corrector combination? [indiscernible]"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So basically, what I'm getting at is would there be a reason to try to get patients on ORKAMBI to switch to 661, in your view, if the efficacy profiles are relatively similar?",33,"So basically, what I'm getting at is would there be a reason to try to get patients on ORKAMBI to switch to 661, in your view, if the efficacy profiles are relatively similar?"
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, I think it really depends on the totality of the profile. And whilst efficacy is one part of the equation, obviously, there's safety as well. So it's really going to depend on what the physician and patients think of the overall profile of the med",112,"I mean, I think it really depends on the totality of the profile. And whilst efficacy is one part of the equation, obviously, there's safety as well. So it's really going to depend on what the physician and patients think of the overall profile of the medicine if it's successful in that population compared to their experience with ORKAMBI. So it's -- at this stage, it's really a very hypothetical discussion, Brian. We'll wait and see how the Phase III program plays out, and when we've got the results in hand, we'll be able to have a much more informed discussion about which patient populations may be eligible for VX-661 and ivacaftor."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question is from Liisa Bayko with JMP Securities.",11,"And our last question is from Liisa Bayko with JMP Securities."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess you saved the best for last. Okay. First question. I just wanted to better understand the guidance. So if we extrapolate the results this quarter and just assume it's flat for the remainder of the year, we actually get to a number that's certainly",84,"I guess you saved the best for last. Okay. First question. I just wanted to better understand the guidance. So if we extrapolate the results this quarter and just assume it's flat for the remainder of the year, we actually get to a number that's certainly above your guidance. So I'm just wondering if there's was any stocking, or if there's some FX kind of considerations or greater gross-to-net in the future. What -- help us better understand the guidance you provided for KALYDECO."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Liisa, thanks, and you certainly did save the best for last. So congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying the last 3 quarters are th",148,"So Liisa, thanks, and you certainly did save the best for last. So congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying the last 3 quarters are the same as the second, and the first quarter's already done, you do get to slightly above the $590 million, that's correct. I made comments earlier on the call, though, which is we do anticipate patients that we expected to come onto KALYDECO treatment will now go towards the 661 Phase III studies. And clearly, we're trying to estimate that, but we have taken a conservative approach, and we anticipate that, that will affect the growth of KALYDECO, specifically in Europe, and therefore, we're not anticipating a significant growth in the second half of this year with KALYDECO."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that makes sense. I didn't totally put that together. And then, just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made or -- in this population? Or h",88,"Okay, that makes sense. I didn't totally put that together. And then, just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made or -- in this population? Or how you powered it, and kind of like what clinical difference you expect to see or makes sense. Just because we're not as familiar with it, and we haven't seen as much of the data. That would be very helpful."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. This is Jeff. We haven't disclosed the numbers there and probably won't until we get towards the end of the study. There is a fair amount of literature out there that we can send you on what kind of numbers one might see, as",82,"Yes, thanks for the question. This is Jeff. We haven't disclosed the numbers there and probably won't until we get towards the end of the study. There is a fair amount of literature out there that we can send you on what kind of numbers one might see, as I said, with KALYDECO as an example. The study is 200 patients, so it's appropriately powered to see the kinds of differences that we think would be important to see clinically and statistically."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow-up questions. I'll also mention that we will be presenting at a few investor conferences in",78,"Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow-up questions. I'll also mention that we will be presenting at a few investor conferences in the coming months, and in early October, we will plan to host analyst and investors at the North American CF Conference in Phoenix, so stay tuned for details on that. Thanks, and have a good night."
36235,306717990,842172,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded,",320,"Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our Second Quarter 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Earlier in July, we announced the approval of ORKAMBI, and many of you joined for that call. Tonight, we will be focused on second quarter performance and our execution against our corporate strategy. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer. Jeff Chodakewitz, our Chief Medical Officer, is traveling and is not with us tonight. 
Our agenda tonight is as follows: Jeff will begin by discussing key priorities for our business; Stuart will review the second quarter performance of KALYDECO and make a few comments on the ORKAMBI launch; and to close, Ian will review the second quarter 2015 financial results and update our 2015 guidance. You can access the webcast live by going to the Events section of the Investor Relations page on our website. 
I will remind you that we will make forward looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10 K, which has been 
[Audio Gap] 
without limitation. Those regarding the ongoing development and potential commercialization of ORKAMBI, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. 
Information regarding our use of GAAP and non GAAP financial measures and a reconciliation of GAAP to non GAAP is available on our second quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast. 
I will now turn the call over to Dr. Jeff Leiden."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. The approval of ORKAMBI on July 2 was an important milestone in our shared journey with the cystic fibrosis community. ORKAMBI is the first FDA approved medicine to treat the underlying cause of CF for the approxim",408,"Thanks, Michael. Good evening, everyone. The approval of ORKAMBI on July 2 was an important milestone in our shared journey with the cystic fibrosis community. ORKAMBI is the first FDA approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S.  12 years and older with 2 copies of the F508del mutation. This is a big step forward toward our long term vision of helping more people with CF. We feel very fortunate to be part of the CF community, and we appreciate all of the positive feedback we have received and continue to receive from patients, caregivers, health care providers and the broader CF community. 
At the beginning of this year, we outlined 3 strategic priorities that will allow Vertex to continue to deliver on our vision to make new transformative medicines available to patients globally. Let me briefly review our progress toward meeting those goals. First, through both geographic and label expansion, we have continued to grow the number of patients treated with KALYDECO, resulting in strong revenue growth. With the ORKAMBI approval and launch in the U.S., we have an even greater opportunity to treat more patients, resulting in additional revenue growth. 
Second, we know that there is still much more to do. We continue to make significant investment into multiple programs to create more CF medicines that may enable us to treat even more patients and to improve the benefit for the patients we treat. All 4 studies included in the VX 661 plus ivacaftor pivotal Phase III development program are initiated, and we also remain on track to bring a next generation CFTR corrector into the clinic by the end of 2015. 
And third, we have expanded and diversified our pipeline, through our collaboration with Parion, to develop and commercialize investigational epithelial sodium channel, or ENaC inhibitors, for CF and other pulmonary diseases. We also continue to advance early stage development programs outside of CF, including clinical programs in oncology and research programs focused on other areas. We look forward to updating you on these programs later this year. 
The continued execution on our strategy has fundamentally changed the outlook for our business. Specifically, moving forward, we expect to deliver a financial profile of growing revenues, earnings and cash flows, while also continuing to invest to create new medicines to treat more patients with CF and other serious diseases. 
With that, I'll hand it over to Stuart."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making ORKAMBI available to eligible patients in the U.S. Global sales of KALYDECO this quarter were $155",414,"Thanks, Jeff, and hello, everyone. I will review KALYDECO performance in the second quarter and also make a few comments regarding our progress in making ORKAMBI available to eligible patients in the U.S. 
Global sales of KALYDECO this quarter were $155 million, comprised of U.S. sales of approximately $93 million and ex U.S. sales of approximately $62 million. This represents a 37% increase compared to $113 million in the same quarter last year. The strong growth of KALYDECO is a result of both geographic and label expansion. We have seen good uptake in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015. 
Internationally, there has also been rapid uptake of KALYDECO by eligible patients in Australia following the reimbursement agreement reached in late 2014. Also, during the second quarter, we achieved reimbursement approval for non G551D gating mutations in several European countries where these mutations are prevalent, including Italy, France, England and The Netherlands. As a result, today, more than 85% of eligible gating patients in Europe now have access to KALYDECO.
Further growth in patients receiving KALYDECO will be tempered by enrollment in the VX 661 pivotal program, as previously described, and this is reflected in our KALYDECO revenue guidance. 
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been working to get the medicine to the approximately 8,500 eligible patients as rapidly as possible. Our field teams around the country have been educating health care providers on the ORKAMBI prescribing information. Since approval, they have visited the vast majority of the 275 CF centers in the U.S. 
As we anticipated, interest in the medicine is very high. We believe that all eligible patients with CF should have access to ORKAMBI. Our public and private payer interactions to date have been productive, and our patient support team has begun to help patients navigate the reimbursement process. Thanks to these efforts and the commitment of health care providers at CF centers across the country, I'm happy to report that the first patients are already receiving ORKAMBI in the U.S. 
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat. 
I'll now hand the call over to Ian."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Tonight, I would like to discuss our second quarter 2015 financial results, and then, update our 2015 financial guidance. Firstly to the financials. KALYDECO revenues were $155 million this quarter and were up",352,"Thanks, Stuart, and good evening, everyone. Tonight, I would like to discuss our second quarter 2015 financial results, and then, update our 2015 financial guidance. 
Firstly to the financials. KALYDECO revenues were $155 million this quarter and were up 37% from the second quarter of 2014 and up 18% sequentially compared to our first quarter this year. We continued to nicely expand the number of eligible patients we treat with KALYDECO. 
Our second quarter non GAAP R&D and SG&A expenses were $254 million, an increase of $17 million compared to last year, mainly due to an increase in SG&A expenses supporting the launch of ORKAMBI. Our non GAAP net loss was $131 million compared to prior year non GAAP net loss of $142 million. 
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter. 
Let's now turn to the 2015 financial guidance and, specifically, KALYDECO revenues and combined R&D and SG&A expenses. Earlier this year, we anticipated 2015 KALYDECO revenues to be between $560 million and $580 million. And based on an increased uptake due to label and geographic expansions, as Stuart previously mentioned, we now expect KALYDECO net revenues to be between $575 million and $590 million for the full year 2015. 
For the non GAAP operating expenses, we continue to expect the combined non GAAP R&D and SG&A expense to be between $1.05 billion and $1.1 billion for the full year. I'll just note that we expect our operating expenses to be higher in the second half of this year compared to the first half, mainly as a result of the anticipated progress with the VX 661 pivotal program and the investment to support the launch of ORKAMBI. 
I will close by stating that we are in a strong financial position today. We are growing our revenues, and we expect to show a additional growth from ORKAMBI. We will continue to invest to create even more medicines and support access to those medicines already approved. 
With that, I'll ask the operator to please open the line for questions."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets.",13,"[Operator Instructions] Our first question is from Michael Yee with RBC Capital Markets."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question for Stuart, and then, a question for Ian. I guess, Stuart, I appreciate the comments on the launch. Maybe you could just comment on    more specifically on reimbursement and the process for reimbursement that you're seeing. Are payers quickly g",138,"A question for Stuart, and then, a question for Ian. I guess, Stuart, I appreciate the comments on the launch. Maybe you could just comment on    more specifically on reimbursement and the process for reimbursement that you're seeing. Are payers quickly getting people on drug? Maybe walk us through that process and how long it takes to get people on drug, which you're seeing out there. And then, for Ian, I know you maintained the guidance for expenses. That's fantastic. I know people are thinking, bigger picture, as you transform to a very profitable company. Maybe you can comment about how R&D expenses    how you're thinking about that given you now have an ENaC inhibitor and all these Phase IIIs, how are you thinking about controlling some of that or making sure we're going to be very profitable?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi Mike, it's Stuart. Thanks for the question. So in terms of the process for reimbursement, essentially, payers fall into a couple of different camps. Some come to making formal decisions very quickly, and we've seen some of those. Most have a process wh",184,"Hi Mike, it's Stuart. Thanks for the question. So in terms of the process for reimbursement, essentially, payers fall into a couple of different camps. Some come to making formal decisions very quickly, and we've seen some of those. Most have a process where they're going to have kind of the equivalent of a P&T committee and review the product. And those will often, then, put in sort of interim policies as it were, where they'll evaluate on a case by case basis whether a patient can be initiated on ORKAMBI. And so as a result of those interim policies and some initial policy decisions, that's why we have already seen patients start on ORKAMBI in the first few weeks following launch. And then, over the next few months, more and more payers will come to their final determinations on their coverage policies for ORKAMBI. As I say, based on the discussions we've had so far, we do continue to anticipate that we are going to have broadened and positive reimbursement for ORKAMBI. And I'll pass it over to Ian handle the expenses question."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, thanks for the question. I'm going to take it a little broader, if you don't mind, and really comment on what is our goal with, let's say, the Vertex financial profile. And it starts with growing    a growing revenue stream, which we are very confid",220,"Mike, thanks for the question. I'm going to take it a little broader, if you don't mind, and really comment on what is our goal with, let's say, the Vertex financial profile. And it starts with growing    a growing revenue stream, which we are very confident around, given the recent approval of ORKAMBI. We look at growing that rapidly, providing access to the medicines that are already approved and, basically, holding at a steady state our operating expenses in a    in the company. The primary driver within our operating expense structure is R&D. That's a function of our commercial model as we get    provide access to the medicines around the world, which is highly leveraged with small investment required to provide access to these medicines, actually. Providing access to the medicines is more about education than it is about selling a drug. So that allows us, as a business, to reinvest in R&D yet still aim to have high operating margins. And as we see out over the next 3, 4 years, we do see ourselves as a business that if we can drive up our medicines to patients and hold our operating expense, which is exactly what we expect, that we'd generate high operating margins and operating margins that are consistent with our, let's say, larger cap biotech peers."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Geoff Meacham with Barclays.",10,"And our next question is from Geoff Meacham with Barclays."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple more clinical questions. I'm hoping someone there can answer it, but I noticed in the press release today, one of the endpoints for the younger population in Europe, the 6 to 11, was absolute change in lung clearance. And I wasn't sure if you guy",86,"A couple more clinical questions. I'm hoping someone there can answer it, but I noticed in the press release today, one of the endpoints for the younger population in Europe, the 6 to 11, was absolute change in lung clearance. And I wasn't sure if you guys were sort of rethinking some of the endpoints overall for development beyond FEV1, or is this just a special case, just given the age of the population? I have a couple of other pipeline questions as a follow up."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. And thanks for asking that question. We've been talking for some time, both with Wall Street and with regulators, about the notion t",186,"Geoff, this is Jeff Leiden. Jeff Chodakewitz is traveling today, so he's not here. So I'm going to take the R&D questions. And thanks for asking that question. We've been talking for some time, both with Wall Street and with regulators, about the notion that we are eager to explore additional endpoints to FEV1, particularly for younger populations where it's more difficult to consistently blow a good FEV1 if you're 2 or 3 years old. And as part of that, we've explored 3 or 4 different endpoints, including lung clearance index. And this was a very nice opportunity, in talking with European regulators about this younger population, to begin to use lung clearance index, which is much less effort dependent and much more consistent, particularly in young patients, as an efficacy endpoint. So it'll be interesting from    to see the results of this study, which, we think, will be highly predictive using this endpoint. And we also plan to use of those kinds of results to begin to discuss with other regulators whether these other endpoints might be useful, particularly in the young, very young patients."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that's helpful, Jeff. And another question just on the ENaC inhibitor. Does this change your priorities for you guys for the    for your next gen corrector? Or is this    would you view this as kind of complementary what    to what you already have?",68,"Okay, that's helpful, Jeff. And another question just on the ENaC inhibitor. Does this change your priorities for you guys for the    for your next gen corrector? Or is this    would you view this as kind of complementary what    to what you already have? And then, are we still on track to identify the third corrector by, I guess, by year end or early part of next year?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Let me    maybe I'll take those in reverse order, Geoff. So yes, we are absolutely on track to identify the third corrector. And just to remind you, I    and I know you know this, that our strategy here has been to bring multiple next gen correctors",217,"Yes. Let me    maybe I'll take those in reverse order, Geoff. So yes, we are absolutely on track to identify the third corrector. And just to remind you, I    and I know you know this, that our strategy here has been to bring multiple next gen correctors into the clinic, and our goal was the first one by the end of this year, with several others following directly behind it. And that's progressing nicely, and we are on track. With respect to the ENaC inhibitors, yes, we do view them very much as complementary. And they could be complementary in a couple of ways, right, because they fall outside of the classic CFTR correction. They may have activity as monotherapy, particularly in populations like het mins that don't have anything and, frankly, in other lung diseases as well. But we're particularly eager to study them on top of our current regimens like ORKAMBI because they may amplify the signal that we're seeing here. So I wouldn't view them as one or the other, I would definitely view them as complementary. And I guess, your question is sort of getting at do they, in any way, slow down or de prioritize our next gen correctors? And the answer is no. We're full speed ahead on next gen correctors."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matt Roden with UBS.",9,"Our next question is from Matt Roden with UBS."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. First, Stuart, I wonder if you could elaborate on some launch metrics that you're seeing. I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from presc",158,"Great. First, Stuart, I wonder if you could elaborate on some launch metrics that you're seeing. I know it's early days here, but is there any sense for the sort of numbers of centers prescribing? Or any other early indicators from maybe a time from prescription to fill? Any other metrics that you can share so we can get a sense of what's happening out there? And then, I think this might be for Ian. If you could help us square the sales and the increase in guidance against your prior comments regarding the impact of enrollment as VX 661 trials on KALYDECO use. Do you have a same store sales metric that enables you to see that, that impact is happening, but that the geographic expansion and the label expansion is compensating for that? Or is it just that it's actually not happening to the extent that you previously thought, that is, the impact of 661 trials?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, it's Stuart here. Just in terms of launch metrics, I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how predictive those are of the kind of the trajectory that we're seeing over",176,"Matt, it's Stuart here. Just in terms of launch metrics, I mean, we're less than 4 weeks in since the approval. So I'm really not going to comment on specific launch metrics and how predictive those are of the kind of the trajectory that we're seeing overall. As we've said before, because of the interest in the product, the unmet need and the fact that it treats the underlying cause, we're certainly expecting the overall penetration of ORKAMBI in the eligible patient population to be high. And we've said all along that we do think, though, it will take longer for ORKAMBI to reach peak penetration compared to KALYDECO for a number of factors that we've gone into previously, like the volume of patients and the    the time it's going to take to educate patients and get them through the reimbursement approval process. But yes, it's really much too early to be kind of throwing around specific launch metrics right now. And then, on the guidance and KALYDECO revenue question, I'll throw that over to Ian."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Matt, thanks for the question. The    well, first off, I'll say, we're very pleased with the expansion of KALYDECO in, let's say, treating more patients through geographic and label expansion. As far as the guidance we've provided for the full year,",166,"Yes, Matt, thanks for the question. The    well, first off, I'll say, we're very pleased with the expansion of KALYDECO in, let's say, treating more patients through geographic and label expansion. As far as the guidance we've provided for the full year, we do actually now anticipate patients that would be available for the medicine, mainly in Europe, actually, to go into the 661 trials. Remember, we    as ORKAMBI was approved in the U.S., we switched recruitment of the VX 661 pivotal studies to Europe. Europe is where we're starting to continue to recruit new patients potentially, based on the label expansion of KALYDECO. And instead of going on to KALYDECO, we're starting to recruit those into our 661 studies. So we have built that into our guidance, and hence, why we come out with something that is between $575 million and $590 million, therefore, reflecting a lower growth rate than where we currently are between Q1 and Q2. We do think it will flatten out."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Geoffrey Porges with Bernstein.",9,"Our next question is from Geoffrey Porges with Bernstein."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A question, first, related to the extension study for the patients that were on ORKAMBI coming into the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled and stayed on treatment? And then, wha",81,"A question, first, related to the extension study for the patients that were on ORKAMBI coming into the approval. Could you give us a sense of, first, how many of the patients who were eligible were actually enrolled and stayed on treatment? And then, what number of them have rolled over to commercial drug? And then, I just wanted a quick follow up on VX 371. Jeff, perhaps you could address why do the study with ORKAMBI rather than with 661."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Jeff Chodakewitz, if he were here, would have the exact numbers. But it",136,"So Geoff, it's Stuart here. In terms of the number of patients who rolled over from TRAFFIC and TRANSPORT into the extension study, that number was very high. It was north of 90%. And Jeff Chodakewitz, if he were here, would have the exact numbers. But it was north of 90% of patients rolled over from TRAFFIC and TRANSPORT into the open label extension. About half of those were in the United States. And the process of informing those centers and those patients that the commercial product is now available, beginning to roll those patients over to commercial product, is just beginning. But it's  about 500 or so of the    of 1,000 who rolled over into the 105 study were here in the United States. And on the VX 371, I'll pitch that to Jeff Leiden."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff. The    in terms of the VX 371 and why we're going with ORKAMBI, it's really a matter of how do we get the medicine, potentially, to patients the fastest. So since ORKAMBI is already approved, simply adding 1 unapproved drug and getting the res",83,"Yes, Geoff. The    in terms of the VX 371 and why we're going with ORKAMBI, it's really a matter of how do we get the medicine, potentially, to patients the fastest. So since ORKAMBI is already approved, simply adding 1 unapproved drug and getting the result will let us, assuming that we have success, will let us get to    get that new drug, VX 371, to patients the quickest. And our goal all along has been improving therapy as quickly as we could."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Terence Flynn with Goldman Sachs.",10,"Our next question is from Terence Flynn with Goldman Sachs."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. Can you just remind us about the anticipated timing of Medicaid coverage for ORKAMBI? And then, regarding the VX 661 KALYDECO trial in het mins, now that you've started that trial, can you just maybe remind us of expectations for when",51,"Maybe just 2 for me. Can you just remind us about the anticipated timing of Medicaid coverage for ORKAMBI? And then, regarding the VX 661 KALYDECO trial in het mins, now that you've started that trial, can you just maybe remind us of expectations for when that interim analysis might occur?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Terence, it's Stuart here. In terms of Medicaid coverage, there really isn't one answer. There's, really, 50 answers because, obviously, Medicaid's managed state by state. So I really can't give you one answer to the Medicaid question. What I can sha",123,"Yes, Terence, it's Stuart here. In terms of Medicaid coverage, there really isn't one answer. There's, really, 50 answers because, obviously, Medicaid's managed state by state. So I really can't give you one answer to the Medicaid question. What I can share is that we've already seen patients initiated on therapy in the first 4 weeks. And within that number of patients, we have patients who have commercial insurance as their primary insurance. We also have patients who have government insurance in the number people who've already been initiated. But to give one specific number for Medicaid is just impractical, because there's really 50 answers to that particular question. And for the second part of the question, I'll hand it over to Jeff."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In terms of the het min trial, just to remind you, Terence, we actually just announced that, that trial is open for enrollment, so it's essentially starting now, if you want to think it about it that way. And to remind you of the design of that trial",159,"Yes. In terms of the het min trial, just to remind you, Terence, we actually just announced that, that trial is open for enrollment, so it's essentially starting now, if you want to think it about it that way. And to remind you of the design of that trial, it actually has 2 parts. We enroll around 150 patients, plus or minus. We then have a DSMB that will do a futility analysis. We won't actually see the numbers at that point. They'll simply tell us to stop if the    if it's futile or to continue. If they tell us to continue, we then enroll another approximately 150 patients. Because it's a shorter study than the 24 week homozygous study, we would still have visibility to that data by the time we had visibility to the homozygous study. We expect that to be some time in 2016, depending on how quickly the enrollment goes. Does that answer your question?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes. And maybe, Stuart, just one follow up on Medicaid. Can you just remind us, in terms of KALYDECO, what the benchmark was there in terms of the    I understand it's at state level, but just what was the range in terms of how long the process took from",56,"Yes. And maybe, Stuart, just one follow up on Medicaid. Can you just remind us, in terms of KALYDECO, what the benchmark was there in terms of the    I understand it's at state level, but just what was the range in terms of how long the process took from the first day to the last day?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, I mean, we're splitting hairs a little bit there, Terence. I mean, the uptake with KALYDECO was so rapid. As you know, we got to 90 plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both comme",80,"Well, I mean, we're splitting hairs a little bit there, Terence. I mean, the uptake with KALYDECO was so rapid. As you know, we got to 90 plus percent of patients. We were at 90% of peak in 6 months, and so it was really incredibly rapid across both commercial payers and Medicaid. So there really wasn't much of a range that I could give you there. It was incredibly rapid for KALYDECO across all patient populations and all insurers."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Cory Kasimov with JP Morgan Chase.",11,"Our next question is from Cory Kasimov with JP Morgan Chase."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, just to follow up on that, just based on your early discussions with payers on ORKAMBI, is there any change to your expectations for gross to net? Or maybe another way, has the reaction to the price been about what you expected when you announced",76,"I guess, just to follow up on that, just based on your early discussions with payers on ORKAMBI, is there any change to your expectations for gross to net? Or maybe another way, has the reaction to the price been about what you expected when you announced it earlier this month? And then, secondly, on the new ENaC product you have, does the ongoing Phase II trial in patients with any CFTR mutation include heterozygous patients?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, on    the reaction to the price, I would say, has been very balanced. Indeed, the focus of our discussions has really been less around the price and more around the clinical profile of ORKAMBI. And in terms of whether it changes our view on the g",144,"So Cory, on    the reaction to the price, I would say, has been very balanced. Indeed, the focus of our discussions has really been less around the price and more around the clinical profile of ORKAMBI. And in terms of whether it changes our view on the gross to net, it really doesn't. The gross to net is almost exclusively driven by the payer mix. And as we've explained previously, we are expecting the Medicaid payer mix to be a higher percentage for ORKAMBI than it was for KALYDECO, and it's likely to be in around that sort of 35% to 40% of eligible patients, we predict, will be covered by Medicaid. The vast majority of the rest will be covered by commercial insurance. But our view on that gross to net hasn't been changed by anything we've seen in the first 4 weeks."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, in terms of the ENaC trial, just to remind you, they're actually    we're planning 2 trials. The first one is already under way, and that trial is basically monotherapy in any mutation. I assume you're referring to het mins, and so the answer is",94,"And then, in terms of the ENaC trial, just to remind you, they're actually    we're planning 2 trials. The first one is already under way, and that trial is basically monotherapy in any mutation. I assume you're referring to het mins, and so the answer is yes. Het mins would be there, with the obvious exception that KALYDECO treated patients, and now going forward, ORKAMBI treated patients wouldn't be included in that study. The second study is going to be the ENaC inhibitor on top of ORKAMBI in patients who are treated with ORKAMBI."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Ying Huang with Bank of America Merrill Lynch.",13,"Our next question is from Ying Huang with Bank of America Merrill Lynch."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one, maybe for Stu. It was reported that the Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking ORKAMBI. I was wondering if that's a single isolated case, or have you se",130,"First one, maybe for Stu. It was reported that the Harvard Pilgrim in Boston is actually discussing with you guys about pricing scheme based on pulmonary function in patients taking ORKAMBI. I was wondering if that's a single isolated case, or have you seen that among the other payers or not? And then, secondly, on the R&D front, I noticed that in the press release, you guys are adding 1 arm in the Phase III trial for 661 for the patients who have 1 allele of 508 and the other allele with residual CFTR function. You're adding 1 monotherapy KALYDECO arm. Is that due to a request from FDA? Or    and also, are you going to add monotherapy on    in the other Phase III trials or not in 661 trial?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Ying, so I'm really not going to comment on what discussion that we're having with individual payers and plans. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to ORKAMBI, and it's for it to be a de",73,"Yes, Ying, so I'm really not going to comment on what discussion that we're having with individual payers and plans. I'll say what we've said all along. Our belief is that all eligible patients deserve to have access to ORKAMBI, and it's for it to be a decision for the physician and patient whether they want to initiate those patients on ORKAMBI. And on the 661 program, I'll hand that off to Jeff."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Just to be clear, the design of the 661 program has not changed. We haven't added any new arms. The residual function arm always had in it both the placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there.",44,"Yes. Just to be clear, the design of the 661 program has not changed. We haven't added any new arms. The residual function arm always had in it both the placebo and ivacaftor monotherapy compared with 661 plus ivacaftor. So nothing has changed there."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Matthew Harrison with Morgan Stanley.",10,"Our next question is from Matthew Harrison with Morgan Stanley."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. So I just wanted to go back to ENaC just for a second. I mean, I think you talked a little bit about the rationale, but maybe you could expand upon the rationale for combining with ORKAMBI. And then, secondly, I mean, what, specifically, might you",115,"Great. So I just wanted to go back to ENaC just for a second. I mean, I think you talked a little bit about the rationale, but maybe you could expand upon the rationale for combining with ORKAMBI. And then, secondly, I mean, what, specifically, might you hope to see? Should we be looking for increased lung function? Should we be looking for a lowering of the exacerbation rate? I mean, what would you be hoping to see with that combination? And then, separately, just on KALYDECO, I just want to make sure I understood your comments correctly. Are you saying that all of the growth came from increased penetration across the new gating mutations?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe I'll take the R&D question first, the ENaC inhibitors. Ian described this in terms of the ocean and seaweed, but I can't be nearly that eloquent, so I'll just take it from a more scientific standpoint, maybe. The way we think about ENaC and the way",285,"Maybe I'll take the R&D question first, the ENaC inhibitors. Ian described this in terms of the ocean and seaweed, but I can't be nearly that eloquent, so I'll just take it from a more scientific standpoint, maybe. The way we think about ENaC and the way the ENaC inhibitors work, as you know, is that ENaC is a separate channel, the sodium channel, that is also involved in hydrating the secretions and the mucus in the lung. And so you could think about it as    and there's actually even an interaction with CFTR. So CFTR's a chloride channel that helps hydrate the mucus; ENaC's the sodium channel, it helps hydrate the mucus. And so the rationale and based upon preclinical studies, is that if you combine an ENaC inhibitor with a potentiator, for example, or corrector potentiator, you'll get even better hydration of the mucus, which, then, should lead to better lung function. So what we're doing with the ENaC inhibitor program is were asking the question, does the ENaC inhibitor alone have activity to help hydrate the mucus and improve lung function in all mutations? And then, if we take the ENaC inhibitor and add it to KALYDECO or ORKAMBI, can we get better hydration than we get with a single agent alone? And the rationale is really based upon the work we've done in our human bronchial epithelial cell assays that say when you add an ENaC inhibitor to a CFTR corrector or to a corrector plus potentiator, you actually get even better hydration. So the question is, does that translate into the clinic and improvements in FEV1? And we definitely are going to be looking at hard endpoints like FEV1."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then, in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where the R117H patient population was added to the label at the back end of 2014",144,"And then, in terms of the KALYDECO growth, it really is a combination of both label expansion and geographic expansion. For instance, in the U.S., we've had label expansions where the R117H patient population was added to the label at the back end of 2014. And then, in March, we were also approved for use in children between 2 and 5 with eligible mutations. So there's label expansion here in the United States, and then, outside of the U.S., it really has been geographic expansion, such as G551D patients in Australia, where the uptake has been very rapid. And then, also, additional gating patients in a number of countries in the EU. So there really isn't one answer to what's been driving that KALYDECO revenue growth. It really has been that combination of label expansions into new populations and geographic expansion into new markets."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Mark Schoenebaum with Evercore ISI.",10,"Our next question is from Mark Schoenebaum with Evercore ISI."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Odysseus, [ph] sitting in for Mark. But just a few questions. One, around the het min trial. Wondering about potential disclosure or lack of disclosure at the interim if it doesn't hit and there    an expansion is required and for an additional 15",176,"This is Odysseus, [ph] sitting in for Mark. But just a few questions. One, around the het min trial. Wondering about potential disclosure or lack of disclosure at the interim if it doesn't hit and there    an expansion is required and for an additional 150 patients. The second question had to do with this lung clearance index. I'm just wondering whether Vertex has previously used that endpoint in any of its trials that have any data from any of these drugs. And if so, or if not, in terms of thinking about the    how Vertex thought about the powering and design of the study based on that. And then, the last question, in terms of the next generation corrector and one coming by year end    but as I understand, there'll be additional, probably, next generation correctors, potentially next generation potentiators    but next generation correctors that may follow. Just wondering if Vertex is, perhaps, eyeing or if Vertex can sort of quantify how many of those they may be eyeing to bring to the clinic in 2016."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. Let me    this is Jeff. Let me take the last 2 questions, and I'll turn it over to Ian on the disclosure question. Starting with the next gen program, we've said previously that we have multiple next gen correctors in lead optimization, which, as yo",199,"Sure. Let me    this is Jeff. Let me take the last 2 questions, and I'll turn it over to Ian on the disclosure question. Starting with the next gen program, we've said previously that we have multiple next gen correctors in lead optimization, which, as you know, is sort of the study of the drug like properties and [indiscernible] data from those molecules. And as I said, we're on track to bring the first of those into the clinic this year, and our goal is to bring at least 2 or 3 additional behind that, following completion of lead optimization for those additional molecules and to compare several different next generation correctors. And then, your question about lung clearance index. Lung clearance index is actually a fairly widely used measure of the ability to empty the lungs of air effectively. And there is data from a number of studies showing, for instance, that when patients, such as G551D patients, were treated with KALYDECO, there's a significant improvement in lung clearance index. And we're happy to send you some of those studies. So it is an endpoint that's been pharmacologically validated, if you want to think about it that way."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Odysseus, thanks for the question. Just to refer to an earlier comment Jeff Leiden made, which was the initial part of    this initial cohort of patients that enters the het min study with 661. And the idea of that is that there is futility assessment",206,"And Odysseus, thanks for the question. Just to refer to an earlier comment Jeff Leiden made, which was the initial part of    this initial cohort of patients that enters the het min study with 661. And the idea of that is that there is futility assessment. That futility assessment, if an independent advisory board deems that it is worth progressing forward, we will just continue to recruit patients and the study will be ongoing. We will not be at a disclosure point. At that point, we'll just continue to recruit into the study and wait for the complete and final results of that study. If the board deems that it is futile, effectively futile in dosing those patients, they will advise us so, and we will curtail the study. On stopping that study and working the patients off drug, we will provide a disclosure to let you know that, that study is no longer going forward. So I think, the way to think about this is that if there is no news, it is because the study will progress, and they will continue to recruit het min patients, and if there is an early closure of that study, we'll advise you at that point in time."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, just to clarify, so there won't be necessarily an increase in the number of patients on ClinicalTrials.gov or anything of that sort?",24,"I guess, just to clarify, so there won't be necessarily an increase in the number of patients on ClinicalTrials.gov or anything of that sort?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, there won't be any disclosures, so.",7,"No, there won't be any disclosures, so."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is from Robyn Karnauskas with Deutsche Bank.",10,"Our next question is from Robyn Karnauskas with Deutsche Bank."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just 2 questions, one for Stuart, one for Ian. So at this rate, you guys have talked a lot about in CF centers, there could be a backlog, like the processing within the CF centers, and there may not be a lot that you can do about that. Can you just talk a",117,"Just 2 questions, one for Stuart, one for Ian. So at this rate, you guys have talked a lot about in CF centers, there could be a backlog, like the processing within the CF centers, and there may not be a lot that you can do about that. Can you just talk a little bit about what you're seeing or anything you've done to like help that process as patients move through, and if it's better or in line with your expectations? And then, for Ian, a lot of your competitors or comps are diversifying and you still are really a CF company. And what are your thoughts on the importance of diversification over the next year?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, it's Stuart here. So yes, I think whilst it's early days, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would. And those factors, just to remind you, is th",313,"Robyn, it's Stuart here. So yes, I think whilst it's early days, I think our experience in the first 4 weeks is the sort of factors that we were anticipating are really playing out as we anticipated they would. And those factors, just to remind you, is that the volume of patients is obviously much greater than it was when KALYDECO was initially approved, just for G551D patients. So there's a volume of patients that centers need to get in. Then, obviously, when a physician is making the decision to start a patient on a new drug, then, obviously, there's a fair amount of discussion. Education is going to want to go on there, explaining the product, the mechanism of action, how to take it, all those sorts of things. And then, obviously, we move on to the sort of reimbursement approval process. And so all of those factors that we anticipated prior to launch, being involved in how the launch is going to go, have certainly been playing out exactly as we thought we    as we thought they would. In terms of what we're doing to support centers, we're doing a number of things, clearly, providing education materials to support their discussions with their patients. We're providing them with help in terms of the sort of materials they need to submit to the various payers, be it prior authorization, documentation and stuff like that; providing them help with what documentation they're going to need, where the right place to send it is. And then, from a patient support point of view, obviously, our patient services group is there to support individual patients navigate the reimbursement process as well. And so we're    as compliantly as possible, we are providing as much support as we can to help patients get access to the medicine. On the second point, I'll pass it over to Ian."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, thanks for that question regarding we're focused on CF. We're very pleased about that. And    but also, I would say that we still need to continue to be focused on CF, and part of our, let's say, corporate or business development strategy, as well",259,"Robyn, thanks for that question regarding we're focused on CF. We're very pleased about that. And    but also, I would say that we still need to continue to be focused on CF, and part of our, let's say, corporate or business development strategy, as well as our investment into research at Vertex, is about strengthening our position and creating even better combination medicines to treat more patients in CF. So that is one tactic. And so we continue in CF, and I think it is    it behooves the company to continue to raise the bar in terms of the benefit we provide patients with our medicines, and that's why we reinvest. We also reinvest in other areas within the company, and I hope that later this year and early next year, we can tell you a little bit more  about those other disease areas that we're in as well as other business development efforts, which are looking to expand our scientific footprint. And then, also, just to consider other products that may diversify and stage our pipeline. It tends to be earlier stage ideas. I think that's appropriate for a company at our stage as we progress forward, and our priority is still cystic fibrosis. I'll throw it over Jeff Leiden, though, because I think there's just much more of a    kind of a strategic comment that's worth making here, which is while we're successful in CF, we're not taking our eye off that we want to go into other disease areas. And maybe Jeff, you have a comment?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Robyn, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it, is CF, and not only increasing the number of patients that we can treat with new medicines but actually",262,"Robyn, I think Ian said it well. If I were to say it in a simple way, I think of this as sort of 3 strategic objectives: Number one, no doubt about it, is CF, and not only increasing the number of patients that we can treat with new medicines but actually increasing the benefit for all the patients we're treating. And we've said many times, our goal is to get to the majority, more than 90% of patients with medicines that have KALYDECO like or better effects. And I think we're executing well on that, and we're well on track. At the same time, obviously, we are investing in areas outside of CF. As I've said, we'll bring more new compounds into the clinic this year at Vertex than we ever have in the history of the company. We're not talking a lot about that yet, but you'll start to hear more news as we begin to get clinical results, I think, later this year and certainly into next year. And then, the third part, as Ian said, is that we're going to have the financial resources to also invest in innovation outside the company. And we're spending significantly more time, effort, and money on our BD activities. You've heard a couple of deals, but I think you can anticipate more, again, typically focused on earlier stage scientific platforms or assets. So it's really a 3 legged stool, and I think, with the launch of ORKAMBI, we'll now have the financial wherewithal to invest in all 3 parts of the stool."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Phil Nadeau with Cowen and Company.",12,"And our next question is from Phil Nadeau with Cowen and Company."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just 2, one scientific    or I guess, actually, both on clinical development. First, on VX 661's Phase III. Have you ever disclosed what the futility analysis hurdle is? Or if not, would you care to disclose it now? And then, second, on the new    the sec",78,"Just 2, one scientific    or I guess, actually, both on clinical development. First, on VX 661's Phase III. Have you ever disclosed what the futility analysis hurdle is? Or if not, would you care to disclose it now? And then, second, on the new    the second generation correctors. Could you give us some idea of what the clinical development path is likely for those? Specifically, how quickly could they get into combination therapy regimens with an FEV1 endpoint?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for both questions. So we haven't disclosed the hurdle, and we're not    we won't we be disclosing it today. As Ian said, the    I think, the first news that you would get on that is if we didn't meet the hurdle and the study was stopped, we w",180,"Yes, thanks for both questions. So we haven't disclosed the hurdle, and we're not    we won't we be disclosing it today. As Ian said, the    I think, the first news that you would get on that is if we didn't meet the hurdle and the study was stopped, we would disclose, at that point, what was going on. With respect to the second generation correctors, we really see them following a fairly straightforward development path. We've sort of pioneered the way here with our previous medicines. They go into Phase I in normal single ascending dose, multi ascending dose. And following, hopefully, successful safety results from those studies, we would put them both as monotherapy and as combination therapy into patients. And I think we've figured out    we've learned a lot over the last few years about how to do those studies very quickly and very efficiently with small numbers of patients. And so I think we can get pretty definitive data using FEV1 as well as other endpoints on how they fare, both by themselves and with    in combination."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question is from Tony Butler with Guggenheim Partners.",11,"And our next question is from Tony Butler with Guggenheim Partners."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Jeff, 2 brief questions. One is, eliminating the sodium channel compounds for the moment, is there a rationale for a next gen corrector to actually be QD or BID, such that it's more easily formulated with either ivacaftor and/or 661? And the second questi",73,"Jeff, 2 brief questions. One is, eliminating the sodium channel compounds for the moment, is there a rationale for a next gen corrector to actually be QD or BID, such that it's more easily formulated with either ivacaftor and/or 661? And the second question is, is there any rationale from HBE experiments that actually suggest to you that there may be the need for 3 correctors and additional    in addition to a potentiator?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines, because they do take very large numbers of pills every day. And so we continue",164,"Yes, thanks for both questions. So with respect to the formulation question, our goal always has been to make it as easy as possible for these patients to take their medicines, because they do take very large numbers of pills every day. And so we continue to push for co formulated products. That's certainly our goal, into one pill or a small number of pills. And either QD or BID, both of those seem pretty acceptable to patients, and that's certainly our target product profile with the next gen correctors in combination. Your other question was, could we need 3 correctors? The answer is we don't yet fully know, but certainly, our goal is to try to keep this to as few medicines as possible, simply from drug drug interaction standpoint, from a co formulation standpoint. So again, if you ask me what our target profile    product profile was today, it would be a first gen corrector, a second gen corrector and a potentiator."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question is going to be from Brian Skorney with Baird.",12,"Our next question is going to be from Brian Skorney with Baird."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, I just want to kind of get your temperature on how we should be thinking about pricing of the VX 661 combination in the context of ORKAMBI and KALYDECO's price. They're obviously at different price points, but    they're in different patient popu",153,"I guess, I just want to kind of get your temperature on how we should be thinking about pricing of the VX 661 combination in the context of ORKAMBI and KALYDECO's price. They're obviously at different price points, but    they're in different patient populations right now, but based on the 661 combo studies, this is probably going to wind up being a significant overlap between KALYDECO and ORKAMBI patients. I guess, about 80% of KALYDECO responders have probably shown improvement on VX 661 plus ivacaftor based on the Phase 2 data, and it doesn't look like there'd be a meaningful amount of clinical efficacy above and beyond ORKAMBI for the combo. So I guess, is it more important to you guys to maintain price per patient for KALYDECO responders or to try to get ORKAMBI patients to switch to the VX 661 combo? Because it doesn't seem like you could really do both."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I think    I mean, the most important things to us, overall, are to increase the number of patients that we're able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our ov",121,"Yes, Brian, I think    I mean, the most important things to us, overall, are to increase the number of patients that we're able to bring a benefit to and continue to increase the benefit we deliver for the patients that we are able to treat. That's our overall strategy. And KALYDECO combined with VX 661 is a part of that overall strategy. But to really be commenting on price, right now, is way too early. As you know, we've got this broad Phase III program, starting it across multiple patient populations. And until we see the results, both safety and efficacy, across those different patient populations, it would really be inappropriate to be speculating on how we might price that combination."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Well, then, I guess, is    would there    would you perceive any benefit outside of a double corrector potentiator combination to have patients on a 661 ivacaftor combo as opposed to ORKAMBI if kind of the Phase II data winds up holding up and they look p",49,"Well, then, I guess, is    would there    would you perceive any benefit outside of a double corrector potentiator combination to have patients on a 661 ivacaftor combo as opposed to ORKAMBI if kind of the Phase II data winds up holding up and they look pretty similar efficacy wise?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not sure I understand your question. Could you ask that again? A double corrector combination potentiator?",18,"I'm not sure I understand your question. Could you ask that again? A double corrector combination potentiator?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So basically, what I'm getting at is would there be a reason to try to get patients on ORKAMBI switched to 661, in your view, if the efficacy profiles are relatively similar?",32,"So basically, what I'm getting at is would there be a reason to try to get patients on ORKAMBI switched to 661, in your view, if the efficacy profiles are relatively similar?"
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, I think it really depends on the totality of the profile. And whilst efficacy is one part of the equation, obviously, there's safety as well. So it's really going to depend on what the physician and patients think of the overall profile of the med",112,"I mean, I think it really depends on the totality of the profile. And whilst efficacy is one part of the equation, obviously, there's safety as well. So it's really going to depend on what the physician and patients think of the overall profile of the medicine if it's successful in that population compared to their experience with ORKAMBI. So it's    at this stage, it's really a very hypothetical discussion, Brian. We'll wait and see how the Phase III program plays out, and when we've got the results in hand, we'll be able to have a much more informed discussion about which patient populations may be eligible for VX 661 and ivacaftor."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question is from Liisa Bayko with JMP Securities.",11,"And our last question is from Liisa Bayko with JMP Securities."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess you saved the best for last. Okay. First question. I just wanted to better understand the guidance. So if we extrapolate the results this quarter and just assume it's flat for the remainder of the year, we actually get to a number that's slightly",85,"I guess you saved the best for last. Okay. First question. I just wanted to better understand the guidance. So if we extrapolate the results this quarter and just assume it's flat for the remainder of the year, we actually get to a number that's slightly above your guidance. So I'm just wondering if there's was any stocking, or if there's some FX kind of considerations or greater gross to net in the future. What    help us better understand the guidance you provided for KALYDECO."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Liisa, thanks, and you certainly did save the best for last. So congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying the last 3 quarters are th",148,"So Liisa, thanks, and you certainly did save the best for last. So congratulations, your math is correct. If you take the first 6 months of this year and then take this quarter and multiply it by 2, which is a way of just saying the last 3 quarters are the same as the second, and the first quarter's already done, you do get to slightly above the $590 million, that's correct. I made comments earlier on the call, though, which is we do anticipate patients that we expected to come onto KALYDECO treatment will now go towards the 661 Phase III studies. And clearly, we're trying to estimate that, but we have taken a conservative approach, and we anticipate that, that will affect the growth of KALYDECO, specifically in Europe, and therefore, we're not anticipating a significant growth in the second half of this year with KALYDECO."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that makes sense. I didn't totally put that together. And then, just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made or    in this population? Or h",87,"Okay, that makes sense. I didn't totally put that together. And then, just a final question. Again, I know a lot of people have asked, but on this lung clearance index, can you maybe give us what kind of assumptions you made or    in this population? Or how you powered it, and kind of like what clinical difference you expect to see or makes sense. Just because we're not as familiar with it, and we haven't seen as much of the data. That would be very helpful."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. This is Jeff. We haven't disclosed the numbers there and probably won't until we get towards the end of the study. There is a fair amount of literature out there that we can send you on what kind of numbers one might see, as",82,"Yes, thanks for the question. This is Jeff. We haven't disclosed the numbers there and probably won't until we get towards the end of the study. There is a fair amount of literature out there that we can send you on what kind of numbers one might see, as I said, with KALYDECO as an example. The study is 200 patients, so it's appropriately powered to see the kinds of differences that we think would be important to see clinically and statistically."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow up questions. I'll also mention that we will be presenting at a few investor conferences in",79,"Okay. That's going to conclude the call. We appreciate everybody joining us tonight. The IR team is available in the office tonight if anyone has additional follow up questions. I'll also mention that we will be presenting at a few investor conferences in the coming months, and in early October, we will plan to host analyst and investors at the North American CF Conference in Phoenix, so stay tuned for details on that. Thanks, and have a good night."
36235,306717990,842242,"Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015",2015-07-29,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, a",302,"Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Ian Smith, Chief Financial Officer; and Dr. David, our Chief Scientific Officer. Dr. Jeff Chodakewitz, Chief Medical Officer, will also be available for Q&A.
Our agenda tonight is as follows: Jeff will review the progress with our cystic fibrosis medicines. Stuart will review the third quarter sales performance of our marketed products. Ian will review the third quarter 2015 financial results and update our 2015 guidance. And to close, David will discuss our research strategy and our early development pipeline. 
You can access the webcast slides by going to the Events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our third quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clearly strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased report that we continue to make excellent progress toward achieving our long",736,"Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clearly strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased report that we continue to make excellent progress toward achieving our long-term vision for 2016 and beyond. Significant revenues and revenue growth for multiple high-value medicines, high operating margins and a pipeline of additional transformational medicines. 
Our goal in CF is to reach the vast majority of people with this serious disease and to continue to enhance the benefits for the patients who we treat, and we continue to build on the track record of innovations discover, develop and deliver transformative medicines more people with CF. 
Let me summarize our recent commercial success in development progress in CF.
In July, ORKAMBI became the first FDA-approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S. 12 years and older, with 2 copies of the F508del mutation. And as of September 30, 2015, we already were treating more than 3,000 of these patients.
Our sNDA has been accepted by the FDA for the expanded use of KALYDECO in people aged 2 and older, with 1 of 23 residual function mutations that result in CF. This may accelerate access to KALYDECO for more than 1,500 patients in the U.S.
The European Union CHMP recently issued 3 positive opinions for KALYDECO and ORKAMBI, all with the potential to significantly expand the number of eligible patients for our CF medicines. In fact, at this time last year, we were approved to treat approximately 2,600 people with CF worldwide. Whereas today, there are more than 25,000 patients approved or under regulatory submissions for our medicines.
We are currently conducting 2 Phase III clinical studies for ORKAMBI in children ages 6 to 11 years old, and plan to submit an sNDA to the FDA in the first half of 2016. There are approximately 5,500 children with CF in the U.S. and Europe with 2 copies of the F508del mutation.
Following closely behind ORKAMBI, we have the VX-661 plus ivacaftor pivotal Phase III development program underway, which is expected to enroll more than 1,000 people with CF across 4 studies. We expect to complete enrollment in mid-2016.
At the North American Cystic Fibrosis Conference, we announced that we are advancing 2 next-generation correctors, VX-152 and VX-440 into the clinic, and we expect to dose first healthy volunteer with VX-440 this week. We believe these new correctors hold tremendous promise as part of a triple combination regimen for the 80% to 90% of CF patients with at least 1 F508del allele. Thereby, possibly allowing us to treat patients we are not yet treating and also to enhance the benefit for those we already treat.
The strength of the ORKAMBI launch to date and the continued expansion of the number of people eligible for KALYDECO are further evidence that we continue to execute against our key goal to become a company that can reinvest to create future medicines and deliver returns to shareholders.
As I noted at the NACF conference, we also continue to advance early stage development programs outside of CF. For the treatment of cancer, pain and other diseases, which represents an important diversification of our development portfolio. 
Dr. David Altshuler, our Chief Scientific Officer, will discuss our research strategy and some of our emerging compounds later on this call. As you know, David was 1 of the 4 founding members of Broad Institute of Harvard and MIT, where he served as Deputy Director and Chief Academic Officer. David is an experienced physician and human geneticist, and we tapped him to lead our research organization earlier this year, so we can bring his experience to bear as we continue to deliver transformational medicines to more people. 
Before I turn the call over to Stuart, I wanted to mention how delighted we are to have entered into a research collaboration with CRISPR Therapeutics to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. 
Gene editing represents a new and powerful technology platform that could represent a future paradigm shift in the treatment of CF as well as other genetic diseases. And we're excited to be working with CRISPR, the company at the forefront of using gene editing to create new treatments. With that, I'll hand it over to Stuart to discuss Vertex's third quarter sales performance."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S. Global sales of KALYDECO this quarter were $166 million, comprised of U.S.",627,"Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S. 
Global sales of KALYDECO this quarter were $166 million, comprised of U.S. sales of approximately $95 million and ex-U.S. sales of approximately $71 million. This represents a 31% increase over the $127 million we recorded in the same quarter last year.
The growth of KALYDECO is a result of continued geographic and label expansion. We have seen strong uptake in patients with the R117H mutation, following approval in the U.S. in late 2014. And in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015. 
Internationally, there's also been a rapid uptake of KALYDECO eligible patients in Australia and in patients with non-G551D gating mutations in several European countries where these mutations are prevalent. 
We've made significant progress in securing reimbursement in Europe this year. As a result, the vast majority of eligible gating patients in Europe now have access to KALYDECO.
We expect that growth in the number of patients receiving KALYDECO globally in the fourth quarter of 2015 and into 2016 will be tempered by enrollment in the VX-661 pivotal program as previously described.
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been focused on educating health care providers on the medicine and working with payers to secure reimbursement for the approximately 8,500 eligible patients in the U.S. 
Sales for the third quarter totaled $131 million. More than 3,000 patients have started treatment in the U.S., underscoring the important advance this medicine represents in the treatment of CF and the strong interest from both patients and their doctors. Our field teams around the country have visited all of the 275 CF centers in the U.S. since approval. And virtually, every center has initiated patients in ORKAMBI. As we anticipated, interest in the medicine is very high, which has put a significant administrative burden on centers as they work to initiate patients on treatment. 
As expected, we're seeing broad coverage of and access to ORKAMBI, which reflects payer understanding and appreciation of the seriousness of the disease and a significant value of a medicine that treats the underlying cause of CF. 
The majority of commercial and government payers with eligible patients are reimbursing for ORKAMBI. In those plans with published policies and/or defined prior authorization criteria, almost all are reimbursing to label. There are a small number of plans not yet allowing access to ORKAMBI. And we anticipate they will complete their formal ORKAMBI reviews and define their final policies in the coming months.
Our patient support team has been working diligently to help patients navigate the reimbursement process and is working to reduce the time it takes the patients to get their prescriptions filled. For any chronic medication, compliance and adherence are important facets of patient care, so they will be increasing their focus to ensure patients are able to take ORKAMBI as prescribed and so benefit from the medicine.
Outside of the U.S., we continue to expect approval in the EU in the fourth quarter of this year. Our EU commercial infrastructure is largely in place. And upon approval, we will then begin pricing and reimbursement discussions on a country-by-country basis to secure reimbursement for eligible patients who may benefit from ORKAMBI.
With KALYDECO, the completion of reimbursement discussions took 9 to 20 months following approval. 
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat.
I'll now hand the call over to Ian."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 31",570,"Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 31% versus the third quarter last year and up 7% versus second quarter of 2015. 
Now ORKAMBI. The launch in the U.S. is off to a strong start. We recorded $131 million in net revenues. Inventory levels are normal, with 1 to 2 weeks in the channel. Gross-to-net adjustments were in the high single digits due to more rapid uptake for patients within commercial plans as compared to government paid plans. We continue to expect Medicaid mix to be 35% to 40% in the longer-term, which will increase gross-to-net adjustment into the midteens by late 2016. We expect continued revenue growth into 26 industry approach peak penetration in the U.S. market in the second half of 2016.
As for Europe and other ex-U.S. countries, we expect to recognize the first  ORKAMBI revenues in Europe in the first half of 2016. These revenues will be mainly generated in Germany, given that pricing and reimbursement approvals in other countries will take some time to finalize.
We do expect French regulatory authority to grant an ATU, or temporary authorization for use, for ORKAMBI in 2015, but we'll not recognize revenue from these sales until we receive formal reimbursement approval in France.
Our third quarter non-GAAP R&D and SG&A expenses were $278 million, an increase of $66 million compared to last year. This increase is mainly attributable to an increase in sales and marketing expenses supporting the launch of ORKAMBI and research and development cost to support the advancement of our CF medicines. The scale of our R&D organization and SG&A infrastructure is appropriate for our business. We expect modest increases in operating expense in 2016, and these will be driven by the progression of our CF medicines in development and geographic expansion to support the international launch of ORKAMBI. But we are rapidly moving towards steady-state. While we expect to continue to invest significantly in R&D, we are committed to managing our operating expenses to ensure significant operating margins moving forward.
Our non-GAAP net loss has narrowed to $32 million compared to prior year non-GAAP net loss of $86 million, and this is primarily driven by a significant increase in CF product revenues. 
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter.
Now let's turn to the 2015 financial guidance specifically KALYDECO revenues and the combined R&D and SG&A expenses. The time of our second quarter 2015 earnings call in July, we anticipate 2015 KALYDECO net revenues to be between $575 million and $590 million. We are now increasing KALYDECO net revenue guidance to be between $605 million and $620 million for the full year of 2015.
For the non-GAAP operating expenses, we now expect our combined non-GAAP R&D and SG&A expense for the full year to be in the middle of the range we provided in January of this year of $1.05 billion to $1.1 billion. 
In summary, we are in a strong financial position today and focused on delivering financial profile that include sustainable revenue and earnings growth, while continuing to invest to create more medicines and support access to those medicines already approved. 
Now over to David."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge because doing anything for the first t",1053,"Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge because doing anything for the first time involves considerable risk. But it's also great opportunity because we live in a time of accelerating breakthroughs in science that can be applied to solve important problems that were previously thought to the intractable. 
There are 3 main points I would like to make about Vertex's research and I'll make comments on each of them. First, CF represents Vertex's most significant success to date, and it's where we expect our research and early development will continue to have the biggest impact in the near-term. Second, cystic fibrosis provides good template to understand the kind of diseases we expect to pursue in the future. And third, lessons from our work in CF are guiding our early clinical programs in other areas. I'll reference 5 different candidate medicines in pain and oncology that were discovered by Vertex's scientists and that are progressing in early development.
As you know, in CF, we are advancing 2 next-generation correctors, VX-152 and VX-440 out of our labs and into first in-human studies. In vitro data show that in combination with VX-661 and ivacaftor, this compound resulted in chloride transport that was approximately threefold greater than the use of lumacaftor/ivacaftor combination in these cells. These data give us optimism in that hopefully one day, we will be able to address the vast majority of CF patients with a triple combination therapy, and also the continue to enhance the benefit for those we are already treating.
Our research strategy with CF is not limited to our internal programs. We're also looking externally to bring in compounds that complement our CFTR modulators, and this is enabled by our CF research expertise. Our CF research platform allows us to robustly characterize the activity of external compounds and their potential to work in combination with our existing regimens. This approach formed the basis for the collaboration we signed with Perry for ENaC inhibitors. And we showed at NACF the of ENaC inhibitor to enhance the effects of ORKAMBI in vitro. 
We are looking far into the future of CF treatment to understand what impact new treatment modalities could have. This week we announced the collaboration with CRISPR Therapeutics to use the CRISPR-Cas9 gene editing platform to create new medicines. 
CRISPR-Cas9 is an important scientific and technical breakthrough that holds significant promise for the future discovery of potentially transformative treatments and this collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics. 
We are excited to begin our initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to CF and sickle cell disease.
Thinking about CF more conceptually, the combination of what we learned through our CF research and the increasing flow of information from human genetics forms a template for our future discovery of precision medicines.
First, our CF research program was directed at a target that was validated as an underlying cost based on human genetics. Second, by understanding the natural history of disease and using proprietary in vitro assays, we have a highly focused goal for CFTR modulations. Third, we had early markers of clinical effect that were highly predictive of late stage success. And finally, these features have led to repeated success from the lab to the clinic. There are many lessons here that we can apply so we can invest wisely and increase our chances of success in the future. Our investments are being evaluated based on insights from human biology, the therapeutic approach and clinical development path criteria that we learn from our work in CF and can now apply to other diseases.
In the area of pain, we have 2 compounds in early development. VX-150 and VX-241 targets sodium channels with strong rationale for the treatment of pain based on human genetics and well-documented roles in pain sensation. Specifically, the basis of our program is a key insight from human biology that gain or loss of function mutations in key sodium channels can increase or decrease pain sensation.
In cancer, we have 3 compounds in early development, VX-970, VX-803 and VX-984 that target key cellular pathways responsible for DNA repair, a fundamental mechanism underlying the development and growth of cancer. In fact, DNA repair was recognized in 2015 with the Nobel Prize in chemistry, citing 3 academic scientists for their pioneering efforts to map at a molecular level how the cells repair damaged DNA. The Nobel committee specifically cited the implication of this work for the development of new cancer treatments.
In healthy cells, properly functioning DNA repair mechanisms protect against the development of problematic mutations. In cancer, however, these systems of DNA repair are known to go awry, allowing cancer cells to both accumulate mutations and increase their ability to survive and proliferate. The new Vertex cancer medicines now in early development, target 2 key nodes in the DNA repair system, kinase known as ATR and DNA PK. Modulating activity of these 2 kinases is predicted to be critical to continued cancer cell survival in the face of DNA damage. In addition, we believe that these new compounds can be targeted to patients based upon the knowledge of the genomic alterations or characteristics in each patient's cancer, allowing a precision medicine approach to help increased benefit by targeting those patients more likely to respond. 
With the most advanced compound, VX-970, we and the National Cancer Institute are now conducting a number of early studies in tumor types that are predicted to be responsive to an ATR inhibitor. The first Phase I clinical data for VX-970, we presented at the Triple meeting in Boston in November.
In closing, we are pleased with the significant progress we are making in developing additional CF medicines, especially for the tens of thousands of patients living with CF, who do not have a medicine that targets the underlying cause of their disease. We look forward to selling you more about our research strategy and our emerging clinical programs as they progress. 
And with, I'll ask the operator to please open the line for questions."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets.",14,"[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two topics I wanted to get some more color. First , just on the launch. Can you speak to more specifically how much inventory you're stocking 1 or 2 weeks, is it like $15 million to $20 million or so, maybe help us there. And you said that centers were bu",138,"Two topics I wanted to get some more color. First , just on the launch. Can you speak to more specifically how much inventory you're stocking 1 or 2 weeks, is it like $15 million to $20 million or so, maybe help us there. And you said that centers were burdened, I just want to understand that comment a little bit. And whether you thought there's any seasonality or things like that as we should be thinking about Q4. So talk about those things. And then my second question, as a follow-up, is on Europe. I know you just got a recommendation for approval but broadly speaking, should we be thinking about price deltas U.S. and Europe, somewhat similar what we see for ORKAMBI -- excuse me, for KALYDECO here? how should we think about any deltas there?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Michael. Thanks for the questions. On inventory, yes, your assessment is right. It's right in that $15 million to $20 million was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our comments",192,"Okay, Michael. Thanks for the questions. On inventory, yes, your assessment is right. It's right in that $15 million to $20 million was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our comments about the burden on CF centers, this is really just reflecting what we heard from centers actually prior to the launch, and we are seeing it play out during the launch that this is just a larger volume of patients than they have to try and get initiated on KALYDECO when we launched it. And so that administrative burden of helping payers -- helping patients through the payer reimbursement process is a very burden in some of the centers. And they certainly are relaying that to us. However, as we said in our prepared remarks, through the end of September, we have seen over 3,000 patients initiating therapies, so that the centers are really working through that process. And I don't think we really are seeing it as a seasonal impact. It's really just a function of working through a new launch with payers. In terms of the EU..."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?",25,"Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I don't think so. Not in terms of patient visits and things like that. I wouldn't imagine that we're going to see is kind of a linear trend in terms of the launch. Our launch isn't just developing that way. I think it's going to be a more launch that laun",231,"I don't think so. Not in terms of patient visits and things like that. I wouldn't imagine that we're going to see is kind of a linear trend in terms of the launch. Our launch isn't just developing that way. I think it's going to be a more launch that launch curve you would normally see. But in terms of seasonality, I don't expect that to be much of a factor. In terms of in Europe, our approach to pricing is going to be very similar to that, which it was here perhaps with 1 exception. We're certainly may taking the same sort of things into account the seriousness of the disease, the clinical value we've demonstrated through treating the underlying cause of the disease, the investments we've made and continue to want to make in R&D to discover and develop future transformative medicines for CF patients and in other diseases, but we're also going to have to be sensitive to the economic environment in Europe, including the potential budget impact that ORKAMBI could have in almost all cases, are single-payer markets. And so to finish on that and just to reiterate what Ian said in our prepared remarks, we do expect to recognize revenues for ORKAMBI in the EU in 2016, but these revenues are going to be primarily from Germany with minimal, if any contribution from other countries."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Geoff Meacham of Barclays.",10,"And our next question comes from Geoff Meacham of Barclays."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A couple for Stuart, and then some for David. For Stuart, just on ORKAMBI. One or few, I know it's early but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then again it's early, but when you look a",89,"A couple for Stuart, and then some for David. For Stuart, just on ORKAMBI. One or few, I know it's early but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then again it's early, but when you look at kind of feedback from the launch in the initial month or 2 in terms of the profile, is there any differences that you see commercially versus the TRAFFIC and TRANSPORT Phase III? And I have some clinical follow-ups."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that numb",161,"Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that number moves around a lot as patients kind of move through the process. But right now, it's approximately a month. In terms of the profile, I guess, I'd say the only difference is [indiscernible] at TRAFFIC and TRANSPORT had FEV1 criteria, inclusion, exclusion criteria, so that the 40 to 90. And certainly, we are aware that there are patients who've been initiated with FEV1 below 40 and patients who've been initiated with FEV1s above 90 because the vast majority of payers are reimbursing to label and the label doesn't include any FEV1 restriction, so that's really the major difference that I would suggest between what we're seeing in clinical practice and what we saw in TRAFFIC and TRANSPORT."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the bi",81,"Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the biggest VX-809 did to that. And then not on the slide, but I was curious if you had looked directionally how the second-gen correctors also synergized with ORKAMBI versus the 661 KALYDECO combination?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs at least with 152",83,"Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs at least with 152 and 440. And your second question was around ORKAMBI. I think we've shown the data with 661, we've shown the data compared to ORKAMBI and it's really quite similar. We see about threefold increase."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir in for Terence. Can you provide any commentary regarding the prescribing trends specifically in October?",18,"This is Samir in for Terence. Can you provide any commentary regarding the prescribing trends specifically in October?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Samir, we're not really going to provide details on a month by month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajecto",59,"Samir, we're not really going to provide details on a month by month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajectory is going to be linear. That's just not the way that product launches go."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matt Roden of UBS.",9,"Our next question comes from Matt Roden of UBS."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that system. Just want to verify tha",101,"I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that system. Just want to verify that that's what you're telling us. And then, I guess, related on the next quarter's trend, I guess it seems like you're approaching already almost 50% penetration and a partial quarter of sales. Is there any reason that the homozygous 508del population won't be practically fully penetrated by the next quarter?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I'll take the first question on the inventory level. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We don't anticipate that to be similar the year end as well. The amount that was",211,"So Matt, I'll take the first question on the inventory level. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We don't anticipate that to be similar the year end as well. The amount that was actually in the channel relating to 1 to 2 weeks at this stage of the launch was approximately $17 million, so that's $15 million to $20 million that was mentioned before. I think the key take away is this is a normal level of inventory as we move quarter-to-quarter through the year end. And then on the actual number of eligible patients who are on it, it's actually more like 35% rather than the 50%, Matt, 3,000 patients out of the approximately 8,500 eligible patients here in the U.S. And so as we said, we wouldn't expect it to continue in a linear way. That's just not the way product launches go. There's obviously a lot of initial pent-up demand and patients and physicians are excited about the launch. We still expect that we are going to get to the vast majority of patients over the course of 2016, but we wouldn't expect the launch trajectory to continue in a linear fashion."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, Ian, if I could sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective. I'm just saying that if we do assume some rob",108,"I guess, Ian, if I could sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective. I'm just saying that if we do assume some robust margins in the business, can you talk about your priorities for the use of cash? Maybe even rank quarter and in terms of importance, allowing the balances to rise or getting involved in M&A and licensing or share repurchase activity. Just want to get a sense of your broad thinking as you approach this swing to cash flow positivity."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation and over the years we have been cash preservation while we reinvest in",276,"Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation and over the years we have been cash preservation while we reinvest in the business, so we are a different company as we head into the fourth quarter. As we think about the allocation of cash, I start with the receipt of cash is actually the revenue, and just to be basic about this, but the receipt of cash is the revenue. As we think about reinvestment on allocation of that capital, it does go towards R&D for our business, the internal R&D. But as we develop our business, we also consider the external investment in R&D. And I think you saw that with the example this week of signing a collaboration with CRISPR Therapeutics that we're very excited about. We've also seen it earlier this year with those licensing products that complement our approach in CF. So we're already starting to allocate that revenue capital towards internal R&D. And also acquire products or expand our scientific footprint. As far as -- we anticipate that to continue. As far as thinking about other allocation of capital, rather than just accumulate on the balance sheet, we do think about our capital structure and the shares outstanding. And we need to continue to think about that going forward. But it becomes a prioritization and first, it is about investments in medicines for the future, which provides growth. However, the capital becomes available that we would consider addressing our capital structure, we'd also make that choice as well."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Cory Kasimov of JPMorgan.",9,"Our next question comes from Cory Kasimov of JPMorgan."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Britney Ann for Cory. Is there anything you're seeing in the early launch of ORKAMBI  in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene",63,"This is Britney Ann for Cory. Is there anything you're seeing in the early launch of ORKAMBI  in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene therapy to CF? And then also just what advantages do you see with CRISPR versus other gene editing technologies?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In short, Britney, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients in the first drug to treat the",96,"In short, Britney, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients in the first drug to treat the underlying cause of the disease, and I expect there'll be a similar level of enthusiasm from physicians and payers in the EU, so there's really nothing we're seeing here which is changing my view about how I think the launch is going to progress in the EU."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And with regard to CRISPR, we believe that CRISPR-Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF, and we're very excited to work with CRISPR Therapeutics as leader i",48,"And with regard to CRISPR, we believe that CRISPR-Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF, and we're very excited to work with CRISPR Therapeutics as leader in that field and it's a good fit for Vertex."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Ying Huang with Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang with Bank of America Merrill Lynch."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then can you set your expeditions for compliance of the ORKAMBI patients versus t",72,"It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then can you set your expeditions for compliance of the ORKAMBI patients versus those in KALYDECO? And then just lastly, for the triple combination, just want to clarify, are you planning to move both combination forward or will you pick one?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second and Jeff Chodakewitz can clean up for us. So first, to the split between the -- let's call it the government channel and the",127,"So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second and Jeff Chodakewitz can clean up for us. So first, to the split between the -- let's call it the government channel and the private payer channel. It was about close to 20% in the government channel. That translated to a gross-to-net adjustment of our gross price of just below 10%. I did make some comments earlier that as this launch proceed, we do anticipate that the government channel does rise up to somewhere closer to 35%. And when we're at that steady state of 35%, government and 55% private, then we would anticipate something in the mid-teens as a gross-to-net adjustment. Stuart?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think Catherine in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do a",146,"I think Catherine in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do a great job explaining to patients and patients I think, on the whole, understand that this is a medicine that's treating the underlying cause of their disease. So I think, overall, the compliance rate is going to be high. I think KALYDECO compliance would be the upper end of my expectation. If I'm perfectly honest, it's the highest compliance rate I've ever seen for any chronic medication. We'll certainly be doing anything we can to appropriately support patients to maintain a high level of compliance with ORKAMBI as well, but I think KALYDECO would be in the upper end of my expectation."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And in terms of next-gen, as you know we're going to move both of those molecules into. We're going to learn about those compounds as they go through the Phase I studies, but assuming that data supports it, we would plan to move both compound into evaluat",50,"And in terms of next-gen, as you know we're going to move both of those molecules into. We're going to learn about those compounds as they go through the Phase I studies, but assuming that data supports it, we would plan to move both compound into evaluation with patients."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is David in for Matt. You mentioned earlier, it's been an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there any",63,"This is David in for Matt. You mentioned earlier, it's been an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there any expectation for how payers might address refills? Will there be some point where they want to reevaluate?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess the patient and look to reauthorize. And then also they differ in terms of the criteria. Of the",112,"Yes, it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess the patient and look to reauthorize. And then also they differ in terms of the criteria. Of the reauthorization criteria that we've seen to date, which is a relatively limited number, that of the ones that we've seen to date, the vast majority have got criteria which are effectively reflective of reimbursing to the label. Or if the physician thinks that the patient has seen clinical benefit across a number of different dimensions reflecting the fact that CF is a complicated multisystem disease."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to jump over a different topic. There's been some data released recently from competitors on their triple combo, and I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose yo",54,"And just to jump over a different topic. There's been some data released recently from competitors on their triple combo, and I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose yours versus theirs, and make any overall comments and comparisons."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So David, we prefer to keep our comments to our own compounds. So we are very excited [indiscernible] with value of the HPE data. I would say that we like our position in terms of we already have 2 marketed medicines. We've got another corrector that is i",187,"So David, we prefer to keep our comments to our own compounds. So we are very excited [indiscernible] with value of the HPE data. I would say that we like our position in terms of we already have 2 marketed medicines. We've got another corrector that is in Phase III development that we've characterized very well given its stage of development. And then with our 2 next-gen duration correctors coming into the clinic, it provides us the opportunity to move quickly given that we already understand the medicines that we would combine our next-gens with. I'd also point out that we did take our time in choosing the right next-generation correctors, and the 2 of them to come into the clinic. And not only where they picked for their performance in preclinical assays with their efficacy and safety, but also their pharmaceutical properties. So we believe that we're in a very good position to move those into clinic very shortly into the healthy studies. And then next year, to move them into triple combination studies and see some results in patients. So we're looking forward to that."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbur",139,"So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbursement timelines or if there's any particular reasons why physicians or patients may not be choosing the drug other than patients just not having gone to their physician's office yet. And then on VX-970, I'm interested in sort of the opportunity there, if you could tell us a little more about the biomarkers you might use for patient selection going forward, perhaps the proportion of common cell of tumors that -- patients with common cell tumors that have complete ATM loss, which I think was the characteristic you saw on the complete response that was observed."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, I'll take the first question on those patients. Not on treatment and obviously we're delighted that we're off to a promising start with over 3,000 patients initiated, but obviously that means that there's somewhere near 5,000 or so who are not yet",133,"Brian, I'll take the first question on those patients. Not on treatment and obviously we're delighted that we're off to a promising start with over 3,000 patients initiated, but obviously that means that there's somewhere near 5,000 or so who are not yet initiated. That's just such a large number of patients. It's hard to say there's 1 reason or 2 reasons why they haven't started on treatment yet. They really represent all types of eligible patients with the 508del mutation. And I just wanted to reiterate, we do still anticipate that the vast majority of those patients will eventually be initiated on ORKAMBI over the course of the rest of this year and into 2016. So there's not really 1 or 2 things that are holding those patients back from initiating therapy."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi, it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is 1 of mutations that actually linked to disorders of DNA repair",135,"Hi, it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is 1 of mutations that actually linked to disorders of DNA repair in patients who have cancer. And so ATM is one another one that we are using. And as we go into our trials, it's the mutations and deficiencies in E53 actually, is the more common one. And that the frequency of that varies widely across tumors, so I can't give you a single number, but it certainly is observed in multiple types of cancer. And we think that those serve as an important foothold as our understanding of the science to tell us where to go clinically."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is actually sitting in for Mark. A lot of the questions already answered. I kind of wanted to take a step back and ask maybe just more big picture question. I guess, congratulations, on what's a great quarter. And I'm just sort of trying to think abo",190,"This is actually sitting in for Mark. A lot of the questions already answered. I kind of wanted to take a step back and ask maybe just more big picture question. I guess, congratulations, on what's a great quarter. And I'm just sort of trying to think about competition and perhaps specifically Galapagos. And then thinking about the development and the development risk. I guess just sort of trying to think about how Vertex might see that. And whether it's use of the drug and just the ability to combine those drugs. Anyway, any thoughts on that? And then I had a question on -- you mentioned reauthorization criteria. You mentioned clinical criteria, and I guess I had 1 of your comments on how high you see the bar for those clinical criteria. Just it seems early to be asking those kinds of questions. And then just based on the pipeline and a number of products that are being moved forward, just maybe speaking to margins a little bit. So I know you made a comment before about expenses, but now just seems like a good time to ask again."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take third. With respect to Galapagos, just as Stuart -- I'm sorry, as to what Ian said, we really don't comment on any of the competitive compou",200,"Yes. This is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take third. With respect to Galapagos, just as Stuart -- I'm sorry, as to what Ian said, we really don't comment on any of the competitive compounds or programs. I would just reiterate what Ian said about our program which is we like our position really. Number one, we have 2 drugs in the combination 661 and KALYDECO that are either approved or very well characterized, so when you put a 3-drug combination together, we feel that's a nice position to be in. And number two, we spend a lot of time optimizing the pharmaceutic properties of both next-gen correctors. And that's important as you put a 3-drug combination together. And number three, we showed you the chloride data from the HBE cells with those -- with that 3-drug combination, in which we're getting at levels, which are at or north of what KALYDECO does in G551D. And so far, those assays have predicted quite well what we see in the clinic. So we're excited to be the first Phase II results. We'll start those studies next year."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on reauthorization criteria, just to reiterate what I said. So far, we've seen a limited number of plans, which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increas",130,"And on reauthorization criteria, just to reiterate what I said. So far, we've seen a limited number of plans, which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increase obviously as plans publish those criteria or make those criteria known. Of the ones that we've seen so far, they aren't really setting a really very high clinical bar to use your terminology, most of them are essentially just ensuring that the patients continue to be within our label or show improvement across a number of clinical parameters in the opinion of the treating physicians. So but as I say, that's on a limited basis right now because it is really for plans to be publishing reauthorization criteria."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And obviously, just to round out your questions, I'll just state again, we're committed into driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have a bus",82,"And obviously, just to round out your questions, I'll just state again, we're committed into driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have a business and we're in an area where we can do that. And so for us, it's execution on the launch both in the U.S. and then in Europe, continue to reinvest the growth of the future, yet still having significant operating margins."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First, one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gon",58,"First, one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone back to same payers in some cases probably several times with the different KALYDECO expansions?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a",106,"Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a number of them, those processes are changing. They're not even the same process that we went through with KALYDECO, so I really can't predict with any sense of confidence or accuracy whether we're going to go faster or slower with ORKAMBI. We won't really know until we begin that process after we receive regulatory approval, which we continue to anticipate will happen later this quarter."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, and then same question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact with the patients. Can you talk a little bit more about that? What exactly is involve",55,"Okay, and then same question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact with the patients. Can you talk a little bit more about that? What exactly is involved in impacting persistence? And what type of message do you find most effective?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a lo",126,"Obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a lot more patients that -- physicians do not want to initiate on ORKAMBI. But for those who are now started on therapy, then we have a number of programs. And essentially, it's really helping educate patients on the motive action of ORKAMBI, how it treats the underlying cause of their disease and providing them to the extent they want to receive educational materials and refill reminders and things of that nature. And so we kind of tailored that to the individual patients as they desire."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Tony Butler of Guggenheim.",10,"And our next question comes from Tony Butler of Guggenheim."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Stuart, I recognize the commentary around the approval in the EU for the end of the quarter. But I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients in Ge",90,"Stuart, I recognize the commentary around the approval in the EU for the end of the quarter. But I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients in Germany? And then my second question is more scientific -- more scientifically-oriented. Beyond the correctors of 440 and 152, I had the impression that you may put additional correctors into second-gen correctors into the clinic. Is that still true? Or did I misinterpret that?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligi",49,"Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligible patient population in Germany."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'll take the second one, which is about the additional correctors. Maybe I'll broaden it out a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so certainly a big part of",174,"I'll take the second one, which is about the additional correctors. Maybe I'll broaden it out a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so certainly a big part of that is going to be next-gen correctors. And as I've said several times before, we have multiple -- we have discovered multiple next-gen correctors. These are the first 2, but there are others behind them. And assuming they pan out as they go through lead off in talks. Yes, our intent would be to put additional correctors and particularly if they have different and interesting properties, so that we can study then. But beyond that, I'd also remind you of things like the ENaC inhibitors, like gene editing. We're really looking at a variety of modalities. And so over the next few years, you can expect to see us bring multiple compounds and frankly, multiple modalities into the clinic to try to create the best combinations."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Liisa Bayko JMP Securities.",10,"And our next question comes from Liisa Bayko JMP Securities."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?",33,"You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's a small number of plans. It's in the single-digit in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the p",80,"Yes, Liisa, it's a small number of plans. It's in the single-digit in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the product. And which door they'll come to you, our formal conclusion over the next few months. But it's, at the minute, it is single digits in terms of the number of lives covered by those plans."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Thanks. And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?",23,"Thanks. And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid, who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state medicates have already reimbursed patients. And so we already have effect",54,"Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid, who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state medicates have already reimbursed patients. And so we already have effectively reimbursements in number of states and through Medicare as well."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's not really any gating factor there then?",10,"Okay. So there's not really any gating factor there then?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is a state by state business on Medicaid. There really isn't 1 answ",57,"I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is a state by state business on Medicaid. There really isn't 1 answer, 1 decision. It really happens on a state by state basis."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, fair enough. And just one question about the oncology portfolio. Can you maybe at all describe some of the data, I've seen triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populations",66,"Okay, fair enough. And just one question about the oncology portfolio. Can you maybe at all describe some of the data, I've seen triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populations. And it seems like maybe you have some data there, could you comment on all on that? And then that's my final question."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi, it's Jeff Chodakewitz. I think it actually goes back to a question that was asked by someone else earlier about how we're selecting the right subset of patients. And that those factors are present actually in patients with multiple kinds of tumors. Wh",124,"Hi, it's Jeff Chodakewitz. I think it actually goes back to a question that was asked by someone else earlier about how we're selecting the right subset of patients. And that those factors are present actually in patients with multiple kinds of tumors. What we've done in those 2 small sets of study of patients is actually to hone in on patients who expect or will require to have some of those kinds of mutations that we spoke about those deficiencies in DNA repair. And then by doing that, we think we are being able to get a very focused relatively rapid answer to the question about how the drug will work. So that's what that represents that you're seeing in our study prescription."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu of William Blair.",11,"And our next question comes from Katherine Xu of William Blair."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective from are there a difficulty -- difficulties in levels of research between asserting the same pairs versus correcting the base parent? And also",74,"I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective from are there a difficulty -- difficulties in levels of research between asserting the same pairs versus correcting the base parent? And also why did you choose CRISPR Therapeutics, there are a few other companies with similar technologies. And if you could comment on the IP side, that will be great as well."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, Catherine, David will take the first 2 questions. And then I'll answer the third question once David is through on the process we went through.",26,"Well, Catherine, David will take the first 2 questions. And then I'll answer the third question once David is through on the process we went through."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I would say that it's still early days in this. And so we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA and that will all be",68,"Yes, thanks for the question. I would say that it's still early days in this. And so we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA and that will all be subject to research we're doing and we look forward to updating you when we have progress to report."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in licensing and M&A. And the",196,"And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in licensing and M&A. And then the third area was always to broaden our scientific platform. And that's what we're doing here. We've been very good at small molecules for a long time at Vertex. And with David helping and coming on board about a year ago. We were able to consider other technologies and how we may expand our scientific footprint, and this was an area that rose to the top as a priority for us. And so we then went to the process as we usually do is that there are a number of companies that have access to this technology. We did our usual diligence process and based on the structure of the arrangement, the collaboration between people and the opportunity of feat with what we want to do at Vertex, our choice was with CRISPR therapeutics, and we're very happy to be a partner of theirs as we move forward. We don't comment on IP, Katherine."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So operator, we will take 2 more questions.",8,"So operator, we will take 2 more questions."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question will come from the line of Ted of Piper Jaffray.",14,"And our next question will come from the line of Ted of Piper Jaffray."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something more m",56,"Question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something more maybe that ENaC inhibitors will be used in different patients? What's your general thinking along those lines?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it in sort of a high-level strategic -- from a high-level strategic standpoint, second-gene",168,"Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it in sort of a high-level strategic -- from a high-level strategic standpoint, second-generation corrector in a triple combination would be expected to address anybody who has a single or double delta 5 allele, so that's about 80% to 90% of all patient. On ENaC inhibitors, again, theoretically and we're going to have to demonstrate from the clinic, should be useful for anybody with any mutation. And in fact, as you know, is running an initial Phase II trial. It's an [indiscernible] trial. We're going to run a Phase II trial with ENaC plus ORKAMBI. And based on the data there, we'll be able to determine how to sort of craft these regimens for each patient subset. But that would be the theoretical expectations based on what we've seen in HBE cell. Does that make sense?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, absolutely.",2,"Yes, absolutely."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question comes from the line of Brian Skorney of Robert W. Baird.",15,"And our last question comes from the line of Brian Skorney of Robert W. Baird."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Nina in for Brian. Just a question on the ORKAMBI launch. So do you have a sense of what percentage of treating since it actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe the product?",46,"This is Nina in for Brian. Just a question on the ORKAMBI launch. So do you have a sense of what percentage of treating since it actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe the product?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad inter",59,"I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad interest in using the medicine both with physicians and with patients."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- can you give us some color around that?",47,"Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- can you give us some color around that?"
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I mean, I'd say the end product of our discussions has been good, and that's reflected in the fact that we have good access, the vast majority of which is, is to label. Obviously, there's been a lot of discussion there, but a lot of it, as I said, be",131,"Yes. I mean, I'd say the end product of our discussions has been good, and that's reflected in the fact that we have good access, the vast majority of which is, is to label. Obviously, there's been a lot of discussion there, but a lot of it, as I said, been very productive because payers, I do think, understand how serious a disease this is. And how this is a disease that -- this is a product which is treating the underlying course of the disease. And the fact that it's an orphan, it's not ultra-orphan indication, and so they have relatively few patients in each of their individual plans. So the discussions have been very productive. And I think that's reflective in the good and broad access that we have."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening.",31,"So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening."
36235,313254007,884539,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, a",303,"Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Ian Smith, Chief Financial Officer; and Dr. David Altshuler, our Chief Scientific Officer. 
Dr. Jeff Chodakewitz, Chief Medical Officer, will also be available for Q&A.
Our agenda tonight is as follows: Jeff will review the progress with our cystic fibrosis medicines; Stuart will review the third quarter sales performance of our marketed products; Ian will review the third quarter 2015 financial results and update our 2015 guidance; and to close, David will discuss our research strategy and our early development pipeline.
You can access the webcast slides by going to the Events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our third quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our lon",740,"Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our long-term vision for 2016 and beyond. Significant revenues and revenue growth for multiple high-value medicines, high operating margins and a pipeline of additional transformational medicines.
Our goal in CF is to reach the vast majority of people with serious disease and to continue to enhance the benefit for the patients who we treat, and we continue to build on a track record of innovations: discover; develop; and deliver transformative medicines to more people with CF.
Let me summarize our recent commercial success and development progress in CF. In July, ORKAMBI became the first FDA-approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S. 12 years and older, with 2 copies of the F508del mutation. And as of September 30, 2015, we already were treating more than 3,000 of these patients.
Our sNDA has been accepted by the FDA for the expanded use of KALYDECO in people aged 2 and older with 1 of 23 residual function mutations that result in CF. This may accelerate access to KALYDECO for more than 1,500 patients in the U.S.
The European Union CHMP recently issued 3 positive opinions for KALYDECO and ORKAMBI, all with the potential to significantly expand the number of eligible patients for our CF medicines. In fact, at this time last year, we were approved to treat approximately 2,600 people with CF worldwide. Whereas today, there are more than 25,000 patients approved or under regulatory submissions for our medicines.
We are currently conducting 2 Phase III clinical studies for ORKAMBI in children ages 6 to 11 years old and plan to submit an sNDA to the FDA in the first half of 2016. There are approximately 5,500 children with CF in the U.S. and Europe with 2 copies of the F508del mutation.
Following closely behind ORKAMBI, we have the VX-661 plus ivacaftor pivotal Phase III development program underway, which is expected to enroll more than 1,000 people with CF across 4 studies. We expect to complete enrollment in mid-2016.
At the North American Cystic Fibrosis Conference, we announced that we are advancing 2 next-generation correctors, VX-152 and VX-440 into the clinic, and we expect to dose the first healthy volunteer with VX-440 this week. We believe these new correctors hold tremendous promise as part of a triple combination regimen for the 80% to 90% of CF patients with at least 1 F508del allele, thereby possibly allowing us to treat patients we are not yet treating and also to enhance the benefit for those we already treat.
The strength of the ORKAMBI launch to date and the continued expansion in the number of people eligible for KALYDECO are further evidence that we continue to execute against our key goal to become a company that can reinvest to create future medicines and deliver returns to shareholders.
As I noted at the NACF Conference, we also continue to advance early stage development programs, outside of CF, for the treatment of cancer, pain and other diseases, which represents an important diversification of our development portfolio.
Dr. David Altshuler, our Chief Scientific Officer, will discuss our research strategy and some of our emerging compounds later on this call. As you know, David was 1 of the 4 founding members of the Broad Institute of Harvard and MIT, where he served as Deputy Director and Chief Academic Officer. David is an experienced physician and human geneticist, and we tapped him to lead our research organization earlier this year so that we can bring his experience to bear as we continue to deliver transformational medicines to more people.
Before I turn the call over to Stuart, I wanted to mention how delighted we are to have entered into a research collaboration with CRISPR Therapeutics to discover and develop potential new treatments aimed at the underlying genetic causes of human disease.
Gene editing represents a new and powerful technology platform that could represent a future paradigm shift in the treatment of CF as well as other genetic diseases, and we're excited to be working with CRISPR, the company at the forefront of using gene editing to create new treatments.
With that, I'll hand it over to Stuart to discuss Vertex's third quarter sales performance."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.Global sales of KALYDECO this quarter were $166 million, comprised of U.S. s",627,"Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.
Global sales of KALYDECO this quarter were $166 million, comprised of U.S. sales of approximately $95 million and ex-U.S. sales of approximately $71 million. This represents a 31% increase over the $127 million we recorded in the same quarter last year.
The growth of KALYDECO is a result of continued geographic and label expansion. We have seen strong uptake in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015.
Internationally, there's also been a rapid uptake of KALYDECO eligible patients in Australia and in patients with non-G551D gating mutations in several European countries where these mutations are prevalent.
We've made significant progress in securing reimbursement in Europe this year. As a result, the vast majority of eligible gating patients in Europe now have access to KALYDECO.
We expect that growth in the number of patients receiving KALYDECO globally in the fourth quarter of 2015 and into 2016 will be tempered by enrollment in the VX-661 pivotal program, as previously described.
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been focused on educating health care providers on the medicine and working with payers to secure reimbursement for the approximately 8,500 eligible patients in the U.S. 
Sales for the third quarter totaled $131 million. More than 3,000 patients have started treatment in the U.S., underscoring the important advance this medicine represents in the treatment of CF and the strong interest from both patients and their doctors. Our field teams around the country have visited all of the 275 CF centers in the U.S. since approval, and virtually, every center has initiated patients in ORKAMBI. As we anticipated, interest in the medicine is very high, which has put a significant administrative burden on centers as they work to initiate patients on treatment.
As expected, we're seeing broad coverage of and access to ORKAMBI, which reflects payer understanding and appreciation of the seriousness of the disease and a significant value of a medicine that treats the underlying cause of CF.
The majority of commercial and government payers with eligible patients are reimbursing for ORKAMBI. In those plans with published policies and/or defined prior authorization criteria, almost all are reimbursing to label. There are a small number of plans not yet allowing access to ORKAMBI, and we anticipate they will complete their formal ORKAMBI reviews and define their final policies in the coming months.
Our patient support team has been working diligently to help patients navigate the reimbursement process and is working to reduce the time it takes for patients to get their prescriptions filled. For any chronic medication, compliance and adherence are important facets of patient care, so they will be increasing their focus to ensure patients are able to take ORKAMBI as prescribed and so benefit from the medicine.
Outside of the U.S., we continue to expect approval in the EU in the fourth quarter of this year. Our EU commercial infrastructure is largely in place. And upon approval, we will then begin pricing and reimbursement discussions on a country-by-country basis to secure reimbursement for eligible patients who may benefit from ORKAMBI. With KALYDECO, the completion of reimbursement discussions took 9 to 20 months following approval.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat.
I'll now hand the call over to Ian."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 3",573,"Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 31% versus the third quarter last year and up 7% versus the second quarter of 2015.
Now ORKAMBI. The launch in the U.S. is off to a strong start. We recorded $131 million in net revenues. Inventory levels are normal with 1 to 2 weeks in the channel. Gross-to-net adjustments were in the high single digits due to a more rapid uptake for patients within commercial plans as compared to government paid plans. We continue to expect Medicaid mix to be 35% to 40% in the longer-term, which will increase gross-to-net adjustments into the midteens by late 2016. We expect continued revenue growth into 2016 as we approach peak penetration in the U.S. market in the second half of 2016.
As for Europe and other ex-U.S. countries, we expect to recognize the first ORKAMBI revenues in Europe in the first half of 2016. These revenues will be mainly generated in Germany, given that pricing and reimbursement approvals in other countries will take some time to finalize.
We do expect French regulatory authority to grant an ATU, or temporary authorization for use, for ORKAMBI in 2015, but we'll not recognize revenues from these sales until we receive formal reimbursement approval in France.
Our third quarter non-GAAP R&D and SG&A expenses were $278 million, an increase of $66 million compared to last year. This increase is mainly attributable to an increase in sales and marketing expenses supporting the launch of ORKAMBI and research and development cost to support the advancement of our CF medicines. The scale of our R&D organization and SG&A infrastructure is appropriate for our business. We expect modest increases in operating expense in 2016, and these will be driven by the progression of our CF medicines in development and geographic expansion to support the international launch of ORKAMBI. But we are rapidly moving towards steady-state. While we expect to continue to invest significantly in R&D, we are committed to managing our operating expenses to ensure significant operating margins moving forward.
Our non-GAAP net loss has narrowed to $32 million compared to prior year non-GAAP net loss of $86 million, and this is primarily driven by a the increase in CF product revenues.
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter.
Now let's turn to the 2015 financial guidance, specifically KALYDECO revenues and the combined R&D and SG&A expenses. By the time of our second quarter 2015 earnings call in July, we anticipated 2015 KALYDECO net revenues to be between $575 million and $590 million. We are now increasing KALYDECO net revenue guidance to be between $605 million and $620 million for the full year of 2015.
For the non-GAAP operating expenses, we now expect our combined non-GAAP R&D and SG&A expense for the full year to be in the middle of the range we provided in January of this year of $1.05 billion to $1.1 billion.
In summary, we're in a strong financial position today and focused on delivering financial profile that includes sustainable revenue and earnings growth, while continuing to invest to create more medicines and support access to those medicines already approved.
Now over to David."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first",1058,"Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first time involves considerable risk. But it's also a great opportunity, because we live in a time of accelerating breakthroughs in science that can be applied to solve important problems that were previously thought to the intractable.
There are 3 main points I would like to make about Vertex's research, and I'll make comments on each of them. First, CF represents Vertex's most significant success to date, and it's where we expect our research and early development will continue to have the biggest impact in the near-term. Second, cystic fibrosis provides a good template to understand the kind of diseases we expect to pursue in the future. And third, lessons from our work in CF are guiding our early clinical programs in other areas. I'll reference 5 different candidate medicines in pain and oncology that were discovered by Vertex's scientists and that are progressing in early development.
As you know, in CF, we are advancing 2 next-generation correctors, VX-152 and VX-440, out of our labs and into first in-human studies. In vitro data show that in combination with VX-661 and ivacaftor, these compounds resulted in chloride transport that was approximately threefold greater than the use of lumacaftor/ivacaftor combination in these cells. These data give us optimism. In that, hopefully, one day, we will be able to address the vast majority of CF patients with a triple combination therapy and also to continue to enhance the benefit for those we are already treating.
Our research strategy with CF is not limited to our internal programs. We're also looking externally to bring in compounds that complement our CFTR modulators, and this is enabled by our CF research expertise. Our CF research platform allows us to robustly characterize the activity of external compounds and their potential to work in combination with our existing regimens. This approach formed the basis for the collaboration we signed with Parion for ENaC inhibitors. And we showed at NACF the ability of Parion's ENaC inhibitor to enhance the effects of ORKAMBI in vitro.
We are looking far into the future of CF treatment to understand what impact new treatment modalities could have. This week, we announced a collaboration with CRISPR Therapeutics to use the CRISPR-Cas9 gene editing platform to create new medicines.
CRISPR-Cas9 is an important scientific and technical breakthrough that holds significant promise for the future discovery of potentially transformative treatments, and this collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics.
We are excited to begin our initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to CF and sickle cell disease.
Thinking about CF more conceptually, the combination of what we learned through our CF research and the increasing flow of information from human genetics forms a template for our future discovery of precision medicines.
First, our CF research program was directed at a target that was validated as an underlying cost based on human genetics. Second, by understanding the natural history of disease and using proprietary in vitro assays, we had a highly focused goal for CFTR modulation. Third, we had early markers of clinical effect that were highly predictive of late stage success. And finally, these features have led to repeated success from the lab to the clinic. There are many lessons here that we can apply, so that we can invest wisely and increase our chances of success in the future. Our investments are being evaluated based on insights from human biology, the therapeutic approach and clinical development path criteria that we learned from our work in CF and can now apply to other diseases.
In the area of pain, we have 2 compounds in early development. VX-150 and VX-241 targets sodium channels with strong rationale for the treatment of pain based on human genetics and well-documented roles in pain sensation. Specifically, the basis of our program is a key insight from human biology that gain or loss of function mutations in key sodium channels can increase or decrease pain sensation.
In cancer, we have 3 compounds in early development; VX-970, VX-803 and VX-984; that target key cellular pathways responsible for DNA repair, a fundamental mechanism underlying the development and growth of cancer. In fact, DNA repair was recognized in 2015 with the Nobel Prize in chemistry, citing 3 academic scientists for their pioneering efforts to map, at a molecular level, how cells repair damaged DNA. The Nobel committee specifically cited the implication of this work for the development of new cancer treatments.
In healthy cells, properly functioning DNA repair mechanisms protect against the development of problematic mutations. In cancer, however, these systems of DNA repair are known to go awry, allowing cancer cells to both accumulate mutations and increase their ability to survive and proliferate. The new Vertex cancer medicines, now in early development, target 2 key nodes in the DNA repair system, kinases known as ATR and DNA PK. Modulating activity of these 2 kinases is predicted to be critical to continued cancer cell survival in the face of DNA damage. In addition, we believe that these new compounds can be targeted to patients based upon the knowledge of the genomic alterations or characteristics in each patient's cancer, allowing a precision medicine approach to help increase benefit by targeting those patients more likely to respond.
With the most advanced compound, VX-970, we and the National Cancer Institute are now conducting a number of early studies in tumor types that are predicted to be responsive to an ATR inhibitor. The first Phase I clinical data for VX-970, we presented at the Triple meeting in Boston in November.
In closing, we are pleased with the significant progress we are making in developing additional CF medicines, especially for the tens of thousands of patients living with CF, who do not have a medicine that targets the underlying cause of their disease. We look forward to telling you more about our research strategy and our emerging clinical programs as they progress.
And with that, I'll ask the operator to please open the line for questions."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets.",14,"[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stocking that was in, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said",148,"Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stocking that was in, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said that centers were burdened, I just want to understand that comment a little bit. And whether you thought there's any seasonality or things like that as we should be thinking about Q4? So talk a little bit about those things. And then my second question, as a follow-up, is on Europe. I know you just got a recommendation for approval, but broadly speaking, should we be thinking about price deltas, U.S. and Europe, somewhat similar to what we see for ORKAMBI -- excuse me, for KALYDECO here? How should we think about any deltas there?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our com",190,"Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our comments about the burden on CF centers, this is really just reflecting what we heard from centers actually prior to the launch, and we are seeing it play out during the launch. This is just a larger volume of patients than they have to try and get initiated on KALYDECO when we launched it. And so that administrative burden of helping payers -- helping patients through the payer reimbursement process is very burdensome one for the centers, and they certainly are relaying that to us. However, as we said in our prepared remarks, through the end of September, we have seen over 3,000 patients initiating on therapies, so the centers are really working through that process. And I don't think we really are seeing it as a seasonal impact. It really is just a function of working through a new launch with payers. In terms of the EU..."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?",25,"Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic la",231,"I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic launch curve that you would normally see. But in terms of seasonality, I don't expect that to be much of a factor. In terms of in Europe, our approach to pricing is going to be very similar to that, which it was here perhaps with 1 exception. We're certainly taking the same sort of things into account, the seriousness of the disease, the clinical value we've demonstrated through treating the underlying cause of the disease, the investments we've made and continue to want to make in R&D to discover and develop future transformative medicines for CF patients and in other diseases, but we're also going to have to be sensitive to the economic environment in Europe, including the potential budget impact that ORKAMBI could have in almost all cases, are single-payer markets. And so to finish on that and just to reiterate what Ian said in our prepared remarks, we do expect to recognize revenues for ORKAMBI in the EU in 2016, but these revenues are going to be primarily from Germany with minimal, if any, contribution from other countries."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Geoff Meacham of Barclays.",10,"And our next question comes from Geoff Meacham of Barclays."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. One or few, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, again, it",94,"Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. One or few, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, again, it's early, but when you look at kind of the feedback from the launch in the initial month or 2 in terms of the profile, is there any differences that you see commercially versus the TRAFFIC and TRANSPORT Phase III? And I have some clinical follow-ups."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that numb",161,"Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that number moves around a lot as patients kind of move through the process. But right now, it's approximately a month. In terms of the profile, I guess, I'd say the only difference is that, obviously, TRAFFIC and TRANSPORT had FEV1 criteria, inclusion, exclusion criteria, so that the 40 to 90. And certainly, we are aware that there are patients who've been initiated with FEV1 below 40 and patients who've been initiated with FEV1's above 90 because the vast majority of payers are reimbursing to label and the label doesn't include any FEV1 restriction. So that's really the major difference that I would suggest between what we're seeing in clinical practice and what we saw in TRAFFIC and TRANSPORT."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the",81,"Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the VX-809 did to that. And then not on the slide, but I was curious if you had looked directionally how the second-gen correctors also synergize with ORKAMBI versus the 661 KALYDECO combination?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152",83,"Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152 and 440. And your second question was around ORKAMBI. I think we've shown the data with 661, we've shown the data compared to ORKAMBI, and it's really quite similar. We see about threefold increase."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?",18,"This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajecto",59,"Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajectory is going to be linear. That's just not the way that kind of product launches go."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matt Roden of UBS.",9,"Our next question comes from Matt Roden of UBS."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that sys",105,"Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that system. Just want to verify that that's what you're telling us. And then, I guess, related on the next quarter's trends, I guess it seems like you're approaching already almost 50% penetration and a partial quarter of sales. Is there any reason that the homozygous 508del population won't be practically fully penetrated by the next quarter?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year end as well. The amount that was",211,"So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year end as well. The amount that was actually in the channel relating to 1 to 2 weeks at this stage of the launch was approximately $17 million, so that's $15 million to $20 million that was mentioned before. I think the key to take away is this is a normal level of inventory as we move quarter-to-quarter through the year end. And then on the actual number of eligible patients who are on it, it's actually more like 35% rather than the 50%, Matt, 3,000 patients out of the approximately 8,500 eligible patients here in the U.S. And so as we said, we wouldn't expect it to continue in a linear way. That's just not the way product launches go. There's obviously a lot of initial pent-up demand, and patients and physicians are excited about the launch. We still expect that we are going to get to the vast majority of patients over the course of 2016, but we wouldn't expect the launch trajectory to continue in a linear fashion."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm ju",114,"I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm just saying that if we do assume some robust margins in the business. Can you talk about your priorities for the use of cash, maybe even rank quarter and in terms of importance, allowing the balances to rise or getting involved in M&A and licensing or share repurchase activity? Just wanted to get a sense of your broad thinking as you approach this swing to cash flow positivity."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest",281,"Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest in the business. So we are a different company as we head into the fourth quarter. As we think about the allocation of cash, I start with the receipt of cash is actually the revenue, just to be basic about this, but the receipt of cash is the revenue. As we think about reinvestment on allocation of that capital, it does go towards R&D for our business, the internal R&D. But as we develop our business, we also consider the external investment in R&D, and I think you saw that with the example this week of signing a collaboration with CRISPR Therapeutics, that we're very excited about. You've also seen it earlier this year with us -- in licensing products that complement our approach in CF. So we're already starting to allocate that revenue capital towards internal R&D and also acquire products or expand our scientific footprint. As far as -- and you should anticipate that to continue. As far as thinking about other allocation of capital rather than just to accumulate on the balance sheet, we do think about our capital structure and the shares outstanding, and we need to continue to think about that going forward. But it becomes a prioritization and first, it is about investments in medicines for the future, which provides growth. However, if the capital becomes available, that we would consider addressing our capital structure, we'd also make that choice as well."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene",63,"This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene therapy to CF? And then also, just what advantages did you see with CRISPR versus other gene editing technologies?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treat",96,"In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treats the underlying cause of their disease. Now, I expect there'll be a similar level of enthusiasm from physicians and payers in the EU. So there's really nothing we're seeing here which is changing my view about how I think the launch is going to progress in the EU."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader",49,"And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader in that field and as a good fit for Vertex."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients v",73,"It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients versus those on KALYDECO? And then just lastly, for the triple combination, just want to clarify, are you planning to move both combinations forward or will you pick one?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the",127,"So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the private payer channel. It was about close to 20% in the government channel. That translated to a gross-to-net adjustment of our gross price of just below 10%. I did make some comments earlier that as this launch proceeds, we do anticipate that the government channel does rise up to somewhere closer to 35%. And when we're at that steady state of 35% government and 65% private, then we would anticipate something in the mid-teens as a gross-to-net adjustment. Stuart?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do",146,"I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do a great job explaining to patients. And patients, I think, on the whole, understand that this is a medicine that's treating the underlying cause of their disease. So I think, overall, the compliance rate is going to be high. I think KALYDECO compliance would be the upper end of my expectations. If I'm perfectly honest, it's the highest compliance rate I've ever seen for any chronic medication. We'll certainly be doing everything we can to appropriately support patients to maintain a high level of compliance with ORKAMBI as well, but I think KALYDECO would be at the upper end of my expectation."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And in terms of next-gen, as you know we're going to move both of those molecules into [indiscernible]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compo",51,"And in terms of next-gen, as you know we're going to move both of those molecules into [indiscernible]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compounds into evaluation with patients."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is David Lebowitz in for Matt. You mentioned earlier, it's been an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is t",64,"This is David Lebowitz in for Matt. You mentioned earlier, it's been an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there any expectation for how payers might address refills? Will there be some point where they want to reevaluate?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of th",113,"Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of the reauthorization criteria that we've seen to date, which is a relatively limited number, but all the ones that we've seen to date, the vast majority have got criteria which are effectively reflective of reimbursing to the label or if the physician thinks that the patient has seen clinical benefit across a number of different dimensions, reflecting the fact that CF is a complicated multisystem disease."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose",55,"And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose yours versus theirs and make any overall comments and comparisons."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have 2 marketed medicines. We've got another corrector that is in P",189,"So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have 2 marketed medicines. We've got another corrector that is in Phase III development that we've characterized very well given its stage of development. And then with our 2 next-generation correctors coming into the clinic, it provides us the opportunity to move quickly given that we already understand the medicines that we would combine our next-gens with. I'd also point out that we did take our time in choosing the right next-generation correctors and the 2 of them to come into the clinic. And not only were they picked for their performance in preclinical assays with -- for efficacy and safety but also their pharmaceutical properties. So we believe that we're in a very good position to move those into the clinic very shortly, into their healthy studies and then, next year, to move them into triple combination studies and see some results in patients. So we're looking forward to that."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbur",139,"So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbursement timelines or if there's any particular reasons why physicians or patients may not be choosing the drug other than patients just not having gone to their physician's office yet. And then on VX-970, I'm interested in sort of the opportunity there. If you could tell us a little more about the biomarkers you might use for patient selection going forward, perhaps the proportion of common solid tumors that -- patients with common solid tumors that have a complete ATM loss, which I think was the characteristic you saw in the complete response that was observed."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are no",135,"Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are not yet initiated. And that's just such a large number of patients. It's hard to say there's 1 reason or 2 reasons why they haven't started on treatment yet. They really represent all types of eligible patients with the 508del mutation. And I just want to reiterate, we do still anticipate that the vast majority of those patients will eventually be initiated on ORKAMBI over the course of the rest of this year and into 2016. So there's not really 1 or 2 things that are holding those patients back from initiating therapy."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repa",134,"And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repair in patients who have cancer. And so ATM is one. Another one that we are using as we go into our trials is the mutations and deficiencies in E53. Actually, it's the more common one. And the frequency of that varies widely across tumors. So I can't give you a single number, but it certainly is observed in multiple types of cancer. And we think that those serve as an important foothold as our understanding of the science to tell us where to go clinically."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on what's a great quarter. And but just sort of trying t",191,"[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on what's a great quarter. And but just sort of trying to think about competition and perhaps specifically Galapagos. And then thinking about the development and the development risk. I guess just sort of trying to think about how Vertex might see that. And whether it's use of the drug, [indiscernible] or just the ability to combine those drugs. Anyway, any thoughts on that? And then I had a question on -- you mentioned reauthorization criteria and you mentioned clinical criteria. And I guess, I wonder if you could comment on how high you see the bar for those clinical criteria. Just it seems early to be asking those kinds of questions. And then just based on the pipeline and number of products that are being moved forward, just maybe speaking to margins a little bit. So I know you made comments before about expenses, but now just seems like a good time to ask again."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart [indiscernible] as Ian said, we really don't comment on any of the competi",202,"Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart [indiscernible] as Ian said, we really don't comment on any of the competitor compounds or programs. I would just reiterate what Ian said about our programs, which is we like our position really for 3 reasons. Number one, we have 2 drugs in the combination, 661 and KALYDECO, that are either approved or very well characterized. So when you put a 3-drug combination together, we feel that's a nice position to be in. And number two, we spend a lot of time optimizing the pharmaceutic properties of both next-gen correctors. And that's important as you put a 3-drug combination together. And number three, we showed you the chloride data from the HBE cells with those -- with that 3-drug combination which were getting at levels which are at or north of what KALYDECO does in G551D. And so far, those assays have predicted quite well what we see in the clinic. So we're excited to see the first Phase II results. We'll start those studies next year."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on reauthorization criteria, just to reiterate what I said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increase",131,"And on reauthorization criteria, just to reiterate what I said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increase obviously as plans publish those criteria or make those criteria known. Of the ones that we've seen so far, they aren't really setting a really very high clinical bar, to use your terminology. Most of them are essentially just ensuring that the patients continue to be within our label or show improvement across a number of clinical parameters in the opinion of the treating physicians. So -- but as I say, that's on a limited basis right now because it is early for plans to be publishing reauthorization criteria."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have",83,"And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have a business, and we're in an area where we can do that. And so for us, it's the execution on the launch both in the U.S. and then in Europe, continue to reinvest the growth of the future, yet still having significant operating margins."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone",60,"First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone back to the same payers, in some cases probably several times with the different KALYDECO label expansions?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a",106,"Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a number of them, those processes are changing. They're not even the same process that we went through with KALYDECO. So I really can't predict with any sense of confidence or accuracy whether we're going to go faster or slower with ORKAMBI. We won't really know until we begin that process after we receive regulatory approval, which we continue to anticipate will happen later this quarter."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And same question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting p",52,"And same question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting persistence? And what type of message do you find most effective?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a",128,"So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a lot more patients that physicians are going to want to initiate on ORKAMBI. But for those who are now started on therapy, then we have a number of programs. And essentially, it's really helping educate patients on the mode of action of ORKAMBI, how it treats the underlying cause of their disease and providing them to the extent they want to receive educational materials and refill reminders and things of that nature. And so we kind of tailor that to the individual patients as they desire."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Tony Butler of Guggenheim.",10,"And our next question comes from Tony Butler of Guggenheim."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients",91,"Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients in Germany? And then, my second question is more scientific-oriented -- more scientifically oriented. Beyond the correctors of 440 and 152, I had the impression that you may put additional correctors, second-gen correctors, into the clinic. Is that still true, or did I misinterpret that?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligi",49,"Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligible patient population in Germany."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so c",178,"This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so certainly a big part of that is going to be next-gen correctors. And as I've said several times before, we have multiple -- we have discovered multiple next-gen correctors. These are the first 2, but there are others behind them. And assuming they pan out as they go through lead up in talks, yes, our intent would be to put additional correctors in, particularly if they have different and interesting properties, so that we can study them. But beyond that, I'd also remind you of things like the ENaC inhibitors, like gene editing, we're really looking at a variety of modalities. And so over the next few years, you can expect to see us bring multiple compounds and, frankly, multiple modalities into the clinic to try to create the best combinations."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Liisa Bayko of JMP Securities.",11,"And our next question comes from Liisa Bayko of JMP Securities."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represent?",33,"You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represent?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the",79,"Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the product and which door they'll come to a formal conclusion over the next few months. But it's -- at the minute, it is single digits in terms of number of lives covered by those plans."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?",22,"And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effecti",55,"Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effectively reimbursements in a number of states and through Medicare as well."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's not really any gating factor there then?",10,"Okay. So there's not really any gating factor there then?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answ",58,"I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answer, 1 decision. It really happens on a state by state basis."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populat",67,"Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populations. And it seems like maybe you have some data there. Could you comment at all on that? And that's my final question."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What",127,"It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What we've done in those 2 small sets of study -- of patients is actually to hone in on patients who we expect or we'll require to have some of those kinds of mutations that we spoke about those deficiencies in DNA repair. And then by doing that, we think we are being able to get a very focused relatively rapid answer to the question about how the drug will work. So that's what that represents that you're seeing in our study prescription."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu of William Blair.",11,"And our next question comes from Katherine Xu of William Blair."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did",72,"I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did you choose CRISPR Therapeutics. There are a few other companies with similar technologies. And if you could comment on the IP side, that will be great as well."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through.",27,"Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that",70,"Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that will all be subject to research we're doing. And we look forward to updating you when we have progress to report."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then",193,"And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then, a third area was always to broaden our scientific platform. And that's what we're doing here. We've been very good at small molecules for a long time at Vertex. And with David helping, coming on board about a year ago, we were able to consider other technologies and how we may expand our scientific footprint. And this was an area that rose to the top as a priority for us. And so we then went through the process as you usually do as there are a number of companies that have access to this technology. We did our usual diligence process. And based on the structure of the arrangement, the collaboration between people and the opportunity of fit with what we want to do at Vertex, our choice was with CRISPR therapeutics. And we're very happy to be a partner of theirs as we move forward. We don't comment on IP, Katherine."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So operator [indiscernible] clock, we will take 2 more questions.",10,"So operator [indiscernible] clock, we will take 2 more questions."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question will come from the line of Ted Tenthoff of Piper Jaffray.",15,"And our next question will come from the line of Ted Tenthoff of Piper Jaffray."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something where",56,"Question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something where maybe the ENaC inhibitors would be used in different patients? What's your general thinking along those lines?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-gene",169,"Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-generation correctors in a triple combination would be expected to address anybody who has a single or a double delta 508 allele. So that's about 80% to 90% of all patients. ENaC inhibitors, again, theoretically and we're going to have to demonstrate from the clinic, should be useful for anybody with any mutation. And in fact, as you know [indiscernible] is running an initial Phase II trial. It's an all-comer trial. We're going to run a Phase II trial with ENaC plus ORKAMBI. And based on the data there, we'll be able to determine how to sort of craft these regimens for each patient subset. But that would be the theoretical expectations based on what we've seen in HBE cell. Does that make sense?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, absolutely. I appreciate that color.",6,"Yes, absolutely. I appreciate that color."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question comes from the line of Brian Skorney of Robert W. Baird.",15,"And our last question comes from the line of Brian Skorney of Robert W. Baird."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. So do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescri",49,"This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. So do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe the product?"
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad",60,"I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad interest in using the medicine both with physicians and with patients."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all.",49,"Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have b",132,"Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have been very productive because payers, I do think, understand how serious a disease this is and how this is a disease that is -- this is a product which is treating the underlying cause of the disease. And the fact that it's an orphan, it's not ultra-orphan indication. And so they have relatively few patients in each of their individual plans. So the discussions have been very productive. And I think that's reflected in the good and broad access that we have."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening.",31,"So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening."
36235,313254007,884769,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, a",303,"Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Ian Smith, Chief Financial Officer; and Dr. David Altshuler, our Chief Scientific Officer. 
Dr. Jeff Chodakewitz, Chief Medical Officer, will also be available for Q&A.
Our agenda tonight is as follows: Jeff will review the progress with our cystic fibrosis medicines; Stuart will review the third quarter sales performance of our marketed products; Ian will review the third quarter 2015 financial results and update our 2015 guidance; and to close, David will discuss our research strategy and our early development pipeline.
You can access the webcast slides by going to the Events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our third quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our lon",740,"Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our long-term vision for 2016 and beyond. Significant revenues and revenue growth for multiple high-value medicines, high operating margins and a pipeline of additional transformational medicines.
Our goal in CF is to reach the vast majority of people with serious disease and to continue to enhance the benefit for the patients who we treat, and we continue to build on a track record of innovations: discover; develop; and deliver transformative medicines to more people with CF.
Let me summarize our recent commercial success and development progress in CF. In July, ORKAMBI became the first FDA-approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S. 12 years and older, with 2 copies of the F508del mutation. And as of September 30, 2015, we already were treating more than 3,000 of these patients.
Our sNDA has been accepted by the FDA for the expanded use of KALYDECO in people aged 2 and older with 1 of 23 residual function mutations that result in CF. This may accelerate access to KALYDECO for more than 1,500 patients in the U.S.
The European Union CHMP recently issued 3 positive opinions for KALYDECO and ORKAMBI, all with the potential to significantly expand the number of eligible patients for our CF medicines. In fact, at this time last year, we were approved to treat approximately 2,600 people with CF worldwide. Whereas today, there are more than 25,000 patients approved or under regulatory submissions for our medicines.
We are currently conducting 2 Phase III clinical studies for ORKAMBI in children ages 6 to 11 years old and plan to submit an sNDA to the FDA in the first half of 2016. There are approximately 5,500 children with CF in the U.S. and Europe with 2 copies of the F508del mutation.
Following closely behind ORKAMBI, we have the VX-661 plus ivacaftor pivotal Phase III development program underway, which is expected to enroll more than 1,000 people with CF across 4 studies. We expect to complete enrollment in mid-2016.
At the North American Cystic Fibrosis Conference, we announced that we are advancing 2 next-generation correctors, VX-152 and VX-440 into the clinic, and we expect to dose the first healthy volunteer with VX-440 this week. We believe these new correctors hold tremendous promise as part of a triple combination regimen for the 80% to 90% of CF patients with at least 1 F508del allele, thereby possibly allowing us to treat patients we are not yet treating and also to enhance the benefit for those we already treat.
The strength of the ORKAMBI launch to date and the continued expansion in the number of people eligible for KALYDECO are further evidence that we continue to execute against our key goal to become a company that can reinvest to create future medicines and deliver returns to shareholders.
As I noted at the NACF Conference, we also continue to advance early stage development programs, outside of CF, for the treatment of cancer, pain and other diseases, which represents an important diversification of our development portfolio.
Dr. David Altshuler, our Chief Scientific Officer, will discuss our research strategy and some of our emerging compounds later on this call. As you know, David was 1 of the 4 founding members of the Broad Institute of Harvard and MIT, where he served as Deputy Director and Chief Academic Officer. David is an experienced physician and human geneticist, and we tapped him to lead our research organization earlier this year so that we can bring his experience to bear as we continue to deliver transformational medicines to more people.
Before I turn the call over to Stuart, I wanted to mention how delighted we are to have entered into a research collaboration with CRISPR Therapeutics to discover and develop potential new treatments aimed at the underlying genetic causes of human disease.
Gene editing represents a new and powerful technology platform that could represent a future paradigm shift in the treatment of CF as well as other genetic diseases, and we're excited to be working with CRISPR, the company at the forefront of using gene editing to create new treatments.
With that, I'll hand it over to Stuart to discuss Vertex's third quarter sales performance."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.Global sales of KALYDECO this quarter were $166 million, comprised of U.S. s",627,"Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.
Global sales of KALYDECO this quarter were $166 million, comprised of U.S. sales of approximately $95 million and ex-U.S. sales of approximately $71 million. This represents a 31% increase over the $127 million we recorded in the same quarter last year.
The growth of KALYDECO is a result of continued geographic and label expansion. We have seen strong uptake in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015.
Internationally, there's also been a rapid uptake of KALYDECO eligible patients in Australia and in patients with non-G551D gating mutations in several European countries where these mutations are prevalent.
We've made significant progress in securing reimbursement in Europe this year. As a result, the vast majority of eligible gating patients in Europe now have access to KALYDECO.
We expect that growth in the number of patients receiving KALYDECO globally in the fourth quarter of 2015 and into 2016 will be tempered by enrollment in the VX-661 pivotal program, as previously described.
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been focused on educating health care providers on the medicine and working with payers to secure reimbursement for the approximately 8,500 eligible patients in the U.S. 
Sales for the third quarter totaled $131 million. More than 3,000 patients have started treatment in the U.S., underscoring the important advance this medicine represents in the treatment of CF and the strong interest from both patients and their doctors. Our field teams around the country have visited all of the 275 CF centers in the U.S. since approval, and virtually, every center has initiated patients in ORKAMBI. As we anticipated, interest in the medicine is very high, which has put a significant administrative burden on centers as they work to initiate patients on treatment.
As expected, we're seeing broad coverage of and access to ORKAMBI, which reflects payer understanding and appreciation of the seriousness of the disease and a significant value of a medicine that treats the underlying cause of CF.
The majority of commercial and government payers with eligible patients are reimbursing for ORKAMBI. In those plans with published policies and/or defined prior authorization criteria, almost all are reimbursing to label. There are a small number of plans not yet allowing access to ORKAMBI, and we anticipate they will complete their formal ORKAMBI reviews and define their final policies in the coming months.
Our patient support team has been working diligently to help patients navigate the reimbursement process and is working to reduce the time it takes for patients to get their prescriptions filled. For any chronic medication, compliance and adherence are important facets of patient care, so they will be increasing their focus to ensure patients are able to take ORKAMBI as prescribed and so benefit from the medicine.
Outside of the U.S., we continue to expect approval in the EU in the fourth quarter of this year. Our EU commercial infrastructure is largely in place. And upon approval, we will then begin pricing and reimbursement discussions on a country-by-country basis to secure reimbursement for eligible patients who may benefit from ORKAMBI. With KALYDECO, the completion of reimbursement discussions took 9 to 20 months following approval.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat.
I'll now hand the call over to Ian."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 3",572,"Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 31% versus the third quarter last year and up 7% versus the second quarter of 2015.
Now ORKAMBI. The launch in the U.S. is off to a strong start. We recorded $131 million in net revenues. Inventory levels are normal with 1 to 2 weeks in the channel. Gross-to-net adjustments were in the high single digits due to a more rapid uptake for patients within commercial plans as compared to government paid plans. We continue to expect Medicaid mix to be 35% to 40% in the longer-term, which will increase gross-to-net adjustments into the midteens by late 2016. We expect continued revenue growth into 2016 as we approach peak penetration in the U.S. market in the second half of 2016.
As for Europe and other ex-U.S. countries, we expect to recognize the first ORKAMBI revenues in Europe in the first half of 2016. These revenues will be mainly generated in Germany, given that pricing and reimbursement approvals in other countries will take some time to finalize.
We do expect French regulatory authority to grant an ATU, or temporary authorization for use, for ORKAMBI in 2015, but we'll not recognize revenues from these sales until we receive formal reimbursement approval in France.
Our third quarter non-GAAP R&D and SG&A expenses were $278 million, an increase of $66 million compared to last year. This increase is mainly attributable to an increase in sales and marketing expenses supporting the launch of ORKAMBI and research and development costs to support the advancement of our CF medicines. The scale of our R&D organization and SG&A infrastructure is appropriate for our business. We expect modest increases in operating expense in 2016, and these will be driven by the progression of our CF medicines in development and geographic expansion to support the international launch of ORKAMBI. But we are rapidly moving towards steady-state. While we expect to continue to invest significantly in R&D, we are committed to managing our operating expenses to ensure significant operating margins moving forward.
Our non-GAAP net loss has narrowed to $32 million compared to prior year non-GAAP net loss of $86 million, and this is primarily driven by the increase in CF product revenues.
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter.
Now let's turn to the 2015 financial guidance, specifically KALYDECO revenues and the combined R&D and SG&A expenses. By the time of our second quarter 2015 earnings call in July, we anticipated 2015 KALYDECO net revenues to be between $575 million and $590 million. We are now increasing KALYDECO net revenue guidance to be between $605 million and $620 million for the full year of 2015.
For the non-GAAP operating expenses, we now expect our combined non-GAAP R&D and SG&A expense for the full year to be in the middle of the range we provided in January of this year of $1.05 billion to $1.1 billion.
In summary, we're in a strong financial position today and focused on delivering financial profile that includes sustainable revenue and earnings growth, while continuing to invest to create more medicines and support access to those medicines already approved.
Now over to David."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first",1058,"Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first time involves considerable risk. But it's also a great opportunity, because we live in a time of accelerating breakthroughs in science that can be applied to solve important problems that were previously thought to the intractable.
There are 3 main points I would like to make about Vertex's research, and I'll make comments on each of them. First, CF represents Vertex's most significant success to date, and is where we expect our research and early development will continue to have the biggest impact in the near-term. Second, cystic fibrosis provides a good template to understand the kind of diseases we expect to pursue in the future. And third, lessons from our work in CF are guiding our early clinical programs in other areas. I'll reference 5 different candidate medicines in pain and oncology that were discovered by Vertex's scientists and that are progressing in early development.
As you know, in CF, we are advancing 2 next-generation correctors, VX-152 and VX-440, out of our labs and into first in-human studies. In vitro data show that in combination with VX-661 and ivacaftor, these compounds resulted in chloride transport that was approximately threefold greater than the use of lumacaftor/ivacaftor combination in these cells. These data give us optimism. In that, hopefully, one day, we will be able to address the vast majority of CF patients with a triple combination therapy and also to continue to enhance the benefit for those we are already treating.
Our research strategy with CF is not limited to our internal programs. We're also looking externally to bring in compounds that complement our CFTR modulators, and this is enabled by our CF research expertise. Our CF research platform allows us to robustly characterize the activity of external compounds and their potential to work in combination with our existing regimens. This approach formed the basis for the collaboration we signed with Parion for ENaC inhibitors. And we showed at NACF the ability of Parion's ENaC inhibitor to enhance the effects of ORKAMBI in vitro.
We are looking far into the future of CF treatment to understand what impact new treatment modalities could have. This week, we announced a collaboration with CRISPR Therapeutics to use the CRISPR-Cas9 gene editing platform to create new medicines.
CRISPR-Cas9 is an important scientific and technical breakthrough that holds significant promise for the future discovery of potentially transformative treatments, and this collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics.
We are excited to begin our initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to CF and sickle cell disease.
Thinking about CF more conceptually, the combination of what we learned through our CF research and the increasing flow of information from human genetics forms a template for our future discovery of precision medicines.
First, our CF research program was directed at a target that was validated as an underlying cost based on human genetics. Second, by understanding the natural history of disease and using proprietary in vitro assays, we had a highly focused goal for CFTR modulation. Third, we had early markers of clinical effect that were highly predictive of late stage success. And finally, these features have led to repeated success from the lab to the clinic. There are many lessons here that we can apply, so that we can invest wisely and increase our chances of success in the future. Our investments are being evaluated based on insights from human biology, the therapeutic approach and clinical development path criteria that we learned from our work in CF and can now apply to other diseases.
In the area of pain, we have 2 compounds in early development. VX-150 and VX-241 targets sodium channels with strong rationale for the treatment of pain based on human genetics and well-documented roles in pain sensation. Specifically, the basis of our program is a key insight from human biology that gain or loss of function mutations in key sodium channels can increase or decrease pain sensation.
In cancer, we have 3 compounds in early development; VX-970, VX-803 and VX-984; that target key cellular pathways responsible for DNA repair, a fundamental mechanism underlying the development and growth of cancer. In fact, DNA repair was recognized in 2015 with the Nobel Prize in chemistry, citing 3 academic scientists for their pioneering efforts to map, at a molecular level, how cells repair damaged DNA. The Nobel committee specifically cited the implication of this work for the development of new cancer treatments.
In healthy cells, properly functioning DNA repair mechanisms protect against the development of problematic mutations. In cancer, however, these systems of DNA repair are known to go awry, allowing cancer cells to both accumulate mutations and increase their ability to survive and proliferate. The new Vertex cancer medicines, now in early development, target 2 key nodes in the DNA repair system, kinases known as ATR and DNA PK. Modulating activity of these 2 kinases is predicted to be critical to continue cancer cell survival in the face of DNA damage. In addition, we believe that these new compounds can be targeted to patients based upon the knowledge of the genomic alterations or characteristics in each patient's cancer, allowing a precision medicine approach to help increase benefit by targeting those patients more likely to respond.
With the most advanced compound, VX-970, we and the National Cancer Institute are now conducting a number of early studies in tumor types that are predicted to be responsive to an ATR inhibitor. The first Phase I clinical data for VX-970, we presented at the Triple meeting in Boston in November.
In closing, we are pleased with the significant progress we are making in developing additional CF medicines, especially for the tens of thousands of patients living with CF, who do not have a medicine that targets the underlying cause of their disease. We look forward to telling you more about our research strategy and our emerging clinical programs as they progress.
And with that, I'll ask the operator to please open the line for questions."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets.",14,"[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stock in that, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said that ce",147,"Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stock in that, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said that centers were burdened, I just want to understand that comment a little bit. And whether you thought there's any seasonality or things like that as we should be thinking about Q4? So talk a little bit about those things. And then my second question, as a follow-up, is on Europe. I know you just got a recommendation for approval, but broadly speaking, should we be thinking about price deltas, U.S. and Europe, somewhat similar to what we see for ORKAMBI -- excuse me, for KALYDECO here? How should we think about any deltas there?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our com",191,"Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our comments about the burden on CF centers, this is really just reflecting what we heard from centers actually prior to the launch, and we are seeing it play out during the launch. This is just a larger volume of patients than they have to try and get initiated on KALYDECO when we launched it. And so that administrative burden of helping payers -- helping patients through the payer reimbursement process is a very burdensome one for the centers, and they certainly are relaying that to us. However, as we said in our prepared remarks, through the end of September, we have seen over 3,000 patients initiating on therapies, so the centers are really working through that process. And I don't think we really are seeing it as a seasonal impact. It really is just a function of working through a new launch with payers. In terms of the EU..."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?",25,"Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic la",235,"I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic launch -- launch curve that you would normally see. But in terms of seasonality, I don't expect that to be much of a factor. In terms of in Europe, our approach to pricing is going to be very similar to that, which it was here perhaps with 1 exception. We're certainly taking the same sort of things into account, the seriousness of the disease, the clinical value we've demonstrated through treating the underlying cause of the disease, the investments we've made and continue to want to make in R&D to discover and develop future transformative medicines for CF patients and in other diseases, but we're also going to have to be sensitive to the economic environment in Europe, including the potential budget impact that ORKAMBI could have in what in almost all cases, are single-payer markets. And so to finish on that and just to reiterate what Ian said in our prepared remarks, we do expect to recognize revenues for ORKAMBI in the EU in 2016, but these revenues are going to be primarily from Germany with minimal, if any, contribution from other countries."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Geoff Meacham of Barclays.",10,"And our next question comes from Geoff Meacham of Barclays."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. I wonder if you, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, agai",95,"Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. I wonder if you, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, again, it's early, but when you look at kind of the feedback from the launch in the initial month or 2 in terms of the profile, is there any differences that you see commercially versus the TRAFFIC and TRANSPORT Phase III? And I have some clinical follow-ups."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that numb",161,"Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that number moves around a lot as patients kind of move through the process. But right now, it's approximately a month. In terms of the profile, I guess, I'd say the only difference is that, obviously, TRAFFIC and TRANSPORT had FEV1 criteria, inclusion, exclusion criteria, so that the 40 to 90. And certainly, we are aware that there are patients who've been initiated with FEV1 below 40 and patients who've been initiated with FEV1's above 90 because the vast majority of payers are reimbursing to label and the label doesn't include any FEV1 restriction. So that's really the major difference that I would suggest between what we're seeing in clinical practice and what we saw in TRAFFIC and TRANSPORT."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the",81,"Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the VX-809 did to that. And then not on the slide, but I was curious if you had looked directionally how the second-gen correctors also synergize with ORKAMBI versus the 661 KALYDECO combination?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152",84,"Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152 and 440. And your second question was around ORKAMBI. I think we've shown the data with 661, we've shown the data compared to ORKAMBI, and it's really quite similar. We see about that threefold increase."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?",18,"This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajecto",59,"Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajectory is going to be linear. That's just not the way that kind of product launches go."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matt Roden of UBS.",9,"Our next question comes from Matt Roden of UBS."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that sys",105,"Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that system. Just want to verify that that's what you're telling us. And then, I guess, related on the next quarter's trends, I guess it seems like you're approaching already almost 50% penetration and a partial quarter of sales. Is there any reason that the homozygous 508del population won't be practically fully penetrated by the next quarter?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year end as well. The amount that was",211,"So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year end as well. The amount that was actually in the channel relating to 1 to 2 weeks at this stage of the launch was approximately $17 million, so that's $15 million to $20 million that was mentioned before. I think the key to take away is this is a normal level of inventory as we move quarter-to-quarter through the year end. And then on the actual number of eligible patients who are on it, it's actually more like 35% rather than the 50%, Matt, 3,000 patients out of the approximately 8,500 eligible patients here in the U.S. And so as we said, we wouldn't expect it to continue in a linear way. That's just not the way product launches go. There's obviously a lot of initial pent-up demand, and patients and physicians are excited about the launch. We still expect that we are going to get to the vast majority of patients over the course of 2016, but we wouldn't expect the launch trajectory to continue in a linear fashion."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm ju",114,"I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm just saying that if we do assume some robust margins in the business. Can you talk about your priorities for the use of cash, maybe even rank order and in terms of importance, allowing the balances to rise or getting involved in M&A and licensing or share repurchase activity? Just wanted to get a sense of your broad thinking as you approach this swing to cash flow positivity."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest",281,"Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest in the business. So we are a different company as we head into the fourth quarter. As we think about the allocation of cash, I start with the receipt of cash is actually the revenue, just to be basic about this, but the receipt of cash is the revenue. As we think about reinvestment on allocation of that capital, it does go towards R&D for our business, the internal R&D. But as we develop our business, we also consider the external investment in R&D, and I think you saw that with the example this week of signing a collaboration with CRISPR Therapeutics, that we're very excited about. You've also seen it earlier this year with us -- in licensing products that complement our approach in CF. So we're already starting to allocate that revenue capital towards internal R&D and also acquire products or expand our scientific footprint. As far as -- and you should anticipate that to continue. As far as thinking about other allocation of capital rather than just to accumulate on the balance sheet, we do think about our capital structure and the shares outstanding, and we need to continue to think about that going forward. But it becomes a prioritization and first, it is about investments in medicines for the future, which provides growth. However, if the capital becomes available, that we would consider addressing our capital structure, we'd also make that choice as well."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene",63,"This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene therapy to CF? And then also, just what advantages did you see with CRISPR versus other gene editing technologies?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treat",96,"In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treats the underlying cause of their disease. Now, I expect there'll be a similar level of enthusiasm from physicians and payers in the EU. So there's really nothing we're seeing here which is changing my view about how I think the launch is going to progress in the EU."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader",49,"And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader in that field and as a good fit for Vertex."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients v",73,"It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients versus those on KALYDECO? And then just lastly, for the triple combination, just want to clarify, are you planning to move both combinations forward or will you pick one?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the",127,"So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the private payer channel. It was about close to 20% in the government channel. That translated to a gross-to-net adjustment of our gross price of just below 10%. I did make some comments earlier that as this launch proceeds, we do anticipate that the government channel does rise up to somewhere closer to 35%. And when we're at that steady state of 35% government and 65% private, then we would anticipate something in the mid-teens as a gross-to-net adjustment. Stuart?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do",146,"I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do a great job explaining to patients. And patients, I think, on the whole, understand that this is a medicine that's treating the underlying cause of their disease. So I think, overall, the compliance rate is going to be high. I think KALYDECO compliance would be the upper end of my expectations. If I'm perfectly honest, it's the highest compliance rate I've ever seen for any chronic medication. We'll certainly be doing everything we can to appropriately support patients to maintain a high level of compliance with ORKAMBI as well, but I think KALYDECO would be at the upper end of my expectation."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And in terms of next-gen, as you know we're going to move both of those molecules into Nan [ph]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compounds in",52,"And in terms of next-gen, as you know we're going to move both of those molecules into Nan [ph]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compounds into evaluation with patients."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is David Lebowitz in for Matt. You mentioned earlier, as an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there an",63,"This is David Lebowitz in for Matt. You mentioned earlier, as an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there any expectation for how payers might address refills? Will there be some point where they want to reevaluate?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of th",113,"Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of the reauthorization criteria that we've seen to date, which is a relatively limited number, but of the ones that we've seen to date, the vast majority have got criteria which are effectively reflective of reimbursing to the label or if the physician thinks that the patient has seen clinical benefit across a number of different dimensions, reflecting the fact that CF is a complicated multisystem disease."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose",55,"And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose yours versus theirs and make any overall comments and comparisons."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have the 2 marketed medicines. We've got another corrector that is",190,"So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have the 2 marketed medicines. We've got another corrector that is in Phase III development that we've characterized very well given its stage of development. And then with our 2 next-generation correctors coming into the clinic, it provides us the opportunity to move quickly given that we already understand the medicines that we would combine our next-gens with. I'd also point out that we did take our time in choosing the right next-generation correctors and the 2 of them to come into the clinic. And not only were they picked for their performance in preclinical assays with -- for efficacy and safety but also their pharmaceutical properties. So we believe that we're in a very good position to move those into the clinic very shortly, into their healthy studies and then, next year, to move them into triple combination studies and see some results in patients. So we're looking forward to that."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbur",140,"So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbursement timelines or if there's any particular reasons why physicians or patients may not be choosing the drug other than patients just not having gone to their physician's office yet. And then on VX-970, I'm interested in sort of the opportunity there. If you could tell us a little more about the biomarkers you might use for patient selection going forward, perhaps the proportion of common solid tumors that -- of patients with common solid tumors that have a complete ATM loss, which I think was the characteristic you saw in the complete response that was observed."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are no",135,"Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are not yet initiated. And that's just such a large number of patients. It's hard to say there's 1 reason or 2 reasons why they haven't started on treatment yet. They really represent all types of eligible patients with the 508del mutation. And I just want to reiterate, we do still anticipate that the vast majority of those patients will eventually be initiated on ORKAMBI over the course of the rest of this year and into 2016. So there's not really 1 or 2 things that are holding those patients back from initiating therapy."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repa",134,"And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repair in patients who have cancer. And so ATM is one. Another one that we are using as we go into our trials is the mutations and deficiencies in E53. Actually, it's the more common one. And the frequency of that varies widely across tumors. So I can't give you a single number, but it certainly is observed in multiple types of cancer. And we think that those serve as an important foothold as our understanding of the science to tell us where to go clinically."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on with the great quarter. And but just sort of trying t",193,"[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on with the great quarter. And but just sort of trying to think about competition and perhaps specifically Galapagos. And then thinking about the development and the development risk. I guess just sort of trying to think about how Vertex might see that. And whether it's use of the drug, in particular or just the ability to combine those drugs. Anyway, any thoughts on that? And then I had a question on -- you mentioned reauthorization criteria and you mentioned clinical criteria. And I guess, I just wonder if you could comment on how high you see the bar for those clinical criteria. Just it seems early to be asking those kinds of questions. And then just based on the pipeline and number of products that are being moved forward, just maybe speaking to margins a little bit. So I know you made comments before about expenses, but now just seems like a good time to ask again."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart -- to empasize what Ian said, we really don't comment on any of the compet",204,"Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart -- to empasize what Ian said, we really don't comment on any of the competitor compounds or programs. I would just reiterate what Ian said about our programs, which is we like our position really for 3 reasons. Number one, we have 2 drugs in the combination, 661 and KALYDECO, that are either approved or very well characterized. So when you put a 3-drug combination together, we feel that's a nice position to be in. And number two, we spent a lot of time optimizing the pharmaceutic properties of both next-gen correctors. And that's important as you put a 3-drug combination together. And number three, we showed you the chloride data from the HBE cells with those -- with that 3-drug combination which were getting us levels which are at or north of what KALYDECO does in G551D. And so far, those assays have predicted quite well what we see in the clinic. So we're excited to see the first Phase II results. We'll start those studies next year."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on reauthorization criteria, just to reiterate what I've said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will incre",131,"And on reauthorization criteria, just to reiterate what I've said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increase obviously as plans publish those criteria or make those criteria known. Of the ones that we've seen so far, they aren't really setting a really very high clinical bar, to use your terminology. Most of them are essentially just ensuring that the patients continue to be within our label or show improvement across a number of clinical parameters in the opinion of the treating physicians. So -- but as I say, that's on a limited basis right now because it is early for plans to be publishing reauthorization criteria."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have",83,"And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have a business, and we're in an area where we can do that. And so for us, it's the execution on the launch both in the U.S. and then in Europe, continuing to reinvest the growth of the future, yet still having significant operating margins."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone",60,"First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone back to the same payers, in some cases probably several times with the different KALYDECO label expansions?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a",106,"Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a number of them, those processes are changing. They're not even the same process that we went through with KALYDECO. So I really can't predict with any sense of confidence or accuracy whether we're going to go faster or slower with ORKAMBI. We won't really know until we begin that process after we receive regulatory approval, which we continue to anticipate will happen later this quarter."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And second question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting",52,"And second question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting persistence? And what type of message do you find most effective?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a",128,"So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a lot more patients that physicians are going to want to initiate on ORKAMBI. But for those who are now started on therapy, then we have a number of programs. And essentially, it's really helping educate patients on the mode of action of ORKAMBI, how it treats the underlying cause of their disease and providing them to the extent they want to receive educational materials and refill reminders and things of that nature. And so we kind of tailor that to the individual patients as they desire."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Tony Butler of Guggenheim.",10,"And our next question comes from Tony Butler of Guggenheim."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients",91,"Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients in Germany? And then, my second question is more scientific-oriented -- more scientifically oriented. Beyond the correctors of 440 and 152, I had the impression that you may put additional correctors, second-gen correctors, into the clinic. Is that still true, or did I misinterpret that?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligi",49,"Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligible patient population in Germany."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so c",178,"This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so certainly a big part of that is going to be next-gen correctors. And as I've said several times before, we have multiple -- we have discovered multiple next-gen correctors. These are the first 2, but there are others behind them. And assuming they pan out as they go through lead up in talks, yes, our intent would be to put additional correctors in, particularly if they have different and interesting properties, so that we can study them. But beyond that, I'd also remind you of things like the ENaC inhibitors, like gene editing, we're really looking at a variety of modalities. And so over the next few years, you can expect to see us bring multiple compounds and, frankly, multiple modalities into the clinic to try to create the best combinations."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Liisa Bayko of JMP Securities.",11,"And our next question comes from Liisa Bayko of JMP Securities."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?",33,"You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the",79,"Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the product and which door they'll come to a formal conclusion over the next few months. But it's -- at the minute, it is single digits in terms of number of lives covered by those plans."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?",22,"And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effecti",55,"Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effectively reimbursements in a number of states and through Medicare as well."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's not really any gating factor there then?",10,"Okay. So there's not really any gating factor there then?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answ",58,"I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answer, 1 decision. It really happens on a state by state basis."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populat",67,"Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populations. And it seems like maybe you have some data there. Could you comment at all on that? And that's my final question."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What",127,"It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What we've done in those 2 small sets of study -- of patients is actually to hone in on patients who we expect or we'll require to have some of those kinds of mutations that we spoke about those deficiencies in DNA repair. And then by doing that, we think we are being able to get a very focused relatively rapid answer to the question about how the drug will work. So that's what that represents that you're seeing in our study prescription."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu of William Blair.",11,"And our next question comes from Katherine Xu of William Blair."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did",72,"I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did you choose CRISPR Therapeutics. There are a few other companies with similar technologies. And if you could comment on the IP side, that will be great as well."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through.",27,"Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that",70,"Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that will all be subject to research we're doing. And we look forward to updating you when we have progress to report."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then",194,"And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then, a third area was always to broaden our scientific platform. And that's what we're doing here. We've been very good at small molecules for a long time at Vertex. And with David's help, on coming on board about a year ago, we were able to consider other technologies and how we may expand our scientific footprint. And this was an area that rose to the top as a priority for us. And so we then went through the process as you usually do as there are a number of companies that have access to this technology. We did our usual diligence process. And based on the structure of the arrangement, the collaboration between people and the opportunity of fit with what we want to do at Vertex, our choice was with CRISPR therapeutics. And we're very happy to be a partner of theirs as we move forward. We don't comment on IP, Katherine."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So operator it is now 6:00, we will take 2 more questions.",13,"So operator it is now 6:00, we will take 2 more questions."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question will come from the line of Ted Tenthoff of Piper Jaffray.",15,"And our next question will come from the line of Ted Tenthoff of Piper Jaffray."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Quick question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something",57,"Quick question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something where maybe the ENaC inhibitors would be used in different patients? What's your general thinking along those lines?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-gene",170,"Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-generation correctors in a triple combination would be expected to address anybody who has a single or a double delta 508 allele. So that's about 80% to 90% of all patients. ENaC inhibitors, again, theoretically and we're going to have to demonstrate this in the clinic, should be useful for anybody with any mutation. And in fact, as you know Parion is running an initial Phase II trial. It's an all-comer trial. We're going to run a Phase II trial with ENaC plus ORKAMBI. And based on the data there, we'll be able to determine how to sort of craft these regimens for each patient subset. But that would be the theoretical expectations based on what we've seen in HBE cell. Does that make sense?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, absolutely. I appreciate that color.",6,"Yes, absolutely. I appreciate that color."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question comes from the line of Brian Skorney of Robert W. Baird.",15,"And our last question comes from the line of Brian Skorney of Robert W. Baird."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. Do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe",48,"This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. Do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe the product?"
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad",60,"I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad interest in using the medicine both with physicians and with patients."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all.",49,"Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have b",132,"Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have been very productive because payers, I do think, understand how serious a disease this is and how this is a disease that is -- this is a product which is treating the underlying cause of the disease. And the fact that it's an orphan, it's not ultra-orphan indication. And so they have relatively few patients in each of their individual plans. So the discussions have been very productive. And I think that's reflected in the good and broad access that we have."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening.",31,"So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening."
36235,313254007,884800,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, a",303,"Good evening, everyone. This is Michael Partridge, Head of Investor Relations for Vertex Pharmaceuticals. Welcome to our third quarter 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be available following the conclusion of tonight's call on our website. 
Joining me on tonight's call are Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Ian Smith, Chief Financial Officer; and Dr. David Altshuler, our Chief Scientific Officer. 
Dr. Jeff Chodakewitz, Chief Medical Officer, will also be available for Q&A.
Our agenda tonight is as follows: Jeff will review the progress with our cystic fibrosis medicines; Stuart will review the third quarter sales performance of our marketed products; Ian will review the third quarter 2015 financial results and update our 2015 guidance; and to close, David will discuss our research strategy and our early development pipeline.
You can access the webcast slides by going to the Events section of the Investor Relations page on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission.
These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, those about Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in our third quarter 2015 financial results press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our lon",740,"Thanks, Michael. Good evening, everyone. 3 years ago, we outlined a clear strategy designed to establish a foundation for sustainable business growth. This evening, I'm pleased to report that we continue to make excellent progress toward achieving our long-term vision for 2016 and beyond. Significant revenues and revenue growth for multiple high-value medicines, high operating margins and a pipeline of additional transformational medicines.
Our goal in CF is to reach the vast majority of people with serious disease and to continue to enhance the benefit for the patients who we treat, and we continue to build on a track record of innovations: discover; develop; and deliver transformative medicines to more people with CF.
Let me summarize our recent commercial success and development progress in CF. In July, ORKAMBI became the first FDA-approved medicine to treat the underlying cause of CF for the approximately 8,500 people in the U.S. 12 years and older, with 2 copies of the F508del mutation. And as of September 30, 2015, we already were treating more than 3,000 of these patients.
Our sNDA has been accepted by the FDA for the expanded use of KALYDECO in people aged 2 and older with 1 of 23 residual function mutations that result in CF. This may accelerate access to KALYDECO for more than 1,500 patients in the U.S.
The European Union CHMP recently issued 3 positive opinions for KALYDECO and ORKAMBI, all with the potential to significantly expand the number of eligible patients for our CF medicines. In fact, at this time last year, we were approved to treat approximately 2,600 people with CF worldwide. Whereas today, there are more than 25,000 patients approved or under regulatory submissions for our medicines.
We are currently conducting 2 Phase III clinical studies for ORKAMBI in children ages 6 to 11 years old and plan to submit an sNDA to the FDA in the first half of 2016. There are approximately 5,500 children with CF in the U.S. and Europe with 2 copies of the F508del mutation.
Following closely behind ORKAMBI, we have the VX-661 plus ivacaftor pivotal Phase III development program underway, which is expected to enroll more than 1,000 people with CF across 4 studies. We expect to complete enrollment in mid-2016.
At the North American Cystic Fibrosis Conference, we announced that we are advancing 2 next-generation correctors, VX-152 and VX-440 into the clinic, and we expect to dose the first healthy volunteer with VX-440 this week. We believe these new correctors hold tremendous promise as part of a triple combination regimen for the 80% to 90% of CF patients with at least 1 F508del allele, thereby possibly allowing us to treat patients we are not yet treating and also to enhance the benefit for those we already treat.
The strength of the ORKAMBI launch to date and the continued expansion in the number of people eligible for KALYDECO are further evidence that we continue to execute against our key goal to become a company that can reinvest to create future medicines and deliver returns to shareholders.
As I noted at the NACF Conference, we also continue to advance early stage development programs, outside of CF, for the treatment of cancer, pain and other diseases, which represents an important diversification of our development portfolio.
Dr. David Altshuler, our Chief Scientific Officer, will discuss our research strategy and some of our emerging compounds later on this call. As you know, David was 1 of the 4 founding members of the Broad Institute of Harvard and MIT, where he served as Deputy Director and Chief Academic Officer. David is an experienced physician and human geneticist, and we tapped him to lead our research organization earlier this year so that we can bring his experience to bear as we continue to deliver transformational medicines to more people.
Before I turn the call over to Stuart, I wanted to mention how delighted we are to have entered into a research collaboration with CRISPR Therapeutics to discover and develop potential new treatments aimed at the underlying genetic causes of human disease.
Gene editing represents a new and powerful technology platform that could represent a future paradigm shift in the treatment of CF as well as other genetic diseases, and we're excited to be working with CRISPR, the company at the forefront of using gene editing to create new treatments.
With that, I'll hand it over to Stuart to discuss Vertex's third quarter sales performance."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.Global sales of KALYDECO this quarter were $166 million, comprised of U.S. s",627,"Thanks, Jeff, and hello, everyone. Tonight, I will review KALYDECO performance in the third quarter and our progress in making ORKAMBI available to eligible patients in the U.S.
Global sales of KALYDECO this quarter were $166 million, comprised of U.S. sales of approximately $95 million and ex-U.S. sales of approximately $71 million. This represents a 31% increase over the $127 million we recorded in the same quarter last year.
The growth of KALYDECO is a result of continued geographic and label expansion. We have seen strong uptake in patients with the R117H mutation following approval in the U.S. in late 2014 and in children ages 2 to 5 with eligible mutations following U.S. approval at the end of March 2015.
Internationally, there's also been a rapid uptake of KALYDECO eligible patients in Australia and in patients with non-G551D gating mutations in several European countries where these mutations are prevalent.
We've made significant progress in securing reimbursement in Europe this year. As a result, the vast majority of eligible gating patients in Europe now have access to KALYDECO.
We expect that growth in the number of patients receiving KALYDECO globally in the fourth quarter of 2015 and into 2016 will be tempered by enrollment in the VX-661 pivotal program, as previously described.
Now turning to ORKAMBI. Since the FDA approval of ORKAMBI on July 2, we have been focused on educating health care providers on the medicine and working with payers to secure reimbursement for the approximately 8,500 eligible patients in the U.S. 
Sales for the third quarter totaled $131 million. More than 3,000 patients have started treatment in the U.S., underscoring the important advance this medicine represents in the treatment of CF and the strong interest from both patients and their doctors. Our field teams around the country have visited all of the 275 CF centers in the U.S. since approval, and virtually, every center has initiated patients in ORKAMBI. As we anticipated, interest in the medicine is very high, which has put a significant administrative burden on centers as they work to initiate patients on treatment.
As expected, we're seeing broad coverage of and access to ORKAMBI, which reflects payer understanding and appreciation of the seriousness of the disease and a significant value of a medicine that treats the underlying cause of CF.
The majority of commercial and government payers with eligible patients are reimbursing for ORKAMBI. In those plans with published policies and/or defined prior authorization criteria, almost all are reimbursing to label. There are a small number of plans not yet allowing access to ORKAMBI, and we anticipate they will complete their formal ORKAMBI reviews and define their final policies in the coming months.
Our patient support team has been working diligently to help patients navigate the reimbursement process and is working to reduce the time it takes for patients to get their prescriptions filled. For any chronic medication, compliance and adherence are important facets of patient care, so they will be increasing their focus to ensure patients are able to take ORKAMBI as prescribed and so benefit from the medicine.
Outside of the U.S., we continue to expect approval in the EU in the fourth quarter of this year. Our EU commercial infrastructure is largely in place. And upon approval, we will then begin pricing and reimbursement discussions on a country-by-country basis to secure reimbursement for eligible patients who may benefit from ORKAMBI. With KALYDECO, the completion of reimbursement discussions took 9 to 20 months following approval.
In summary, geographic and label expansion continue to drive significant growth in the number of patients we treat with KALYDECO. And with the launch of ORKAMBI, we are significantly expanding the number of eligible CF patients we treat.
I'll now hand the call over to Ian."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 3",572,"Thanks, Stuart, and good evening, everyone. Firstly to the financials. Our CF revenues were $297 million this quarter, as we significantly increased the number of eligible people we treat with KALYDECO and ORKAMBI. KALYDECO sales of $166 million were up 31% versus the third quarter last year and up 7% versus the second quarter of 2015.
Now ORKAMBI. The launch in the U.S. is off to a strong start. We recorded $131 million in net revenues. Inventory levels are normal with 1 to 2 weeks in the channel. Gross-to-net adjustments were in the high single digits due to a more rapid uptake for patients within commercial plans as compared to government paid plans. We continue to expect Medicaid mix to be 35% to 40% in the longer-term, which will increase gross-to-net adjustments into the mid-teens by late 2016. We expect continued revenue growth into 2016 as we approach peak penetration in the U.S. market in the second half of 2016.
As for Europe and other ex-U.S. countries, we expect to recognize the first ORKAMBI revenues in Europe in the first half of 2016. These revenues will be mainly generated in Germany, given that pricing and reimbursement approvals in other countries will take some time to finalize.
We do expect French regulatory authority to grant an ATU, or temporary authorization for use, for ORKAMBI in 2015, but we'll not recognize revenues from these sales until we receive formal reimbursement approval in France.
Our third quarter non-GAAP R&D and SG&A expenses were $278 million, an increase of $66 million compared to last year. This increase is mainly attributable to an increase in sales and marketing expenses supporting the launch of ORKAMBI and research and development costs to support the advancement of our CF medicines. The scale of our R&D organization and SG&A infrastructure is appropriate for our business. We expect modest increases in operating expense in 2016, and these will be driven by the progression of our CF medicines in development and geographic expansion to support the international launch of ORKAMBI. But we are rapidly moving towards steady-state. While we expect to continue to invest significantly in R&D, we are committed to managing our operating expenses to ensure significant operating margins moving forward.
Our non-GAAP net loss has narrowed to $32 million compared to prior year non-GAAP net loss of $86 million, and this is primarily driven by the increase in CF product revenues.
From a balance sheet perspective, we maintained a strong position with approximately $1 billion of cash at the end of the quarter.
Now let's turn to the 2015 financial guidance, specifically KALYDECO revenues and the combined R&D and SG&A expenses. By the time of our second quarter 2015 earnings call in July, we anticipated 2015 KALYDECO net revenues to be between $575 million and $590 million. We are now increasing KALYDECO net revenue guidance to be between $605 million and $620 million for the full year of 2015.
For the non-GAAP operating expenses, we now expect our combined non-GAAP R&D and SG&A expense for the full year to be in the middle of the range we provided in January of this year of $1.05 billion to $1.1 billion.
In summary, we're in a strong financial position today and focused on delivering financial profile that includes sustainable revenue and earnings growth, while continuing to invest to create more medicines and support access to those medicines already approved.
Now over to David."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first",1058,"Thanks, Ian. It's great to be here. Good evening, everyone. At Vertex, our strategy is to invest in science to create transformative medicines for serious diseases and specialty markets. This is an enormous challenge, because doing anything for the first time involves considerable risk. But it's also a great opportunity, because we live in a time of accelerating breakthroughs in science that can be applied to solve important problems that were previously thought to the intractable.
There are 3 main points I would like to make about Vertex's research, and I'll make comments on each of them. First, CF represents Vertex's most significant success to date, and is where we expect our research and early development will continue to have the biggest impact in the near-term. Second, cystic fibrosis provides a good template to understand the kind of diseases we expect to pursue in the future. And third, lessons from our work in CF are guiding our early clinical programs in other areas. I'll reference 5 different candidate medicines in pain and oncology that were discovered by Vertex's scientists and that are progressing in early development.
As you know, in CF, we are advancing 2 next-generation correctors, VX-152 and VX-440, out of our labs and into first in-human studies. In vitro data show that in combination with VX-661 and ivacaftor, these compounds resulted in chloride transport that was approximately threefold greater than the use of lumacaftor/ivacaftor combination in these cells. These data give us optimism. In that, hopefully, one day, we will be able to address the vast majority of CF patients with a triple combination therapy and also to continue to enhance the benefit for those we are already treating.
Our research strategy with CF is not limited to our internal programs. We're also looking externally to bring in compounds that complement our CFTR modulators, and this is enabled by our CF research expertise. Our CF research platform allows us to robustly characterize the activity of external compounds and their potential to work in combination with our existing regimens. This approach formed the basis for the collaboration we signed with Parion for ENaC inhibitors. And we showed at NACF the ability of Parion's ENaC inhibitor to enhance the effects of ORKAMBI in vitro.
We are looking far into the future of CF treatment to understand what impact new treatment modalities could have. This week, we announced a collaboration with CRISPR Therapeutics to use the CRISPR-Cas9 gene editing platform to create new medicines.
CRISPR-Cas9 is an important scientific and technical breakthrough that holds significant promise for the future discovery of potentially transformative treatments, and this collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics.
We are excited to begin our initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to CF and sickle cell disease.
Thinking about CF more conceptually, the combination of what we learned through our CF research and the increasing flow of information from human genetics forms a template for our future discovery of precision medicines.
First, our CF research program was directed at a target that was validated as an underlying cost based on human genetics. Second, by understanding the natural history of disease and using proprietary in vitro assays, we had a highly focused goal for CFTR modulation. Third, we had early markers of clinical effect that were highly predictive of late stage success. And finally, these features have led to repeated success from the lab to the clinic. There are many lessons here that we can apply, so that we can invest wisely and increase our chances of success in the future. Our investments are being evaluated based on insights from human biology, the therapeutic approach and clinical development path criteria that we learned from our work in CF and can now apply to other diseases.
In the area of pain, we have 2 compounds in early development. VX-150 and VX-241 targets sodium channels with strong rationale for the treatment of pain based on human genetics and well-documented roles in pain sensation. Specifically, the basis of our program is a key insight from human biology that gain or loss of function mutations in key sodium channels can increase or decrease pain sensation.
In cancer, we have 3 compounds in early development; VX-970, VX-803 and VX-984; that target key cellular pathways responsible for DNA repair, a fundamental mechanism underlying the development and growth of cancer. In fact, DNA repair was recognized in 2015 with the Nobel Prize in chemistry, citing 3 academic scientists for their pioneering efforts to map, at a molecular level, how cells repair damaged DNA. The Nobel committee specifically cited the implication of this work for the development of new cancer treatments.
In healthy cells, properly functioning DNA repair mechanisms protect against the development of problematic mutations. In cancer, however, these systems of DNA repair are known to go awry, allowing cancer cells to both accumulate mutations and increase their ability to survive and proliferate. The new Vertex cancer medicines, now in early development, target 2 key nodes in the DNA repair system, kinases known as ATR and DNA PK. Modulating activity of these 2 kinases is predicted to be critical to continue cancer cell survival in the face of DNA damage. In addition, we believe that these new compounds can be targeted to patients based upon the knowledge of the genomic alterations or characteristics in each patient's cancer, allowing a precision medicine approach to help increase benefit by targeting those patients more likely to respond.
With the most advanced compound, VX-970, we and the National Cancer Institute are now conducting a number of early studies in tumor types that are predicted to be responsive to an ATR inhibitor. The first Phase I clinical data for VX-970, we presented at the Triple meeting in Boston in November.
In closing, we are pleased with the significant progress we are making in developing additional CF medicines, especially for the tens of thousands of patients living with CF, who do not have a medicine that targets the underlying cause of their disease. We look forward to telling you more about our research strategy and our emerging clinical programs as they progress.
And with that, I'll ask the operator to please open the line for questions."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets.",14,"[Operator Instructions] And our first question comes from Michael Yee of RBC Capital Markets."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stock in that, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said that ce",147,"Two topics I wanted to get some more color. On the first, just on the launch, can you speak to more specifically how much inventory stock in that, is it 1 or 2 weeks or is it like $15 million to $20 million or so, maybe help us there? And you said that centers were burdened, I just want to understand that comment a little bit. And whether you thought there's any seasonality or things like that as we should be thinking about Q4? So talk a little bit about those things. And then my second question, as a follow-up, is on Europe. I know you just got a recommendation for approval, but broadly speaking, should we be thinking about price deltas, U.S. and Europe, somewhat similar to what we see for ORKAMBI -- excuse me, for KALYDECO here? How should we think about any deltas there?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our com",191,"Okay, Michael. Thanks for the questions. On inventory, yes, your assessment's right. It's right, in that $15 million to $20 million range was the initial inventory build for ORKAMBI. The rest is really driven by organic patient demand. In terms of our comments about the burden on CF centers, this is really just reflecting what we heard from centers actually prior to the launch, and we are seeing it play out during the launch. This is just a larger volume of patients than they have to try and get initiated on KALYDECO when we launched it. And so that administrative burden of helping payers -- helping patients through the payer reimbursement process is a very burdensome one for the centers, and they certainly are relaying that to us. However, as we said in our prepared remarks, through the end of September, we have seen over 3,000 patients initiating on therapies, so the centers are really working through that process. And I don't think we really are seeing it as a seasonal impact. It really is just a function of working through a new launch with payers. In terms of the EU..."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?",25,"Would you see seasonality in the fourth quarter? There's a lot of things going on in the fourth quarter. Do you expect any impact there?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic la",235,"I don't think so, not in terms of patient visits and things like that. I wouldn't imagine that what we're going to see is a kind of linear trend in terms of the launch. Launches just don't develop in that way. I think it's going to be a more asymptotic launch -- launch curve that you would normally see. But in terms of seasonality, I don't expect that to be much of a factor. In terms of in Europe, our approach to pricing is going to be very similar to that, which it was here perhaps with 1 exception. We're certainly taking the same sort of things into account, the seriousness of the disease, the clinical value we've demonstrated through treating the underlying cause of the disease, the investments we've made and continue to want to make in R&D to discover and develop future transformative medicines for CF patients and in other diseases, but we're also going to have to be sensitive to the economic environment in Europe, including the potential budget impact that ORKAMBI could have in what in almost all cases, are single-payer markets. And so to finish on that and just to reiterate what Ian said in our prepared remarks, we do expect to recognize revenues for ORKAMBI in the EU in 2016, but these revenues are going to be primarily from Germany with minimal, if any, contribution from other countries."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Geoff Meacham of Barclays.",10,"And our next question comes from Geoff Meacham of Barclays."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. I wonder if you, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, agai",95,"Congrats on the ORKAMBI launch. A couple for Stuart and some for David. For Stuart, just on ORKAMBI. I wonder if you, I know it's early, but can you speak to the wait time to get a script approved? Does it differ among the different payers? And then, again, it's early, but when you look at kind of the feedback from the launch in the initial month or 2 in terms of the profile, is there any differences that you see commercially versus the TRAFFIC and TRANSPORT Phase III? And I have some clinical follow-ups."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that numb",161,"Sure, Jeff. In terms of wait time, the average time from a kind of prescription being written to a patient actually initiating treatment or getting a pack through specialty pharmacies is about a month right now. Obviously, it's very early and so that number moves around a lot as patients kind of move through the process. But right now, it's approximately a month. In terms of the profile, I guess, I'd say the only difference is that, obviously, TRAFFIC and TRANSPORT had FEV1 criteria, inclusion, exclusion criteria, so that the 40 to 90. And certainly, we are aware that there are patients who've been initiated with FEV1 below 40 and patients who've been initiated with FEV1's above 90 because the vast majority of payers are reimbursing to label and the label doesn't include any FEV1 restriction. So that's really the major difference that I would suggest between what we're seeing in clinical practice and what we saw in TRAFFIC and TRANSPORT."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the",81,"Okay. And then for David, on the 2 next-gen correctors, and congrats on getting those -- advancing those. Do they change the half-life of CFTR? Mature CFTR, that's delta FNO, that was a little bit of a hot topic last year at NACF when you look at what the VX-809 did to that. And then not on the slide, but I was curious if you had looked directionally how the second-gen correctors also synergize with ORKAMBI versus the 661 KALYDECO combination?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152",84,"Yes, Jeff, this is Jeff Leiden, maybe I'll take those. So on the first question, at least so far, we're seeing that when you add all 3 drugs together, you don't get the effect on corrected CFTR half-life that we've seen with the 2 drugs, at least with 152 and 440. And your second question was around ORKAMBI. I think we've shown the data with 661, we've shown the data compared to ORKAMBI, and it's really quite similar. We see about that threefold increase."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?",18,"This is Samir on for Terence. Can you provide any commentary regarding the prescribing trends, specifically in October?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajecto",59,"Samir, we're not really going to provide details on a month-by-month basis over the course of the quarter. As we said, we saw just over 3,000 patients initiated. Obviously, that's been a fairly steep ramp and I wouldn't anticipate that the launch trajectory is going to be linear. That's just not the way that kind of product launches go."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matt Roden of UBS.",9,"Our next question comes from Matt Roden of UBS."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that sys",105,"Congrats on a great launch. I just want to make sure we're crystal clear on the inventory part. With the levels of inventory that you have, it sounds to me like we should not expect that in the fourth quarter that there's any slack to come out of that system. Just want to verify that that's what you're telling us. And then, I guess, related on the next quarter's trends, I guess it seems like you're approaching already almost 50% penetration and a partial quarter of sales. Is there any reason that the homozygous 508del population won't be practically fully penetrated by the next quarter?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year-end as well. The amount that was",210,"So Matt, I'll take the first question on the inventory levels. So I did mention on my prepared remarks that we are at normal inventory levels, which are between 1 and 2 weeks. We'd anticipate that being similar at the year-end as well. The amount that was actually in the channel relating to 1 to 2 weeks at this stage of the launch was approximately $17 million, so that's $15 million to $20 million that was mentioned before. I think the key to take away is this is a normal level of inventory as we move quarter-to-quarter through the year end. And then on the actual number of eligible patients who are on it, it's actually more like 35% rather than the 50%, Matt, 3,000 patients out of the approximately 8,500 eligible patients here in the U.S. And so as we said, we wouldn't expect it to continue in a linear way. That's just not the way product launches go. There's obviously a lot of initial pent-up demand, and patients and physicians are excited about the launch. We still expect that we are going to get to the vast majority of patients over the course of 2016, but we wouldn't expect the launch trajectory to continue in a linear fashion."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm ju",114,"I really appreciate the comments. I guess, Ian, if I could just sneak in a quick capital allocation question, I'm sure you'll be getting a lot of these as your cash flows ramp up. I don't really mean this from a margin or profitability perspective, I'm just saying that if we do assume some robust margins in the business. Can you talk about your priorities for the use of cash, maybe even rank order and in terms of importance, allowing the balances to rise or getting involved in M&A and licensing or share repurchase activity? Just wanted to get a sense of your broad thinking as you approach this swing to cash flow positivity."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest",281,"Sure, thanks for the question, Matt. And just to comment, it's a great question because as we turn profitable, which we do anticipate in the fourth quarter, we're now cash accumulation, and over the years, we have been cash preservation while we reinvest in the business. So we are a different company as we head into the fourth quarter. As we think about the allocation of cash, I start with the receipt of cash is actually the revenue, just to be basic about this, but the receipt of cash is the revenue. As we think about reinvestment on allocation of that capital, it does go towards R&D for our business, the internal R&D. But as we develop our business, we also consider the external investment in R&D, and I think you saw that with the example this week of signing a collaboration with CRISPR Therapeutics, that we're very excited about. You've also seen it earlier this year with us -- in licensing products that complement our approach in CF. So we're already starting to allocate that revenue capital towards internal R&D and also acquire products or expand our scientific footprint. As far as -- and you should anticipate that to continue. As far as thinking about other allocation of capital rather than just to accumulate on the balance sheet, we do think about our capital structure and the shares outstanding, and we need to continue to think about that going forward. But it becomes a prioritization and first, it is about investments in medicines for the future, which provides growth. However, if the capital becomes available, that we would consider addressing our capital structure, we'd also make that choice as well."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene",63,"This is Brittany in for Cory. Is there anything you're seeing in the early launch of ORKAMBI in the U.S. that changes your expectations for Europe? And then on the CRISPR collaboration, are there any early signs you're seeing in the applicability of gene therapy to CF? And then also, just what advantages did you see with CRISPR versus other gene editing technologies?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treat",96,"In short, Brittany, the answer to your first part of the question is no, not really. I mean, we're seeing what we anticipate we'd see with the launch here in the U.S., which is a lot of enthusiasm from physicians and patients for the first drug that treats the underlying cause of their disease. Now, I expect there'll be a similar level of enthusiasm from physicians and payers in the EU. So there's really nothing we're seeing here which is changing my view about how I think the launch is going to progress in the EU."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader",49,"And with regard to CRISPR, we believe that CRISPR/Cas9 is a powerful technology that holds really great promise for discovering transformative medicines for genetic diseases including CF. And we're very excited to work with CRISPR Therapeutics as a leader in that field and as a good fit for Vertex."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients v",73,"It's actually Catherine for Ying. A couple of questions from us. On the payer mix, of the over 3,000 patients that started in 3Q, what percentage were Medicaid patients? And then, can you speak to your expectations for compliance of the ORKAMBI patients versus those on KALYDECO? And then just lastly, for the triple combination, just want to clarify, are you planning to move both combinations forward or will you pick one?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the",127,"So Catherine, a few questions there. Maybe I'll take the first one in terms of the revenue split. And Stuart will take the second, and Jeff Chodakewitz can clean up for us. So first to the split between the -- let's call it the government channel and the private payer channel. It was about close to 20% in the government channel. That translated to a gross-to-net adjustment of our gross price of just below 10%. I did make some comments earlier that as this launch proceeds, we do anticipate that the government channel does rise up to somewhere closer to 35%. And when we're at that steady state of 35% government and 65% private, then we would anticipate something in the mid-teens as a gross-to-net adjustment. Stuart?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do",146,"I think, Catherine, in terms of compliance, obviously, early days so far in the launch. But in terms of what we would anticipate, overall, my anticipation is that our compliance with the therapy will be high. And that's because I think physicians will do a great job explaining to patients. And patients, I think, on the whole, understand that this is a medicine that's treating the underlying cause of their disease. So I think, overall, the compliance rate is going to be high. I think KALYDECO compliance would be the upper end of my expectations. If I'm perfectly honest, it's the highest compliance rate I've ever seen for any chronic medication. We'll certainly be doing everything we can to appropriately support patients to maintain a high level of compliance with ORKAMBI as well, but I think KALYDECO would be at the upper end of my expectation."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And in terms of next-gen, as you know we're going to move both of those molecules into Nan [ph]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compounds in",52,"And in terms of next-gen, as you know we're going to move both of those molecules into Nan [ph]. We're going to learn about those compounds as they go through the Phase I studies. But assuming that data supports it, we would plan to move both compounds into evaluation with patients."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is David Lebowitz in for Matt. You mentioned earlier, as an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there an",63,"This is David Lebowitz in for Matt. You mentioned earlier, as an answer to another question that it was taking about 1 month to get reimbursement for patients. And I was just curious, going forward, as patients start to look to obtain refills, is there any expectation for how payers might address refills? Will there be some point where they want to reevaluate?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of th",113,"Yes, so it's very common for payers to have reauthorization criteria. It will differ from payer to payer, both in terms of the time to when they want to reassess a patient and look to reauthorize. And then also, they differ in terms of the criteria. Of the reauthorization criteria that we've seen to date, which is a relatively limited number, but of the ones that we've seen to date, the vast majority have got criteria which are effectively reflective of reimbursing to the label or if the physician thinks that the patient has seen clinical benefit across a number of different dimensions, reflecting the fact that CF is a complicated multisystem disease."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose",55,"And just to jump over to a different topic, there's been some data released recently from competitors on their triple combo. And I know you recently at NACF presented some data, some preclinical data on yours. And I was just curious if you could juxtapose yours versus theirs and make any overall comments and comparisons."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have the 2 marketed medicines. We've got another corrector that is",190,"So David, we'd prefer to keep our comments to our own compounds. So we are very excited about them with value of the HBE data. I would say that we like our position in terms of we already have the 2 marketed medicines. We've got another corrector that is in Phase III development that we've characterized very well given its stage of development. And then with our 2 next-generation correctors coming into the clinic, it provides us the opportunity to move quickly given that we already understand the medicines that we would combine our next-gens with. I'd also point out that we did take our time in choosing the right next-generation correctors and the 2 of them to come into the clinic. And not only were they picked for their performance in preclinical assays with -- for efficacy and safety but also their pharmaceutical properties. So we believe that we're in a very good position to move those into the clinic very shortly, into their healthy studies and then, next year, to move them into triple combination studies and see some results in patients. So we're looking forward to that."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbur",140,"So obviously, you have very rapid penetration. It sounds like a lot of enthusiasm for ORKAMBI. I was wondering if you could tell us if there's any sort of commonalities amongst patients who are not yet on treatment if it's mostly administrative or reimbursement timelines or if there's any particular reasons why physicians or patients may not be choosing the drug other than patients just not having gone to their physician's office yet. And then on VX-970, I'm interested in sort of the opportunity there. If you could tell us a little more about the biomarkers you might use for patient selection going forward, perhaps the proportion of common solid tumors that -- of patients with common solid tumors that have a complete ATM loss, which I think was the characteristic you saw in the complete response that was observed."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are no",135,"Yes, Brian, I'll take the first question on those patients not on treatment. And obviously, we're delighted that we're off to a promising start with over 3,000 patients initiated. But obviously that means that there's somewhere near 5,000 or so who are not yet initiated. And that's just such a large number of patients. It's hard to say there's 1 reason or 2 reasons why they haven't started on treatment yet. They really represent all types of eligible patients with the 508del mutation. And I just want to reiterate, we do still anticipate that the vast majority of those patients will eventually be initiated on ORKAMBI over the course of the rest of this year and into 2016. So there's not really 1 or 2 things that are holding those patients back from initiating therapy."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repa",134,"And it's Jeff Chodakewitz. Maybe just a couple of comments on your 970 question. You focused on ATM, but I would step back just a little bit because I think, in my mind, that ATM deficiency is one of mutations that actually linked to disorders of DNA repair in patients who have cancer. And so ATM is one. Another one that we are using as we go into our trials is the mutations and deficiencies in E53. Actually, it's the more common one. And the frequency of that varies widely across tumors. So I can't give you a single number, but it certainly is observed in multiple types of cancer. And we think that those serve as an important foothold as our understanding of the science to tell us where to go clinically."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on with the great quarter. And but just sort of trying t",193,"[indiscernible] actually sitting in for Mark. A lot of the questions are already asked so I kind of wanted to take a step back and ask maybe just more big picture questions. I guess, congratulations on with the great quarter. And but just sort of trying to think about competition and perhaps specifically Galapagos. And then thinking about the development and the development risk. I guess just sort of trying to think about how Vertex might see that. And whether it's use of the drug, in particular or just the ability to combine those drugs. Anyway, any thoughts on that? And then I had a question on -- you mentioned reauthorization criteria and you mentioned clinical criteria. And I guess, I just wonder if you could comment on how high you see the bar for those clinical criteria. Just it seems early to be asking those kinds of questions. And then just based on the pipeline and number of products that are being moved forward, just maybe speaking to margins a little bit. So I know you made comments before about expenses, but now just seems like a good time to ask again."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart -- to emphasize what Ian said, we really don't comment on any of the compe",204,"Yes. Maybe -- this is Jeff Leiden, I'll start with the first one. And I guess Stuart can take the second. And Ian will take the third. But with respect to Galapagos, just as Stuart -- to emphasize what Ian said, we really don't comment on any of the competitor compounds or programs. I would just reiterate what Ian said about our programs, which is we like our position really for 3 reasons. Number one, we have 2 drugs in the combination, 661 and KALYDECO, that are either approved or very well characterized. So when you put a 3-drug combination together, we feel that's a nice position to be in. And number two, we spent a lot of time optimizing the pharmaceutic properties of both next-gen correctors. And that's important as you put a 3-drug combination together. And number three, we showed you the chloride data from the HBE cells with those -- with that 3-drug combination which were getting us levels which are at or north of what KALYDECO does in G551D. And so far, those assays have predicted quite well what we see in the clinic. So we're excited to see the first Phase II results. We'll start those studies next year."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on reauthorization criteria, just to reiterate what I've said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will incre",131,"And on reauthorization criteria, just to reiterate what I've said. So far, we've seen a limited number of plans which have published their reauthorization criteria. So we're really talking about a small end at this stage. Our knowledge of those will increase obviously as plans publish those criteria or make those criteria known. Of the ones that we've seen so far, they aren't really setting a really very high clinical bar, to use your terminology. Most of them are essentially just ensuring that the patients continue to be within our label or show improvement across a number of clinical parameters in the opinion of the treating physicians. So -- but as I say, that's on a limited basis right now because it is early for plans to be publishing reauthorization criteria."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have",83,"And [indiscernible], just to round out your questions, I'll just state again, we're committing to driving this business forward and having high operating margins. We'd get to that position by revenue growth and controlling our operating expenses. We have a business, and we're in an area where we can do that. And so for us, it's the execution on the launch both in the U.S. and then in Europe, continuing to reinvest the growth of the future, yet still having significant operating margins."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone",60,"First one on European reimbursement. In the prepared remarks, you noted that KALYDECO took I think between 9 and 20 months to get country by country reimbursement. I'm curious whether you think that could go faster this time around, given that you've gone back to the same payers, in some cases probably several times with the different KALYDECO label expansions?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a",106,"Yes, Phil, thanks for the question. I won't really know until our team over in Europe begins those reimbursement discussions with the relevant authorities. That's why I said it's really, really difficult to predict. They all have different processes and a number of them, those processes are changing. They're not even the same process that we went through with KALYDECO. So I really can't predict with any sense of confidence or accuracy whether we're going to go faster or slower with ORKAMBI. We won't really know until we begin that process after we receive regulatory approval, which we continue to anticipate will happen later this quarter."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And second question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting",52,"And second question, also in your prepared remarks, you mentioned that the reimbursement assistance team is beginning to shift to impact persistence and contact the patients. Can you talk a little bit more about that? What exactly is involved in impacting persistence? And what type of message do you find most effective?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a",128,"So obviously, they do a number of things. One is to help patients who are initiating on treatment navigate the reimbursement process. And they'll obviously need to continue to do that because whilst there are over 3,000 patients initiated, there's still a lot more patients that physicians are going to want to initiate on ORKAMBI. But for those who are now started on therapy, then we have a number of programs. And essentially, it's really helping educate patients on the mode of action of ORKAMBI, how it treats the underlying cause of their disease and providing them to the extent they want to receive educational materials and refill reminders and things of that nature. And so we kind of tailor that to the individual patients as they desire."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Tony Butler of Guggenheim.",10,"And our next question comes from Tony Butler of Guggenheim."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients",91,"Stuart, I recognize the commentary around the approval in the EU toward the end of the quarter. But if I make some assumptions that, as you alluded to earlier, Germany is the first country to be purchasing. Can you comment on the number of 508del patients in Germany? And then, my second question is more scientific-oriented -- more scientifically oriented. Beyond the correctors of 440 and 152, I had the impression that you may put additional correctors, second-gen correctors, into the clinic. Is that still true, or did I misinterpret that?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligi",49,"Yes. In Germany, Tony, there's about 2,500 patients who are 12 and over, who are homozygous for the F508del mutation. And so assuming that our approval comes through at the end of this quarter and that that's our labeled indication, that will be the eligible patient population in Germany."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so c",178,"This is Jeff. I'll take the second one, which is about the additional correctors. And maybe I'll broaden it out just a little bit, if you don't mind. Our goal is to create the best portfolio of medicines for each one of these patient populations. And so certainly a big part of that is going to be next-gen correctors. And as I've said several times before, we have multiple -- we have discovered multiple next-gen correctors. These are the first 2, but there are others behind them. And assuming they pan out as they go through lead up in talks, yes, our intent would be to put additional correctors in, particularly if they have different and interesting properties, so that we can study them. But beyond that, I'd also remind you of things like the ENaC inhibitors, like gene editing, we're really looking at a variety of modalities. And so over the next few years, you can expect to see us bring multiple compounds and, frankly, multiple modalities into the clinic to try to create the best combinations."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Liisa Bayko of JMP Securities.",11,"And our next question comes from Liisa Bayko of JMP Securities."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?",33,"You mentioned that there were a couple of plans that are not yet covering ORKAMBI. Can you maybe give us a sense of what percentage of lives that matter to you that represents?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the",79,"Yes, Liisa, it's a small number of plans. It's in the single-digits in terms of the number of lives that they are responsible for. And essentially, they are not reimbursing yet. And we know they're continuing to work through the process of evaluating the product and which door they'll come to a formal conclusion over the next few months. But it's -- at the minute, it is single digits in terms of number of lives covered by those plans."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?",22,"And then just on CMS, can you walk us through the timing there in getting a coverage for the Medicare, Medicaid population?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effecti",55,"Well, in terms of payer mix, we already have had patients both in Medicare and Medicaid who have got access and have been reimbursed for ORKAMBI. The vast majority of in fact state Medicaids have already reimbursed patients. And so we already have effectively reimbursements in a number of states and through Medicare as well."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's not really any gating factor there then?",10,"Okay. So there's not really any gating factor there then?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answ",58,"I mean, there are some Medicaid plans who are still considering the products and have decided that they're not going to cover ORKAMBI until they've come to a formal decision. So it really is on a state by state basis on Medicaid. There really isn't 1 answer, 1 decision. It really happens on a state by state basis."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populat",67,"Okay, fair enough. And then just one question about the oncology portfolio. Can you maybe at all describe some of the data? I see in triple negative breast cancer patients and nonsmall cell lung, you're going to kind of enhance maybe some of those populations. And it seems like maybe you have some data there. Could you comment at all on that? And that's my final question."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What",127,"It's Jeff Chodakewitz. I think it actually goes back to the question that was asked by someone else earlier about how are we selecting the right subset of patients and that those factors are present actually in patients with multiple kinds of tumors. What we've done in those 2 small sets of study -- of patients is actually to hone in on patients who we expect or we'll require to have some of those kinds of mutations that we spoke about those deficiencies in DNA repair. And then by doing that, we think we are being able to get a very focused relatively rapid answer to the question about how the drug will work. So that's what that represents that you're seeing in our study prescription."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu of William Blair.",11,"And our next question comes from Katherine Xu of William Blair."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did",72,"I just have a few questions on the CRISPR program. How far is it from the clinic? From a scientific perspective, are there difficulty -- difficulties in levels of research between inserting the same pairs versus correcting the base pairs? And also why did you choose CRISPR Therapeutics. There are a few other companies with similar technologies. And if you could comment on the IP side, that will be great as well."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through.",27,"Look, Katherine, David will take the first 2 questions. And then, I'll answer the third question once David is through it on the process we went through."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that",70,"Yes, thanks for the question. I would say that it's still early days in this. And so it's -- we really can't comment or predict exactly how long it will take. And in terms of things like the different methods of using CRISPR to modify the DNA, again that will all be subject to research we're doing. And we look forward to updating you when we have progress to report."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then",194,"And to the process, on previous calls, when asked about our business and corporate development strategy, we've always had 3 main approaches. One was to complement what we're doing in cystic fibrosis. Two was the opportunistic in-licensing in M&A. And then, a third area was always to broaden our scientific platform. And that's what we're doing here. We've been very good at small molecules for a long time at Vertex. And with David's help, on coming on board about a year ago, we were able to consider other technologies and how we may expand our scientific footprint. And this was an area that rose to the top as a priority for us. And so we then went through the process as you usually do as there are a number of companies that have access to this technology. We did our usual diligence process. And based on the structure of the arrangement, the collaboration between people and the opportunity of fit with what we want to do at Vertex, our choice was with CRISPR therapeutics. And we're very happy to be a partner of theirs as we move forward. We don't comment on IP, Katherine."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So operator it is now 6:00, we will take 2 more questions.",13,"So operator it is now 6:00, we will take 2 more questions."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question will come from the line of Ted Tenthoff of Piper Jaffray.",15,"And our next question will come from the line of Ted Tenthoff of Piper Jaffray."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Quick question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something",57,"Quick question, just with respect to differentiation between triple therapy with a second-gen corrector and also the ENaC inhibitor. How ultimately do you see sort of patient selection there? Obviously, it's going to be data-driven, but is this something where maybe the ENaC inhibitors would be used in different patients? What's your general thinking along those lines?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-gene",170,"Yes, and you're absolutely right. It will obviously, in the end, be driven by the data which is why we're going to explore this in Phase II. But if you think about it sort of at a high-level strategic -- from a high-level strategic standpoint, second-generation correctors in a triple combination would be expected to address anybody who has a single or a double delta 508 allele. So that's about 80% to 90% of all patients. ENaC inhibitors, again, theoretically and we're going to have to demonstrate this in the clinic, should be useful for anybody with any mutation. And in fact, as you know Parion is running an initial Phase II trial. It's an all-comer trial. We're going to run a Phase II trial with ENaC plus ORKAMBI. And based on the data there, we'll be able to determine how to sort of craft these regimens for each patient subset. But that would be the theoretical expectations based on what we've seen in HBE cell. Does that make sense?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, absolutely. I appreciate that color.",6,"Yes, absolutely. I appreciate that color."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our last question comes from the line of Brian Skorney of Robert W. Baird.",15,"And our last question comes from the line of Brian Skorney of Robert W. Baird."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. Do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe",48,"This is Nina [ph] in for Brian. So I just have a question on the ORKAMBI launch. Do you have a sense of what percentage of treating physicians actually started patients on ORKAMBI? And have you seen any hurdles in terms of getting physicians to prescribe the product?"
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad",60,"I can't tell you exactly how many physicians have actually have a patient on ORKAMBI. What I do know is that just about every CF center in the United States has put a patient on ORKAMBI. So we are really seeing, again, what we anticipated, which is broad interest in using the medicine both with physicians and with patients."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all.",49,"Great. And one last question. So I know you said that there has been good feedback from payers in terms of getting ORKAMBI covered. Has there been any sort of pushback at all? And if so, what was -- could you give us some color around that? That's all."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have b",132,"Yes. I mean, I'd say the end product of our discussions has been good. And that's reflected in the fact that we have good access, the vast majority of which is to label. Obviously, there's been a lot of discussion there. But a lot of it, as I said, have been very productive because payers, I do think, understand how serious a disease this is and how this is a disease that is -- this is a product which is treating the underlying cause of the disease. And the fact that it's an orphan, it's not ultra-orphan indication. And so they have relatively few patients in each of their individual plans. So the discussions have been very productive. And I think that's reflected in the good and broad access that we have."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening.",31,"So we appreciate everyone joining us for the call tonight. The Investor Relations team will be in the office if you have additional questions. Thank you, and have a good evening."
36235,313254007,885598,"Vertex Pharmaceuticals Incorporated, Q3 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day everyone."
